<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840219</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3181</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Annales de cardiologie et d'angeiologie</Title><ISOAbbreviation>Ann Cardiol Angeiol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[What the e-MUST Registry Reveals About Myocardial Infarction in Women].</ArticleTitle><Pagination><StartPage>101925</StartPage><MedlinePgn>101925</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ancard.2025.101925</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0003-3928(25)00064-2</ELocationID><Abstract><AbstractText>The issue of gender in acute myocardial infarction (AMI) emerged in the literature over 25 years ago. It became evident that, all other factors being equal, women with AMI had higher mortality rates than men. The e-MUST registry, which includes patients with ST-segment elevation myocardial infarction (STEMI) of less than 24 hours' duration managed by one of the 39 Mobile Emergency and Resuscitation Services (SMUR) in the &#xce;le-de-France region, has allowed for numerous gender-focused analyses. Key findings include: [1] higher mortality in women: women experiencing AMI have a higher mortality risk (OR = 1.4; 95% CI: 1.1-1.8) compared to men [2]. Younger age of onset in women: while the average age at AMI onset increased by 2.9 years in men between 2002 and 2021 (from 57.6 to 60.5 years; p &lt; 0.05), it decreased by 3.1 years in women (from 73.7 to 70.6 years; p &lt; 0.0001) [3]. Advanced age in a subset of women: women represented 22% of the total registry population but accounted for over 60% of nonagenarian patients. In this very elderly subgroup, the rate of myocardial reperfusion decisions rose from 50% in the early 2000s to over 90% by the early 2020s. This intervention was associated with a 58% reduction in mortality [4]. Nontraditional risk profiles: women with AMI often presented without traditional cardiovascular risk factors, or with risk factors not routinely screened for [5]. Circadian patterns and delayed calls: AMI in women frequently occurred in the early morning, peaking at 08:00. Call delays to emergency services increased with age and nighttime onset, reaching up to 300 minutes in women over 65 experiencing chest pain at 1 a.m [6]. Prehospital management: except for a slightly lower rate of myocardial reperfusion in women (93% vs. 96% in men; p &lt; 0.0001), prehospital management, including anticoagulant and antiplatelet therapy, was comparable between genders [7]. Gender bias in medical regulation: analysis of SAMU call regulation revealed that both the patient's and the physician's gender influenced the decision to dispatch a SMUR unit-ranging from 49% when both regulator and patient were men to just 18% when both were women [8]. Need for targeted approaches: these findings underscore the necessity for increased awareness, dedicated training, and gender-specific emergency care protocols to improve outcomes in women with AMI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Masson SAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lapostolle</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>SAMU 93 (local emergency medical service), UF Recherche-Enseignement-Qualit&#xe9;, (Research, teaching and quality training unit) Avicenne Hospital - Public hospitals of Paris, Bobigny, France; Universit&#xe9; Paris 13, INSERM Unit 942, Sorbonne Paris Cit&#xe9;, Bobigny, France. Electronic address: frederic.lapostolle@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benamer</LastName><ForeName>Hakim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiology Department, Institut Cardiovasculaire Paris Sud (ICPS), Massy, France. Electronic address: h.benamer@angio-icps.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loyeau</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Data Science Department, Sesan, Paris, France. Electronic address: aurelie.loyeau@sesan.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalak</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>SAMU 93 (local emergency medical service), UF Recherche-Enseignement-Qualit&#xe9;, (Research, teaching and quality training unit) Avicenne Hospital - Public hospitals of Paris, Bobigny, France; Universit&#xe9; Paris 13, INSERM Unit 942, Sorbonne Paris Cit&#xe9;, Bobigny, France. Electronic address: hugo.michalak@orange.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovic</LastName><ForeName>Tomislav</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>SAMU 93 (local emergency medical service), UF Recherche-Enseignement-Qualit&#xe9;, (Research, teaching and quality training unit) Avicenne Hospital - Public hospitals of Paris, Bobigny, France; Universit&#xe9; Paris 13, INSERM Unit 942, Sorbonne Paris Cit&#xe9;, Bobigny, France. Electronic address: tomislav.petrovic@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bataille</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Greater Paris Regional Health Authority, Paris, France. Electronic address: Sophie.BATAILLE@ars.sante.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>SAMU 78 (EMS), Versailles Hospital, Le Chesnay, France. Electronic address: yl.samu78@wanadoo.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Ce que le registre e-MUST dit de l&#x2019;infarctus de la femme.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Cardiol Angeiol (Paris)</MedlineTA><NlmUniqueID>0142167</NlmUniqueID><ISSNLinking>0003-3928</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">Emergency</Keyword><Keyword MajorTopicYN="N">Gender</Keyword><Keyword MajorTopicYN="N">Genre</Keyword><Keyword MajorTopicYN="N">Prehsopital</Keyword><Keyword MajorTopicYN="N">Pr&#xe9;hospitalier</Keyword><Keyword MajorTopicYN="N">Samu</Keyword><Keyword MajorTopicYN="N">Syndrome coronaire aigu ST+</Keyword><Keyword MajorTopicYN="N">Urgence</Keyword></KeywordList><CoiStatement>Conflits d'int&#xe9;r&#xea;ts Les auteurs d&#xe9;clarent n'avoir aucun conflit d'int&#xe9;r&#xea;ts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>18</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840219</ArticleId><ArticleId IdType="doi">10.1016/j.ancard.2025.101925</ArticleId><ArticleId IdType="pii">S0003-3928(25)00064-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40842949</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-0640</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in psychiatry</Title><ISOAbbreviation>Front Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Factors associated with kinesiophobia among myocardial infarction survivors: a biopsychosocial perspective.</ArticleTitle><Pagination><StartPage>1551758</StartPage><MedlinePgn>1551758</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1551758</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2025.1551758</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This study aimed to examine the factors associated with kinesiophobia among myocardial infarction (MI) survivors.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This study was based on the Biopsychosocial (BPS) model. A multicenter, descriptive, cross-sectional study was conducted at three tertiary hospitals in Changsha, Hunan Province, China, with MI survivors as participants. The Tampa Scale for Kinesiophobia Heart (TSK-SV Heart), Exercise Self-Efficacy Scale (ESES), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Self-Perceived Burden Scale (SPBS), the 10-Item Connor-Davidson Resilience Scale (CD-RISC-10), Family Resilience Assessment Scale (FRAS), Multidimensional Scale of Perceived Social Support (MSPSS) and Social Support Rating Scale (SSRS) were used to collect data. Hierarchical regression analysis was employed to identify significant predictors of kinesiophobia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 414 MI survivors participated. Hierarchical regression analysis showed that the total explanatory power of the model was 56.9%, with sociodemographic factors accounting for 17.0% and cognitive, behavioral, psychological and social support factors accounting for 39.9%. Kinesiophobia was significantly associated with age, gender, education level, disease duration, number of complications, exercise intensity, exercise duration, exercise frequency, exercise self-efficacy (ESE), depression, self-perceived burden (SPB), mental resilience, family resilience, perceived social support (PSS), and actual social support (ASS).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This study identified several sociodemographic, psychosocial, and behavioral factors associated with kinesiophobia in MI survivors. Based on these findings, integrating psychological support, behavior-focused interventions, and strengthened social support systems may help reduce kinesiophobia in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Zhang, Li, Ma, Jiang, Han, Yi and Cao.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaodan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yamin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Nursing Teaching and Research Section, Second Xiangya Hospital, Central South University, Changsha,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qiuping</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zheyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Xinrui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Keming</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Lifang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Psychiatry</MedlineTA><NlmUniqueID>101545006</NlmUniqueID><ISSNLinking>1664-0640</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biopsychosocial model</Keyword><Keyword MajorTopicYN="N">exercise rehabilitation</Keyword><Keyword MajorTopicYN="N">fear-avoidance model</Keyword><Keyword MajorTopicYN="N">kinesiophobia</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40842949</ArticleId><ArticleId IdType="pmc">PMC12365802</ArticleId><ArticleId IdType="doi">10.3389/fpsyt.2025.1551758</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fanaroff AC, Faggioni M. Managing myocardial infarction in the age of multimorbidity. J Am Coll Cardiol. (2023) 82:982&#x2013;4. doi:&#xa0; 10.1016/j.jacc.2023.06.023, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.06.023</ArticleId><ArticleId IdType="pubmed">37648356</ArticleId></ArticleIdList></Reference><Reference><Citation>Salari N, Morddarvanjoghi F, Abdolmaleki A, Rasoulpoor S, Khaleghi AA, Hezarkhani LA, et al. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. (2023) 23:206&#x2013;18. doi:&#xa0; 10.1186/s12872-023-03231-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-023-03231-w</ArticleId><ArticleId IdType="pmc">PMC10122825</ArticleId><ArticleId IdType="pubmed">37087452</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur&#xa0;Heart J. (2023) 44:452&#x2013;69. doi:&#xa0; 10.1093/eurheartj/ehac747, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac747</ArticleId><ArticleId IdType="pmc">PMC9902155</ArticleId><ArticleId IdType="pubmed">36746187</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;akal B, Y&#x131;ld&#x131;r&#x131;m M, Emren SV. Kinesiophobia, physical performance, and health-related quality of life in patients with coronary artery disease. Postepy w Kardiologii Interwencyjnej. (2022) 18:246&#x2013;54. doi:&#xa0; 10.5114/aic.2022.122892, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aic.2022.122892</ArticleId><ArticleId IdType="pmc">PMC9885221</ArticleId><ArticleId IdType="pubmed">36751297</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpalh&#xe3;o V, Cordeiro N, Pezarat-Correia P. Kinesiophobia and fear avoidance in older adults: a systematic review on constructs and related measures. J Geriatric Phys Ther. (2022) 45:207&#x2013;14. doi:&#xa0; 10.1519/jpt.0000000000000354, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1519/jpt.0000000000000354</ArticleId><ArticleId IdType="pubmed">35939664</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakut Ozdemir H, Ozalevli S, Felekoglu E, Baskurt AA, Dursun H. Kinesiophobia and associated factors in patients with myocardial infarction. Perceptual Motor Skills. (2023) 130:2564&#x2013;81. doi:&#xa0; 10.1177/00315125231204059, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00315125231204059</ArticleId><ArticleId IdType="pubmed">37909184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lethem J, Slade PD, Troup JD, Bentley G. Outline of a Fear-avoidance model of exaggerated pain perception&#x2013;i. Behav Res Ther. (1983) 21:401&#x2013;8. doi:&#xa0; 10.1016/0005-7967(83)90009-, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-7967(83)90009-</ArticleId><ArticleId IdType="pubmed">6626110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordeleau M, Vincenot M, Lefevre S, Duport A, Seggio L, Breton T, et al. Treatments for kinesiophobia in people with chronic pain: a scoping review. Front Behav Neurosci. (2022) 16:933483. doi:&#xa0; 10.3389/fnbeh.2022.933483, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2022.933483</ArticleId><ArticleId IdType="pmc">PMC9531655</ArticleId><ArticleId IdType="pubmed">36204486</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsaleem MK, Alkhars AM, Alalwan HA, Almutairi A, Alonayzan A, AlYaeesh IA. Kinesiophobia post total hip arthroplasty: a retrospective study. cureus. (2021) 13:e15991&#x2013;9. doi:&#xa0; 10.7759/cureus.15991, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.15991</ArticleId><ArticleId IdType="pmc">PMC8318043</ArticleId><ArticleId IdType="pubmed">34336482</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L, Liu Y, Xu H, Xu Q, Wang Y, Lyu P. Incidence and risk factors of kinesiophobia after total knee arthroplasty in zhengzhou, China: a cross-sectional study. J Arthroplasty. (2018) 33:2858&#x2013;62. doi:&#xa0; 10.1016/j.arth.2018.04.028, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2018.04.028</ArticleId><ArticleId IdType="pubmed">29776855</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapik A, D&#x105;bek J, Brz&#x119;k A. Kinesiophobia as a problem in adherence to physical activity recommendations in elderly polish patients with coronary artery disease. Patient Preference Adherence. (2019) 13:2129&#x2013;35. doi:&#xa0; 10.2147/ppa.S216196, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ppa.S216196</ArticleId><ArticleId IdType="pmc">PMC6924585</ArticleId><ArticleId IdType="pubmed">31908420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhao Q, Wang M, Yang M, Fan X. Fear of movement and its associated psychosocial factors in heart failure patients: a cross-sectional study. Eur J Cardiovasc Nursing. (2023) 22:273&#x2013;81. doi:&#xa0; 10.1093/eurjcn/zvac075, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjcn/zvac075</ArticleId><ArticleId IdType="pubmed">35989416</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler RH. Engel&#x2019;s biopsychosocial model is still relevant today. J Psychosom Res. (2009) 67:607&#x2013;11. doi:&#xa0; 10.1016/j.jpsychores.2009.08.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2009.08.008</ArticleId><ArticleId IdType="pubmed">19913665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugg W. The biopsychosocial model - history, controversy and Engel. Australas Psychiatry. (2022) 30:55&#x2013;9. doi:&#xa0; 10.1177/10398562211037333, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10398562211037333</ArticleId><ArticleId IdType="pubmed">34748708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandura A. Human agency in social cognitive theory. Am Psychol. (1989) 44:1175&#x2013;84. doi:&#xa0; 10.1037/0003-066x.44.9.1175, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0003-066x.44.9.1175</ArticleId><ArticleId IdType="pubmed">2782727</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Chen X, Li X, Liu F, Deng C, Jia P, et al. Influencing factors of kinesiophobia in knee arthroplasty patients under the social cognitive theory: A structural equation model. Geriatric Nursing. (2024) 60:270&#x2013;80. doi:&#xa0; 10.1016/j.gerinurse.2024.09.004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gerinurse.2024.09.004</ArticleId><ArticleId IdType="pubmed">39342894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandura A. Self-efficacy: toward a unifying theory of behavioral change. psychol Review. (1977) 84:191&#x2013;215. doi:&#xa0; 10.1037//0033-295x.84.2.191, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1037//0033-295x.84.2.191</ArticleId><ArticleId IdType="pubmed">847061</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques-Sule E, S&#xf6;derlund A, Almenar L, Esp&#xed;-L&#xf3;pez GV, L&#xf3;pez-Vilella R, B&#xe4;ck M. Influence on kinesiophobia by disability, physical, and behavioural variables after a heart transplantation. Eur J Cardiovasc Nursing. (2022) 21:537&#x2013;43. doi:&#xa0; 10.1093/eurjcn/zvab134, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjcn/zvab134</ArticleId><ArticleId IdType="pubmed">35018421</ArticleId></ArticleIdList></Reference><Reference><Citation>Pudkasam S, Polman R, Pitcher M, Fisher M, Chinlumprasert N, Stojanovska L, et al. Physical activity and breast cancer survivors: Importance of adherence, motivational interviewing and psychological health. Maturitas. (2018) 116:66&#x2013;72. doi:&#xa0; 10.1016/j.maturitas.2018.07.010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2018.07.010</ArticleId><ArticleId IdType="pubmed">30244781</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson CJ, Wilson KG, Lobchuk MM, Brajtman S. Self-perceived burden to others: patient and family caregiver correlates. J Palliative Care. (2007) 23:135&#x2013;42. doi:&#xa0; 10.1177/082585970702300303</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/082585970702300303</ArticleId><ArticleId IdType="pubmed">18069434</ArticleId></ArticleIdList></Reference><Reference><Citation>Cousineau N, McDowell I, Hotz S, H&#xe9;bert P. Measuring chronic patients&#x2019; feelings of being a burden to their caregivers: development and preliminary validation of a scale. Med Care. (2003) 41:110&#x2013;8. doi:&#xa0; 10.1097/00005650-200301000-00013, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-200301000-00013</ArticleId><ArticleId IdType="pubmed">12544548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren XR, Wei YY, Su XN, Hua Y, Shao P, Xiao T, et al. Correlation between self-perceived burden and self-management behavior in elderly stroke survivors: A longitudinal observational study. Med (Baltimore). (2020) 99:e22862&#x2013;8. doi:&#xa0; 10.1097/md.0000000000022862, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000022862</ArticleId><ArticleId IdType="pmc">PMC7598859</ArticleId><ArticleId IdType="pubmed">33126330</ArticleId></ArticleIdList></Reference><Reference><Citation>Davydov DM, Stewart R, Ritchie K, Chaudieu I. Resilience and mental health. Clin Psychol Review. (2010) 30:479&#x2013;95. doi:&#xa0; 10.1016/j.cpr.2010.03.003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpr.2010.03.003</ArticleId><ArticleId IdType="pubmed">20395025</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh F. Family resilience: a framework for clinical practice. Family Process. (2003) 42:1&#x2013;18. doi:&#xa0; 10.1111/j.1545-5300.2003.00001.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1545-5300.2003.00001.x</ArticleId><ArticleId IdType="pubmed">12698595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay Smith G, Banting L, Eime R, O&#x2019;Sullivan G, van Uffelen JGZ. The association between social support and physical activity in older adults: a systematic review. Int J Behav Nutr Phys Activity. (2017) 14:56&#x2013;77. doi:&#xa0; 10.1186/s12966-017-0509-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12966-017-0509-8</ArticleId><ArticleId IdType="pmc">PMC5408452</ArticleId><ArticleId IdType="pubmed">28449673</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined&#x2013;a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. (2000) 36:959&#x2013;69. doi:&#xa0; 10.1016/s0735-1097(00)00804-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(00)00804-4</ArticleId><ArticleId IdType="pubmed">10987628</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ck M, Jansson B, Cider A, Herlitz J, Lundberg M. Validation of a questionnaire to detect kinesiophobia (fear of movement) in patients with coronary artery disease. J Rehabil Med. (2012) 44:363&#x2013;9. doi:&#xa0; 10.2340/16501977-0942, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/16501977-0942</ArticleId><ArticleId IdType="pubmed">22366980</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Xiong J, Chen C, Wang X, Gao Y, Zhou Y, et al. Influencing factors of kinesiophobia in older patients with chronic heart failure: A structural equation model. Clin Cardiol. (2023) 46:729&#x2013;36. doi:&#xa0; 10.1002/clc.24024, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.24024</ArticleId><ArticleId IdType="pmc">PMC10352966</ArticleId><ArticleId IdType="pubmed">37114367</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WC, Gillett PA, Pattillo RE. Applying the Transtheoretical Model to physical activity in family caregivers in Taiwan. Public Health Nursing. (2005) 22:299&#x2013;310. doi:&#xa0; 10.1111/j.0737-1209.2005.220405.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0737-1209.2005.220405.x</ArticleId><ArticleId IdType="pubmed">16150011</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yan L, Xing W, Zhou C, Li Y, Wan B, et al. The effect of fear-avoidance intervention on kinesiophobia and self-efficacy in patients after percutaneous coronary intervention: study protocol for a clinical randomized controlled trial. Trials. (2024) 25:517&#x2013;28. doi:&#xa0; 10.1186/s13063-024-08349-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-024-08349-6</ArticleId><ArticleId IdType="pmc">PMC11293134</ArticleId><ArticleId IdType="pubmed">39085967</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Zhou H, Zhang Y, Zhu X, Wang X, Shen B, et al. Validation of the 7-item generalized anxiety disorder scale (GAD-7) as a screening tool for anxiety among pregnant Chinese women. J Affect Disord. (2021) 282:98&#x2013;103. doi:&#xa0; 10.1016/j.jad.2020.12.129, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.12.129</ArticleId><ArticleId IdType="pubmed">33401129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolgeo T, Di Matteo R, Simonelli N, Dal Molin A, Lusignani M, Bassola B, et al. Psychometric properties and measurement invariance of the 7-item general anxiety disorder scale (GAD-7) in an Italian coronary heart disease population. J Affect Disord. (2023) 334:213&#x2013;9. doi:&#xa0; 10.1016/j.jad.2023.04.140, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2023.04.140</ArticleId><ArticleId IdType="pubmed">37149049</ArticleId></ArticleIdList></Reference><Reference><Citation>Levis B, Benedetti A, Thombs BD. Accuracy of patient health questionnaire-9 (phq-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. (2019) 365:1476&#x2013;87. doi:&#xa0; 10.1136/bmj.l1476, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l1476</ArticleId><ArticleId IdType="pmc">PMC6454318</ArticleId><ArticleId IdType="pubmed">30967483</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini L, Pasquarella C, Odone A, Colucci ME, Costanza A, Serafini G, et al. Screening for depression in primary care with patient health questionnaire-9 (phq-9): a systematic review. J Affect Disord. (2021) 279:473&#x2013;83. doi:&#xa0; 10.1016/j.jad.2020.09.131, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.09.131</ArticleId><ArticleId IdType="pubmed">33126078</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholizadeh L, Shahmansouri N, Heydari M, Davidson PM. Assessment and detection of depression in patients with coronary artery disease: validation of the Persian version of the PHQ-9. Contemp Nurse. (2019) 55:185&#x2013;94. doi:&#xa0; 10.1080/10376178.2019.1641119, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10376178.2019.1641119</ArticleId><ArticleId IdType="pubmed">31280682</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang B, Fu Y, Liu B, Yi Q. Self-perceived burden and associated factors in Chinese adult epilepsy patients: A cross-sectional study. Front Neurol. (2022) 13:994664. doi:&#xa0; 10.3389/fneur.2022.994664, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.994664</ArticleId><ArticleId IdType="pmc">PMC9513448</ArticleId><ArticleId IdType="pubmed">36176558</ArticleId></ArticleIdList></Reference><Reference><Citation>He M, Zhou J, Wang Y, Chen Z, Wang F. Mediating effect of self-efficacy on self-perceived burden and kinesiophobia in patients with coronary heart disease after percutaneous coronary intervention in China: a cross-sectional study. BMJ Open. (2025) 15:e083220&#x2013;e083227. doi:&#xa0; 10.1136/bmjopen-2023-083220, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-083220</ArticleId><ArticleId IdType="pmc">PMC12049945</ArticleId><ArticleId IdType="pubmed">40306917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Shi Z, Zhang Y, Zhang Z. Psychometric properties of the 10-item connor-davidson resilience scale in chinese earthquake victims. Psychiatry Clin Neurosciences. (2010) 64:499&#x2013;504. doi:&#xa0; 10.1111/j.1440-1819.2010.02130.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1819.2010.02130.x</ArticleId><ArticleId IdType="pubmed">20923429</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown T, Chen S, Ou Z, McDonald N, Bennett-Murphy L, Schneider L, et al. Feasibility of assessing adolescent and young adult heart transplant recipient mental health and resilience using patient-reported outcome measures. J Acad Consult Liaison Psychiatry. (2022) 63:153&#x2013;62. doi:&#xa0; 10.1016/j.jaclp.2021.08.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaclp.2021.08.002</ArticleId><ArticleId IdType="pmc">PMC8866525</ArticleId><ArticleId IdType="pubmed">34438097</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu T, Liu H. Development of family resilience assessment scale. psychol Techniques Applications. (2019) 7:173&#x2013;82.</Citation></Reference><Reference><Citation>Zhou J, He B, He Y, Huang W, Zhu H, Zhang M, et al. Measurement properties of family resilience assessment questionnaires: a systematic review. Fam Pract. (2020) 37:581&#x2013;91. doi:&#xa0; 10.1093/fampra/cmaa027, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmaa027</ArticleId><ArticleId IdType="pubmed">32270181</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CS, Chin XY, Chng ST, Lee J, Ooi CS. Perceived Social support increases creativity: experimental evidence. Int J Environ Res. (2022) 19:1&#x2013;8. doi:&#xa0; 10.3390/ijerph191811841, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191811841</ArticleId><ArticleId IdType="pmc">PMC9517368</ArticleId><ArticleId IdType="pubmed">36142114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazukauskiene N, Bunevicius A, Gecaite-Stonciene J, Burkauskas J. Fatigue, social support, and depression in individuals with coronary artery disease. Front Psychol. (2021) 12:732795. doi:&#xa0; 10.3389/fpsyg.2021.732795, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2021.732795</ArticleId><ArticleId IdType="pmc">PMC8565598</ArticleId><ArticleId IdType="pubmed">34744903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yan Z, Fornah L, Zhao J, Wu S. The mediation effect of social support between stigma and social alienation in patients with stroke. Front Public Health. (2023) 11:1290177. doi:&#xa0; 10.3389/fpubh.2023.1290177, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1290177</ArticleId><ArticleId IdType="pmc">PMC10716442</ArticleId><ArticleId IdType="pubmed">38094234</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Ma HX, Liu SS, Gong Q. Correlation among anxiety and depression, fear of disease progression, and social support in coronary heart disease. World J Psychiatry. (2024) 14:1708&#x2013;17. doi:&#xa0; 10.5498/wjp.v14.i11.1708, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.5498/wjp.v14.i11.1708</ArticleId><ArticleId IdType="pmc">PMC11572683</ArticleId><ArticleId IdType="pubmed">39564166</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. J Clin Epidemiol. (2015) 68:627&#x2013;36. doi:&#xa0; 10.1016/j.jclinepi.2014.12.014, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.12.014</ArticleId><ArticleId IdType="pubmed">25704724</ArticleId></ArticleIdList></Reference><Reference><Citation>Presto P, Mazzitelli M, Junell R, Griffin Z, Neugebauer V. Sex differences in pain along the neuraxis. Neuropharmacology. (2022) 210:109030&#x2013;62. doi:&#xa0; 10.1016/j.neuropharm.2022.109030, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2022.109030</ArticleId><ArticleId IdType="pmc">PMC9354808</ArticleId><ArticleId IdType="pubmed">35331712</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine M, Tousignant-Laflamme Y, Kloda LA, Dion D, Dupuis G, Choini&#xe8;re M. A systematic literature review of 10 years of research on sex/gender and experimental pain perception - part 1: are there really differences between women and men? Pain. (2012) 153:602&#x2013;18. doi:&#xa0; 10.1016/j.pain.2011.11.025, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2011.11.025</ArticleId><ArticleId IdType="pubmed">22192712</ArticleId></ArticleIdList></Reference><Reference><Citation>Stormacq C, Van den Broucke S, Wosinski J. Does health literacy mediate the relationship between socioeconomic status and health disparities? Integrative review. Health Promot Int. (2019) 34:e1&#x2013;e17. doi:&#xa0; 10.1093/heapro/day062, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/heapro/day062</ArticleId><ArticleId IdType="pubmed">30107564</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittencourt JV, de Souza PAC, Corr&#xea;a LA, Volot&#xe3;o AN, Mathieson S, Nogueira LAC. Health literacy, pain-related interference and pain-related distress of patients with musculoskeletal pain. Health Promot Int. (2023) 38:1&#x2013;9. doi:&#xa0; 10.1093/heapro/daab183, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/heapro/daab183</ArticleId><ArticleId IdType="pubmed">34718561</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuRuz ME, Masa&#x2019;Deh R. Gender differences in anxiety and complications early after acute myocardial infarction. J Cardiovasc Nurs. (2017) 32:538&#x2013;43. doi:&#xa0; 10.1097/jcn.0000000000000375, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/jcn.0000000000000375</ArticleId><ArticleId IdType="pubmed">28591003</ArticleId></ArticleIdList></Reference><Reference><Citation>Vancheri F, Longo G, Vancheri E, Henein MY. Mental stress and cardiovascular health-part i. J Clin Med. (2022) 11:1&#x2013;17. doi:&#xa0; 10.3390/jcm11123353, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11123353</ArticleId><ArticleId IdType="pmc">PMC9225328</ArticleId><ArticleId IdType="pubmed">35743423</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwaltney C, Reaney M, Krohe M, Martin MM, Falvey H, Mollon P. Symptoms and functional limitations in the first year following a myocardial infarction: a qualitative study. Patient. (2017) 10:225&#x2013;35. doi:&#xa0; 10.1007/s40271-016-0194-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40271-016-0194-8</ArticleId><ArticleId IdType="pubmed">27637486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bing&#xf6;l E, Tiryaki K, T&#xfc;mt&#xfc;rk &#x130;, &#xd6;zden F. Investigation of exercise-related leg pain, fear of pain, kinesiophobia, and injury anxiety in athletes. BMC Sports Sci Med Rehabil. (2025) 17:40&#x2013;8. doi:&#xa0; 10.1186/s13102-025-01079-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13102-025-01079-5</ArticleId><ArticleId IdType="pmc">PMC11884190</ArticleId><ArticleId IdType="pubmed">40050954</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan H, Li Z, Gu HQ, Zhou Q, Tong X, Ma G, et al. Myocardial infarction is associated with increased stroke severity, in-hospital mortality, and complications: insights from China stroke center alliance registries. J Am Heart Assoc. (2021) 10:e021602&#x2013;e021611. doi:&#xa0; 10.1161/jaha.121.021602, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/jaha.121.021602</ArticleId><ArticleId IdType="pmc">PMC8751876</ArticleId><ArticleId IdType="pubmed">34612071</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelle DM, Corpeleijn E, Klaassen G, Schutte E, Navis G, Bakker SJ. Fear of movement and low self-efficacy are important barriers in physical activity after renal transplantation. PloS One. (2016) 11:e0147609&#x2013;e0147624. doi:&#xa0; 10.1371/journal.pone.0147609, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0147609</ArticleId><ArticleId IdType="pmc">PMC4742485</ArticleId><ArticleId IdType="pubmed">26844883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebina A, Sawa R, Kondo Y, Murata S, Takada M, Fujii H, et al. Influence of kinesiophobia with pregnancy-related lumbopelvic pain at late pregnancy on postpartum depressive symptoms. Phys Ther Res. (2020) 23:92&#x2013;8. doi:&#xa0; 10.1298/ptr.E9999, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1298/ptr.E9999</ArticleId><ArticleId IdType="pmc">PMC7344362</ArticleId><ArticleId IdType="pubmed">32995108</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi KW, Chen CY, Stein MB, Klimentidis YC, Wang MJ, Koenen KC, et al. Assessment of bidirectional relationships between physical activity and depression among adults: a 2-sample mendelian randomization study. JAMA Psychiatry. (2019) 76:399&#x2013;408. doi:&#xa0; 10.1001/jamapsychiatry.2018.4175, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2018.4175</ArticleId><ArticleId IdType="pmc">PMC6450288</ArticleId><ArticleId IdType="pubmed">30673066</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce M, Garcia L, Abbas A, Strain T, Schuch FB, Golubic R, et al. Association between physical activity and risk of depression: a systematic review and meta-analysis. JAMA Psychiatry. (2022) 79:550&#x2013;9. doi:&#xa0; 10.1001/jamapsychiatry.2022.0609, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2022.0609</ArticleId><ArticleId IdType="pmc">PMC9008579</ArticleId><ArticleId IdType="pubmed">35416941</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall PWM, Schabrun S, Knox MF. Physical activity and the mediating effect of fear, depression, anxiety, and catastrophizing on pain related disability in people with chronic low back pain. PloS One. (2017) 12:e0180788&#x2013;e0180803. doi:&#xa0; 10.1371/journal.pone.0180788, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180788</ArticleId><ArticleId IdType="pmc">PMC5501599</ArticleId><ArticleId IdType="pubmed">28686644</ArticleId></ArticleIdList></Reference><Reference><Citation>Debeer P, Commeyne O, De Cupere I, Tijskens D, Verhaegen F, Dankaerts W, et al. The outcome of hydrodilation in frozen shoulder patients and the relationship with kinesiophobia, depression, and anxiety. J Exp Orthop. (2021) 8:85&#x2013;93. doi:&#xa0; 10.1186/s40634-021-00394-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40634-021-00394-3</ArticleId><ArticleId IdType="pmc">PMC8484410</ArticleId><ArticleId IdType="pubmed">34591188</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowal J, Wilson KG, McWilliams LA, P&#xe9;loquin K, Duong D. Self-perceived burden in chronic pain: relevance, prevalence, and predictors. Pain. (2012) 153:1735&#x2013;41. doi:&#xa0; 10.1016/j.pain.2012.05.009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2012.05.009</ArticleId><ArticleId IdType="pmc">PMC3999031</ArticleId><ArticleId IdType="pubmed">22703692</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir M, Scott EJ, Westermann RC. Pain catastrophizing, kinesiophobia, stress, depression, and poor resiliency are associated with pain and dysfunction in the hip preservation population. Iowa Orthopedic J. (2023) 43:125&#x2013;32., PMID:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10777701</ArticleId><ArticleId IdType="pubmed">38213857</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbell K, Breitenstein SM, Melnyk BM, Guo J. Family resilience and flourishment: well-being among children with mental, emotional, and behavioral disorders. Res Nurs Health. (2020) 43:465&#x2013;77. doi:&#xa0; 10.1002/nur.22066, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nur.22066</ArticleId><ArticleId IdType="pubmed">32797699</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PJ, Merwin RM. The role of exercise in management of mental health disorders: an integrative review. Annu Rev Med. (2021) 72:45&#x2013;62. doi:&#xa0; 10.1146/annurev-med-060619-022943, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-060619-022943</ArticleId><ArticleId IdType="pmc">PMC8020774</ArticleId><ArticleId IdType="pubmed">33256493</ArticleId></ArticleIdList></Reference><Reference><Citation>Heissel A, Heinen D, Brokmeier LL, Skarabis N, Kangas M, Vancampfort D, et al. Exercise as medicine for depressive symptoms? a systematic review and meta-analysis with meta-regression. Br J Sports Med. (2023) 57:1049&#x2013;57. doi:&#xa0; 10.1136/bjsports-2022-106282, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjsports-2022-106282</ArticleId><ArticleId IdType="pmc">PMC10423472</ArticleId><ArticleId IdType="pubmed">36731907</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ck M, Caldenius V, Svensson L, Lundberg M. Perceptions of kinesiophobia in relation to physical activity and exercise after myocardial infarction: a qualitative study. Phys Ther. (2020) 100:2110&#x2013;9. doi:&#xa0; 10.1093/ptj/pzaa159, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ptj/pzaa159</ArticleId><ArticleId IdType="pubmed">32886775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846364</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Hybrid Approach as a Salvage Strategy for Post-Myocardial Infarction Ventricular Septal Defect.</ArticleTitle><Pagination><StartPage>104749</StartPage><MedlinePgn>104749</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104749</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01529-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-myocardial infarction ventricular septal defect (post-MI VSD) is a life-threatening complication of acute myocardial infarction, associated with high mortality if untreated. Advances in surgical repair and percutaneous closure have reduced its incidence, but post-MI VSD remains challenging to manage.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 67-year-old man with an evolved inferior ST-segment elevation myocardial infarction developed cardiogenic shock. After the diagnosis of post-MI VSD, an initial surgical repair was performed. However, residual ventricular septal defect was detected, likely because of patch dehiscence, along with an additional serpiginous septal defect. After discussion within the heart team, a decision was made to proceed with percutaneous closure of the defect using an Amplatzer vascular plug II (Abbott), achieving an excellent clinical outcome.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">A hybrid approach combining surgery and percutaneous intervention for post-MI VSD demonstrates successful outcomes, especially when reoperation poses high risk. This approach could improve management and survival in complex post-MI VSD cases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizza</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Interventional Cardiology Unit, Heart Hospital, National Research Council-Tuscany Foundation "G. Monasterio," Massa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casula</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Experimental Cardiology, Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy. Electronic address: casulamarta681@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasbarri</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Adult Cardiac Surgery Unit, Heart Hospital, National Research Council-Tuscany Foundation "G. Monasterio," Massa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ujka</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pediatric Cardiology and GUCH Unit, Heart Hospital, National Research Council-Tuscany Foundation "G.Monasterio," Massa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmieri</LastName><ForeName>Cataldo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Interventional Cardiology Unit, Heart Hospital, National Research Council-Tuscany Foundation "G. Monasterio," Massa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solinas</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Adult Cardiac Surgery Unit, Heart Hospital, National Research Council-Tuscany Foundation "G. Monasterio," Massa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monteleone</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Heart Hospital, National Research Council-Tuscany Foundation "G. Monasterio," Massa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berti</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Interventional Cardiology Unit, Heart Hospital, National Research Council-Tuscany Foundation "G. Monasterio," Massa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santoro</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pediatric Cardiology and GUCH Unit, Heart Hospital, National Research Council-Tuscany Foundation "G.Monasterio," Massa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">computed tomography</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">ventricular septal defect</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846364</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104749</ArticleId><ArticleId IdType="pii">S2666-0849(25)01529-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40845544</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>164</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>Anemoside B4 improves cardiac function after myocardial infarction by regulating HTR2A/ERK pathway.</ArticleTitle><Pagination><StartPage>115394</StartPage><MedlinePgn>115394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2025.115394</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(25)01385-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Assessing the role of anemoside B4 (B4) in myocardial infarction (MI) and the regulatory mechanism was the purpose of this study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We established MI rat model through ligation of the left anterior descending coronary artery and cardiomyocyte injury model through H<sub>2</sub>O<sub>2</sub> stimulation. The effects of B4 on cardiac function in MI rat model were assessed utilizing echocardiography, histological staining, and western blot. In vitro, CCK-8, flow cytometer, and ELISA were utilized for assessing B4's effects on cardiomyocyte viability, apoptosis, inflammatory response. The network pharmacology was applied for exploring B4's mechanism in MI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In vivo, B4 alleviated myocardial injury, as evidenced by improving cardiac function parameters, reduced collagen synthesis and deposition, preserved cardiac structure, and decreased apoptosis, inflammation response, and oxidative stress. In vitro, B4 enhanced cell viability and inhibited oxidative stress, apoptosis, and inflammation response. Mechanistically, based on molecular docking, B4-HTR2A complex was found to have a good binding activity. Furthermore, B4 reduced HTR2A and p-ERK/ERK protein expression in MI rat model and cardiomyocyte injury model. More importantly, the effects of B4 on cardiomyocyte viability, oxidative stress, apoptosis, and inflammation were reversed by HTR2A overexpression. HTR2A knockdown alleviated H<sub>2</sub>O<sub>2</sub>-induced oxidative stress, apoptosis, and inflammation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">B4 protected cardiomyocytes and alleviated cardiac dysfunction, oxidative stress, inflammation, and apoptosis, which were partly mediated by inhibiting HTR2A/ERK pathway. B4 may be a promising therapeutic drug for MI treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Medicine Department, Yantaishan Hospital, Yantai, Shandong 264000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Yantaishan Hospital, Yantai, Shandong 264000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yilin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Preventive medicine, Shandong University, Jinan, Shandong 250000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Yantaishan Hospital, Yantai, Shandong 264000, China. Electronic address: 13356998338@189.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anemoside B4</Keyword><Keyword MajorTopicYN="N">Apoptosis</Keyword><Keyword MajorTopicYN="N">HTR2A</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845544</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2025.115394</ArticleId><ArticleId IdType="pii">S1567-5769(25)01385-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40836914</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-7705</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Circulation. Cardiovascular quality and outcomes</Title><ISOAbbreviation>Circ Cardiovasc Qual Outcomes</ISOAbbreviation></Journal><ArticleTitle>Disrupting the Status Quo: Reimagining How We Use Troponin for Diagnosing Myocardial Infarction.</ArticleTitle><Pagination><StartPage>e012131</StartPage><MedlinePgn>e012131</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCOUTCOMES.125.012131</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daniels</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><Identifier Source="ORCID">0000-0002-4841-9922</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla (L.B.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peacock</LastName><ForeName>W Frank</ForeName><Initials>WF</Initials><Identifier Source="ORCID">0000-0002-2730-6742</Identifier><AffiliationInfo><Affiliation>Comprehensive Research Associates LLC and Department of Emergency Medicine, Baylor College of Medicine, Houston, TX (W.F.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindahl</LastName><ForeName>Bertil</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5795-0061</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Uppsala University, Sweden (B.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lemos</LastName><ForeName>James A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-2211-7261</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, UT Southwestern Medical Center, Dallas, TX (J.A.d.L.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Cardiovasc Qual Outcomes</MedlineTA><NlmUniqueID>101489148</NlmUniqueID><ISSNLinking>1941-7713</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">ischemia</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">troponin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40836914</ArticleId><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.125.012131</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40832756</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1742-4658</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>The FEBS journal</Title><ISOAbbreviation>FEBS J</ISOAbbreviation></Journal><ArticleTitle>Collagen XV preserves heart function and protects from pathological remodelling after myocardial infarction.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.70212</ELocationID><Abstract><AbstractText>Increasing knowledge of the components involved in left ventricle (LV) remodelling and fibrotic processes after a myocardial infarction is crucial to understanding heart pathology. We have here analysed collagen XV (ColXV) expression in human myocardial infarct samples and assessed how its deficiency affects cardiac responses, such as fibrogenesis and tissue stiffness, after acute myocardial infarction (AMI) in mice. We first observed high ColXV expression in human infarction scars. After ligating the left anterior descending artery in mice, cardiac function and remodelling were monitored by echocardiography, elasticity assessment, immunohistochemical analysis and ultrastructural assessments. After AMI, Col15a1<sup>-/-</sup> mice showed significantly increased tissue stiffness and upregulation of fibrosis-related genes in the remote myocardium. Striking differences were observed between the genotypes in the scar ultrastructure, protein compositions, cardiomyocyte morphology and intracellular architecture. Furthermore, the proportion of immature collagen fibres in the infarct border zone increased in Col15a1<sup>-/-</sup> mice, suggesting fragility and poor scar resistance to mechanical stress. Structural parameters indicated more substantial LV remodelling in the knockout mice, leading to a more dilated ventricle. Functionally, the ejection fraction and fractional shortening decreased significantly in Col15a1<sup>-/-</sup> mice, indicating impaired heart contractile capacity. The results show that in the event of an AMI, ColXV plays an essential role in sustaining cardiac structure and function. In the absence of ColXV, dysregulated remodelling results in disrupted scar and infarct border zone, and stiffer left ventricle. These changes lead to a more severe cardiac phenotype and may affect long-term survival after AMI.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). The FEBS Journal published by John Wiley &amp; Sons Ltd on behalf of Federation of European Biochemical Societies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karppinen</LastName><ForeName>Sanna-Maria</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-6233-9075</Identifier><AffiliationInfo><Affiliation>ECM-Hypoxia Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aho</LastName><ForeName>Miki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ECM-Hypoxia Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szabo</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Molecular Cardiology Group, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biocenter Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magga</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4688-9098</Identifier><AffiliationInfo><Affiliation>Molecular Cardiology Group, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biocenter Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vainio</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Molecular Cardiology Group, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biocenter Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Erhe</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Aging and Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janmey</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eklund</LastName><ForeName>Lauri</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ECM-Hypoxia Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biocenter Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasi</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>ECM-Hypoxia Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miinalainen</LastName><ForeName>Ilkka</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Biocenter Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakai</LastName><ForeName>Lynn Y</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Molecular &amp; Medical Genetics, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pakanen</LastName><ForeName>Lasse</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Forensic Medicine Unit, Finnish Institute for Health and Welfare, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Research Unit of Biomedicine and Internal Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huikuri</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biocenter Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Research Group, Research Unit of Biomedicine and Internal Medicine, University of Oulu/Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junttila</LastName><ForeName>Juhani</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biocenter Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Research Group, Research Unit of Biomedicine and Internal Medicine, University of Oulu/Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerkel&#xe4;</LastName><ForeName>Risto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Molecular Cardiology Group, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biocenter Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pihlajaniemi</LastName><ForeName>Taina</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1664-9045</Identifier><AffiliationInfo><Affiliation>ECM-Hypoxia Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Jane &amp; Aatos Erkko Foundation</Agency><Country/></Grant><Grant><Agency>Finnish Foundation for Cardiovascular Research</Agency><Country/></Grant><Grant><Agency>Sigrid Jus&#xe9;lius Foundation</Agency><Country/></Grant><Grant><GrantID>259872</GrantID><Agency>Research Council of Finland</Agency><Country/></Grant><Grant><GrantID>297094</GrantID><Agency>Research Council of Finland</Agency><Country/></Grant><Grant><GrantID>333284</GrantID><Agency>Research Council of Finland</Agency><Country/></Grant><Grant><GrantID>308867</GrantID><Agency>Research Council of Finland</Agency><Country/></Grant><Grant><GrantID>284605</GrantID><Agency>Research Council of Finland</Agency><Country/></Grant><Grant><GrantID>251314</GrantID><Agency>Research Council of Finland</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>FEBS J</MedlineTA><NlmUniqueID>101229646</NlmUniqueID><ISSNLinking>1742-464X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">collagen XV</Keyword><Keyword MajorTopicYN="N">extracellular matrix remodelling</Keyword><Keyword MajorTopicYN="N">fibrosis</Keyword><Keyword MajorTopicYN="N">infarct scar</Keyword><Keyword MajorTopicYN="N">tissue stiffness</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40832756</ArticleId><ArticleId IdType="doi">10.1111/febs.70212</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Frangogiannis NG (2021) Cardiac fibrosis. Cardiovasc Res 117, 1450&#x2013;1488.</Citation></Reference><Reference><Citation>Frangogiannis NG (2017) The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest 127, 1600&#x2013;1612.</Citation></Reference><Reference><Citation>Sutton MG &amp; Sharpe N (2000) Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101, 2981&#x2013;2988.</Citation></Reference><Reference><Citation>Olivetti G, Capasso JM, Sonnenblick EH &amp; Anversa P (1990) Side&#x2010;to&#x2010;side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 67, 23&#x2013;34.</Citation></Reference><Reference><Citation>Talman V &amp; Ruskoaho H (2016) Cardiac fibrosis in myocardial infarction&#x2010; from repair and remodeling to regeneration. Cell Tissue Res 365, 563&#x2013;581.</Citation></Reference><Reference><Citation>Shinde AV &amp; Frangogiannis NG (2014) Fibroblasts in myocardial infarction: a role in inflammation and repair. J Mol Cell Cardiol 70, 74&#x2013;82.</Citation></Reference><Reference><Citation>Bretaud S, Guillon E, Karppinen S&#x2010;M, Pihlajaniemi T &amp; Ruggiero F (2020) Collagen XV, a multifaceted multiplexin present across tissues and species. Matrix Biol Plus 6&#x2010;7, 100023.</Citation></Reference><Reference><Citation>Muona A, Eklund L, V&#xe4;is&#xe4;nen T &amp; Pihlajaniemi T (2002) Developmentally regulated expression of type XV collagen correlates with abnormalities in Col15a1(&#x2212;/&#x2212;) mice. Matrix Biol 21, 89&#x2013;102.</Citation></Reference><Reference><Citation>Amenta PS, Scivoletti NA, Newman MD, Sciancalepore JP, Li D &amp; Myers JC (2005) Proteoglycan&#x2010;collagen XV in human tissues is seen linking banded collagen fibers subjacent to the basement membrane. J Histochem Cytochem 53, 165&#x2013;176.</Citation></Reference><Reference><Citation>H&#xe4;gg PM, H&#xe4;gg PO, Peltonen S, Autio&#x2010;Harmainen H &amp; Pihlajaniemi T (1997) Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol 150, 2075&#x2013;2086.</Citation></Reference><Reference><Citation>Sun J, Wang J, Zhang N, Yang R, Chen K &amp; Kong D (2019) Identification of global mRNA expression profiles and comprehensive bioinformatic analyses of abnormally expressed genes in cholestatic liver disease. Gene 707, 9&#x2013;21.</Citation></Reference><Reference><Citation>Lemoinne S, Thabut D &amp; Housset C (2016) Portal myofibroblasts connect angiogenesis and fibrosis in liver. Cell Tissue Res 365, 583&#x2013;589.</Citation></Reference><Reference><Citation>Satish L, LaFramboise WA, O'Gorman DB, Johnson S, Janto B, Gan BS, Baratz ME, Hu FZ, Post JC, Ehrlich GD et&#xa0;al. (2008) Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's contracture. BMC Med Genet 1, 1&#x2013;12.</Citation></Reference><Reference><Citation>Eklund L, Piuhola J, Komulainen J, Sormunen R, Ongvarrasopone C, F&#xe4;ssler R, Muona A, Ilves M, Ruskoaho H, Takala TES et&#xa0;al. (2001) Lack of type XV collagen causes a skeletal myopathy and cardiovascular defects in mice. Proc Natl Acad Sci USA 98, 1194&#x2013;1199.</Citation></Reference><Reference><Citation>Rasi K, Piuhola J, Czabanka M, Sormunen R, Ilves M, Leskinen H, Rys&#xe4; J, Kerkel&#xe4; R, Janmey P, Heljasvaara R et&#xa0;al. (2010) Collagen XV is necessary for modeling of the extracellular matrix and its deficiency predisposes to cardiomyopathy. Circ Res 107, 1241&#x2013;1252.</Citation></Reference><Reference><Citation>Kielty CM, Sherratt MJ &amp; Shuttleworth CA (2002) Elastic fibres. J Cell Sci 115, 2817&#x2013;2828.</Citation></Reference><Reference><Citation>Katsuda S, Okada Y, Okada Y, Imai K &amp; Nakanishi I (1994) Matrix metalloproteinase&#x2010;9 (92&#x2010;kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial elastin. Am J Pathol 145, 1208&#x2013;1218.</Citation></Reference><Reference><Citation>Patel VB, Zhabyeyev P, Chen X, Wang F, Paul M, Fan D, McLean BA, Basu R, Zhang P, Shah S et&#xa0;al. (2018) PI3K&#x3b1;&#x2010;regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease. Nat Commun 9, 5390.</Citation></Reference><Reference><Citation>Frangogiannis NG (2019) The extracellular matrix in ischemic and non&#x2010;ischemic heart failure. Circ Res 125, 117&#x2013;146.</Citation></Reference><Reference><Citation>Yokota T, McCourt J, Ma F, Ren S, Li S, Kim T&#x2010;H, Kurmangaliyev YZ, Nasiri R, Ahadian S, Nguyen T et&#xa0;al. (2020) Type V collagen in scar tissue regulates the size of scar after heart injury. Cell 182, 545&#x2013;562.e23.</Citation></Reference><Reference><Citation>Carland C, Zhao L, Salman O, Cohen JB, Zamani P, Xiao Q, Dongre A, Wang Z, Ebert C, Greenawalt D et&#xa0;al. (2024) Urinary proteomics and outcomes in heart failure with preserved ejection fraction. J Am Heart Assoc 13, e033410.</Citation></Reference><Reference><Citation>Cook JR, Carta L, B&#xe9;nard L, Chemaly ER, Chiu E, Rao SK, Hampton TG, Yurchenco P, GenTAC Registry Consortium, Costa KD et&#xa0;al. (2014) Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest 124, 1329&#x2013;1339.</Citation></Reference><Reference><Citation>Schrenk S, Cenzi C, Bertalot T, Conconi MT &amp; Di Liddo R (2018) Structural and functional failure of fibrillin 1 in human diseases. Int J Mol Med 41, 1213&#x2013;1223.</Citation></Reference><Reference><Citation>Weis SM, Zimmerman SD, Shah M, Covell JW, Omens JH, Ross J Jr, Dalton N, Jones Y, Reed CC, Iozzo RV et&#xa0;al. (2005) A role for decorin in the remodeling of myocardial infarction. Matrix Biol 24, 313&#x2013;324.</Citation></Reference><Reference><Citation>Ursell PC, Gardner PI, Albala A, Fenoglio JJ Jr &amp; Wit AL (1985) Structural and electrophysiological changes in the epicardial border zone of canine myocardial infarcts during infarct healing. Circ Res 56, 436&#x2013;451.</Citation></Reference><Reference><Citation>Monaghan MG, Holeiter M, Brauchle E, Layland SL, Lu Y, Deb A, Pandit A, Nsair A &amp; Schenke&#x2010;Layland K (2018) Exogenous miR&#x2010;29B delivery via a hyaluronan&#x2010;based injectable system yields functional maintenance of the infarcted myocardium. Tissue Eng Part A 24, 57&#x2013;67.</Citation></Reference><Reference><Citation>Maruyama K &amp; Imanaka&#x2010;Yoshida K (2022) The pathogenesis of cardiac fibrosis: a review of recent Progress. Int J Mol Sci 23, 2617.</Citation></Reference><Reference><Citation>Manabe I, Shindo T &amp; Nagai R (2002) Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91, 1103&#x2013;1113.</Citation></Reference><Reference><Citation>Gonz&#xe1;lez&#x2010;Santamar&#xed;a J, Villalba M, Busnadiego O, L&#xf3;pez&#x2010;Ola&#xf1;eta MM, Sandoval P, Snabel J, L&#xf3;pez&#x2010;Cabrera M, Erler JT, Hanemaaijer R, Lara&#x2010;Pezzi E et&#xa0;al. (2016) Matrix cross&#x2010;linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction. Cardiovasc Res 109, 67&#x2013;78.</Citation></Reference><Reference><Citation>Buechler MB, Pradhan RN, Krishnamurty AT, Cox C, Calviello AK, Wang AW, Yang YA, Tam L, Caothien R, Roose&#x2010;Girma M et&#xa0;al. (2021) Cross&#x2010;tissue organization of the fibroblast lineage. Nature 593, 575&#x2013;579.</Citation></Reference><Reference><Citation>Zhu L, Wang Y, Zhao S &amp; Lu M (2022) Detection of myocardial fibrosis: where we stand. Front Cardiovasc Med 9, 926378.</Citation></Reference><Reference><Citation>Biering&#x2010;S&#xf8;rensen T, Mogelvang R &amp; Jensen JS (2015) Prognostic value of cardiac time intervals measured by tissue doppler imaging M&#x2010;mode in the general population. Heart 101, 954&#x2013;960.</Citation></Reference><Reference><Citation>Regitz&#x2010;Zagrosek V &amp; Gebhard C (2023) Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes. Nat Rev Cardiol 20, 236&#x2013;247.</Citation></Reference><Reference><Citation>Pullen AB, Kain V, Serhan CN &amp; Halade GV (2020) Molecular and cellular differences in cardiac repair of male and female mice. J Am Heart Assoc 9, e015672.</Citation></Reference><Reference><Citation>Bray MA, Sheehy SP &amp; Parker KK (2008) Sarcomere alignment is regulated by myocyte shape. Cell Motil Cytoskeleton 65, 641&#x2013;651.</Citation></Reference><Reference><Citation>McCain ML, Yuan H, Pasqualini FS, Campbell PH &amp; Parker KK (2014) Matrix elasticity regulates the optimal cardiac myocyte shape for contractility. Am J Physiol Heart Circ Physiol 306, H1525&#x2013;H1539.</Citation></Reference><Reference><Citation>M&#xfc;nch J &amp; Abdelilah&#x2010;Seyfried S (2021) Sensing and responding of cardiomyocytes to changes of tissue stiffness in the diseased heart. Front Cell Dev Biol 9, 642840.</Citation></Reference><Reference><Citation>Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, Bauer E, Kl&#xf6;vekorn WP, Schlepper M, Schaper W et&#xa0;al. (2000) Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 86, 846&#x2013;853.</Citation></Reference><Reference><Citation>Martini JS, Raake P, Vinge LE, DeGeorge BR Jr, Chuprun JK, Harris DM, Gao E, Eckhart AD, Pitcher JA &amp; Koch WJ (2008) Uncovering G protein&#x2010;coupled receptor kinase&#x2010;5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA 105, 12457&#x2013;12462.</Citation></Reference><Reference><Citation>Hurskainen M, Ruggiero F, H&#xe4;gg P, Pihlajaniemi T &amp; Huhtala P (2010) Recombinant human collagen XV regulates cell adhesion and migration. J Biol Chem 285, 5258&#x2013;5265.</Citation></Reference><Reference><Citation>Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Boucher M, Fan Q, Chuprun JK, Ma XL &amp; Koch WJ (2010) A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 107, 1445&#x2013;1453.</Citation></Reference><Reference><Citation>Levental I, Levental KR, Klein EA, Assoian R, Miller RT, Wells RG &amp; Janmey PA (2010) A simple indentation device for measuring micrometer&#x2010;scale tissue stiffness. J Phys Condens Matter 22, 194120.</Citation></Reference><Reference><Citation>Pereira L, Andrikopoulos K, Tian J, Lee SY, Keene DR, Ono R, Reinhardt DP, Sakai LY, Biery NJ, Bunton T et&#xa0;al. (1997) Targetting of the gene encoding fibrillin&#x2013;1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 17, 218&#x2013;222.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40834806</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Cardiogenic Shock With Acute Myocardial Infarction Among Older Adults in the United States.</ArticleTitle><Pagination><StartPage>102078</StartPage><MedlinePgn>102078</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2025.102078</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2772-963X(25)00503-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Characteristics and outcomes associated with cardiogenic shock (CS) with acute myocardial infarction (AMI) in older patients have not been well characterized.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The purpose of this study was to investigate characteristics and outcomes of older patients admitted with CS with AMI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used the National Inpatient Sample database to evaluate clinical characteristics of hospitalizations, clinical outcomes, and health care utilization of hospitalizations of older patients &#x2265;80 years with CS and AMI from 2003 to 2021. We also compared data from older patients with a reference relatively younger patient population (18-79 years).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the study period, 207,333 hospitalizations of older patients &#x2265;80 years and 675,491 hospitalizations of patients 18 to 79 years were identified. Between the first 4 years of the study period (2003-2006) and the final 4-year interval of the study period (2016-2019), there was an increase in the number of hospitalizations of older patients with AMI and CS (39,220-51,640). On adjusted analysis, there were increases in the percentage of older patients undergoing treatment with percutaneous coronary intervention (19.2% to 34.1%; P &lt; 0.001) and encounters for palliative care (2.0% to 32.4%; P &lt; 0.001) alongside a decline in in-hospital mortality (61.4% to 49.0%; P &lt; 0.001) over the study period. Compared to patients 18 to 79 years of age, those aged &#x2265;80 years had greater in-hospital mortality (51.8% vs 33.0%; P &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">From 2003 to 2021, for older patients with CS and AMI, hospitalizations increased, and mortality decreased.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mansoor</LastName><ForeName>Taha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA. Electronic address: taha.mansoor@wmed.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jabbar</LastName><ForeName>Ali Bin Abdul</ForeName><Initials>ABA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Creighton University School of Medicine, Omaha, Nebraska, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismayl</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Kartik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Henry Ford Hospital, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Sachin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Henry Ford Hospital, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brubaker</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan Minhas</LastName><ForeName>Abdul Mannan</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abramov</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, Loma Linda University Medical Center, Loma Linda, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalavakunta</LastName><ForeName>Jagadeesh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beacon Hospital, Kalamazoo, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Vishal</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beacon Hospital, Kalamazoo, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virani</LastName><ForeName>Salim S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Aga Khan University, Karachi, Pakistan; Department of Population Health, Aga Khan University, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koshy</LastName><ForeName>Santhosh K G</ForeName><Initials>SKG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, USA; Department of Cardiology, Beacon Hospital, Kalamazoo, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">older patients</Keyword></KeywordList><CoiStatement>Funding support and author disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834806</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2025.102078</ArticleId><ArticleId IdType="pii">S2772-963X(25)00503-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40842283</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-2412</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>European heart journal. Cardiovascular Imaging</Title><ISOAbbreviation>Eur Heart J Cardiovasc Imaging</ISOAbbreviation></Journal><ArticleTitle>Associations and Prognostic Implications of Myocardial Tissue Injury Stages in ST-Elevation Myocardial Infarction Using the Canadian Cardiovascular Society Classification.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jeaf250</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjci/jeaf250</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The recently proposed Canadian Cardiovascular Society (CCS) classification categorizes post-infarction tissue injury into four stages, potentially improving risk stratification and guiding cardioprotective strategies. Its clinical and prognostic relevance in ST-elevation myocardial infarction (STEMI) remains unclear. We aimed to compare clinical characteristics across CCS stages and validate their prognostic implications in STEMI.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We analysed 1,109 STEMI patients included in three prospective studies. Cardiac magnetic resonance (CMR) imaging was performed 3 (interquartile range 2-5) days after MI and patients were classified as follows: stage 1 (aborted MI), stage 2 (MI with necrosis and absence of microvascular injury), stage 3 (MI with necrosis and microvascular obstruction) and stage 4 (MI with necrosis and intramyocardial haemorrhage).This analysis revealed distinct patterns of clinical presentation, biomarker profiles and cardiac function at different CCS stages. There were differences in adverse clinical event rates and mortality between CCS stages (major adverse cardiovascular event [MACE]: 0.7%, 3.4%, 3.1%, 15.7%, p&lt;0.001 and mortality: 0.7%, 1.7%, 0.9%, 6.3%, p&lt;0.001). The CCS stage had a moderate to good predictive value for MACE and mortality (AUC 0.74 [95% CI: 0.68-0.80], p&lt;0.001 and AUC 0.71 [95% CI: 0.61-0.80], p&lt;0.001) at 12 months, respectively. CCS stages were independently associated with MACE in multivariable Cox regression (HR: 2.18 [95% CI, 1.70-2.78], p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study describes clinical characteristics across CCS stages and provides insights into their prognostic implications in a large cohort of STEMI patients reperfused by PCI. These data should inform the use of CCS stages in future trial designs.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lechner</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-1379-3233</Identifier><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carberry</LastName><ForeName>Jaclyn</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4184-0714</Identifier><AffiliationInfo><Affiliation>British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stiermaier</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1957-3741</Identifier><AffiliationInfo><Affiliation>University Heart Centre L&#xfc;beck, Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine), University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiller</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holzknecht</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2415-8622</Identifier><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberhollenzer</LastName><ForeName>Fritz</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5979-2108</Identifier><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaser</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mair</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1706-5962</Identifier><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayr</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9363-873X</Identifier><AffiliationInfo><Affiliation>University Clinic of Radiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feistritzer</LastName><ForeName>Hans-Josef</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Centre Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrick</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Hairmyres, East Kilbride, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dlaska</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8798-0827</Identifier><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Digital Cardiology Lab, Medical University of Innsbruck, A-6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-0169-998X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine/Cardiology, Heart Centre Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eitel</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6442-246X</Identifier><AffiliationInfo><Affiliation>University Heart Centre L&#xfc;beck, Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine), University Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzler</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Colin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4547-8636</Identifier><AffiliationInfo><Affiliation>British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reindl</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8414-9552</Identifier><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinstadler</LastName><ForeName>Sebastian J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-7700-1357</Identifier><AffiliationInfo><Affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Cardiovasc Imaging</MedlineTA><NlmUniqueID>101573788</NlmUniqueID><ISSNLinking>2047-2404</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40842283</ArticleId><ArticleId IdType="doi">10.1093/ehjci/jeaf250</ArticleId><ArticleId IdType="pii">8239543</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837914</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Correlation of Fibrinogen-Albumin Ratio With Gensini Score in ST-Segment Elevation Myocardial Infarction.</ArticleTitle><Pagination><StartPage>e88317</StartPage><MedlinePgn>e88317</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e88317</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.88317</ELocationID><Abstract><AbstractText>Introduction ST-segment elevation myocardial infarction (STEMI) is a severe form of coronary artery disease (CAD) often associated with systemic inflammation. The fibrinogen-albumin ratio (FAR) has been proposed as a novel inflammatory marker with potential prognostic value. The Gensini score, derived from coronary angiography, quantifies the severity of CAD. This study aimed to assess the correlation between FAR and Gensini score in STEMI patients. Materials and methods A cross-sectional observational study was conducted at a tertiary care center in Karnataka, India, from May 2023 to December 2024. Seventy patients with a clinical diagnosis of STEMI were enrolled. Clinical evaluation, blood tests (including fibrinogen and albumin levels), echocardiography, and coronary angiography were performed. FAR was calculated by dividing fibrinogen (g/L) by albumin (g/L), and Gensini scores were computed to assess CAD severity. Statistical analysis included Pearson's correlation and the chi-squared test. Results The study population comprised mostly men (47, 67.14%) and individuals aged over 60 years (40, 57.14%). Single and double vessel disease were each present in 24 (34.3%) patients. FAR &gt;0.1 was seen in 37 (52.86%). A significant association was found between Gensini score and the extent of vessel disease (p=0.0001); however, FAR did not show a statistically significant correlation with Gensini score (r=-0.002; p=0.989). FAR also lacked a significant association with heart failure types. Conclusion FAR may have limited utility in predicting angiographic severity in patients with STEMI. While it remains a simple and economical inflammatory marker, its prognostic relevance in acute coronary events appears uncertain. Further research with larger cohorts is warranted to validate its clinical applicability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Utnal et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Utnal</LastName><ForeName>Abhijit Hanamantaraya</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Internal Medicine, BLDE (Deemed to be University) Shri B. M. Patil Medical College, Hospital and Research Centre, Vijayapura, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biradar</LastName><ForeName>Siddanagouda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Medicine, BLDE (Deemed to be University) Shri B. M. Patil Medical College, Hospital and Research Centre, Vijayapura, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadagud</LastName><ForeName>Anuja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>General Medicine, BLDE (Deemed to be University) Shri B. M. Patil Medical College, Hospital and Research Centre, Vijayapura, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N</LastName><ForeName>Shreyas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Medicine, BLDE (Deemed to be University) Shri B. M. Patil Medical College, Hospital and Research Centre, Vijayapura, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Manoj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Medicine, BLDE (Deemed to be University) Shri B. M. Patil Medical College, Hospital and Research Centre, Vijayapura, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">fibrinogen-albumin ratio</Keyword><Keyword MajorTopicYN="N">gensini score</Keyword><Keyword MajorTopicYN="N">inflammatory biomarkers</Keyword><Keyword MajorTopicYN="N">stemi</Keyword></KeywordList><CoiStatement>Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Institutional Ethics Committee of BLDE (Deemed to be University) issued approval BLDE(DU)/IEC/929/2023-24. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837914</ArticleId><ArticleId IdType="pmc">PMC12362330</ArticleId><ArticleId IdType="doi">10.7759/cureus.88317</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acute myocardial infarction: etiologies and mimickers in young patients. Krittanawong C, Khawaja M, Tamis-Holland JE, Girotra S, Rao SV. J Am Heart Assoc. 2023;12:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10547302</ArticleId><ArticleId IdType="pubmed">37724944</ArticleId></ArticleIdList></Reference><Reference><Citation>2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Ibanez B, James S, Agewall S, et al. Eur Heart J. 2018;39:119&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886621</ArticleId></ArticleIdList></Reference><Reference><Citation>STEMI, primary percutaneous coronary intervention and recovering of life expectancy: insights from the SurviSTEMI study. Pascual I, Avanzas P, Almend&#xe1;rez M, et al. Rev Esp Cardiol (Engl Ed) 2021;74:829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">32978098</ArticleId></ArticleIdList></Reference><Reference><Citation>Racial and socioeconomic determinants of cardiovascular health: a comprehensive review. Borkowski P, Borkowska N, Mangeshkar S, Adal BH, Singh N. Cureus. 2024;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11143437</ArticleId><ArticleId IdType="pubmed">38826910</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibrinogen and atherosclerotic cardiovascular diseases-review of the literature and clinical studies. Surma S, Banach M. Int J Mol Sci. 2021;23:193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8745133</ArticleId><ArticleId IdType="pubmed">35008616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pro-inflammatory effect of fibrinogen on vascular smooth muscle cells by regulating the expression of PPAR&#x3b1;, PPAR&#x3b3; and MMP-9. Wang S, Liu J, Wu DI, Pang X, Zhao J, Zhang X. Biomed Rep. 2015;3:513&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486936</ArticleId><ArticleId IdType="pubmed">26171158</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibrin(ogen) and thrombotic disease. Ari&#xeb;ns RA. J Thromb Haemost. 2013;11:294&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">23809133</ArticleId></ArticleIdList></Reference><Reference><Citation>Serum albumin levels: a biomarker to be repurposed in different disease settings in clinical practice. Gremese E, Bruno D, Varriano V, Perniola S, Petricca L, Ferraccioli G. J Clin Med. 2023;12:6017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10532125</ArticleId><ArticleId IdType="pubmed">37762957</ArticleId></ArticleIdList></Reference><Reference><Citation>Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Nelson JJ, Liao D, Sharrett AR, et al. Am J Epidemiol. 2000;151:468&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707915</ArticleId></ArticleIdList></Reference><Reference><Citation>Evaluation of serum albumin levels in acute myocardial infarction. Shilpa HD. https://www.researchgate.net/publication/289495124_EVALUATION_OF_SERUM_ALBUMIN_LEVELS_IN_ACUTE_MYOCARDIAL_INFARCTION J Evid Based Med Healthc. 2015;2:7416&#x2013;7421.</Citation></Reference><Reference><Citation>The Gensini score system is a useful tool in assessing the burden and severity of coronary artery atherosclerotic lesions [letter] Naser A. Int J Gen Med. 2024;17:4227&#x2013;4228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11416100</ArticleId><ArticleId IdType="pubmed">39308963</ArticleId></ArticleIdList></Reference><Reference><Citation>Prognostic value of fibrinogen-to-albumin ratio combined with coronary calcification score in patients with suspected coronary artery disease. Tian XX, Luo JY, Liu F, et al. BMC Cardiovasc Disord. 2023;23:181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10071697</ArticleId><ArticleId IdType="pubmed">37016312</ArticleId></ArticleIdList></Reference><Reference><Citation>Strategies to measure and improve emergency department performance: a review. Mostafa R, El-Atawi K. Cureus. 2024;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10890971</ArticleId><ArticleId IdType="pubmed">38406097</ArticleId></ArticleIdList></Reference><Reference><Citation>Using the Gensini score to estimate severity of STEMI, NSTEMI, unstable angina, and anginal syndrome. Charach L, Blatt A, Jonas M, et al. Medicine (Baltimore) 2021;100:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8519204</ArticleId><ArticleId IdType="pubmed">34731103</ArticleId></ArticleIdList></Reference><Reference><Citation>The association between whole blood viscosity and coronary collateral circulation in patients with chronic total occlusion. Cetin MS, Ozcan Cetin EH, Balc&#x131; KG, et al. Korean Circ J. 2016;46:784&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099333</ArticleId><ArticleId IdType="pubmed">27826336</ArticleId></ArticleIdList></Reference><Reference><Citation>Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. Chojkier M. J Clin Gastroenterol. 2005;39:0&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15758650</ArticleId></ArticleIdList></Reference><Reference><Citation>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. O'Gara PT, Kushner FG, Ascheim DD, et al. Circulation. 2013;127:0&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">23247304</ArticleId></ArticleIdList></Reference><Reference><Citation>STEMI care 2021: addressing the knowledge gaps. Yildiz M, Wade SR, Henry TD. Am Heart J Plus. 2021;11:100044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515361</ArticleId><ArticleId IdType="pubmed">34664037</ArticleId></ArticleIdList></Reference><Reference><Citation>The relationship between fibrinogen to albumin ratio and severity of coronary artery disease in patients with STEMI. Karahan O, Acet H, Erta&#x15f; F, et al. Am J Emerg Med. 2016;34:1037&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">27017405</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevalence of risk factors of ST elevated myocardial infarction. Rasool F, Khan MS, Ali A, Masood J. https://www.valueinhealthjournal.com/article/S1098-3015(13)04057-6/fulltext#:~:text=Results,LMW%2Dheparin%20(33%20%25). Value Health. 2013;16:704.</Citation></Reference><Reference><Citation>Electrocardiogram predictors of multivessel disease in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Sharma AK, Kumar T, Dhaka MK. Res Cardiovasc Med. 2021;10:1&#x2013;6.</Citation></Reference><Reference><Citation>Fibrinogen-albumin ratio predicting major adverse cardiovascular outcomes post-percutaneous coronary intervention: a systematic review and exploratory meta-analysis. Desai R, Fadah K, Srikanth S, Neha NF, Jain A. Clin Cardiol. 2023;46:455&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10106656</ArticleId><ArticleId IdType="pubmed">36722364</ArticleId></ArticleIdList></Reference><Reference><Citation>High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort. Wang P, Yuan D, Zhang C, et al. Cardiovasc Diabetol. 2022;21:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939137</ArticleId><ArticleId IdType="pubmed">35313877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40839905</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Trends in Risk Factor Prevalence and Incidence of Acute Myocardial Infarction in Young Adults.</ArticleTitle><Pagination><StartPage>102082</StartPage><MedlinePgn>102082</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2025.102082</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2772-963X(25)00507-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Contemporary trends in traditional and nontraditional risk factors (RFs) among young adults with acute myocardial infarction (AMI) are not well understood.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study sought to determine differences and trends in the prevalence of traditional and nontraditional RFs among young and older adults hospitalized with incident AMI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Incident AMI hospitalizations were analyzed from 2011 to 2021 from the National Inpatient Sample and stratified by age (young adults 18-54 years of age and older adults &gt;54 years of age). Overall RF prevalence and trends in traditional (eg, hypertension) and nontraditional (eg, psychosocial factors) RFs were assessed. Subgroup analysis by sex and race/ethnicity was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4,431,901 incident AMI hospitalizations, 974,521 (22%) were young adults. Hypertension (64.8%) and tobacco use (57.8%) were the most prevalent RFs in young adults overall. Among 5 traditional RFs, tobacco smoking and obesity were significantly higher in young adults compared to older adults. Among 12 nontraditional RFs, lowest income quartile, family history of ischemic heart disease, and psychiatric disorders were significantly higher in young adults. Within young adults, women and non-Whites had a higher prevalence of both traditional and nontraditional RFs. Across the study period, the prevalence of most traditional and nontraditional RFs in young adults increased significantly (P<sub>trend</sub> &lt; 0.050 for all).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Young adults with AMI have a different and increasing burden of both traditional and nontraditional RFs compared to older adults. These findings could help guide strategies for primary prevention of AMI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Satish</LastName><ForeName>Mohan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, New York-Presbyterian/Weill Cornell Medicine, New York, New York, USA. Electronic address: gnj9002@nyp.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>Ryan W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Clinical Research and Public Health, Creighton University School of Medicine, Omaha, Nebraska, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safford</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, New York-Presbyterian/Weill Cornell Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kini</LastName><ForeName>Vinay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Cardiology, New York-Presbyterian/Weill Cornell Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">young adults</Keyword></KeywordList><CoiStatement>Funding support and author disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>17</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839905</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2025.102082</ArticleId><ArticleId IdType="pii">S2772-963X(25)00507-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40844746</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7241</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Cardiovascular drugs and therapy</Title><ISOAbbreviation>Cardiovasc Drugs Ther</ISOAbbreviation></Journal><ArticleTitle>Crocetin Attenuates Fibroblast-to-Myofibroblast Transition after Myocardial Infarction in Mice by Regulating Autophagy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10557-025-07758-2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Myocardial infarction (MI) triggers pathological remodeling characterized by fibrosis and subsequent fibroblast-to-myofibroblast transition (FMT). Autophagy exerts a dual role in cardiac repair, balancing protective and detrimental effects. Crocetin, a carotenoid derived from saffron, exhibits anti-inflammatory and cardioprotective properties; however, its influence on autophagy-related FMT following MI remains unclear.This study aims to determine whether crocetin mitigates post-MI fibrosis and FMT by modulating autophagy in cardiac fibroblasts (CFs), while also evaluating its effects on cardiac function, infarct size, and autophagic flux.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In vivo: Mice subjected to MI were administered crocetin (25-100&#xa0;mg/kg). Cardiac function was assessed via echocardiography, and fibrosis was evaluated through Masson's trichrome staining and immunofluorescence analysis for &#x3b1;-SMA/LC3. In vitro: Hypoxic CFs were treated with crocetin or the autophagy inhibitor 3-methyladenine (3-MA). The effects on autophagic flux (GFP-RFP-LC3), protein expression (Beclin-1, LC3-II/I, P62), and mitochondrial membrane potential (JC-1) were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Crocetin enhanced cardiac function, and reduced infarct size and fibrosis in a dose-dependent manner, while suppressing &#x3b1;-SMA expression. It promoted autophagic flux (as evidenced by increased LC3-II levels and autolysosome formation) and mitophagy (indicated by decreased mitochondrial membrane potential). Treatment with 3-MA negated the antifibrotic effects of crocetin.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Crocetin attenuates post-MI pathological remodeling by enhancing autophagic flux to inhibit FMT, thereby identifying it as a promising candidate for antifibrotic therapy.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ruhui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6985-144X</Identifier><AffiliationInfo><Affiliation>School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, No.788 Xueyuan Road, Jiaojiang District, Taizhou, 318000, P. R. China. yangruhui2008@tzvtc.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Drug Innovation, Taizhou Vocational and Technical College, Taizhou, 318000, P. R. China. yangruhui2008@tzvtc.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zhengyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Medical Image Center, Taian City Central Hospital, Taian, 271000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Haili</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pathology Department, Taizhou Enze Medical Center (Group) Enze Hospital, Taizhou, 318000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chunli</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gynecology Department, Taian City Central Hospital, Taian, 271000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jia Shuo</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, No.788 Xueyuan Road, Jiaojiang District, Taizhou, 318000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bingjin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, No.788 Xueyuan Road, Jiaojiang District, Taizhou, 318000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, No.788 Xueyuan Road, Jiaojiang District, Taizhou, 318000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yinxiu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, No.788 Xueyuan Road, Jiaojiang District, Taizhou, 318000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yinping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, No.788 Xueyuan Road, Jiaojiang District, Taizhou, 318000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Meifen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine and Pharmaceutical Engineering, Taizhou Vocational and Technical College, No.788 Xueyuan Road, Jiaojiang District, Taizhou, 318000, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Songquan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8570-6912</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Lishui University School of Medicine, No. 1 Xueyuan Road, Liandu District, Lishui, 323000, P. R. China. wsq@lsu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2024DKC01</GrantID><Agency>Science and Technology Innovation Project of Students of Taizhou Vocational and Technical College</Agency><Country/></Grant><Grant><GrantID>2022BSZX02</GrantID><Agency>Funda&#xe7;&#xe3;o de Apoio a Servi&#xe7;os T&#xe9;cnicos, Ensino e Fomento a Pesquisas</Agency><Country/></Grant><Grant><GrantID>2024R485A001</GrantID><Agency>Zhejiang University Student Science and Technology Innovation Activity Plan</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Drugs Ther</MedlineTA><NlmUniqueID>8712220</NlmUniqueID><ISSNLinking>0920-3206</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autophagy</Keyword><Keyword MajorTopicYN="N">Crocetin</Keyword><Keyword MajorTopicYN="N">Fibroblast-to-Myofibroblast Transition</Keyword><Keyword MajorTopicYN="N">Myocardial Infarction</Keyword></KeywordList><CoiStatement>Declarations. Ethics Approval: This study was approved by the Animal Research Ethics Committee at Lishui University (Lishui, Zhejiang, approval No: 0411&#x2013;2022). Consent to Participate: Not applicable. Consent for Publication: Not applicable. Competing interests: The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>11</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844746</ArticleId><ArticleId IdType="doi">10.1007/s10557-025-07758-2</ArticleId><ArticleId IdType="pii">10.1007/s10557-025-07758-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schumacher D, Curaj A, Staudt M, et al. Endogenous modulation of extracellular matrix collagen during scar formation after myocardial infarction. Int J Mol Sci. 2022;23(23):14571. https://doi.org/10.3390/ijms232314571 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232314571</ArticleId><ArticleId IdType="pubmed">36498897</ArticleId><ArticleId IdType="pmc">9741070</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43(27):2549&#x2013;61. https://doi.org/10.1093/eurheartj/ehac223 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac223</ArticleId><ArticleId IdType="pubmed">35511857</ArticleId><ArticleId IdType="pmc">9336586</ArticleId></ArticleIdList></Reference><Reference><Citation>Daseke MJ II, Tenkorang MA, Chalise U, Konfrst SR, Lindsey ML. Cardiac fibroblast activation during myocardial infarction wound healing: fibroblast polarization after MI. Matrix Biol. 2020;91:109&#x2013;16. https://doi.org/10.1016/j.matbio.2020.03.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2020.03.010</ArticleId><ArticleId IdType="pubmed">32446909</ArticleId></ArticleIdList></Reference><Reference><Citation>Venugopal H, Hanna A, Humeres C, Frangogiannis NG. Properties and functions of fibroblasts and myofibroblasts in myocardial infarction. Cells. 2022;11(9):1386. https://doi.org/10.3390/cells11091386 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11091386</ArticleId><ArticleId IdType="pubmed">35563692</ArticleId><ArticleId IdType="pmc">9102016</ArticleId></ArticleIdList></Reference><Reference><Citation>Humeres C, Shinde AV, Hanna A, et al. Smad7 effects on TGF-&#x3b2; and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure. J Clin Invest. 2022. https://doi.org/10.1172/JCI146926 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI146926</ArticleId><ArticleId IdType="pubmed">34905511</ArticleId><ArticleId IdType="pmc">8803336</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Zhou Z, Yang Z, et al. AGEs&#x2013;RAGE axis mediates myocardial fibrosis via activation of cardiac fibroblasts induced by autophagy in heart failure. Exp Physiol. 2022;107(8):879&#x2013;91. https://doi.org/10.1113/EP090042 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/EP090042</ArticleId><ArticleId IdType="pubmed">35598104</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R, Song Z, Wu S, et al. Toll-like receptor 4 contributes to a myofibroblast phenotype in cardiac fibroblasts and is associated with autophagy after myocardial infarction in a mouse model. Atherosclerosis. 2018;279:23&#x2013;31. https://doi.org/10.1016/j.atherosclerosis.2018.10.018 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2018.10.018</ArticleId><ArticleId IdType="pubmed">30399463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaffari S, Roshanravan N. Saffron; an updated review on biological properties with special focus on cardiovascular effects. Biomed Pharmacother. 2019;109:21&#x2013;7. https://doi.org/10.1016/j.biopha.2018.10.031 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.10.031</ArticleId><ArticleId IdType="pubmed">30391705</ArticleId></ArticleIdList></Reference><Reference><Citation>Moshiri M, Vahabzadeh M, Hosseinzadeh H. Clinical applications of saffron (Crocus sativus) and its constituents: a review. Drug Res. 2015;65(06):287&#x2013;95. https://doi.org/10.1055/s-0034-1375681 .</Citation></Reference><Reference><Citation>Ikeda S, Zablocki D, Sadoshima J. The role of autophagy in death of cardiomyocytes. J Mol Cell Cardiol. 2022;165:1&#x2013;8. https://doi.org/10.1016/j.yjmcc.2021.12.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2021.12.006</ArticleId><ArticleId IdType="pubmed">34919896</ArticleId></ArticleIdList></Reference><Reference><Citation>Popov SV, Mukhomedzyanov AV, Voronkov NS, et al. Regulation of autophagy of the heart in ischemia and reperfusion. Apoptosis. 2023;28(1):55&#x2013;80. https://doi.org/10.1007/s10495-022-01786-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-022-01786-1</ArticleId><ArticleId IdType="pubmed">36369366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatica D, Chiong M, Lavandero S, Klionsky DJ. The role of autophagy in cardiovascular pathology. Cardiovasc Res. 2022;118(4):934&#x2013;50. https://doi.org/10.1093/cvr/cvab158 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab158</ArticleId><ArticleId IdType="pubmed">33956077</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z-L, Li M-X, Li X-L, et al. Crocetin: a systematic review. Front Pharmacol. 2022;12: 745683. https://doi.org/10.3389/fphar.2021.745683 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.745683</ArticleId><ArticleId IdType="pubmed">35095483</ArticleId><ArticleId IdType="pmc">8795768</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen XC, Qian ZY. Effect of crocetin on cardiac hypertrophy induced by overloading pressure in rats. Yao Xue Xue Bao. 2004;39(3):172&#x2013;5.&#xa0; https://www.cabidigitallibrary.org/doi/full/10.5555/20043061186 . Accessed&#xa0;March 2004.</Citation></Reference><Reference><Citation>Yang R, Yang L, Shen X, et al. Suppression of NF-&#x3ba;B pathway by crocetin contributes to attenuation of lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol. 2012;674(2&#x2013;3):391&#x2013;6. https://doi.org/10.1016/j.ejphar.2011.08.029 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2011.08.029</ArticleId><ArticleId IdType="pubmed">21925167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wani A, Al Rihani SB, Sharma A, et al. Crocetin promotes clearance of amyloid-&#x3b2; by inducing autophagy via the STK11/LKB1-mediated AMPK pathway. Autophagy. 2021;17(11):3813&#x2013;32. https://doi.org/10.1080/15548627.2021.1872187 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2021.1872187</ArticleId><ArticleId IdType="pubmed">33404280</ArticleId><ArticleId IdType="pmc">8632093</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Li Y-f, Zhang Y-s, et al. Protection of H9c2 myocardial cells from oxidative stress by crocetin via PINK1/Parkin pathway-mediated mitophagy. JoVE (Journal of Visualized Experiments). 2023;(195):e65105. https://doi.org/10.3791/65105 .</Citation></Reference><Reference><Citation>Xi L, Qian Z, Shen X, Wen N, Zhang Y. Crocetin prevents dexamethasone-induced insulin resistance in rats. Planta Med. 2005;71(10):917&#x2013;22. https://doi.org/10.1055/s-2005-871248 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2005-871248</ArticleId><ArticleId IdType="pubmed">16254822</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast&#x2013;derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest. 2014;124(5):2136&#x2013;46. https://doi.org/10.1172/JCI70577 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI70577</ArticleId><ArticleId IdType="pubmed">24743145</ArticleId><ArticleId IdType="pmc">4001534</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo G, Jian Z, Zhu Y, et al. Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress. Int J Mol Med. 2019;43(5):2033&#x2013;43. https://doi.org/10.3892/ijmm.2019.4125 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2019.4125</ArticleId><ArticleId IdType="pubmed">30864731</ArticleId><ArticleId IdType="pmc">6443335</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Xu Z, Chen M. Study on the mechanism of OSM participating in myocardial fibrosis by inhibiting TGF&#x3b2;-induced EndMT of cardiac microvascular endothelial cells through SPARC/SMAD signaling. Naunyn-Schmiedebergs Arch Pharmacol. 2024. https://doi.org/10.1007/s00210-024-03472-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-024-03472-2</ArticleId><ArticleId IdType="pubmed">39718608</ArticleId><ArticleId IdType="pmc">11825621</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X, Wang L, Zhang X, et al. Halofuginone-induced autophagy suppresses the migration and invasion of MCF-7 cells via regulation of STMN1 and p53. J Cell Biochem. 2018;119(5):4009&#x2013;20. https://doi.org/10.1002/jcb.26559 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26559</ArticleId><ArticleId IdType="pubmed">29231257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanamori H, Naruse G, Yoshida A, et al. Morphological characteristics in diabetic cardiomyopathy associated with autophagy. J Cardiol. 2021;77(1):30&#x2013;40. https://doi.org/10.1016/j.jjcc.2020.05.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2020.05.009</ArticleId><ArticleId IdType="pubmed">32907780</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Meng H, Xiao J, et al. Pretreatment of 3-MA prevents doxorubicin-induced cardiotoxicity through inhibition of autophagy initiation. Toxicology. 2023;490:153512. https://doi.org/10.1016/j.tox.2023.1535122 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2023.1535122</ArticleId><ArticleId IdType="pubmed">37062353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciatore S, Spadafora L, Bernardi M, et al. Management of coronary artery disease in older adults: recent advances and gaps in evidence. J Clin Med. 2023;12(16):5233. https://doi.org/10.3390/jcm12165233 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12165233</ArticleId><ArticleId IdType="pubmed">37629275</ArticleId><ArticleId IdType="pmc">10455820</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, Xu J, Long X, et al. Myocardial fibrosis induced by nonylphenol and its regulatory effect on the TGF-&#x3b2;1/LIMK1 signaling pathway. Ecotoxicol Environ Saf. 2024;272: 116110. https://doi.org/10.1016/j.ecoenv.2024.116110 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ecoenv.2024.116110</ArticleId><ArticleId IdType="pubmed">38364763</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelini A, Trial J, Saltzman AB, Malovannaya A, Cieslik KA. A defective mechanosensing pathway affects fibroblast-to-myofibroblast transition in the old male mouse heart. iScience. 2023. https://doi.org/10.1016/j.isci.2023.107283 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107283</ArticleId><ArticleId IdType="pubmed">38205246</ArticleId><ArticleId IdType="pmc">10777118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakatos BK, Ruppert M, Tokodi M, et al. Myocardial work index: a marker of left ventricular contractility in pressure-or volume overload-induced heart failure. ESC Heart Fail. 2021;8(3):2220&#x2013;31. https://doi.org/10.1002/ehf2.13314 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13314</ArticleId><ArticleId IdType="pubmed">33754487</ArticleId><ArticleId IdType="pmc">8120402</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-C, Hsing S-C, Chao Y-P, et al. Clinical relevance of the LVEDD and LVESD trajectories in HF patients With LVEF&lt; 35%. Front Med. 2022;9:846361. https://doi.org/10.3389/fmed.2022.846361 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.846361</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde AV, Humeres C, Frangogiannis NG. The role of &#x3b1;-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochim Biophys Acta (BBA) Mol Basis Dis. 2017;1863(1):298&#x2013;309. https://doi.org/10.1016/j.bbadis.2016.11.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.11.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu Y, Tan Y. Research progress and prospect on the mechanism of extracellular matrix remodeling based on myocardial cells. Int J Front Med. 2024;6(2). https://doi.org/10.25236/IJFM.2024.060211 .</Citation></Reference><Reference><Citation>Van Den Borne SW, Diez J, Blankesteijn WM, et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7(1):30&#x2013;7. https://doi.org/10.1038/nrcardio.2009.199 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2009.199</ArticleId><ArticleId IdType="pubmed">19949426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida K, Otsu K. Autophagy during cardiac remodeling. J Mol Cell Cardiol. 2016;95:11&#x2013;8. https://doi.org/10.1016/j.yjmcc.2015.12.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2015.12.003</ArticleId><ArticleId IdType="pubmed">26678624</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisa Z, Liao G-C, Shen X-L, et al. Effect of autophagy on myocardial infarction and its mechanism. Eur Rev Med Pharmacol Sci. 2017;21(16):3705&#x2013;13. https://doi.org/10.26355/eurrev_201708_13288 .</Citation></Reference><Reference><Citation>Wang X, Guo Z, Ding Z, Mehta JL. Inflammation, autophagy, and apoptosis after myocardial infarction. J Am Heart Assoc. 2018;7(9): e008024. https://doi.org/10.1161/JAHA.117.008024 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.117.008024</ArticleId><ArticleId IdType="pubmed">29680826</ArticleId><ArticleId IdType="pmc">6015297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin PW, Chu ML, Liu HS. Autophagy and metabolism. Kaohsiung J Med Sci. 2021;37(1):12&#x2013;9. https://doi.org/10.1126/science.1193497 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1193497</ArticleId><ArticleId IdType="pubmed">33021078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yim WW-Y, Mizushima N. Lysosome biology in autophagy. Cell Discov. 2020;6(1): 6. https://doi.org/10.1038/s41421-020-0141-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0141-7</ArticleId><ArticleId IdType="pubmed">32047650</ArticleId><ArticleId IdType="pmc">7010707</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara N, Shibutani S, Ohama T, Sato K. Protein phosphatase 6 dissociates the Beclin 1/Vps34 complex and inhibits autophagy. Biochem Biophys Res Commun. 2021;552:191&#x2013;5. https://doi.org/10.1016/j.bbrc.2021.02.136 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.02.136</ArticleId><ArticleId IdType="pubmed">33751937</ArticleId></ArticleIdList></Reference><Reference><Citation>Stempels FC, Janssens MH, Ter Beest M, et al. Novel and conventional inhibitors of canonical autophagy differently affect LC3-associated phagocytosis. FEBS Lett. 2022;596(4):491&#x2013;509. https://doi.org/10.1002/1873-3468.14280 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.14280</ArticleId><ArticleId IdType="pubmed">35007347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou R, Wu S, Wang Y, et al. Role of integrin-linked kinase in static compressive stress-induced autophagy via phosphatidylinositol 3 kinase in human periodontal ligament cells. Int J Mol Med. 2021;48(3):1&#x2013;11. https://doi.org/10.3892/ijmm.2021.5000 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2021.5000</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H, Yang F, Hu Q, et al. The ubiquitin-specific protease USP8 directly deubiquitinates SQSTM1/p62 to suppress its autophagic activity. Autophagy. 2020;16(4):698&#x2013;708. https://doi.org/10.1080/15548627.2019.1635381 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1635381</ArticleId><ArticleId IdType="pubmed">31241013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher ER, Holzbaur EL. The selective autophagy adaptor p62/SQSTM1 forms phase condensates regulated by HSP27 that facilitate the clearance of damaged lysosomes via lysophagy. Cell Rep. 2023. https://doi.org/10.1016/j.celrep.2023.112037 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112037</ArticleId><ArticleId IdType="pubmed">36701233</ArticleId><ArticleId IdType="pmc">10366342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Fei F, Zhen L, et al. Sensitive analysis and simultaneous assessment of pharmacokinetic properties of crocin and crocetin after oral administration in rats. J Chromatogr B. 2017;1044:1&#x2013;7. https://doi.org/10.1016/j.jchromb.2016.12.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2016.12.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Xiao J, Zang L-H, Quan P, Liu D-C. Preparation of trans-Crocetin with high solubility, stability, and oral bioavailability by incorporation into three types of cyclodextrins. Pharmaceutics. 2023;15(12):2790. https://doi.org/10.3390/pharmaceutics15122790 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15122790</ArticleId><ArticleId IdType="pubmed">38140130</ArticleId><ArticleId IdType="pmc">10747661</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med (Maywood). 2002;227(1):20&#x2013;5. https://doi.org/10.1177/153537020222700104 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/153537020222700104</ArticleId><ArticleId IdType="pubmed">11788779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J, Yi F-F, Bian Z-Y, et al. Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med. 2010;14(6b):1868. https://doi.org/10.1111/j.1582-4934.2008.00620.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00620.x</ArticleId><ArticleId IdType="pmc">3829046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma R, Li S, Mo Q, et al. Preventive and therapeutic effects of crocetin in rats with heart failure. Pharmaceuticals. 2024;17(4):496. https://doi.org/10.3390/ph17040496 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph17040496</ArticleId><ArticleId IdType="pubmed">38675456</ArticleId><ArticleId IdType="pmc">11054188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-Y, Yu Y, Yu C. Antifibrotic roles of RAAS blockers: update. Renal fibrosis: mechanisms and therapies. 2019. pp. 671&#x2013;91. https://doi.org/10.1007/978-981-13-8871-2_33 .</Citation></Reference><Reference><Citation>Gutheil WG, Reed G, Ray A, Anant S, Dhar A. Crocetin: an agent derived from saffron for prevention and therapy for cancer. Curr Pharm Biotechnol. 2012;13(1):173&#x2013;9. https://doi.org/10.2174/138920112798868566 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920112798868566</ArticleId><ArticleId IdType="pubmed">21466430</ArticleId><ArticleId IdType="pmc">4461363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40831997</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2688-1152</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of the American College of Emergency Physicians open</Title><ISOAbbreviation>J Am Coll Emerg Physicians Open</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal Cardiopulmonary Resuscitation for Cardiac Arrest and Myocardial Infarction: A Diagnosis Beyond the Obvious.</ArticleTitle><Pagination><StartPage>100238</StartPage><MedlinePgn>100238</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100238</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acepjo.2025.100238</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abi Abdallah</LastName><ForeName>Georges</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, AP-HP, European Georges Pompidou Hospital, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, Universit&#xe9; Paris Cit&#xe9;, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaultier</LastName><ForeName>Anne-Laure</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Radiology, AP-HP, European Georges Pompidou Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godier</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care, AP-HP, European Georges Pompidou Hospital, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, Universit&#xe9; Paris Cit&#xe9;, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Emerg Physicians Open</MedlineTA><NlmUniqueID>101764779</NlmUniqueID><ISSNLinking>2688-1152</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute type A aortic dissection</Keyword><Keyword MajorTopicYN="N">extracorporeal cardiopulmonary resuscitation</Keyword><Keyword MajorTopicYN="N">misdiagnosis</Keyword></KeywordList><CoiStatement>All authors have affirmed they have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40831997</ArticleId><ArticleId IdType="pmc">PMC12359210</ArticleId><ArticleId IdType="doi">10.1016/j.acepjo.2025.100238</ArticleId><ArticleId IdType="pii">S2688-1152(25)00196-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Evangelista A., Isselbacher E.M., Bossone E., et al. IRAD Investigators Insights from the international registry of acute aortic dissection: a 20-year experience of collaborative clinical research. Circulation. 2018;137(17):1846&#x2013;1860. doi: 10.1161/CIRCULATIONAHA.117.031264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.031264</ArticleId><ArticleId IdType="pubmed">29685932</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki M., Yoshino H., Kunihara T., et al. Outcomes of type A acute aortic dissection with cardiopulmonary arrest: Tokyo Acute Aortic Super-network registry. Eur J Cardiothorac Surg. 2023;63(4) doi: 10.1093/ejcts/ezad056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezad056</ArticleId><ArticleId IdType="pubmed">36806920</ArticleId></ArticleIdList></Reference><Reference><Citation>Teran F., Prats M.I., Nelson B.P., et al. Focused transesophageal echocardiography during cardiac arrest resuscitation: JACC review topic of the week. J Am Coll Cardiol. 2020;76(6):745&#x2013;754. doi: 10.1016/j.jacc.2020.05.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.05.074</ArticleId><ArticleId IdType="pubmed">32762909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaisendrees C., Luehr M., Wahlers T., Yannopoulos D. Extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest caused by acute aortic dissection type A-a word of caution. Eur J Cardiothorac Surg. 2023;64(6) doi: 10.1093/ejcts/ezad420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezad420</ArticleId><ArticleId IdType="pubmed">38123501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40834883</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1361-6579</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Physiological measurement</Title><ISOAbbreviation>Physiol Meas</ISOAbbreviation></Journal><ArticleTitle>Improved state refinement for LSTM determined 3D CAISR-LSTM model for automatic myocardial infarction detection.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1088/1361-6579/adfda9</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Electrocardiograms (ECGs) contain valuable information in the clinical diagnosis of myocardial infarction (MI). However, its interpretation process is dependent on cardiologists with extensive clinical experience and expertise. The issue not only causes a paucity of medical resources, but also restricts patients from receiving timely diagnoses. Thus, a novel approach for MI automatic detection is developed, based on 12-lead ECG and an improved state refinement for long short-term memory (LSTM) determined 3D convolution-attention (3D CAISR-LSTM) model.</AbstractText><AbstractText Label="APPROACH" NlmCategory="METHODS">The proposed 3D CAISR-LSTM model is trained in an end-to-end fashion. The input 12-lead ECG signals are preprocessed to eliminate power line interference, high-frequency noise and baseline wander. Then, the ECG signals are transformed into time-frequency images using continuous wavelet transform (CWT) and bilinear interpolation. The obtained images are constructed into three-dimensional spatiotemporal features, serving as input to the 3D CAISR-LSTM model. In the 3D CAISR-LSTM model, there are three main components: a convolutional module, four identical convolutional attention modules, and an improved state refinement for LSTM. Performance of the 3D CAISR-LSTM model in automatic detection of MI versus healthy controls (HC) is evaluated through ten-fold cross validation on the publicly available PTB diagnostic ECG database.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Experimental results demonstrate that the 3D CAISR-LSTM model achieves an accuracy of 98.45%, sensitivity of 98.69%, specificity of 97.50%, and F1 score of 99.03%, outperforming various advanced 2D and 3D deep neural network architectures.</AbstractText><AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">The proposed approach is expected to provide an early warning before obvious MI symptoms appear. It also has the potential to be developed into a lightweight embedded MI detection equipment.</AbstractText><CopyrightInformation>&#xa9; 2025 Institute of Physics and Engineering in Medicine. All rights, including for text and data mining, AI training, and similar technologies, are reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Muqing</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Guangdong University of Technology School of Automation, No.100 Waihuan West Road, Xiaoguwei Street, Guangzhou University Town, Panyu District, Guangzhou City, Guangdong Province, China, Guangzhou, Guangdong, 510006, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Boyan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Guangdong University of Technology School of Automation, No.100 Waihuan West Road, Xiaoguwei Street, Guangzhou University Town, Panyu District, Guangzhou City, Guangdong Province, China, Guangzhou, Guangdong, 510006, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Mingying</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Guangdong University of Technology School of Automation, No.100 Waihuan West Road, Xiaoguwei Street, Guangzhou University Town, Panyu District, Guangzhou City, Guangdong Province, China, Guangzhou, Guangdong, 510006, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Guangdong University of Technology School of Automation, No.100 Waihuan West Road, Xiaoguwei Street, Guangzhou University Town, Panyu District, Guangzhou City, Guangdong Province, China, Guangzhou, Guangdong, 510006, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xinghui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Information, People's Hospital of Yangjiang, No. 42, Dongshan Road, Jiangcheng District, Yangjiang City, Guangdong Province,, Yangjiang, Guangdong, 529500, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanjiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangdong University of Technology School of Automation, No.100 Waihuan West Road, Xiaoguwei Street, Guangzhou University Town, Panyu District, Guangzhou City, Guangdong Province, China, Guangzhou, Guangdong, 510006, CHINA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0003-1552-0295</Identifier><AffiliationInfo><Affiliation>Center of Preventive Disease, People's Hospital of Yangjiang, No. 42, Dongshan Road, Jiangcheng District, Yangjiang City, Guangdong Province, China, Yangjiang, Guangdong, 529500, CHINA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Physiol Meas</MedlineTA><NlmUniqueID>9306921</NlmUniqueID><ISSNLinking>0967-3334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3D CAISR-LSTM model</Keyword><Keyword MajorTopicYN="N">Myocardial infarction detection</Keyword><Keyword MajorTopicYN="N">State refinement mechanism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>19</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834883</ArticleId><ArticleId IdType="doi">10.1088/1361-6579/adfda9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40835966</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1601-5223</ISSN><JournalIssue CitedMedium="Internet"><Volume>162</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Hereditas</Title><ISOAbbreviation>Hereditas</ISOAbbreviation></Journal><ArticleTitle>Suppression of circ_0091761 ameliorates acute myocardial infarction-induced endothelial injury through regulation of miR-1278.</ArticleTitle><Pagination><StartPage>169</StartPage><MedlinePgn>169</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">169</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41065-025-00519-z</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The main objective of the article was to explore the role of circ_0091761 in acute myocardial infarction (AMI)-induced endothelial injury.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cellular model of AMI was constructed by hypoxia-induced HUVECs. miRNAs that may interact with circ_0091761 were recognized by the ENCORI and circular RNA Interactom databases. RT-qPCR was performed to analyze the levels of circ_0091761 in AMI patients as well as miR-1278, ICAM1, and VCAM1 in hypoxia-induced HUVECs. Flow cytometry was used to detect apoptosis. ROS kit and LDH kit were used to detect the levels of ROS and LDH, respectively. Dual-luciferase reporter assay, RIP assay, and RNA pull-down assay were performed to validate their interaction between circ_0091761 and miR-1278.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">circ_0091761 was elevated in AMI patients compared to healthy controls. Silencing circ_0091761 reduced apoptosis, ICAM1, and VCAM1 levels, as well as ROS and LDH. circ_0091761 could interact with miR-1278 and negatively regulate miR-1278 expression in hypoxia-induced HUVECs. At the same time, inhibiting miR-1278 reverses the protective effect of transfected si-circ_0091761 on HUVECs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Down-regulation of circ_0091761 ameliorates AMI-induced endothelial injury by targeting miR-1278.</AbstractText><AbstractText Label="CLINICAL TRIAL NUMBER" NlmCategory="BACKGROUND">Not applicable.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Emergency, Wuhan Third Hospital, Tongren Hospital of WuHan University, Hubei, 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Emergency Department, The 970th Hospital of the Joint Logistics Support Force of The Chinese People's Liberation Army, Yantai, 264002, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Zhangqiu District People's Hospital, Jinan, 250200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency, Zhangqiu District People's Hospital, Jinan, 250200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Cuicui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhangqiu District People's Hospital, Jinan, 250200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhangqiu District People's Hospital, Jinan, 250200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Zhangqiu District People's Hospital, Jinan, 250200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency, Zhangqiu District People's Hospital, Jinan, 250200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhengnan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, Geriatric Hospital Affiliated to Wuhan University of Science and Technology, No. 2, West Huangjiahu Road, Qingling Street, Hongshan District, Wuhan, Hubei Province, 430065, China. zhengnanzhangdr@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hereditas</MedlineTA><NlmUniqueID>0374654</NlmUniqueID><ISSNLinking>0018-0661</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079962">RNA, Circular</NameOfSubstance></Chemical><Chemical><RegistryNumber>126547-89-5</RegistryNumber><NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573420">ICAM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019010">Vascular Cell Adhesion Molecule-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079962" MajorTopicYN="Y">RNA, Circular</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019010" MajorTopicYN="N">Vascular Cell Adhesion Molecule-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Endothelial injury</Keyword><Keyword MajorTopicYN="N">circ_0091761</Keyword><Keyword MajorTopicYN="N">miR-1278</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Zhangqiu District People&#x2019;s Hospital before the study began. The written informed consent has been obtained from the participants involved. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40835966</ArticleId><ArticleId IdType="pmc">PMC12369235</ArticleId><ArticleId IdType="doi">10.1186/s41065-025-00519-z</ArticleId><ArticleId IdType="pii">10.1186/s41065-025-00519-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang T, Zhang X, Ma C, Chen Y. TGF-beta/Smad3 pathway enhances the cardio-protection of S1R/SIPR1 in in vitro ischemia-reperfusion myocardial cell model. Exp Ther Med. 2018;16(1):178&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5995059</ArticleId><ArticleId IdType="pubmed">29896238</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Chen HK, Huang YH, Zhi YP, Li YE, Lin KY, et al. Identification of mitophagy-related genes in patients with acute myocardial infarction. Hereditas. 2025;162(1):70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12034215</ArticleId><ArticleId IdType="pubmed">40287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Willerson JT, Buja LM. Myocardial cellular alterations during myocardial ischemia and evolving infarction. Postgrad Med. 1988; Spec No69-75.</Citation><ArticleIdList><ArticleId IdType="pubmed">2894662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tombor LS, John D, Glaser SF, Luxan G, Forte E, Furtado M, et al. Single cell sequencing reveals endothelial plasticity with transient mesenchymal activation after myocardial infarction. Nat Commun. 2021;12(1):681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846794</ArticleId><ArticleId IdType="pubmed">33514719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, He S, Wang B, Yang W, Zheng Y, Jiang S et al. Construction and bioinformatics analysis of circRNA-miRNA-mRNA network in acute myocardial infarction. Front Genet. 2022; 13854993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9002054</ArticleId><ArticleId IdType="pubmed">35422846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SL, Li L, Zhang HP. Progress on translation ability of circular RNA. Yi Chuan. 2020;42(5):423&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">32431294</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao T, Peng X, Yang D, Hou C, Chen Z. CircSMARCC1 and circlrba are potential biomarkers in forensic postmortem diagnosis of acute myocardial infarction. Leg Med (Tokyo). 2023; 60102184.</Citation><ArticleIdList><ArticleId IdType="pubmed">36502647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Li G, Peng J, Ren L, Lei L, Ye H, et al. CircMACF1 attenuates acute myocardial infarction through miR-500b-5p-EMP1 axis. J Cardiovasc Transl Res. 2021;14(1):161&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">32162171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai C, Qian G, Wu H, Pan H, Xie S, Sun Z, et al. Knockdown of circ_0060745 alleviates acute myocardial infarction by suppressing NF-kappaB activation. J Cell Mol Med. 2020;24(21):12401&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687010</ArticleId><ArticleId IdType="pubmed">32977365</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wang J, Zhao X, Li W, Liu Y, Li X et al. CDR1as promotes arrhythmias in myocardial infarction via targeting the NAMPT-NAD(+) pathway. Biomed Pharmacother. 2023; 165115267.</Citation><ArticleIdList><ArticleId IdType="pubmed">37542851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Wang Z, Cheng Q, Wang Z, Lv X, Wang Z et al. Circular RNA (circRNA) CDYL induces myocardial regeneration by CeRNA after myocardial infarction. Med Sci Monit. 2020; 26e923188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304314</ArticleId><ArticleId IdType="pubmed">32522972</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Liu J, Ge W, Li Z, Lv M, Feng Y et al. Identification of regulatory circrnas involved in the pathogenesis of acute myocardial infarction. Front Genet. 2020; 11626492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7886988</ArticleId><ArticleId IdType="pubmed">33613625</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Jiang M, Tang B, You L, Zhao L. Downregulation of circular RNA 00091761 protects against heart failure after myocardial infarction via microRNA-335-3p/ ASCL4 axis. Acta Biochim Pol. 2023;70(3):509&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">37672718</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Qiao C, Luo H. MicroRNA-1278 ameliorates the inflammation of cardiomyocytes during myocardial ischemia by targeting both IL-22 and CXCL14. Life Sci. 2021; 269118817.</Citation><ArticleIdList><ArticleId IdType="pubmed">33275986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Sun L, Zhao P, Liu Y, Zhang J, Zhang Y, et al. Macrophage migration inhibitory factor facilitates the therapeutic efficacy of mesenchymal stem cells derived exosomes in acute myocardial infarction through upregulating miR-133a-3p. J Nanobiotechnol. 2021;19(1):61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7916292</ArticleId><ArticleId IdType="pubmed">33639970</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong ZT, Xiong YY, Ning Y, Tang RJ, Xu JY, Jiang WY et al. Nicorandil-Pretreated mesenchymal stem cell-derived exosomes facilitate cardiac repair after myocardial infarction via promoting macrophage M2 polarization by targeting miR-125a-5p/TRAF6/IRF5 signaling pathway. Int J Nanomed. 2024; 192005&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10926597</ArticleId><ArticleId IdType="pubmed">38469055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LW, He JF, Xu HY, Zhao PF, Zhao J, Zhuang CC et al. Effects and mechanisms of 6-hydroxykaempferol 3,6-di-O-glucoside-7-O-glucuronide from safflower on endothelial injury in vitro and on thrombosis in vivo. Front Pharmacol. 2022; 13974216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9541210</ArticleId><ArticleId IdType="pubmed">36210813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Sun X, Cui G, Wang S. Mir-150-5p distinguishes acute pulmonary embolism, predicts the occurrence of pulmonary arterial hypertension, and regulates ox-LDL-induced endothelial cell injury. Hereditas. 2024;161(1):33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11384695</ArticleId><ArticleId IdType="pubmed">39256826</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordo R, Nasrallah GK, Posadino AM, Galimi F, Capobianco G, Eid AH et al. Resveratrol-Elicited PKC Inhibition counteracts NOX-Mediated endothelial to mesenchymal transition in human retinal endothelial cells exposed to high glucose. Antioxid (Basel). 2021; 10(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7913144</ArticleId><ArticleId IdType="pubmed">33540918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Liu L, Zhang L, Guo J, Yu L, Li T. Circ_0057583 facilitates brain microvascular endothelial cell injury through modulating miR-204-5p/NR4A1 axis. Metab Brain Dis. 2022;37(2):501&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">34767155</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Gao B, Wang Y. CircIRAK1 aggravates ox-LDL-induced endothelial cell injury in atherosclerosis via TRIM14 upregulation by binding to miR-330-5p. Clin Hemorheol Microcirc. 2023;85(3):195&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">36336926</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TP, Zhang NJ, Wang HJ, Hu SG, Geng X. Knockdown of circROBO2 attenuates acute myocardial infarction through regulating the miR-1184/TRADD axis. Mol Med. 2021;27(1):21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931513</ArticleId><ArticleId IdType="pubmed">33658002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Li J, Long C, Han Y, Fan J, Misrani A et al. Regulatory mechanism of circEIF4G2 targeting miR-26a in acute myocardial infarction. J Healthc Eng. 2022; 20225308372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942649</ArticleId><ArticleId IdType="pubmed">35340248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Liu Y, Fei A, Tan L. CircMACF1 alleviates myocardial fibrosis after acute myocardial infarction by suppressing cardiac fibroblast activation via the miR-16-5p/SMAD7 axis. Med (Baltim). 2023;102(37):e35119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10508453</ArticleId><ArticleId IdType="pubmed">37713818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadrdoost Nakhchi B, Kosuru R, Chrzanowska M. Towards targeting endothelial Rap1B to overcome vascular immunosuppression in cancer. Int J Mol Sci. 2024; 25(18).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11432579</ArticleId><ArticleId IdType="pubmed">39337337</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie A, Li H, Hao Y, Zhang Y. Tuning the toxicity of reactive oxygen species into advanced tumor therapy. Nanoscale Res Lett. 2021;16(1):142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8438097</ArticleId><ArticleId IdType="pubmed">34518937</ArticleId></ArticleIdList></Reference><Reference><Citation>You Y, Zhou X, Tang Q, Zhao T, Wang J, Huang H, et al. Echinatin mitigates sevoflurane-induced neurotoxicity through regulation of ferroptosis and iron homeostasis. Aging. 2024;16(5):4670&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10968708</ArticleId><ArticleId IdType="pubmed">38446592</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiu J, Yang Z, Sui Y, Zhang L, Zhou Y. CircNMD3 relieves endothelial cell injury induced by oxidatively modified low-density lipoprotein through regulating miR-498/ BMP and activin membrane-bound inhibitor (BAMBI) axis. Bioengineered. 2022;13(5):12558&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9276052</ArticleId><ArticleId IdType="pubmed">35603423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Yang Y. Oxidized low-density lipoprotein contributes to injury of endothelial cells via the circ_0090231/miR-9-5p/TXNIP axis. Cent Eur J Immunol. 2022;47(1):41&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115597</ArticleId><ArticleId IdType="pubmed">35600155</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie JB, Zhang H, Li XF, Han SY, Li XL. MiR-1278 targets CALD1 and suppresses the progression of gastric cancer via the MAPK pathway. Open Med (Wars). 2023;18(1):20230776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10656762</ArticleId><ArticleId IdType="pubmed">38025524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Lv L, Zhang Z, Wei S, Zheng T. LINC00294 negatively modulates cell proliferation in glioma through a neurofilament medium-mediated pathway via interacting with miR-1278. J Gene Med. 2020;22(10):e3235.</Citation><ArticleIdList><ArticleId IdType="pubmed">32450002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40834835</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8171</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>The American journal of emergency medicine</Title><ISOAbbreviation>Am J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Differentiating Type 1 and Type 2 myocardial infarction using a machine learning algorithm and biomarkers.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>56</EndPage><MedlinePgn>50-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajem.2025.08.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-6757(25)00546-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatment of myocardial infarction (MI) differs based on MI type, which can be difficult to determine in the emergency department. This study sought to evaluate whether a machine learning algorithm (MI<sup>3</sup>) in combination with N-Terminal pro B-type natriuretic peptide (NT-proBNP) and galectin-3 (Gal-3) can accurately differentiate MI type.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a secondary analysis of the multisite CMR-IMPACT trial, which prospectively enrolled adults with symptoms of acute coronary syndrome and an initial indeterminate troponin. Patients with an adjudicated diagnosis of MI and an initial high-sensitivity cardiac troponin I (hs-cTnI; Abbott Laboratories) measure were included. Incidence of MI and MI type were adjudicated by expert reviewers. Receiver operator characteristic curves for MI-type were created and area under the curve (AUC) calculated for MI<sup>3</sup> and MI<sup>3</sup> with NT-proBNP and Gal-3. AUCs were compared using DeLong's method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 123 patients with adjudicated MI, the mean age was 60&#xb1;12 years and 37.4% (46/123) were female. Type 1 MI occurred in 58.5% (72/123) and type 2 MI in 41.5% (51/123). MI<sup>3</sup> based on an initial hs-cTnI yielded an AUC of 0.704 (95% CI 0.611-0.797) for MI type. When combined with NT-proBNP and Gal-3, AUC improved to 0.789 (95% CI 0.709-0.869, p=0.0165). In patients with serial hs-cTnIs (n = 86), the AUC of MI<sup>3</sup> for MI type was 0.721 (95% CI 0.614-0.829) and increased to 0.797 (95% CI 0.700-0.894, p=0.09) with the addition of NT-proBNP and Gal-3.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Adding NT-proBNP and Gal-3 to the MI<sup>3</sup> machine learning algorithm shows promise in differentiating type 1 from type 2 MI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snavely</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Laurel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Core Diagnostics, Abbott Laboratories, Abbott Park, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Christian John</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Core Diagnostics, Abbott Laboratories, Abbott Park, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murtagh</LastName><ForeName>Gillian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Core Diagnostics, Abbott Laboratories, Abbott Park, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stopyra</LastName><ForeName>Jason P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashburn</LastName><ForeName>Nicklaus P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Supples</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christenson</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Maryland, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Chadwick D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahler</LastName><ForeName>Simon A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Electronic address: smahler@wakehealth.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Emerg Med</MedlineTA><NlmUniqueID>8309942</NlmUniqueID><ISSNLinking>0735-6757</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Galectin-3</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Natriuretic peptide</Keyword><Keyword MajorTopicYN="N">Troponin</Keyword></KeywordList><CoiStatement>Declaration of competing interest Dr. Mahler receives funding/support from Roche Diagnostics, Abbott Laboratories, QuidelOrtho Clinical Diagnostics, Siemens, Grifols, Pathfast, Genetesis, Cytovale, Beckman Coulter, Brainbox, AHRQ (R01HS029017 and R21HS029234), The Duke Endowment, National Foundation of Emergency Medicine, and HRSA (1H2ARH399760100). He is a consultant for Roche, Abbott, Siemens, QuidelOrtho, Genetesis, Inflammatix, and Radiometer, and the Chief Medical Officer for Impathiq Inc. Dr. Ashburn receives funding from AHRQ (R01HS029017) Dr. Supples receives funding from the NIH (UL1TR001420), HRSA (1H2ARH399760100), and the National Foundation of Emergency Medicine. Dr. Snavely receives funding from Abbott Laboratories, AHRQ (R01HS029017 and R21HS029234), NHLBI (K23HL169929), and HRSA (1H2ARH399760100). Dr. Murtagh and Dr. Hunter are full-time employees and shareholders of Abbott Laboratories. Laurel Jackson is a full-time employee of Abbott Laboratories.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834835</ArticleId><ArticleId IdType="doi">10.1016/j.ajem.2025.08.019</ArticleId><ArticleId IdType="pii">S0735-6757(25)00546-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837617</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of cardiology. Heart &amp; vasculature</Title><ISOAbbreviation>Int J Cardiol Heart Vasc</ISOAbbreviation></Journal><ArticleTitle>Effect of intravenous methotrexate carried by lipid nanoemulsion in patients with anterior ST-elevation myocardial infarction.</ArticleTitle><Pagination><StartPage>101771</StartPage><MedlinePgn>101771</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101771</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcha.2025.101771</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Inflammation plays a central role in the pathophysiology of ST-elevation myocardial infarction (STEMI), being associated with larger infarct size (IS) and worse left ventricular remodeling (LVR). Methotrexate (MTX) is a potent anti-inflammatory drug with potential benefits in the treatment of STEMI. Experimental studies have suggested that a formulation of MTX incorporated into lipid nanoemulsion (LDE-MTX) could be beneficial and safe.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To evaluate the efficacy and safety of LDE-MTX in patients with STEMI.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Randomized, double-blinded, placebo-controlled, proof-of-concept study. Patients were randomized 4&#xa0;&#xb1;&#xa0;2&#xa0;days after first anterior STEMI to receive LDE-MTX (40&#xa0;mg/m<sup>2</sup> intravenous infusion) or LDE-placebo weekly for 6&#xa0;weeks. The primary efficacy endpoint was left ventricle end-diastolic volume (LVEDV) assessed by cardiac magnetic resonance at 90&#xa0;&#xb1;&#xa0;7&#xa0;days post-randomization; the main secondary endpoints were changes in LVEDV, other LVR parameters and IS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Due to the COVID-19 pandemic the study was stopped prematurely, with 32 randomized patients (15 LDE-placebo, 17 LDE-MTX) completing the protocol. At 90&#xa0;days, there was no difference in LVEDV between groups. Among other secondary endpoints, there appeared to be a greater reduction of IS (%LV) in favor of the LDE-MTX group (-3.9&#xa0;&#xb1;&#xa0;6.9 vs -9.4&#xa0;&#xb1;&#xa0;8.4, p&#xa0;=&#xa0;0.030). LDE-MTX was well tolerated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In patients with STEMI, LDE-MTX appears to be safe but did not influence LVEDV and other LVR parameters, although it possibly reduced infarct size at 90&#xa0;days. These hypothesis-generating results support further investigation of a novel nanomedicine approach to STEMI in larger trials.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Aline G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maranh&#xe3;o</LastName><ForeName>Raul C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salsoso</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldo</LastName><ForeName>Vanessa M G T F</ForeName><Initials>VMGTF</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furtado</LastName><ForeName>Remo H M</ForeName><Initials>RHM</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brazilian Clinical Research Institute, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dal&#xe7;&#xf3;quio</LastName><ForeName>Talia F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Carlos A K</ForeName><Initials>CAK</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baracioli</LastName><ForeName>Luciano M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Felipe G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morikawa</LastName><ForeName>Aleksandra T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liberato</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rochitte</LastName><ForeName>Carlos E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomura</LastName><ForeName>Cesar H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalil Filho</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ridker</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giugliano</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabatine</LastName><ForeName>Marc S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavoni</LastName><ForeName>Thauany M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giraldez</LastName><ForeName>Roberto R C V</ForeName><Initials>RRCV</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolau</LastName><ForeName>Jos&#xe9; C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Instituto do Coracao (InCor), Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Cardiol Heart Vasc</MedlineTA><NlmUniqueID>101649525</NlmUniqueID><ISSNLinking>2352-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Infarct size</Keyword><Keyword MajorTopicYN="N">Left ventricle remodeling</Keyword><Keyword MajorTopicYN="N">Lipid nanoemulsion</Keyword><Keyword MajorTopicYN="N">Methotrexate</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837617</ArticleId><ArticleId IdType="pmc">PMC12363469</ArticleId><ArticleId IdType="doi">10.1016/j.ijcha.2025.101771</ArticleId><ArticleId IdType="pii">S2352-9067(25)00174-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Byrne R.A., Rossello X., Coughlan J.J., Barbato E., Berry C., Chieffo A., et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur. Heart J. 2023;44(38):3720&#x2013;3826.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P., Ridker P.M., Hansson G.K. Leducq transatlantic network on a. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 2009;54(23):2129&#x2013;2138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834169</ArticleId><ArticleId IdType="pubmed">19942084</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangogiannis N.G. The inflammatory response in myocardial injury, repair, and remodelling. Nat. Rev. Cardiol. 2014;11(5):255&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407144</ArticleId><ArticleId IdType="pubmed">24663091</ArticleId></ArticleIdList></Reference><Reference><Citation>Orn S., Manhenke C., Ueland T., Damas J.K., Mollnes T.E., Edvardsen T., et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur. Heart J. 2009;30(10):1180&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">19299430</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolau J.C., Maia L.N., Jo V., Vaz V.D., Machado M.N., Godoy M.F., et al. ST-segment resolution and late (6-month) left ventricular remodeling after acute myocardial infarction. Am. J. Cardiol. 2003;91(4):451&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempf T., Zarbock A., Vestweber D., Wollert K.C. Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. J. Mol. Med. (Berl) 2012;90(4):361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">22228177</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardif J.C., Kouz S., Waters D.D., Bertrand O.F., Diaz R., Maggioni A.P., et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 2019;381(26):2497&#x2013;2505.</Citation><ArticleIdList><ArticleId IdType="pubmed">31733140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017;377(12):1119&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">28845751</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly S.S., d'Entremont M.A., Lee S.F., Mian R., Tyrwhitt J., Kedev S., et al. Colchicine in acute myocardial infarction. N. Engl. J. Med. 2025;392(7):633&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">39555823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahaffey K.W., Granger C.B., Nicolau J.C., Ruzyllo W., Weaver W.D., Theroux P., et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108(10):1176&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925455</ArticleId></ArticleIdList></Reference><Reference><Citation>Micha R., Imamura F., Wyler von Ballmoos M., Solomon D.H., Hernan M.A., Ridker P.M., Mozaffarian D. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am. J. Cardiol. 2011;108(9):1362&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196048</ArticleId><ArticleId IdType="pubmed">21855836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker P.M., Everett B.M., Pradhan A., MacFadyen J.G., Solomon D.H., Zaharris E., et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 2019;380(8):752&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6587584</ArticleId><ArticleId IdType="pubmed">30415610</ArticleId></ArticleIdList></Reference><Reference><Citation>Asanuma H., Sanada S., Ogai A., Minamino T., Takashima S., Asakura M., et al. Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts. J. Cardiovasc. Pharmacol. 2004;43(4):574&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">15085069</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira D.M., Vieira J.L., Gottschall C.A. The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial) J. Card. Fail. 2009;15(10):828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">19944358</ArticleId></ArticleIdList></Reference><Reference><Citation>Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">18512708</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura J.A., Valduga C.J., Tavares E.R., Kretzer I.F., Maria D.A., Maranhao R.C. Novel formulation of a methotrexate derivative with a lipid nanoemulsion. Int. J. Nanomed. 2011;6:2285&#x2013;2295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205125</ArticleId><ArticleId IdType="pubmed">22072866</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranhao R.C., Garicochea B., Silva E.L., Dorlhiac-Llacer P., Cadena S.M., Coelho I.J., et al. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res. 1994;54(17):4660&#x2013;4666.</Citation><ArticleIdList><ArticleId IdType="pubmed">8062260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hungria V.T., Latrilha M.C., Rodrigues D.G., Bydlowski S.P., Chiattone C.S., Maranhao R.C. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother. Pharmacol. 2004;53(1):51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">14574458</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro K.V., Hungria V.T., Ficker E.S., Valduga C.J., Mesquita C.H., Maranhao R.C. Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin&#x2019;s and non-Hodgkin&#x2019;s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother. Pharmacol. 2006;57(5):624&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">16133527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulgarelli A., Leite A.C., Jr., Dias A.A., Maranhao R.C. Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits. Cardiovasc. Drugs Ther. 2013;27(6):531&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">24065615</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranhao R.C., Guido M.C., de Lima A.D., Tavares E.R., Marques A.F., Tavares de Melo M.D., et al. Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats. Int. J. Nanomed. 2017;12:3767&#x2013;3784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5440040</ArticleId><ArticleId IdType="pubmed">28553113</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., et al. Third universal definition of myocardial infarction. Eur. Heart J. 2012;33(20):2551&#x2013;2567.</Citation><ArticleIdList><ArticleId IdType="pubmed">22922414</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 2006;145(4):247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908915</ArticleId></ArticleIdList></Reference><Reference><Citation>Everett B.M., Pradhan A.D., Solomon D.H., Paynter N., Macfadyen J., Zaharris E., et al. Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am. Heart J. 2013;166(2):199&#x2013;207 e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888829</ArticleId><ArticleId IdType="pubmed">23895801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosowsky A., Forsch R.A., Yu C.S., Lazarus H., Beardsley G.P. Methotrexate analogues. 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters. J. Med. Chem. 1984;27(5):605&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">6585550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bainey K.R., Patel M.R., Armstrong P.W. Evaluation of cardiac magnetic resonance as a surrogate in ST-segment elevation myocardial infarction. Am. J. Cardiol. 2015;115(11):1607&#x2013;1614.</Citation><ArticleIdList><ArticleId IdType="pubmed">25890632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Huttin O., Marie P.Y., Felblinger J., Beaumont M., Chillou C., et al. Myocardial infarct sizing by late gadolinium-enhanced MRI: comparison of manual, full-width at half-maximum, and n-standard deviation methods. J. Magn. Reson. Imaging. 2016;44(5):1206&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">27096741</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizarro G., Fernandez-Friera L., Fuster V., Fernandez-Jimenez R., Garcia-Ruiz J.M., Garcia-Alvarez A., et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an acute myocardial infarction) J. Am. Coll. Cardiol. 2014;63(22):2356&#x2013;2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">24694530</ArticleId></ArticleIdList></Reference><Reference><Citation>Chareonthaitawee P., Christian T.F., Hirose K., Gibbons R.J., Rumberger J.A. Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. J. Am. Coll. Cardiol. 1995;25(3):567&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">7860898</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns R.J., Gibbons R.J., Yi Q., Roberts R.S., Miller T.D., Schaer G.L., et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J. Am. Coll. Cardiol. 2002;39(1):30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755283</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira D.M., Lueneberg M.E., da Silva R.L., Fattah T., Gottschall C.A.M. MethotrexaTE THerapy in ST-segment elevation MYocardial infarctions: a randomized double-blind, placebo-controlled trial (TETHYS trial) J. Cardiovasc. Pharmacol. Ther. 2017;22(6):538&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">28325070</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantz S., Hundertmark M.J., Schulz-Menger J., Bengel F.M., Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur. Heart J. 2022;43(27):2549&#x2013;2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9336586</ArticleId><ArticleId IdType="pubmed">35511857</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A., Meris A., Skali H., Ghali J.K., Arnold J.M., Bourgoun M., et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc. Imaging. 2008;1(5):582&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">19356485</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.S., Shin J.S., Lee Y.H., Seo K.W., Choi B.J., Choi S.Y., et al. Prognostic impact of left ventricular mass change in patients with ST-elevation myocardial infarction. Medicine (Baltimore) 2018;97(4):e9748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794406</ArticleId><ArticleId IdType="pubmed">29369222</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodi V., Monmeneu J.V., Ortiz-Perez J.T., Lopez-Lereu M.P., Bonanad C., Husser O., et al. Prediction of reverse remodeling at cardiac MR imaging soon after first ST-segment-elevation myocardial infarction: results of a large prospective registry. Radiology. 2016;278(1):54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">26348232</ArticleId></ArticleIdList></Reference><Reference><Citation>Broch K., Anstensrud A.K., Woxholt S., Sharma K., Tollefsen I.M., Bendz B., et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2021;77(15):1845&#x2013;1855.</Citation><ArticleIdList><ArticleId IdType="pubmed">33858620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling&#x2013;concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J. Am. Coll. Cardiol. 2000;35(3):569&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">10716457</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognese L., Neskovic A.N., Parodi G., Cerisano G., Buonamici P., Santoro G.M., Antoniucci D. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106(18):2351&#x2013;2357.</Citation><ArticleIdList><ArticleId IdType="pubmed">12403666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer C.M., Rogers W.J., Theobald T.M., Power T.P., Geskin G., Reichek N. Dissociation between changes in intramyocardial function and left ventricular volumes in the eight weeks after first anterior myocardial infarction. J. Am. Coll. Cardiol. 1997;30(7):1625&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">9385886</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar S.S., Rao S.V., Melloni C., Raman S.V., Povsic T.J., Melton L., et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011;305(18):1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486644</ArticleId><ArticleId IdType="pubmed">21558517</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir R.A., Tsorlalis I.K., Steedman T., Dargie H.J., Fraser R., McMurray J.J., Connell J.M. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. Eur. J. Heart Fail. 2011;13(12):1305&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">21940729</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lemos J.A., Antman E.M., Giugliano R.P., McCabe C.H., Murphy S.A., Van de Werf F., et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am. J. Cardiol. 2000;85(3):299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">11078296</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccoli G., Scalone G., Lerman A., Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur. Heart J. 2016;37(13):1024&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">26364289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghobrial M., Bawamia B., Cartlidge T., Spyridopoulos I., Kunadian V., Zaman A., et al. Microvascular obstruction in acute myocardial infarction, a potential therapeutic target. J. Clin. Med. 2023;12(18)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10532390</ArticleId><ArticleId IdType="pubmed">37762875</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40833396</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1535-1386</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>16</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of bone and joint surgery. American volume</Title><ISOAbbreviation>J Bone Joint Surg Am</ISOAbbreviation></Journal><ArticleTitle>Navigating Total Knee Arthroplasty After Myocardial Infarction: Commentary on an article by Alejandro M. Holle, BS, et al.: "Myocardial Infarction Prior to TKA Is Associated with Increased Risk of Medical and Surgical Complications in a Time-Dependent Manner".</ArticleTitle><Pagination><StartPage>e79</StartPage><MedlinePgn>e79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2106/JBJS.25.00583</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halawi</LastName><ForeName>Mohamad J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-9433-2994</Identifier><AffiliationInfo><Affiliation>OrthoDallas, Dallas, Texas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Bone Joint Surg Am</MedlineTA><NlmUniqueID>0014030</NlmUniqueID><ISSNLinking>0021-9355</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Disclosure: The Disclosure of Potential Conflicts of Interest form is provided with the online version of the article (http://links.lww.com/JBJS/I693).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>10</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40833396</ArticleId><ArticleId IdType="doi">10.2106/JBJS.25.00583</ArticleId><ArticleId IdType="pii">00004623-202508200-00020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40845590</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-095X</ISSN><JournalIssue CitedMedium="Internet"><Volume>147</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title><ISOAbbreviation>Phytomedicine</ISOAbbreviation></Journal><ArticleTitle>The total xanthones from Gentianella acuta alleviate acute myocardial infarction by targeting BRD4-mediated cardiomyocyte pyroptosis and inflammation.</ArticleTitle><Pagination><StartPage>157156</StartPage><MedlinePgn>157156</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2025.157156</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0944-7113(25)00795-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gentianella acuta (G. acuta), a traditional remedy for cardiovascular ailments among the Ewenki people of China, has been reported to contain xanthones as its primary bioactive components. However, the complete chemical composition of G. acuta's total xanthones (TXG) and their therapeutic targets in the treatment of acute myocardial infarction (AMI) remain inadequately characterized.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aims to investigate the chemical composition of TXG and identify its therapeutic targets in AMI, focusing on its role and mechanism in the suppression of pyroptosis-mediated inflammatory myocardial injury.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">UPLC-Q/TOF-MS/MS analysis revealed 29 constituents in TXG, including xanthones, flavonoids, lignans, iridoids, and coumarins. And 7 compounds (including 4 xanthones) in TXG can be absorbed into the blood. Xanthones, which constituted 68.1% of TXG's total content as determined by high-performance liquid chromatography (HPLC), were the predominant compounds. Key xanthones identified included swertianolin, norswertianolin, bellidifolin, demethylbellidifolin, and mangiferin. Network pharmacology analysis, supported by qRT-PCR, molecular docking, and surface plasmon resonance (SPR) experimental validation, revealed that TXG's anti-AMI effects are linked to the modulation of inflammatory responses. Key therapeutic targets identified include TLR4, NF-&#x3ba;B, and NLRP3, along with their associated signaling pathways. In vivo and in vitro experiments confirmed that TXG reduced BRD4 expression, thereby inhibiting TLR4/NF-&#x3ba;B/NLRP3 signaling. This inhibition attenuated cardiomyocyte pyroptosis and inflammation, reduced infarct size, and improved functional and pathological outcomes in AMI.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates that xanthones, the major constituents of G. acuta, are absorbed into the bloodstream and exert their therapeutic effects by inhibiting pyroptosis-mediated cardiac inflammation. The underlying mechanism involves multi-target inhibition of the BRD4/TLR4/NF-&#x3ba;B/NLRP3 pathway, underscoring the potential of G. acuta in AMI treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier GmbH. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jiahuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China; Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, Shijiazhuang, 050091, Hebei, China; Hebei Higher Education Institute Applied Technology Research Center of TCM Development and Industrialization, Shijiazhuang, 050091, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Gaoshan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China; Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, Shijiazhuang, 050091, Hebei, China; Hebei Higher Education Institute Applied Technology Research Center of TCM Development and Industrialization, Shijiazhuang, 050091, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chuang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yajing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Qiuhang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xingchao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hebei Higher Education Institute Applied Technology Research Center of TCM Development and Industrialization, Shijiazhuang, 050091, Hebei, China; College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Xuhong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China. Electronic address: duanxuhong@hebcm.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongxia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, Shijiazhuang, 050091, Hebei, China; Hebei Higher Education Institute Applied Technology Research Center of TCM Development and Industrialization, Shijiazhuang, 050091, Hebei, China; Department of Epidemic Febrile Disease, College of Traditional Chinese Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China. Electronic address: yanghongxia@hebcm.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Aiying</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Hebei, China; Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, Shijiazhuang, 050091, Hebei, China; Hebei Higher Education Institute Applied Technology Research Center of TCM Development and Industrialization, Shijiazhuang, 050091, Hebei, China. Electronic address: aiyingli1963@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Phytomedicine</MedlineTA><NlmUniqueID>9438794</NlmUniqueID><ISSNLinking>0944-7113</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMI</Keyword><Keyword MajorTopicYN="N">BRD4/TLR4/NF-&#x3ba;B/NLRP3 signaling</Keyword><Keyword MajorTopicYN="N">Network pharmacology</Keyword><Keyword MajorTopicYN="N">TXG</Keyword><Keyword MajorTopicYN="N">UPLC-Q/TOF-MS/MS and HPLC</Keyword><Keyword MajorTopicYN="N">cardiomyocyte pyroptosis</Keyword></KeywordList><CoiStatement>Declaration of competing interest No declaration of interest is required.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845590</ArticleId><ArticleId IdType="doi">10.1016/j.phymed.2025.157156</ArticleId><ArticleId IdType="pii">S0944-7113(25)00795-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843126</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-042X</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in physiology</Title><ISOAbbreviation>Front Physiol</ISOAbbreviation></Journal><ArticleTitle>Effects of bisoprolol combined with torasemide on cardiac electrophysiology in patients with acute myocardial infarction and heart failure.</ArticleTitle><Pagination><StartPage>1629758</StartPage><MedlinePgn>1629758</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1629758</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphys.2025.1629758</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This paper aims to assess the impact of bisoprolol combined with torasemide on cardiac electrophysiological parameters in acute myocardial infarction (AMI) patients complicated by heart failure (HF).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 140 AMI-HF patients were randomized to either the control group (bisoprolol alone for 3 months, n = 70) or an experimental group (bisoprolol for 3 months plus torasemide for 2 weeks, n = 70). The corrected QT (QTc) interval, QT dispersion, B-type natriuretic peptide (BNP) levels, left ventricular ejection fraction (LVEF), serum creatinine, serum potassium, New York Heart Association (NYHA) classification, Borg dyspnea score, lower-limb edema resolution, systolic/diastolic blood pressure (SBP/DBP), heart rate (HR), incidence of ventricular arrhythmia (VA) and atrial flutter/fibrillation (AFL/AF), and cardiovascular and all-cause mortality were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Both groups demonstrated statistically significant reductions in QTc interval, QT dispersion, BNP, NYHA class, Borg score, SBP, DBP, HR, along with increased LVEF at 2 weeks and 3 months post-treatment versus baseline, with the experimental group showing moderate improvement at 2 weeks post-treatment in all parameters than the control group (<i>P</i> &lt; 0.05). The experimental group had high serum potassium levels and a greater rate of lower-limb edema-resolution at 2 weeks post-treatment than the control group (<i>P</i> &lt; 0.05). No significant differences were observed between groups in cardiovascular or all-cause mortality (<i>P</i> &gt; 0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Bisoprolol combined with torasemide improves cardiac electrophysiological parameters, cardiac function, symptoms, and hemodynamics in AMI-HF patients as early as 2 weeks into treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Jing, Shi and Zhao.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Qiangwei</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shihao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Physiol</MedlineTA><NlmUniqueID>101549006</NlmUniqueID><ISSNLinking>1664-042X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">bisoprolol</Keyword><Keyword MajorTopicYN="N">cardiac electrophysiology</Keyword><Keyword MajorTopicYN="N">cardiac function</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">torasemide</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843126</ArticleId><ArticleId IdType="pmc">PMC12364864</ArticleId><ArticleId IdType="doi">10.3389/fphys.2025.1629758</ArticleId><ArticleId IdType="pii">1629758</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acuna C. (2010). Update: prolonged-release torasemide. Drugs Today (Barc) 46 (Suppl. E), 1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">20882198</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsam P., Ozieranski K., Marchel M., Gawalko M., Niedziela L., Tyminska A., et al. (2019). Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: preliminary results from the randomized TORNADO trial. Cardiol. J. 26 (6), 661&#x2013;668. 10.5603/CJ.a2019.0114</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/CJ.a2019.0114</ArticleId><ArticleId IdType="pmc">PMC8083045</ArticleId><ArticleId IdType="pubmed">31909470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett J. A., Riegel B., Bittner V., Nichols J. (2002). Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung 31 (4), 262&#x2013;270. 10.1067/mhl.2002.124554</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mhl.2002.124554</ArticleId><ArticleId IdType="pubmed">12122390</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg G. A. (1982). Psychophysical bases of perceived exertion. Med. Sci. Sports Exerc 14 (5), 377&#x2013;381. 10.1249/00005768-198205000-00012</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/00005768-198205000-00012</ArticleId><ArticleId IdType="pubmed">7154893</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan M. T., Harmouch K. M., Basit J., Alraies M. C. (2024). Beta-blocker usage in patients with heart failure with reduced ejection fraction during acute decompensated heart failure hospitalizations. Ochsner J. 24 (3), 198&#x2013;203. 10.31486/toj.24.0011</Citation><ArticleIdList><ArticleId IdType="doi">10.31486/toj.24.0011</ArticleId><ArticleId IdType="pmc">PMC11398626</ArticleId><ArticleId IdType="pubmed">39280877</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler J., Jones W. S., Udell J. A., Anker S. D., Petrie M. C., Harrington J., et al. (2024). Empagliflozin after acute myocardial infarction. N. Engl. J. Med. 390 (16), 1455&#x2013;1466. 10.1056/NEJMoa2314051</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2314051</ArticleId><ArticleId IdType="pubmed">38587237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V. K., Mohanan P. P., Kher V., Mantri R. R., Isaacs R., Jadhav U., et al. (2023). The potential role of torsemide in optimizing loop diuretic therapy for heart failure patients. Cureus 15 (7), e41957. 10.7759/cureus.41957</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.41957</ArticleId><ArticleId IdType="pmc">PMC10426810</ArticleId><ArticleId IdType="pubmed">37588313</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton S., Devereux G., Abbas H., Briggs A., Campbell K., Chaudhuri R., et al. (2022). Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials 23 (1), 307. 10.1186/s13063-022-06226-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-022-06226-8</ArticleId><ArticleId IdType="pmc">PMC9009490</ArticleId><ArticleId IdType="pubmed">35422024</ArticleId></ArticleIdList></Reference><Reference><Citation>Czubryt M. P., Hale T. M. (2021). Cardiac fibrosis: pathobiology and therapeutic targets. Cell Signal 85, 110066. 10.1016/j.cellsig.2021.110066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2021.110066</ArticleId><ArticleId IdType="pmc">PMC8355135</ArticleId><ArticleId IdType="pubmed">34146658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Z., Nishihata Y., Urayama K. Y., Komiyama N. (2024). Early initiation of oral beta-blocker improves long-term survival in patients with acute myocardial infarction who underwent primary percutaneous coronary intervention. BMC Cardiovasc Disord. 24 (1), 511. 10.1186/s12872-024-04188-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-024-04188-0</ArticleId><ArticleId IdType="pmc">PMC11429823</ArticleId><ArticleId IdType="pubmed">39327569</ArticleId></ArticleIdList></Reference><Reference><Citation>Definition of VA (2022). According to the expert consensus on ventricular arrhythmias (VA) in primary care in China, the diagnosis of VA is primarily based on electrocardiogram (ECG) and holter monitoring. Chinese society of pacing and electrophysiology, Chinese society of cardiology; cardiac electrophysiology branch, Chinese medical doctor association. Expert consensus on ventricular arrhythmias in primary care. Chin. J. Card. Arrhyth 26 (2), 106126.</Citation></Reference><Reference><Citation>Dong L., Li M., Cao T., Zhao Y., Wang S., Zou P., et al. (2025). Protective effect of carbon dots derived from salvia miltiorrhiza pretreatment in acute myocardial infarction in rats. Nanomater. (Basel) 15 (3), 242. 10.3390/nano15030242</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano15030242</ArticleId><ArticleId IdType="pmc">PMC11821062</ArticleId><ArticleId IdType="pubmed">39940217</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene S. J., Velazquez E. J., Anstrom K. J., Clare R. M., DeWald T. A., Psotka M. A., et al. (2023). Effect of torsemide versus furosemide on symptoms and quality of life among patients hospitalized for heart failure: the TRANSFORM-HF randomized clinical trial. Circulation 148 (2), 124&#x2013;134. 10.1161/CIRCULATIONAHA.123.064842</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.064842</ArticleId><ArticleId IdType="pmc">PMC10524905</ArticleId><ArticleId IdType="pubmed">37212600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassen M., Ebsa T. K., Muhammed O. S., Solomon T., Demessie M. B., Wendie T. F., et al. (2025). Patterns of beta-blocker use and dose optimization among ambulatory heart failure patients with reduced ejection fraction (HFrEF) attending public hospitals in Northeast Ethiopia: a multi-center cross-sectional study. BMC Cardiovasc Disord. 25 (1), 43. 10.1186/s12872-025-04501-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-025-04501-5</ArticleId><ArticleId IdType="pmc">PMC11756068</ArticleId><ArticleId IdType="pubmed">39849374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim J., Fabrizio C., Sezer A., Thoma F., Boyle B., Mulukutla S. R., et al. (2024). Beta blockers are associated with lower all-cause mortality among HFpEF patients. Clin. Res. Cardiol. 113 (6), 951&#x2013;958. 10.1007/s00392-024-02451-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-024-02451-0</ArticleId><ArticleId IdType="pubmed">38695899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapelios C. J., Greene S. J., Mentz R. J., Ikeaba U., Wojdyla D., Anstrom K. J., et al. (2024). Torsemide versus furosemide after discharge in patients hospitalized with heart failure across the spectrum of ejection fraction: findings from TRANSFORM-HF. Circ. Heart Fail 17 (3), e011246. 10.1161/CIRCHEARTFAILURE.123.011246</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.123.011246</ArticleId><ArticleId IdType="pmc">PMC10950535</ArticleId><ArticleId IdType="pubmed">38436075</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan L. A., Jamil A., Greene S. J., Khan M. S., Butler J. (2024). Aldosterone and potassium in heart failure: overcoming this major impediment in clinical practice. Card. Fail Rev. 10, e18. 10.15420/cfr.2024.09</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/cfr.2024.09</ArticleId><ArticleId IdType="pmc">PMC11770538</ArticleId><ArticleId IdType="pubmed">39872850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Tran S., Ngo T. H., Phuong Nguyen A. T., Ngoc Huynh H. T., Vo C. T., Bao Nguyen N. N., et al. (2023). The effect of bisoprolol on premature ventricular complex in Vietnamese patients with hypertension and left ventricular hypertrophy. Curr. Hypertens. Rev. 19 (1), 42&#x2013;51. 10.2174/1573402119666230110101228</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573402119666230110101228</ArticleId><ArticleId IdType="pubmed">36627790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitahiro Y., Hashimoto M., Sonda Y., Yagi M., Itohara K., Kido T., et al. (2025). Neonatal metabolic alkalosis and mild diuresis resulting from torasemide self-medication by the mother: a case report. J. Pharm. Health Care Sci. 11 (1), 31. 10.1186/s40780-025-00436-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40780-025-00436-3</ArticleId><ArticleId IdType="pmc">PMC11992707</ArticleId><ArticleId IdType="pubmed">40217334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittipibul V., Mentz R. J., Clare R. M., Wojdyla D. M., Anstrom K. J., Eisenstein E. L., et al. (2024). On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: a post-hoc analysis of TRANSFORM-HF. Eur. J. Heart Fail 26 (7), 1518&#x2013;1523. 10.1002/ejhf.3293</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.3293</ArticleId><ArticleId IdType="pmc">PMC11269016</ArticleId><ArticleId IdType="pubmed">38745502</ArticleId></ArticleIdList></Reference><Reference><Citation>Koev I., Yarkoni M., Luria D., Amir O., Biton Y. (2023). Sudden cardiac death prevention in the era of novel heart failure medications. Am. Heart J. Plus 27, 100281. 10.1016/j.ahjo.2023.100281</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahjo.2023.100281</ArticleId><ArticleId IdType="pmc">PMC10945958</ArticleId><ArticleId IdType="pubmed">38511092</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Si J., Liu Y., Xu D. (2025). Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF. Esc. Heart Fail 12 (1), 71&#x2013;79. 10.1002/ehf2.15071</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.15071</ArticleId><ArticleId IdType="pmc">PMC11769599</ArticleId><ArticleId IdType="pubmed">39238285</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Wang T., Han K., Zhuo X., Lu Q., Ma A. (2011). Bisoprolol reverses down-regulation of potassium channel proteins in ventricular tissues of rabbits with heart failure. J. Biomed. Res. 25 (4), 274&#x2013;279. 10.1016/S1674-8301(11)60037-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1674-8301(11)60037-7</ArticleId><ArticleId IdType="pmc">PMC3597065</ArticleId><ArticleId IdType="pubmed">23554701</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C., Zhang C., Gan S., Chen X., Tan Z. (2022). Long-term effect of beta-blocker use on clinical outcomes in postmyocardial infarction patients: a systematic review and meta-analysis. Front. Cardiovasc Med. 9, 779462. 10.3389/fcvm.2022.779462</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.779462</ArticleId><ArticleId IdType="pmc">PMC9024047</ArticleId><ArticleId IdType="pubmed">35463744</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Zhang G., Liang X., Qin D. (2024). Effect of a patient health engagement (PHE) model on rehabilitation participation in patients with acute myocardial infarction after PCI: a study protocol for a randomized controlled trial. Trials 25 (1), 786. 10.1186/s13063-024-08643-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-024-08643-3</ArticleId><ArticleId IdType="pmc">PMC11583480</ArticleId><ArticleId IdType="pubmed">39574197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Li Y., Li P., Yang X., Zhu S., Ma K., et al. (2024). S100A8/A9 as a prognostic biomarker with causal effects for post-acute myocardial infarction heart failure. Nat. Commun. 15 (1), 2701. 10.1038/s41467-024-46973-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46973-7</ArticleId><ArticleId IdType="pmc">PMC10973499</ArticleId><ArticleId IdType="pubmed">38538601</ArticleId></ArticleIdList></Reference><Reference><Citation>Maqsood M. H., Alam M., Atar D., Birnbaum Y. (2021). Efficacy of long-term oral beta-blocker therapy in patients who underwent percutaneous coronary intervention for ST-segment elevation myocardial infarction with preserved left ventricular ejection fraction: a systematic review and meta-analysis. J. Cardiovasc Pharmacol. 77 (1), 87&#x2013;93. 10.1097/FJC.0000000000000922</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000000922</ArticleId><ArticleId IdType="pubmed">33136764</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh T. A., Metra M., Adamo M., Gardner R. S., Baumbach A., Bohm M., et al. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42 (36), 3599&#x2013;3726. 10.1093/eurheartj/ehab368</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab368</ArticleId><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentz R. J., Anstrom K. J., Eisenstein E. L., Sapp S., Greene S. J., Morgan S., et al. (2023). Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA 329 (3), 214&#x2013;223. 10.1001/jama.2022.23924</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.23924</ArticleId><ArticleId IdType="pmc">PMC9857435</ArticleId><ArticleId IdType="pubmed">36648467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K., Inokuchi R., Hiruma T., Tokunaga K., Doi K., Nakajima S. (2016). Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. J. Anesth. 30 (5), 891&#x2013;894. 10.1007/s00540-016-2199-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-016-2199-9</ArticleId><ArticleId IdType="pubmed">27262288</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzuoli A., Mazzeo P., Fortunato M., Cadeddu Dessalvi C., Mariano E., Salzano A., et al. (2024). The changing role of loop diuretics in heart failure management across the last century. J. Clin. Med. 13 (6), 1674. 10.3390/jcm13061674</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13061674</ArticleId><ArticleId IdType="pmc">PMC10970945</ArticleId><ArticleId IdType="pubmed">38541899</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter B. M., Ames M. K., Hess A., Poglitsch M. (2019). Comparison between the effects of torsemide and furosemide on the renin-angiotensin-aldosterone system of normal dogs. J. Vet. Cardiol. 26, 51&#x2013;62. 10.1016/j.jvc.2019.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvc.2019.11.003</ArticleId><ArticleId IdType="pubmed">31809955</ArticleId></ArticleIdList></Reference><Reference><Citation>Roghani S. H., Khan D. S., Shafiq A., Akbar A., Mustafa W., Shah S. Q. A., et al. (2024). Efficacy of different beta blockers in reducing mortality in heart-failure patients. Cureus 16 (11), e74171. 10.7759/cureus.74171</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.74171</ArticleId><ArticleId IdType="pmc">PMC11604132</ArticleId><ArticleId IdType="pubmed">39611070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabina M., Shah S., Grimm M., Daher J. C., Campillo P., Boozo M. B., et al. (2024). Beta-blockers in patients with myocardial infarction and preserved left ventricular ejection: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Med. 14 (1), 150. 10.3390/jcm14010150</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm14010150</ArticleId><ArticleId IdType="pmc">PMC11721919</ArticleId><ArticleId IdType="pubmed">39797234</ArticleId></ArticleIdList></Reference><Reference><Citation>Safi S., Sethi N. J., Nielsen E. E., Feinberg J., Jakobsen J. C., Gluud C. (2019). Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database Syst. Rev. 12 (12), CD012484. 10.1002/14651858.CD012484.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD012484.pub2</ArticleId><ArticleId IdType="pmc">PMC6915833</ArticleId><ArticleId IdType="pubmed">31845756</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Goel S., Duhan S., Chaudhary R., Garg A., Tantry U. S., et al. (2023). Effect of furosemide versus torsemide on hospitalizations and mortality in patients with heart failure: a meta-analysis of randomized controlled trials. Am. J. Cardiol. 206, 42&#x2013;48. 10.1016/j.amjcard.2023.08.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2023.08.079</ArticleId><ArticleId IdType="pmc">PMC10824237</ArticleId><ArticleId IdType="pubmed">37677884</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi S., Honda S., Nishihira K., Kojima S., Takegami M., Asaumi Y., et al. (2024). Prognostic impact of heart failure admission in survivors of acute myocardial infarction. Esc. Heart Fail 11 (4), 2344&#x2013;2353. 10.1002/ehf2.14790</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.14790</ArticleId><ArticleId IdType="pmc">PMC11287335</ArticleId><ArticleId IdType="pubmed">38685603</ArticleId></ArticleIdList></Reference><Reference><Citation>Tin N. T., Van Minh H., Thang D. C., Phuong P. T. M. (2023). Serum periostin levels in acute myocardial infarction patients: a 3-month follow-up study. Acta Inf. Med. 31 (3), 195&#x2013;199. 10.5455/aim.2023.31.195-199</Citation><ArticleIdList><ArticleId IdType="doi">10.5455/aim.2023.31.195-199</ArticleId><ArticleId IdType="pmc">PMC10540933</ArticleId><ArticleId IdType="pubmed">37781497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C. H., Chen Z. W., Lee B. C., Liao C. W., Chang Y. Y., Tsai Y. R., et al. (2024). Aldosterone, mitochondria and regulation of cardiovascular metabolic disease. J. Endocrinol. 263 (1), e230350. 10.1530/JOE-23-0350</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JOE-23-0350</ArticleId><ArticleId IdType="pubmed">39121045</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbrugge F. H., Menon V. (2022). Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF) trial. Eur. Heart J. Acute Cardiovasc Care 11 (12), 931&#x2013;932. 10.1093/ehjacc/zuac144</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuac144</ArticleId><ArticleId IdType="pubmed">36351030</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Rodriguez M., El Hachem K., Krittanawong C. (2024). Diuretic treatment in heart failure: a practical guide for clinicians. J. Clin. Med. 13 (15), 4470. 10.3390/jcm13154470</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13154470</ArticleId><ArticleId IdType="pmc">PMC11313642</ArticleId><ArticleId IdType="pubmed">39124738</ArticleId></ArticleIdList></Reference><Reference><Citation>Yndigegn T., Lindahl B., Mars K., Alfredsson J., Benatar J., Brandin L., et al. (2024). Beta-blockers after myocardial infarction and preserved ejection fraction. N. Engl. J. Med. 390 (15), 1372&#x2013;1381. 10.1056/NEJMoa2401479</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2401479</ArticleId><ArticleId IdType="pubmed">38587241</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng T., Luo C., Xu S., Li X., Tian G. (2025). Association of the systemic immune-inflammation index with clinical outcomes in acute myocardial infarction patients with hypertension. BMC Immunol. 26 (1), 10. 10.1186/s12865-025-00690-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-025-00690-y</ArticleId><ArticleId IdType="pmc">PMC11869594</ArticleId><ArticleId IdType="pubmed">40016638</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40842346</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0903</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><PubDate><Year>2025</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Human &amp; experimental toxicology</Title><ISOAbbreviation>Hum Exp Toxicol</ISOAbbreviation></Journal><ArticleTitle>Pelargonidin-3-O-glucoside prevents isoproterenol-induced myocardial infarction via modulating cardiac and inflammatory markers expression in experimental rats.</ArticleTitle><Pagination><StartPage>9603271251369054</StartPage><MedlinePgn>9603271251369054</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09603271251369054</ELocationID><Abstract><AbstractText>IntroductionThis study examined the cardioprotective effects of Pelargonidin-3-O-glucoside (Pg3G) against myocardial infarction induced by isoproterenol (ISO) in male Wistar rats.MethodsAnimals were divided into four groups each groups contain six animals. Group 1 control; Group 2 Pg3G treated control; Group 3 ISO-control; Group 4 Pg3G + ISO treated rats. At the end of the experiment period the animals were sacrificed and collected the serum, heart tissue used for the experimental work.ResultsAccording to the network pharmacology analysis, Prostaglandin-endoperoxide Synthase 2 (PTGS2), Matrix metallo proteins -9 (MMP-9), and tumour necrosis factor-alpha (TNF-&#x3b1;) were identified as potential targets among the 97 common targets between Pg3G and myocardial injury. Further, we investigated that prominent cardiac indicator such creatine kinase (CK), CK-MB, cardiac troponin T (cTnT), and cardiac troponin I (cTnI) were not elevated by ISO in the presence of Pg3G administration. Additionally, Pg3G administration decreased the pro-inflammatory cytokines generated by ISO, including as interleukin-6 (IL-6), interleukin-1 beta (IL-1&#x3b2;), and TNF-&#x3b1;, suggesting its anti-inflammatory qualities. Additionally, Pg3G increased levels of reduced glutathione (GSH) and restored the activity of important antioxidant enzymes that were depleted by ISO-induced oxidative stress, including glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD).DiscussionPg3G capacity to reduce ISO-induced inflammatory, fibrotic, and cardiac toxicity markers in myocardial tissue was demonstrated by gene expression investigations. Therefore, Pg3G may be considered for ISO-induced cardiac injury since it provides significant cardioprotection by reducing oxidative stress, inflammation, and fibrosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jianmei</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0005-9128-8162</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Shanghai Pudong New Area People's Hospital, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0006-8640-1762</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Huai&#xe1;n Clinical Medical College of Jiangsu University (Huai&#xe1;n Hospital of Huai&#xe1;n City), China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Peng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0003-5807-9575</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The Third People's Hospital of Gansu Province, Lanzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Exp Toxicol</MedlineTA><NlmUniqueID>9004560</NlmUniqueID><ISSNLinking>0960-3271</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>L628TT009W</RegistryNumber><NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000872">Anthocyanins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007545" MajorTopicYN="N">Isoproterenol</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="Y">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000872" MajorTopicYN="Y">Anthocyanins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="Y">Glucosides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="Y">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardioprotection</Keyword><Keyword MajorTopicYN="N">isoproterenol</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">pelargonidin-3-O-glucoside</Keyword><Keyword MajorTopicYN="N">troponin</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40842346</ArticleId><ArticleId IdType="doi">10.1177/09603271251369054</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40837650</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1729-0503</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>African health sciences</Title><ISOAbbreviation>Afr Health Sci</ISOAbbreviation></Journal><ArticleTitle>Associated factors of spontaneous reperfusion in patients with acute ST-segment elevation myocardial infarction before primary percutaneous coronary intervention.</ArticleTitle><Pagination><StartPage>85</StartPage><EndPage>93</EndPage><MedlinePgn>85-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4314/ahs.v25i2.12</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">This is a retrospective analysis of the relationship between preoperative factors and spontaneous reperfusion (SR) in infarct-related arteries (IRAs) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI).</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="UNASSIGNED">834 patients who were classified into the SR group (TIMI flow grade 2-3) and non-spontaneous reperfusion (NSR) group (TIMI flow grade 0-1) based on coronary angiography. The baseline characteristics and preoperative factors of the two groups were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Compared with the NSR group, the SR group had shorter time from symptom onset to first medical contact (P=0.002) and from symptom onset to antiplatelet loading (P=0.003), however, there was no statistically significant difference in the mode of admission and loading of antiplatelet drugs between the two groups. Multivariate logistic regression analysis indicated that diabetes history, smoking history, triglyceride level, time from symptom onset to first medical contact, time from symptom onset to antiplatelet loading, and time from antiplatelet loading to coronary angiography were all factors influencing SR were all factors influencing SR.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The occurrence of SR is related to early medical contact and timely use of antiplatelet drugs. Patients with diabetes history, smoking history, higher triglyceride level may benefit more.</AbstractText><CopyrightInformation>&#xa9; 2025 He W et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Weimin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Sixth Affiliated Hospital, South China University of Technology, Foshan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yixuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Sixth Affiliated Hospital, South China University of Technology, Foshan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Fengxin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Sixth Affiliated Hospital, South China University of Technology, Foshan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Sixth Affiliated Hospital, South China University of Technology, Foshan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Afr Health Sci</MedlineTA><NlmUniqueID>101149451</NlmUniqueID><ISSNLinking>1680-6905</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute ST-segment elevation myocardial infarction</Keyword><Keyword MajorTopicYN="N">preoperative factors</Keyword><Keyword MajorTopicYN="N">spontaneous reperfusion</Keyword></KeywordList><CoiStatement>The authors declared no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837650</ArticleId><ArticleId IdType="pmc">PMC12361933</ArticleId><ArticleId IdType="doi">10.4314/ahs.v25i2.12</ArticleId><ArticleId IdType="pii">jAFHS.v25.i2.pg85</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu S, Yang Y, Liu L, et al. [Summary of the 2018 Report on Cardiovascular Diseases in China] Chinese Circukiticn Journal. 2019;034(003):209&#x2013;220.</Citation></Reference><Reference><Citation>Puymirat E, Simon T, Steg PG, Schiele F, Gueret P, Blanchard D, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA-J Am Med Assoc. 2012;308:998&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">22928184</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale CP, Allan V, Cattle BA, Hall AS, West RM, Timmis A, et al. Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003-2010: a multilevel and relative survival analysis for the National Institute for Cardiovascular Outcomes Research (NICOR) Heart. 2014;100:582&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">24436220</ArticleId></ArticleIdList></Reference><Reference><Citation>[2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction] Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47:766&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">31648459</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimar D, Crystal E, Battler A, Gottlieb S, Freimark D, Hod H, et al. Improved prognosis of patients presenting with clinical markers of spontaneous reperfusion during acute myocardial infarction. Heart. 2002;88:352&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1767387</ArticleId><ArticleId IdType="pubmed">12231590</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao R, Yu J, Yan L, et al. Clinical analysis on acute ST-segment elevation myocardial infarction in patients with normal coronary angiography. Chin J Intervent Cardiol. 2012;020(002):94&#x2013;96.</Citation></Reference><Reference><Citation>Kim JW, Seo HS, Suh SY, Choi CU, Kim EJ, Rha SW, et al. Relationship between lipoprotein(a) and spontaneous recanalization of infarct-related arteries in the early phase of acute myocardial infarction. Clin Cardiol. 2008;31:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6653200</ArticleId><ArticleId IdType="pubmed">18473375</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhou Y, Zhang Y, Zheng J. Admission homocysteine is an independent predictor of spontaneous reperfusion and early infarct-related artery patency before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. BMCmc Cardiovasc Disor. 2018;18:125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6020223</ArticleId><ArticleId IdType="pubmed">29940881</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YP, Ji YY, Wang FY, Wang SL, Lai GK, Wang T, et al. [Value of fibrinogen to albumin ratio on predicting spontaneous recanalization of infarct-related artery in patients with acute ST-segment elevation myocardial infarction] Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47:123&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">30818940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, He SY. Clinical and angiographic characteristics of patients with spontaneous reperfusion in ST-segment elevation myocardial infarction. Medicine. 2020;99:e19267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478519</ArticleId><ArticleId IdType="pubmed">32150062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bainey KR, Fu Y, Wagner GS, Goodman SG, Ross A, Granger CB, et al. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. Am Heart J. 2008;156:248&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">18657653</ArticleId></ArticleIdList></Reference><Reference><Citation>Steg PG, Himbert D, Benamer H, Karrillon G, Boccara A, Aubry P, et al. Conservative management of patients with acute myocardial infarction and spontaneous acute patency of the infarct-related artery. Am Heart J. 1997;134:248&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">9313604</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian TF, Milavetz JJ, Miller TD, Clements IP, Holmes DR, Gibbons RJ. Prevalence of spontaneous reperfusion and associated myocardial salvage in patients with acute myocardial infarction. Am Heart J. 1998;135:421&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Hong MK, Lee JH, Yang HS, Kim JJ, Park SW, et al. Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction. Am J Cardiol. 2001;87:951&#x2013;954. A3.</Citation><ArticleIdList><ArticleId IdType="pubmed">11305984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol. 1999;34:1954&#x2013;1962.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588209</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001;104:636&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">11489767</ArticleId></ArticleIdList></Reference><Reference><Citation>Fefer P, Hod H, Hammerman H, Boyko V, Behar S, Matetzky S. Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction. Am J Cardiol. 2009;103:149&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">19121427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakowski T, Dudek D, Dziewierz A, Yu J, Witzenbichler B, Guagliumi G, et al. Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Euro Intervention. 2013;8(11):1307&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pubmed">23538158</ArticleId></ArticleIdList></Reference><Reference><Citation>Brener SJ, Mehran R, Brodie BR, Guagliumi G, Witzenbichler B, Cristea E, et al. Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials) Am J Cardiol. 2011;108:918&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">21764028</ArticleId></ArticleIdList></Reference><Reference><Citation>Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol. 2003;41:1013&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">12651051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupia E, Bosco O, Goffi A, Poletto C, Locatelli S, Spatola T, et al. Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis. 2010;210:314&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">20006331</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakowski T, Dziewierz A, Siudak Z, Mielecki W, Bierca K, Legutko J, et al. Predictors of infarct-related artery patency following combined lytic therapy in patients with ST-segment elevation myocardial infarction treated with immediate percutaneous coronary intervention. Kardiol Pol. 2011;69(5):452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">21594830</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Xu J, Fu L, Li L. Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients. Int J Clin Pract. 2020;74:e13508.</Citation><ArticleIdList><ArticleId IdType="pubmed">32279396</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao M, Zhao B, Liu P, et al. Pathological analysis of coronary artery thrombus in different ischemic time in patients with ST-segment elevation acute myocardial infarction. Med J Chin PLA. 2017;42(2):5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40834218</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1678-4170</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Arquivos brasileiros de cardiologia</Title><ISOAbbreviation>Arq Bras Cardiol</ISOAbbreviation></Journal><ArticleTitle>Association between Glucose/lymphocytes Ratio and Contrast-Induced Acute Kidney Injury in Patients with Myocardial Infarction without Diabetes Mellitus.</ArticleTitle><Pagination><StartPage>e20240869</StartPage><MedlinePgn>e20240869</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.36660/abc.20240869</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0066-782X2025000800301</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Glucose metabolism and systemic inflammation appears to be strongly related to many cardiovascular diseases. Glucose to lymphocyte ratio (GLR), a novel promising marker, has been recognized as a reliable predictor of prognosis in various cancers. However, there are still no studies on the association of cardiovascular disease with GLR.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This analysis aimed to uncover the potential association between GLR and the risk for contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PPCI) in a ST-elevation acute myocardial infarction (STEMI) population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Clinical data of 592 nondiabetic STEMI patients managed with PPCI from February 2021 to February 2023 were retrospectively analyzed. Patients with end-stage kidney disease, missing laboratory data, cancers, inflammatory/infectious diseases, or died during the procedure or within 24 hours after the procedure were excluded. The receiver operating characteristic curve was used to determine the optimal cutoff of GLR in CI-AKI. Based on the cutoff value, the study population was categorized into high-GLR (&#x2265;4.16) and low-GLR (&lt;4.16) groups. The level of significance adopted in the statistical analysis was 5%.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall CI-AKI incidence was 7.4%. The high-GLR group showed a higher CI-AKI incidence in comparison to the low-GLR group (30.9%vs1.3%, p&lt;0.001). Following adjustment for potential confounders, high-GLR still served as an independent predictor for CI-AKI (odds ratio [OR] 45.100, 95% confidence interval [CI] 7.312-278.174, p&lt;0.001), as well as creatinine at admission (OR:10.459, 95%CI 1.169-93.583, p=0.036).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, a high GLR level served as an independent risk factor for CI-AKI evolution after PPCI in subjects with STEMI without diabetes mellitus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf6;k</LastName><ForeName>Murat</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3118-9064</Identifier><AffiliationInfo><Affiliation>Trakya University Faculty of Medicine, Edirne - Turquia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurtul</LastName><ForeName>Alparslan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mustafa Kemal Universitesi Tayfur Ata Sokmen Tip Fakultesi, Hatay - Turquia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demir</LastName><ForeName>Or&#xe7;un</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Trakya University Faculty of Medicine, Edirne - Turquia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yalta</LastName><ForeName>Kenan</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5966-2488</Identifier><AffiliationInfo><Affiliation>Trakya University Faculty of Medicine, Edirne - Turquia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>por</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Associa&#xe7;&#xe3;o entre Rela&#xe7;&#xe3;o Glicose/Linf&#xf3;cito e Les&#xe3;o Renal Aguda Induzida por Contraste em Pacientes com Infarto do Mioc&#xe1;rdio N&#xe3;o Diab&#xe9;ticos.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Bras Cardiol</MedlineTA><NlmUniqueID>0421031</NlmUniqueID><ISSNLinking>0066-782X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="Y">Contrast Media</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="Y">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="Y">Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="FUNDAMENTO" NlmCategory="OBJECTIVE">O metabolismo da glicose e a inflama&#xe7;&#xe3;o sist&#xea;mica parecem estar fortemente relacionados a muitas doen&#xe7;as cardiovasculares. A rela&#xe7;&#xe3;o glicose-linf&#xf3;cito (RGL), um novo marcador promissor, tem sido reconhecida como um preditor confi&#xe1;vel de progn&#xf3;stico em v&#xe1;rios tipos de c&#xe2;ncer. No entanto, ainda n&#xe3;o existem estudos sobre a associa&#xe7;&#xe3;o entre doen&#xe7;as cardiovasculares e GLR.</AbstractText><AbstractText Label="OBJETIVOS" NlmCategory="OBJECTIVE">Esta an&#xe1;lise teve como objetivo investigar a poss&#xed;vel associa&#xe7;&#xe3;o entre RGL e o risco de les&#xe3;o renal aguda induzida por contraste (LRAIC) ap&#xf3;s interven&#xe7;&#xe3;o coron&#xe1;ria percut&#xe2;nea prim&#xe1;ria (ICPP) em uma popula&#xe7;&#xe3;o de pacientes com infarto agudo do mioc&#xe1;rdio com eleva&#xe7;&#xe3;o do segmento ST (IAMST).</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Os dados cl&#xed;nicos de 592 pacientes com IAMST n&#xe3;o diab&#xe9;ticos tratados com ICPP entre fevereiro de 2021 e fevereiro de 2023 foram analisados retrospectivamente. Pacientes com doen&#xe7;a renal terminal, dados laboratoriais ausentes, c&#xe2;ncer, doen&#xe7;as inflamat&#xf3;rias/infecciosas ou que faleceram durante o procedimento ou dentro de 24 horas ap&#xf3;s o procedimento foram exclu&#xed;dos. A curva caracter&#xed;stica de opera&#xe7;&#xe3;o do receptor (ROC) foi utilizada para determinar o valor de corte ideal da RGL na LRAIC. Com base nesse valor de corte, a popula&#xe7;&#xe3;o do estudo foi categorizada em grupos de RGL alta (&#x2265;4,16) e RGL baixa (&lt;4,16). O n&#xed;vel de signific&#xe2;ncia adotado na an&#xe1;lise estat&#xed;stica foi de 5%.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">A incid&#xea;ncia geral de LRAIC foi de 7,4%. O grupo de RGL alta apresentou uma incid&#xea;ncia maior de LRAIC em compara&#xe7;&#xe3;o ao grupo de RGL baixa (30,9% vs. 1,3%, p&lt;0,001). Ap&#xf3;s ajuste para potenciais fatores de confus&#xe3;o, a RGL alta continuou sendo um preditor independente para LRAIC [raz&#xe3;o de chances (OR) 45,100, intervalo de confian&#xe7;a (IC) 95% 7,312-278,174, p&lt;0,001], assim como a creatinina na admiss&#xe3;o (OR: 10,459, IC 95% 1,169-93,583, p=0,036).</AbstractText><AbstractText Label="CONCLUS&#xc3;O" NlmCategory="UNASSIGNED">Em conclus&#xe3;o, a RGL elevada foi um fator de risco independente para o desenvolvimento de LRAIC ICPP em indiv&#xed;duos com IAMST sem diabetes mellitus.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>14</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834218</ArticleId><ArticleId IdType="doi">10.36660/abc.20240869</ArticleId><ArticleId IdType="pii">S0066-782X2025000800301</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40839534</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-5830</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Coronary artery disease</Title><ISOAbbreviation>Coron Artery Dis</ISOAbbreviation></Journal><ArticleTitle>Temporal trends in the treatment with beta-blocker and the effect on outcome of patients with acute myocardial infarction.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/MCA.0000000000001568</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early beta-blocker treatment has long been recommended for patients with acute myocardial infarction (AMI), particularly when left ventricular ejection fraction (LVEF) is reduced; however, whether beta-blocker therapy improves outcomes in patients with AMI receiving contemporary treatment remains uncertain. This study aimed to investigate temporal trends in the effect of beta-blocker therapy on outcomes of patients with AMI in a large, nationwide cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with AMI enrolled in the Acute Coronary Syndromes Israeli Survey from 2000 to 2021 were included. They were categorized into three periods: early (2000-2004), mid (2006-2016), and late (2018-2021). Each period group was further divided into two subgroups based on LVEF (&gt;40 and &#x2264;40%) and then stratified by beta-blocker treatment status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The cohort consisted of 11 569 patients. Among patients with LVEF less than 40%, beta-blocker treatment was associated with improved 1-year survival rates in the early (9.1 vs. 20.4%; P &lt; 0.001) and mid (10 vs. 20.6%; P &lt; 0.001) periods only. Among patients with LVEF greater than or equal to 40%, beta-blocker treatment was linked to enhanced 1-year survival in patients enrolled in the early period (3.4 vs. 7.6%; P &lt; 0.001), but not in the mid and late periods.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The association between beta-blocker treatment and improved survival in patients with AMI has diminished over recent decades, regardless of LVEF. These findings are likely attributed to the advancements in contemporary medical and revascularization therapy. As such, our results may challenge current recommendations regarding beta-blocker therapy in AMI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giladi</LastName><ForeName>Ela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losin</LastName><ForeName>Ilya</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arow</LastName><ForeName>Ziad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilu</LastName><ForeName>Ranin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabah</LastName><ForeName>Oded</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sheba Medical Center, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barashi</LastName><ForeName>Rami</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omelchenko</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnson</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assali</LastName><ForeName>Abid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereg</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiology Department, Meir Medical Center, Kfar-Saba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gray Faculty of Medical &amp; Health Sciences, Tel-Aviv University, Ramat Aviv.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Coron Artery Dis</MedlineTA><NlmUniqueID>9011445</NlmUniqueID><ISSNLinking>0954-6928</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">beta-blocker</Keyword><Keyword MajorTopicYN="N">left ventricular ejection fraction</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839534</ArticleId><ArticleId IdType="doi">10.1097/MCA.0000000000001568</ArticleId><ArticleId IdType="pii">00019501-990000000-00406</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Freemantle N, Cleland J, Young P, Mason J, Harrison J. &#x3b2; Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730&#x2013;1737.</Citation></Reference><Reference><Citation>Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357:1385&#x2013;1390.</Citation></Reference><Reference><Citation>Kim J, Kang D, Park H, Kang M, Park TK, Lee JM, et al. Long-term &#x3b2;-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J 2020; 41:3521&#x2013;3529.</Citation></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al.; ESC Scientific Document Group. ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2023; 44:P3720&#x2013;P3826.</Citation></Reference><Reference><Citation>Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs: challenges for research and for patient care. J Am Coll Cardiol 2015; 66:1273&#x2013;1285.</Citation></Reference><Reference><Citation>Raposeiras-Roub&#xed;n S, Abu-Assi E, Rdondo-Di&#xe9;guez A, Gonz&#xe1;lez-Ferreiro R, L&#xf3;pez-L&#xf3;pez A, Bouzas-Cruz N, et al. Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still relevant today? Rev Esp Cardiol (Engl Ed) 2015; 68:585&#x2013;591.</Citation></Reference><Reference><Citation>Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, et al. &#x3b2;-Blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol 2017; 69:2710&#x2013;2720.</Citation></Reference><Reference><Citation>Braunwald E, Muller JE, Kloner RA, Maroko PR. Role of beta-adrenergic blockade in the therapy of patients with myocardial infarction. Am J Med 1983; 74:113&#x2013;123.</Citation></Reference><Reference><Citation>Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, Mukherjee D. Early intravenous beta-blockers in patients with acute coronary syndrome &#x2013; a meta-analysis of randomized trials. Int J Cardiol 2013; 168:915&#x2013;921.</Citation></Reference><Reference><Citation>Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335&#x2013;371.</Citation></Reference><Reference><Citation>Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328:673&#x2013;679.</Citation></Reference><Reference><Citation>Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336:1621&#x2013;1628.</Citation></Reference><Reference><Citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045&#x2013;1057.</Citation></Reference><Reference><Citation>Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al.; CAPITAL-RCT investigators. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One 2018; 13:e0199347.</Citation></Reference><Reference><Citation>Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366:1622&#x2013;1632.</Citation></Reference><Reference><Citation>Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, et al.; REDUCE-AMI Investigators. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med 2024; 390:1372&#x2013;1381.</Citation></Reference><Reference><Citation>Silvain J, Cayla G, Ferrari E, Range G, Puymirat E, Delarche N, et al.; ABYSS Investigators of the ACTION Study Group. Beta-blocker interruption or continuation after myocardial infarction. N Engl J Med 2024; 391:1277&#x2013;1286.</Citation></Reference><Reference><Citation>Miranda C, Gasevic D, Trin C, Stub D, Zoungas S, Kaye DM, et al. Beta-blocker therapy after myocardial infarction. JACC Adv 2025; 4:101582.</Citation></Reference><Reference><Citation>Safi S, Sethi NJ, Nielsen EE, Feinberg J, Jakobsen JC, Gluud C. Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database Syst Rev 2019; 12:CD012484.</Citation></Reference><Reference><Citation>Bristow MR. &#x3b2;-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101:558&#x2013;569.</Citation></Reference><Reference><Citation>Bonnemeier H, Hartmann F, Wiegand UK, Irmer C, Kurz T, T&#xf6;lg R, et al. Heart rate variability in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2000; 85:815&#x2013;820.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840598</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Reply to: Letter to the editor: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients.</ArticleTitle><Pagination><StartPage>133807</StartPage><MedlinePgn>133807</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2025.133807</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(25)00850-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nilsen</LastName><ForeName>D W T</ForeName><Initials>DWT</Initials><AffiliationInfo><Affiliation>Stavanger University Hospital, Department of Cardiology, Stavanger, Norway; University of Bergen, Department of Clinical Science, Bergen, Norway. Electronic address: nide@sus.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leon De La Fuente</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Stavanger University Hospital, Department of Cardiology, Stavanger, Norway; Hospital Papa Francisco, Internal Medicine Program, Salta, Argentina; Cardiovascular Center of Salta, Department of Cardiology, Salta, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Center of Salta, Department of Cardiology, Salta, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naesgaard</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Stavanger University Hospital, Department of Cardiology, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dib Ashur</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular Center of Salta, Department of Cardiology, Salta, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michelsen</LastName><ForeName>A E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>University of Oslo, Faculty of Medicine, Oslo, Norway; Oslo University Hospital, Rikshospitalet, Research Institute of Internal Medicine, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aukrust</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Oslo, Faculty of Medicine, Oslo, Norway; Oslo University Hospital, Rikshospitalet, Research Institute of Internal Medicine, Oslo, Norway; Oslo University Hospital, Rikshospitalet, Section of Clinical Immunology and Infectious Diseases, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staines</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sigma Statistical Services, Balmullo, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueland</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Oslo, Faculty of Medicine, Oslo, Norway; Oslo University Hospital, Rikshospitalet, Research Institute of Internal Medicine, Oslo, Norway; Thrombosis Research Center (TREC), Division of Internal Medicine, University Hospital of Northern Norway, Troms&#xf8;, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">All-cause mortality</Keyword><Keyword MajorTopicYN="N">Cardiac mortality</Keyword><Keyword MajorTopicYN="N">Interleukin-1 receptor antagonist (IL-1RA)</Keyword><Keyword MajorTopicYN="N">Prognostic biomarkers</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840598</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2025.133807</ArticleId><ArticleId IdType="pii">S0167-5273(25)00850-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846118</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-3117</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</Title><ISOAbbreviation>J Heart Lung Transplant</ISOAbbreviation></Journal><ArticleTitle>Outcomes with Impella CP in Acute Myocardial Infarction versus Heart Failure Cardiogenic Shock: Insights from the Cardiogenic Shock Working Group.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1053-2498(25)02209-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.healun.2025.08.010</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Impella CP (Abiomed, Danvers, MA) microaxial flow pumps are commonly used in acute myocardial infarction (AMI) and heart failure (HF) cardiogenic shock (CS). Contemporary data from large, unselected populations are needed to understand differences between these groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Cardiogenic Shock Working Group (CSWG) registry enrolls patients with CS at 36 international sites. We analyzed patients with Impella CP enrolled from 2019-2024, categorized by CS etiology and mechanical support device exposure. Baseline characteristics, complications, and outcomes were compared. Outcomes included survival to discharge, native heart survival, and heart replacement therapy. Multivariable analysis was performed to identify predictors of in-hospital mortality and complications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1486 patients with CS (57.9% AMI-CS, 34.9% HF-CS) and Impella CP were analyzed. Patients with HF-CS were younger (60 vs 64 years; p&lt;0.001) and more likely to have chronic kidney disease (26.4% vs 13.6; p&lt;0.001) than those with AMI-CS. Impella CP alone was used in 38.3%, CP+ECMO in 23.1%, and CP+&#x2265;2 other devices in 20.4%. Acute kidney injury was more common in HF-CS than AMI-CS (66.5% vs 59.7%, p=0.03) and acute limb ischemia more common in AMI-CS than HF-CS (14.4% vs 11.0%; p=0.05). Survival to discharge was 53.4% and was higher in HF-CS than AMI-CS (59.7% vs 49.8%; p&lt;0.001). Those with &#x2265;2 other devices had the lowest survival (43.8%). Total device number was significantly associated with in-hospital mortality, limb ischemia, and bleeding.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Differences in baseline characteristics, device exposure, and hospital complications between patients with HF-CS and AMI-CS supported by Impella CP may influence outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carnicelli</LastName><ForeName>Anthony P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Shashank S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Advanced Cardiac Care, Medical City Healthcare, Dallas, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Borui</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Cardiovascular Center, Tufts Medical Center, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataria</LastName><ForeName>Rachna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Brown University Health Cardiovascular Institute, Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garan</LastName><ForeName>Arthur R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ton</LastName><ForeName>Van-Khue</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Cardiovascular Center, Tufts Medical Center, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zweck</LastName><ForeName>Elric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Pulmonology, and Vascular Medicine Heinrich-Heine-University, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez-Montfort</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Baylor Scott &amp; White Health, Advanced Heart Disease Program, Temple, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Cardiovascular Analytics, Research and Data Science, Providence Heart Institute, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkhoff</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Foundation, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanwar</LastName><ForeName>Manreet K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>University of Chicago, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapur</LastName><ForeName>Navin K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>The Cardiovascular Center, Tufts Medical Center, Boston, MA. Electronic address: Nkapur@tuftsmedicalcenter.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Cardiogenic Shock Working Group Academic Consortium (see attached for full list)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Heart Lung Transplant</MedlineTA><NlmUniqueID>9102703</NlmUniqueID><ISSNLinking>1053-2498</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiogenic shock</Keyword><Keyword MajorTopicYN="N">Heart Failure</Keyword><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">Mechanical Circulatory Support</Keyword><Keyword MajorTopicYN="N">Myocardial Infarction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846118</ArticleId><ArticleId IdType="doi">10.1016/j.healun.2025.08.010</ArticleId><ArticleId IdType="pii">S1053-2498(25)02209-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837564</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Inflammation-related biomarkers for intracardiac thrombosis in acute myocardial infarction: predictive value and mechanistic implications of NLR and LDL-C.</ArticleTitle><Pagination><StartPage>1643933</StartPage><MedlinePgn>1643933</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1643933</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2025.1643933</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Inflammatory pathways critically contribute to the pathogenesis of intracardiac thrombosis (ICT) following acute myocardial infarction (AMI) patients. This study evaluated the predictive value of inflammation biomarkers for ICT.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective case-control study included 8,999 AMI patients hospitalized at the First Affiliated Hospital of Xi'an Jiaotong University from January 2018 to December 2022, among whom 88 developed ICT. To address class imbalance, 891 non-ICT patients were randomly selected as controls using a 1:10 ratio. Inflammation-related biomarkers were screened using univariate and multivariate logistic regression, and a risk heatmap was generated based on key predictors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Multivariate logistic regression identified elevated neutrophil-to-lymphocyte ratio (NLR), N-terminal pro-B-type natriuretic peptide (NT-proBNP), low-density lipoprotein cholesterol (LDL-C), and reduced albumin-to-globulin ratio (AGR) as independent risk factors for ICT. NLR demonstrated the highest discriminatory capacity, demonstrating superior predictive performance [receiver operating characteristic (ROC) curve, area under the curve (AUC)&#x202f;=&#x202f;0.774, 95% confidence interval (CI): 0.724-0.823, <i>p</i>&#x202f;&lt;&#x202f;0.001] that persisted after full covariate adjustment, and remained significant after full adjustment [odds ratio (OR)&#x202f;=&#x202f;2.54, 95% CI: 1.98-3.15, <i>p</i>&#x202f;=&#x202f;0.002]. Integration of NLR and LDL-C into a sex-stratified risk stratification matrix significantly enhanced diagnostic accuracy (AUC&#x202f;=&#x202f;0.838, 95% CI: 0.799-0.878).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study established NLR as a robust indicator for ICT assessment and presents a practical, visual risk heatmap that may facilitate personalized thromboprophylaxis in AMI management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Zhao, Lian, Wang and Mei.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Sijie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Zizhu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoning</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hematology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Interventional Operating Room, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">inflammatory biomarkers</Keyword><Keyword MajorTopicYN="N">intracardiac thrombosis</Keyword><Keyword MajorTopicYN="N">low-density lipoprotein cholesterol</Keyword><Keyword MajorTopicYN="N">neutrophil-to-lymphocyte ratio</Keyword><Keyword MajorTopicYN="N">risk prediction</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837564</ArticleId><ArticleId IdType="pmc">PMC12361238</ArticleId><ArticleId IdType="doi">10.3389/fmed.2025.1643933</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med. (2017) 376:2053&#x2013;64. doi: 10.1056/NEJMra1606915</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1606915</ArticleId><ArticleId IdType="pubmed">28538121</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M, Wei X, Weigel K, Gertz ZM, Kron J, Robinson AA, et al. Diagnosis and treatment of intracardiac thrombus. J Cardiovasc Pharmacol. (2021) 78:361&#x2013;71. doi: 10.1097/FJC.0000000000001064, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000001064</ArticleId><ArticleId IdType="pubmed">34074905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaffarpasand E, Tehrani MD, Marszalek J, Chi G. Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis. J Thromb Thrombolysis. (2018) 46:332&#x2013;8. doi: 10.1007/s11239-018-1693-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-018-1693-3</ArticleId><ArticleId IdType="pubmed">29876713</ArticleId></ArticleIdList></Reference><Reference><Citation>Branigan B, Brown S, Zavala R, Merritt H. Contemporary management of intracardiac thrombi: a tale of two clots. J ExtraCorporeal Technol. (2023) 55:82&#x2013;5. doi: 10.1051/ject/2023010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/ject/2023010</ArticleId><ArticleId IdType="pmc">PMC10304866</ArticleId><ArticleId IdType="pubmed">37378440</ArticleId></ArticleIdList></Reference><Reference><Citation>Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J. (2011) 75:2739&#x2013;48. doi: 10.1253/circj.CJ-11-1184, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-11-1184</ArticleId><ArticleId IdType="pubmed">22067929</ArticleId></ArticleIdList></Reference><Reference><Citation>Strom J, Manning W. Identification of Intracardiac Thrombus. Essential echocardiography: A companion to Braunwald&#x2019;s heart disease. St. Louis, NY: Elsevier Health Sciences; (2017).</Citation></Reference><Reference><Citation>Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol. (2018) 72:2071&#x2013;81. doi: 10.1016/j.jacc.2018.08.1043, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.08.1043</ArticleId><ArticleId IdType="pmc">PMC6196735</ArticleId><ArticleId IdType="pubmed">30336831</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudurachi B-S, Anghel L, Tudurachi A, Sasc&#x103;u RA, St&#x103;tescu C. Assessment of inflammatory hematological ratios (NLR, PLR, MLR, LMR and monocyte/HDL&#x2013;cholesterol ratio) in acute myocardial infarction and particularities in young patients. Int J Mol Sci. (2023) 24:14378. doi: 10.3390/ijms241814378, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241814378</ArticleId><ArticleId IdType="pmc">PMC10531986</ArticleId><ArticleId IdType="pubmed">37762680</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattanzi S, Brigo F, Trinka E, Cagnetti C, Di Napoli M, Silvestrini M. Neutrophil-to-lymphocyte ratio in acute cerebral hemorrhage: a system review. Transl Stroke Res. (2019) 10:137&#x2013;45. doi: 10.1007/s12975-018-0649-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12975-018-0649-4</ArticleId><ArticleId IdType="pubmed">30090954</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep. (2021) 11:464. doi: 10.1038/s41598-020-79431-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-79431-7</ArticleId><ArticleId IdType="pmc">PMC7801737</ArticleId><ArticleId IdType="pubmed">33431958</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Can neutrophil&#x2013;lymphocyte ratio be independent risk factor for predicting acute kidney injury in patients with severe sepsis? Ren Fail. (2015) 37:225&#x2013;9. doi: 10.3109/0886022X.2014.982477, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/0886022X.2014.982477</ArticleId><ArticleId IdType="pubmed">25394529</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non&#x2013;ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. (2016) 134:e123&#x2013;55. doi: 10.1161/CIR.0000000000000404, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000404</ArticleId><ArticleId IdType="pubmed">27026020</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. (2022) 327:662&#x2013;75. doi: 10.1001/jama.2022.0358, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0358</ArticleId><ArticleId IdType="pubmed">35166796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. (2016) 68:1116&#x2013;39. doi: 10.1016/j.jacc.2016.03.512, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.03.512</ArticleId><ArticleId IdType="pubmed">27036919</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J Acute Cardiovasc Care. (2024) 13:55&#x2013;161. doi: 10.1093/ehjacc/zuad156</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjacc/zuad156</ArticleId><ArticleId IdType="pubmed">37740496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. (1997) 336:973&#x2013;9. doi: 10.1056/NEJM199704033361401, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199704033361401</ArticleId><ArticleId IdType="pubmed">9077376</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. (2002) 105:1135&#x2013;43. doi: 10.1161/hc0902.104353</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hc0902.104353</ArticleId><ArticleId IdType="pubmed">11877368</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. (2011) 12:204&#x2013;12. doi: 10.1038/ni.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2001</ArticleId><ArticleId IdType="pubmed">21321594</ArticleId></ArticleIdList></Reference><Reference><Citation>Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, Pariggiano I, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. (2014) 16:1&#x2013;7. doi: 10.1007/s11883-014-0435-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-014-0435-z</ArticleId><ArticleId IdType="pubmed">25037581</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. (2014) 11:255&#x2013;65. doi: 10.1038/nrcardio.2014.28, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2014.28</ArticleId><ArticleId IdType="pmc">PMC4407144</ArticleId><ArticleId IdType="pubmed">24663091</ArticleId></ArticleIdList></Reference><Reference><Citation>Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart. (2012) 98:1743&#x2013;9. doi: 10.1136/heartjnl-2012-301962, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2012-301962</ArticleId><ArticleId IdType="pmc">PMC3505867</ArticleId><ArticleId IdType="pubmed">23151669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattuca B, Bouziri N, Kerneis M, Portal J-J, Zhou J, Hauguel-Moreau M, et al. Antithrombotic therapy for patients with left ventricular mural thrombus. J Am Coll Cardiol. (2020) 75:1676&#x2013;85. doi: 10.1016/j.jacc.2020.01.057, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.01.057</ArticleId><ArticleId IdType="pubmed">32273033</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi JL, Bhatt DL, McEvoy JW. Left ventricular thrombus after acute myocardial infarction: screening, prevention, and treatment. JAMA Cardiol. (2018) 3:642&#x2013;9. doi: 10.1001/jamacardio.2018.1086, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2018.1086</ArticleId><ArticleId IdType="pubmed">29800958</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratton JR, Lighty JG, Pearlman AS, Ritchie J. Detection of left ventricular thrombus by two-dimensional echocardiography: sensitivity, specificity, and causes of uncertainty. Circulation. (1982) 66:156&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">7083502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sia CH, Leow AS, Tan BY, Low CJ, Kaur R, Yeo TC, et al. The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention. Thromb Res. (2020) 194:16&#x2013;20. doi: 10.1016/j.thromres.2020.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.06.003</ArticleId><ArticleId IdType="pubmed">32559523</ArticleId></ArticleIdList></Reference><Reference><Citation>Brill A, Fuchs T, Savchenko A, Thomas G, Martinod K, De Meyer S, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. (2012) 10:136&#x2013;44. doi: 10.1111/j.1538-7836.2011.04544.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2011.04544.x</ArticleId><ArticleId IdType="pmc">PMC3319651</ArticleId><ArticleId IdType="pubmed">22044575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. (2013) 11:55&#x2013;9. doi: 10.1586/erc.12.159</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erc.12.159</ArticleId><ArticleId IdType="pubmed">23259445</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Liu M, Wang G. The neutrophil&#x2013;lymphocyte ratio is associated with all-cause and cardiovascular mortality in cardiovascular patients. Sci Rep. (2024) 14:26692. doi: 10.1038/s41598-024-76836-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-76836-6</ArticleId><ArticleId IdType="pmc">PMC11535400</ArticleId><ArticleId IdType="pubmed">39496711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Tao W, Shen F, Du W, Xu Z, Liu Z. The emerging role of neutrophil extracellular traps in arterial, venous and cancer-associated thrombosis. Front Cardiovas Med. (2021) 8:786387. doi: 10.3389/fcvm.2021.786387, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.786387</ArticleId><ArticleId IdType="pmc">PMC8674622</ArticleId><ArticleId IdType="pubmed">34926629</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamhane UU, Aneja S, Montgomery D, Rogers E-K, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. (2008) 102:653&#x2013;7. doi: 10.1016/j.amjcard.2008.05.006, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2008.05.006</ArticleId><ArticleId IdType="pubmed">18773982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan W, Zhang Y, Gao X, Liu Y, Shi F, Liu J, et al. The prognostic value of a derived neutrophil-lymphocyte ratio in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clin Appl Thromb Hemost. (2021) 27:10760296211034579. doi: 10.1177/10760296211034579, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10760296211034579</ArticleId><ArticleId IdType="pmc">PMC8299898</ArticleId><ArticleId IdType="pubmed">34286626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcin M, Aparci M, Uz O, Isilak Z, Balta S, Dogan M, et al. Neutrophil-lymphocyte ratio may predict left atrial thrombus in patients with nonvalvular atrial fibrillation. Clin Appl Thromb Hemost. (2015) 21:166&#x2013;71. doi: 10.1177/1076029613503398, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029613503398</ArticleId><ArticleId IdType="pubmed">24057399</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Zhou F, Li Q, Guo J, Cai B, Li G, et al. Associations between neutrophil-lymphocyte ratio and monocyte to high-density lipoprotein ratio with left atrial spontaneous echo contrast or thrombus in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. (2023) 23:234. doi: 10.1186/s12872-023-03270-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-023-03270-3</ArticleId><ArticleId IdType="pmc">PMC10157900</ArticleId><ArticleId IdType="pubmed">37142962</ArticleId></ArticleIdList></Reference><Reference><Citation>Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol. (2017) 17:248&#x2013;61. doi: 10.1038/nri.2017.10, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.10</ArticleId><ArticleId IdType="pubmed">28287106</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. (2014) 34:1977&#x2013;84. doi: 10.1161/ATVBAHA.114.304114, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.114.304114</ArticleId><ArticleId IdType="pubmed">25012129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Lin Y, Wang F. Development of a risk score model for the prediction of patients needing percutaneous coronary intervention. J Clin Lab Anal. (2023) 37:e24849. doi: 10.1002/jcla.24849, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.24849</ArticleId><ArticleId IdType="pmc">PMC10020842</ArticleId><ArticleId IdType="pubmed">36808769</ArticleId></ArticleIdList></Reference><Reference><Citation>Natorska J, Z&#x105;bczyk M, Undas A. Neutrophil extracellular traps (NETs) in cardiovascular diseases: from molecular mechanisms to therapeutic interventions. Polish Heart J. (2023) 81:1205&#x2013;16. doi: 10.33963/v.kp.98520</Citation><ArticleIdList><ArticleId IdType="doi">10.33963/v.kp.98520</ArticleId><ArticleId IdType="pubmed">38189504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci. (2010) 107:15880&#x2013;5. doi: 10.1073/pnas.1005743107, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1005743107</ArticleId><ArticleId IdType="pmc">PMC2936604</ArticleId><ArticleId IdType="pubmed">20798043</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Philadelphia, PA: Lippincott Williams &amp; Wilkins; (2001) 1718&#x2013;1720. doi: 10.1161/01.cir.103.13.1718</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.103.13.1718</ArticleId><ArticleId IdType="pubmed">11282900</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;rek&#xe7;i A, G&#xfc;r M, T&#xfc;rko&#x11f;lu C, Baykan AO, &#x15e;eker T, &#x15e;ahin DY, et al. Neutrophil to lymphocyte ratio predicts left ventricular remodeling in patients with ST elevation myocardial infarction after primary percutaneous coronary intervention. Korean Circulation J. (2016) 46:15&#x2013;22. doi: 10.4070/kcj.2016.46.1.15, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2016.46.1.15</ArticleId><ArticleId IdType="pmc">PMC4720845</ArticleId><ArticleId IdType="pubmed">26798381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Z, Liu G, Guo J, Zhang R, Su Y, Carvalho A, et al. The neutrophil-to-lymphocyte ratio is an important indicator predicting in-hospital death in AMI patients. Front Cardiovascular Med. (2021) 8:706852. doi: 10.3389/fcvm.2021.706852, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.706852</ArticleId><ArticleId IdType="pmc">PMC8488114</ArticleId><ArticleId IdType="pubmed">34616780</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and ca++/NFAT. Blood. (2002) 99:199&#x2013;206. doi: 10.1182/blood.v99.1.199, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v99.1.199</ArticleId><ArticleId IdType="pubmed">11756172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y, Liu C, Feng J, Li J-F, Fan Z-C. Curcumin affects ox-LDL-induced IL-6, TNF-&#x3b1;, MCP-1 secretion and cholesterol efflux in THP-1 cells by suppressing the TLR4/NF-&#x3ba;B/miR33a signaling pathway. Exp Ther Med. (2020) 20:1856&#x2013;70. doi: 10.3892/etm.2020.8915, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.8915</ArticleId><ArticleId IdType="pmc">PMC7401289</ArticleId><ArticleId IdType="pubmed">32782494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Murugesan G, Chen K, Zhang L, Wang Q, Febbraio M, et al. Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood. (2011) 117:6355&#x2013;66. doi: 10.1182/blood-2011-02-338582, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-02-338582</ArticleId><ArticleId IdType="pmc">PMC3122954</ArticleId><ArticleId IdType="pubmed">21478428</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Zhou Y, Nabavi SM, Sahebkar A, Little PJ, Xu S, et al. Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis. Front Cardiovas Med. (2022) 9:925923. doi: 10.3389/fcvm.2022.925923, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.925923</ArticleId><ArticleId IdType="pmc">PMC9199460</ArticleId><ArticleId IdType="pubmed">35722128</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermayer G, Afonyushkin T, Binder CJ. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost. (2018) 16:418&#x2013;28. doi: 10.1111/jth.13925, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13925</ArticleId><ArticleId IdType="pubmed">29316215</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsioupa M, Kourampi I, Oikonomou E, Tsigkou V, Theofilis P, Charalambous G, et al. Novel biomarkers and their role in the diagnosis and prognosis of acute coronary syndrome. Life. (2023) 13:1992. doi: 10.3390/life13101992, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13101992</ArticleId><ArticleId IdType="pmc">PMC10608753</ArticleId><ArticleId IdType="pubmed">37895374</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerico A, Passino C. Predictive value of NT-proBNP in patients with acute myocardial infarction. Clin Chem. (2017) 63:1045&#x2013;6. doi: 10.1373/clinchem.2016.269522</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2016.269522</ArticleId><ArticleId IdType="pubmed">28320763</ArticleId></ArticleIdList></Reference><Reference><Citation>Azab B, Bibawy J, Harris K, Khoueiry G, Akerman M, Selim J, et al. Value of albumin&#x2013;globulin ratio as a predictor of all-cause mortality after non-ST elevation myocardial infarction. Angiology. (2013) 64:137&#x2013;45. doi: 10.1177/0003319712436577, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0003319712436577</ArticleId><ArticleId IdType="pubmed">22345150</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Fu W, Bo Y, Zhu Y. Effect of albumin-globulin score and albumin to globulin ratio on survival in patients with heart failure: a retrospective cohort study in China. BMJ Open. (2018) 8:e022960. doi: 10.1136/bmjopen-2018-022960, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-022960</ArticleId><ArticleId IdType="pmc">PMC6042582</ArticleId><ArticleId IdType="pubmed">29982222</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Guo R, Huang M, Li Z, Lai Z, Yang R, et al. Fibrinogen-to-albumin ratio and glucose metabolic states in patients with coronary heart disease. Angiology. (2025) 76:271&#x2013;80. doi: 10.1177/00033197231206235, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00033197231206235</ArticleId><ArticleId IdType="pubmed">37939004</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circ Heart Fail. (2011) 4:324&#x2013;31. doi: 10.1161/CIRCHEARTFAILURE.110.959890, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.110.959890</ArticleId><ArticleId IdType="pmc">PMC3100162</ArticleId><ArticleId IdType="pubmed">21350053</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehli J, Martin C, Brennan A, Dinh DT, Lefkovits J, Zaman S. Sex differences persist in time to presentation, revascularization, and mortality in myocardial infarction treated with percutaneous coronary intervention. J Am Heart Assoc. (2019) 8:e012161. doi: 10.1161/JAHA.119.012161, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.012161</ArticleId><ArticleId IdType="pmc">PMC6585344</ArticleId><ArticleId IdType="pubmed">31092091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansky AJ, Ng VG, Maehara A, Weisz G, Lerman A, Mintz GS, et al. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. Cardiovascular Imaging. (2012) 5:S62&#x2013;72. doi: 10.1016/j.jcmg.2012.02.003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2012.02.003</ArticleId><ArticleId IdType="pubmed">22421232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. (2016) 133:916&#x2013;47. doi: 10.1161/CIR.0000000000000351, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000351</ArticleId><ArticleId IdType="pubmed">26811316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianstefani S, Douiri A, Delithanasis I, Rogers T, Sen A, Kalra S, et al. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention. Am J Cardiol. (2014) 113:1111&#x2013;6. doi: 10.1016/j.amjcard.2013.12.015, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2013.12.015</ArticleId><ArticleId IdType="pubmed">24485697</ArticleId></ArticleIdList></Reference><Reference><Citation>Osherov AB, Borovik-Raz M, Aronson D, Agmon Y, Kapeliovich M, Kerner A, et al. Incidence of early left ventricular thrombus after acute anterior wall myocardial infarction in the primary coronary intervention era. Am Heart J. (2009) 157:1074&#x2013;80. doi: 10.1016/j.ahj.2009.03.020, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2009.03.020</ArticleId><ArticleId IdType="pubmed">19464419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40834159</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1678-4170</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Arquivos brasileiros de cardiologia</Title><ISOAbbreviation>Arq Bras Cardiol</ISOAbbreviation></Journal><ArticleTitle>Association between Renal Function and the Incidence of Major Adverse Cardiovascular Outcomes 1 Year After the First Acute Myocardial Infarction.</ArticleTitle><Pagination><StartPage>e20250082</StartPage><MedlinePgn>e20250082</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.36660/abc.20250082</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0066-782X2025000700308</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiovascular diseases are the leading cause of death worldwide, with substantial social and economic impacts. These conditions are frequently associated with comorbidities, including renal dysfunction.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the association between creatinine clearance and the incidence of cardiovascular outcomes within 1 year in patients diagnosed with acute myocardial infarction (AMI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective cohort study included patients hospitalized for their first AMI. Creatinine clearance was assessed in relation to cardiovascular outcomes, including recurrent AMI, stroke, and cardiovascular death. A p-value of &lt;0.05 was considered statistically significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1,324 patients were analyzed, with a mean age of 60.9 &#xb1; 11.4 years; 67.4% were male. Creatinine clearance &lt;60 mL/min was significantly associated with systemic arterial hypertension (79.6% vs. 55.1%, p&lt;0.001), diabetes mellitus (40.8% vs. 24.5%, p&lt;0.001), and dyslipidemia (38.8% vs. 31.4%, p=0.043). Higher creatinine clearance values were associated with a reduced risk of major adverse cardiovascular events (MACE) at 1 year (HR: 0.992; 95% CI: 0.984-0.999; p=0.030). Additionally, higher clearance was linked to lower overall mortality (HR: 0.984; 95% CI: 0.970-0.998; p=0.021).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Higher creatinine clearance values are associated with a lower hazard ratio for MACE and overall mortality within 1 year following AMI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreira</LastName><ForeName>Daniel Medeiros</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0003-0605-8003</Identifier><AffiliationInfo><Affiliation>Universidade do Sul de Santa Catarina, Palho&#xe7;a, SC - Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Cardiologia de Santa Catarina, S&#xe3;o Jos&#xe9;, SC - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sousa</LastName><ForeName>Marco Ant&#xf4;nio de</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Universidade do Sul de Santa Catarina, Palho&#xe7;a, SC - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cechinel</LastName><ForeName>Maria Fernanda Scarduelli</ForeName><Initials>MFS</Initials><AffiliationInfo><Affiliation>Universidade do Sul de Santa Catarina, Palho&#xe7;a, SC - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Roberto L&#xe9;o da</ForeName><Initials>RLD</Initials><AffiliationInfo><Affiliation>Instituto de Cardiologia de Santa Catarina, S&#xe3;o Jos&#xe9;, SC - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fattah</LastName><ForeName>Tammuz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Instituto de Cardiologia de Santa Catarina, S&#xe3;o Jos&#xe9;, SC - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joaquim</LastName><ForeName>Rodrigo de Moura</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Universidade do Sul de Santa Catarina, Palho&#xe7;a, SC - Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Cardiologia de Santa Catarina, S&#xe3;o Jos&#xe9;, SC - Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>por</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Associa&#xe7;&#xe3;o entre a Fun&#xe7;&#xe3;o Renal e a Incid&#xea;ncia de Desfechos Cardiovasculares Maiores em 1 Ano Ap&#xf3;s o Primeiro Infarto Agudo do Mioc&#xe1;rdio.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Bras Cardiol</MedlineTA><NlmUniqueID>0421031</NlmUniqueID><ISSNLinking>0066-782X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="Y">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="FUNDAMENTO" NlmCategory="OBJECTIVE">As doen&#xe7;as cardiovasculares constituem a principal causa de mortalidade no mundo, gerando impactos sociais e econ&#xf4;micos significativos. Essas condi&#xe7;&#xf5;es frequentemente coexistem com comorbidades, como a disfun&#xe7;&#xe3;o renal.</AbstractText><AbstractText Label="OBJETIVOS" NlmCategory="OBJECTIVE">Avaliar a associa&#xe7;&#xe3;o entre a depura&#xe7;&#xe3;o de creatinina e a incid&#xea;ncia de desfechos cardiovasculares no per&#xed;odo de 1 ano em pacientes com diagn&#xf3;stico de infarto agudo do mioc&#xe1;rdio (IAM).</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Este estudo de coorte prospectivo incluiu pacientes hospitalizados em decorr&#xea;ncia do primeiro epis&#xf3;dio de IAM. A depura&#xe7;&#xe3;o de creatinina foi analisada em rela&#xe7;&#xe3;o aos desfechos cardiovasculares, incluindo recidiva de IAM, acidente vascular cerebral e &#xf3;bito de causa cardiovascular. Valores de p &lt;0,05 foram considerados estatisticamente significativos.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Foram analisados 1.324 pacientes, com idade m&#xe9;dia de 60,9 &#xb1; 11,4 anos, dos quais 67,4% do sexo masculino. Depura&#xe7;&#xe3;o de creatinina inferior a 60 ml/min apresentou associa&#xe7;&#xe3;o significativa com hipertens&#xe3;o arterial sist&#xea;mica (79,6% vs. 55,1%; p&lt;0,001), diabetes mellitus (40,8% vs. 24,5%; p&lt;0,001) e dislipidemia (38,8% vs. 31,4%; p=0,043). Valores mais elevados de depura&#xe7;&#xe3;o de creatinina associaram-se a menor risco de eventos adversos cardiovasculares maiores (MACEs) em 1 ano (HR: 0,992; IC 95%: 0,984-0,999; p=0,030). Ademais, verificou-se associa&#xe7;&#xe3;o com menor mortalidade geral (HR: 0,984; IC 95%: 0,970-0,998; p=0,021).</AbstractText><AbstractText Label="CONCLUS&#xc3;O" NlmCategory="UNASSIGNED">Valores mais elevados de depura&#xe7;&#xe3;o de creatinina associaram-se a menores raz&#xf5;es de risco para MACEs e mortalidade geral no per&#xed;odo de 1 ano ap&#xf3;s o IAM.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>14</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834159</ArticleId><ArticleId IdType="doi">10.36660/abc.20250082</ArticleId><ArticleId IdType="pii">S0066-782X2025000700308</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40832831</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-2586</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of magnetic resonance imaging : JMRI</Title><ISOAbbreviation>J Magn Reson Imaging</ISOAbbreviation></Journal><ArticleTitle>Atrioventricular Coupling Index: A Novel Approach to Risk-Stratification for Major Adverse Cardiovascular Events in Patients With ST-Elevation Myocardial Infarction.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmri.70088</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Left atrioventricular coupling index (LACI) has prognostic value in acute myocardial infarction (AMI) patients, while the role of right atrioventricular coupling index (RACI) remains unclear.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To explore the prognostic value of LACI and RACI in AMI patients.</AbstractText><AbstractText Label="STUDY TYPE" NlmCategory="METHODS">Retrospective.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">1083 ST-elevation AMI patients (median (interquartile range (IQR)) age, 59 (50-67) years; 916 men; 196 right ventricular myocardial infarction (RVMI) patients) from 2 centers, with MRI within 7&#x2009;days of percutaneous coronary intervention performed within 12&#x2009;h of symptoms.</AbstractText><AbstractText Label="FIELD STRENGTH/SEQUENCE" NlmCategory="UNASSIGNED">3-T, balanced steady state free precession cine sequence.</AbstractText><AbstractText Label="ASSESSMENT" NlmCategory="RESULTS">LACI and RACI were calculated as the percentage ratio of indexed atrial to indexed ventricular end-diastolic volume. Patients were followed up via medical records or telephone consultation. The primary outcome, major adverse cardiac events (MACE), includes all-cause death, reinfarction, and hospitalization for heart failure. Incremental prognostic value of LACI and/or RACI for MACE was assessed beyond traditional factors (age, diabetes mellitus, Killip class, LVEF and LGE, which were assessed by MRI images).</AbstractText><AbstractText Label="STATISTICAL TESTS" NlmCategory="METHODS">The prognostic value of LACI and RACI was evaluated using Cox regression. Harrell's C index was used to determine goodness of fit of models. p&#x2009;&lt;&#x2009;0.05 indicated statistical significance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During a median 38-month (IQR: 21-55&#x2009;months) follow-up, 161 of 1083 AMI patients experienced MACE, and 29 of 196 RVMI patients experienced MACE. LACI and RACI were independently associated with MACE and provided significantly improved prognostic value in MACE beyond traditional risk factors in AMI patients (Harrell's C index increased from 0.679 to 0.756 with LACI, to 0.730 with RACI, and to 0.762 with LACI and RACI). Notably, RACI outperformed LACI in RVMI patients (Harrell's C index: 0.84 vs. 0.76).</AbstractText><AbstractText Label="DATA CONCLUSION" NlmCategory="CONCLUSIONS">LACI and RACI were associated with MACE independently and provided incremental prognostic value beyond established risk factors.</AbstractText><AbstractText Label="EVIDENCE LEVEL" NlmCategory="METHODS">2.</AbstractText><AbstractText Label="TECHNICAL EFFICACY" NlmCategory="UNASSIGNED">Stage 5.</AbstractText><CopyrightInformation>&#xa9; 2025 International Society for Magnetic Resonance in Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing-Ping</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Xing-Yu</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Bing-Hua</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7235-8955</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andong</LastName><ForeName>Ao-Lei</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ruo-Yang</ForeName><Initials>RY</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chong-Wen</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yi-Si</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Jin-Yi</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lian-Ming</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0001-7381-5436</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23Y11906900</GrantID><Agency>Shanghai Municipal Commission of Science and Technology Medical Innovation Research Special Project</Agency><Country/></Grant><Grant><GrantID>82171884</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><Agency>Shanghai "Yiyuan New Star" Outstanding Youth Talent (Excellent Program)</Agency><Country/></Grant><Grant><Agency>National Youth Talent Support Program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Magn Reson Imaging</MedlineTA><NlmUniqueID>9105850</NlmUniqueID><ISSNLinking>1053-1807</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">atrioventricular coupling index</Keyword><Keyword MajorTopicYN="N">major adverse cardiac events</Keyword><Keyword MajorTopicYN="N">right ventricular myocardial infarction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40832831</ArticleId><ArticleId IdType="doi">10.1002/jmri.70088</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>G. W. Reed, J. E. Rossi, and C. P. Cannon, &#x201c;Acute Myocardial Infarction,&#x201d; Lancet 389 (2017): 197&#x2013;210.</Citation></Reference><Reference><Citation>T. Jernberg, P. Johanson, C. Held, B. Svennblad, J. Lindb&#xe4;ck, and L. Wallentin, &#x201c;Association Between Adoption of Evidence&#x2010;Based Treatment and Survival for Patients With ST&#x2010;Elevation Myocardial Infarction,&#x201d; JAMA 305 (2011): 1677&#x2013;1684.</Citation></Reference><Reference><Citation>I. Eitel, S. de Waha, J. W&#xf6;hrle, et&#xa0;al., &#x201c;Comprehensive Prognosis Assessment by CMR Imaging After ST&#x2010;Segment Elevation Myocardial Infarction,&#x201d; Journal of the American College of Cardiology 64 (2014): 1217&#x2013;1226.</Citation></Reference><Reference><Citation>I. Eitel, T. Stiermaier, T. Lange, et&#xa0;al., &#x201c;Cardiac Magnetic Resonance Myocardial Feature Tracking for Optimized Prediction of Cardiovascular Events Following Myocardial Infarction,&#x201d; JACC: Cardiovascular Imaging 11 (2018): 1433&#x2013;1444.</Citation></Reference><Reference><Citation>A. Schuster, S. J. Backhaus, T. Stiermaier, et&#xa0;al., &#x201c;Left Atrial Function With MRI Enables Prediction of Cardiovascular Events After Myocardial Infarction: Insights From the AIDA STEMI and TATORT NSTEMI Trials,&#x201d; Radiology 293 (2019): 292&#x2013;302.</Citation></Reference><Reference><Citation>B. D. Hoit, &#x201c;Left Atrial Size and Function: Role in Prognosis,&#x201d; Journal of the American College of Cardiology 63 (2014): 493&#x2013;505.</Citation></Reference><Reference><Citation>S. Leng, H. Ge, J. He, et&#xa0;al., &#x201c;Long&#x2010;Term Prognostic Value of Cardiac MRI Left Atrial Strain in ST&#x2010;Segment Elevation Myocardial Infarction,&#x201d; Radiology 296 (2020): 299&#x2013;309.</Citation></Reference><Reference><Citation>T. Lange, S. J. Backhaus, A. Schulz, et&#xa0;al., &#x201c;Cardiovascular Magnetic Resonance&#x2010;Derived Left Atrioventricular Coupling Index and Major Adverse Cardiac Events in Patients Following Acute Myocardial Infarction,&#x201d; Journal of Cardiovascular Magnetic Resonance 25 (2023): 24.</Citation></Reference><Reference><Citation>T. Pezel, B. A. Venkatesh, H. D. De Vasconcellos, et&#xa0;al., &#x201c;Left Atrioventricular Coupling Index as a Prognostic Marker of Cardiovascular Events: The MESA Study,&#x201d; Hypertension 78 (2021): 661&#x2013;671.</Citation></Reference><Reference><Citation>M. Gunsaulus, A. Bueno, C. Bright, et&#xa0;al., &#x201c;The Use of Automated Atrial CMR Measures and a Novel Atrioventricular Coupling Index for Predicting Risk in Repaired Tetralogy of Fallot,&#x201d; Children (Basel) 10 (2023): 10.</Citation></Reference><Reference><Citation>P. P. Sengupta and J. Narula, &#x201c;&#xc0; LA Mode Atrioventricular Mechanical Coupling,&#x201d; JACC: Cardiovascular Imaging 7 (2014): 109&#x2013;111.</Citation></Reference><Reference><Citation>A. W. Bowman and S. J. Kov&#xe1;cs, &#x201c;Left Atrial Conduit Volume Is Generated by Deviation From the Constant&#x2010;Volume State of the Left Heart: A Combined MRI&#x2010;Echocardiographic Study,&#x201d; American Journal of Physiology. Heart and Circulatory Physiology 286 (2004): H2416&#x2013;H2424.</Citation></Reference><Reference><Citation>P. Barbier, S. B. Solomon, N. B. Schiller, and S. A. Glantz, &#x201c;Left Atrial Relaxation and Left Ventricular Systolic Function Determine Left Atrial Reservoir Function,&#x201d; Circulation 100 (1999): 427&#x2013;436.</Citation></Reference><Reference><Citation>Y. Zhao, J. Cui, X. Zhang, J. Li, J. Yang, and T. Li, &#x201c;Right Ventricular Function and Determining Factors of Dysfunction in ST&#x2010;Segment&#x2010;Elevation Myocardial Infarction: A Cross&#x2010;Sectional Study With Cardiac Magnetic Resonance Imaging (MRI),&#x201d; Quantitative Imaging in Medicine and Surgery 14 (2024): 6895&#x2013;6907.</Citation></Reference><Reference><Citation>A. Pasipoularides, &#x201c;Right and Left Ventricular Diastolic Pressure&#x2010;Volume Relations: A Comprehensive Review,&#x201d; Journal of Cardiovascular Translational Research 6 (2013): 239&#x2013;252.</Citation></Reference><Reference><Citation>M. Tadic, C. Cuspidi, V. Kocijancic, V. Celic, and V. Vukomanovic, &#x201c;Does Left Ventricular Geometric Patterns Impact Right Atrial Phasic Function? Findings From the Hypertensive Population,&#x201d; Echocardiography (Mount Kisco, N.Y.) 33 (2016): 1186&#x2013;1194.</Citation></Reference><Reference><Citation>B. G. Kanar, M. Sunbul, A. A. Sahin, Z. Dogan, and M. K. Tigen, &#x201c;Evaluation of Right Atrial Volumes and Functions by Real&#x2010;Time Three&#x2010;Dimensional Echocardiography in Patients After Acute Inferior Myocardial Infarction,&#x201d; Echocardiography 35 (2018): 1806&#x2013;1811.</Citation></Reference><Reference><Citation>M. Grothoff, C. Elpert, J. Hoffmann, et&#xa0;al., &#x201c;Right Ventricular Injury in ST&#x2010;Elevation Myocardial Infarction: Risk Stratification by Visualization of Wall Motion, Edema, and Delayed&#x2010;Enhancement Cardiac Magnetic Resonance,&#x201d; Circulation. Cardiovascular Imaging 5 (2012): 60&#x2013;68.</Citation></Reference><Reference><Citation>T. Stiermaier, S. J. Backhaus, J. Matz, et&#xa0;al., &#x201c;Frequency and Prognostic Impact of Right Ventricular Involvement in Acute Myocardial Infarction,&#x201d; Heart 41 (2020): 317&#x2013;325.</Citation></Reference><Reference><Citation>A. Meloni, L. Saba, V. Positano, et&#xa0;al., &#x201c;Left and Right Atrioventricular Coupling Index in Patients With Beta&#x2010;Thalassemia Major,&#x201d; International Journal of Cardiovascular Imaging 40 (2024): 1631&#x2013;1640.</Citation></Reference><Reference><Citation>T. Pezel, B. A. Venkatesh, H. D. Vasconcellos, et&#xa0;al., &#x201c;Determinants of Left Atrioventricular Coupling Index: The Multi&#x2010;Ethnic Study of Atherosclerosis (MESA),&#x201d; Archives of Cardiovascular Diseases 115 (2022): 414&#x2013;425.</Citation></Reference><Reference><Citation>K. Thygesen, J. S. Alpert, A. S. Jaffe, et&#xa0;al., &#x201c;Fourth Universal Definition of Myocardial Infarction (2018),&#x201d; Journal of the American College of Cardiology 72 (2018): 2231&#x2013;2264.</Citation></Reference><Reference><Citation>P. Ponikowski, A. A. Voors, S. D. Anker, et&#xa0;al., &#x201c;2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC)developed With the Special Contribution of the Heart Failure Association (HFA) of the ESC,&#x201d; European Heart Journal 37 (2016): 2129&#x2013;2200.</Citation></Reference><Reference><Citation>A. Kumar, H. Abdel&#x2010;Aty, I. Kriedemann, et&#xa0;al., &#x201c;Contrast&#x2010;Enhanced Cardiovascular Magnetic Resonance Imaging of Right Ventricular Infarction,&#x201d; Journal of the American College of Cardiology 48 (2006): 1969&#x2013;1976.</Citation></Reference><Reference><Citation>G. N. Levine, E. R. Bates, J. C. Blankenship, et&#xa0;al., &#x201c;2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST&#x2010;Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST&#x2010;Elevation Myocardial Infarction,&#x201d; Journal of the American College of Cardiology 67 (2016): 1235&#x2013;1250.</Citation></Reference><Reference><Citation>A. Pascaud, A. Assun&#xe7;&#xe3;o, Jr., G. Garcia, et&#xa0;al., &#x201c;Left Atrial Remodeling Following ST&#x2010;Segment&#x2010;Elevation Myocardial Infarction Correlates With Infarct Size and Age Older Than 70&#x2009;Years,&#x201d; Journal of the American Heart Association 12 (2023): e026048.</Citation></Reference><Reference><Citation>T. Pezel, B. Ambale Venkatesh, Y. Kato, et&#xa0;al., &#x201c;Left Atrioventricular Coupling Index to Predict Incident Heart Failure: The Multi&#x2010;Ethnic Study of Atherosclerosis,&#x201d; Frontiers in Cardiovascular Medicine 8 (2021): 704611.</Citation></Reference><Reference><Citation>T. Pezel, B. Ambale&#x2010;Venkatesh, T. Quinaglia, et&#xa0;al., &#x201c;Change in Left Atrioventricular Coupling Index to Predict Incident Atrial Fibrillation: The Multi&#x2010;Ethnic Study of Atherosclerosis (MESA),&#x201d; Radiology 303 (2022): 317&#x2013;326.</Citation></Reference><Reference><Citation>S. J. Backhaus, T. Lange, A. Schulz, et&#xa0;al., &#x201c;Cardiovascular Magnetic Resonance Rest and Exercise&#x2010;Stress Left Atrioventricular Coupling Index to Detect Diastolic Dysfunction,&#x201d; American Journal of Physiology. Heart and Circulatory Physiology 324 (2023): H686&#x2013;h695.</Citation></Reference><Reference><Citation>T. Lange, S. J. Backhaus, A. Schulz, et&#xa0;al., &#x201c;CMR&#x2010;Based Cardiac Phenotyping in Different Forms of Heart Failure,&#x201d; International Journal of Cardiovascular Imaging 40 (2024): 1585&#x2013;1596.</Citation></Reference><Reference><Citation>A. S. Bhatt, A. P. Ambrosy, and E. J. Velazquez, &#x201c;Adverse Remodeling and Reverse Remodeling After Myocardial Infarction,&#x201d; Current Cardiology Reports 19 (2017): 71.</Citation></Reference><Reference><Citation>V. Anastasiou, S. Daios, D. V. Moysidis, et&#xa0;al., &#x201c;Right Ventricular Global Longitudinal Strain and Short&#x2010;Term Prognosis in Patients With First Acute Myocardial Infarction,&#x201d; American Journal of Cardiology 205 (2023): 302&#x2013;310.</Citation></Reference><Reference><Citation>G. D. Buckberg, N. C. Nanda, C. Nguyen, and M. J. Kocica, &#x201c;What Is the Heart? Anatomy, Function, Pathophysiology, and Misconceptions,&#x201d; Journal of Cardiovascular Development and Disease 5 (2018): 33.</Citation></Reference><Reference><Citation>W. P. Santamore and L. Papa, &#x201c;Alterations in Diastolic Ventricular Interdependence due to Myocardial Infarction,&#x201d; Cardiovascular Research 22 (1988): 726&#x2013;731.</Citation></Reference><Reference><Citation>A. Schuster, S. J. Backhaus, T. Stiermaier, et&#xa0;al., &#x201c;Impact of Right Atrial Physiology on Heart Failure and Adverse Events After Myocardial Infarction,&#x201d; Journal of Clinical Medicine 9 (2020): 9.</Citation></Reference><Reference><Citation>J. Seo, I. H. Jung, J. H. Park, et&#xa0;al., &#x201c;The Prognostic Value of 2D Strain in Assessment of the Right Ventricle in Patients With Dilated Cardiomyopathy,&#x201d; European Heart Journal Cardiovascular Imaging 20 (2019): 1043&#x2013;1050.</Citation></Reference><Reference><Citation>A. V&#xee;j&#xee;iac, R. V&#x103;t&#x103;&#x219;escu, S. Onciul, et&#xa0;al., &#x201c;Right Atrial Phasic Function and Outcome in Patients With Heart Failure and Reduced Ejection Fraction: Insights From Speckle&#x2010;Tracking and Three&#x2010;Dimensional Echocardiography,&#x201d; Kardiologia Polska 80 (2022): 322&#x2013;331.</Citation></Reference><Reference><Citation>A. V&#xee;j&#xee;iac, A. I. Sc&#x103;rl&#x103;tescu, I. G. Petre, C. V&#xee;j&#xee;iac, and R. G. V&#x103;t&#x103;&#x219;escu, &#x201c;Three&#x2010;Dimensional Combined Atrioventricular Coupling Index&#x2010;A Novel Prognostic Marker in Dilated Cardiomyopathy,&#x201d; Biomedicine 12 (2024): 12.</Citation></Reference><Reference><Citation>J. A. Goldstein, S. Lerakis, and P. R. Moreno, &#x201c;Right Ventricular Myocardial Infarction&#x2010;A Tale of Two Ventricles: JACC Focus Seminar 1/5,&#x201d; Journal of the American College of Cardiology 83 (2024): 1779&#x2013;1798.</Citation></Reference><Reference><Citation>P. G. Masci, M. Francone, W. Desmet, et&#xa0;al., &#x201c;Right Ventricular Ischemic Injury in Patients With Acute ST&#x2010;Segment Elevation Myocardial Infarction: Characterization With Cardiovascular Magnetic Resonance,&#x201d; Circulation 122 (2010): 1405&#x2013;1412.</Citation></Reference><Reference><Citation>M. von Roeder, J. T. Kowallick, K. P. Rommel, et&#xa0;al., &#x201c;Right Atrial&#x2010;Right Ventricular Coupling in Heart Failure With Preserved Ejection Fraction,&#x201d; Clinical Research in Cardiology 109 (2020): 54&#x2013;66.</Citation></Reference><Reference><Citation>J. A. Goldstein, B. Barzilai, T. L. Rosamond, P. R. Eisenberg, and A. S. Jaffe, &#x201c;Determinants of Hemodynamic Compromise With Severe Right Ventricular Infarction,&#x201d; Circulation 82 (1990): 359&#x2013;368.</Citation></Reference><Reference><Citation>J. A. Goldstein, &#x201c;Acute Right Ventricular Infarction: Insights for the Interventional Era,&#x201d; Current Problems in Cardiology 37 (2012): 533&#x2013;557.</Citation></Reference><Reference><Citation>J. A. Goldstein, &#x201c;Hemodynamic Complications of Right Ventricular Infarction: Role of the Right Atrium,&#x201d; JACC Case Reports 3 (2021): 1174&#x2013;1176.</Citation></Reference><Reference><Citation>T. Pezel, P. Garot, S. Toupin, et&#xa0;al., &#x201c;AI&#x2010;Based Fully Automated Left Atrioventricular Coupling Index as a Prognostic Marker in Patients Undergoing Stress CMR,&#x201d; JACC: Cardiovascular Imaging 16 (2023): 1288&#x2013;1302.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840676</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1885-5857</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Revista espanola de cardiologia (English ed.)</Title><ISOAbbreviation>Rev Esp Cardiol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Impact of fine particulate matter (PM<sub>2.5</sub>) pollution on hospital admissions and mortality due to acute myocardial infarction in Spain.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1885-5857(25)00221-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rec.2025.06.011</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">Atherosclerotic vascular disease is the main cause of mortality attributable to air pollution. This study analyzes, for the first time, the association between levels of fine particulate matter (PM<sub>2.5</sub>, particles &#x2264; 2.5&#x2009;&#x3bc;m in diameter) and hospital admissions and in-hospital mortality due to acute myocardial infarction (AMI) in hospitals of the Spanish National Health System.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data on air pollution, temperature, and humidity were obtained from the Ministry for the Ecological Transition and the Demographic Challenge, covering the period from 2016 to 2021. A total of 122 National Health System hospitals were geographically matched with environmental monitoring stations located within a 10&#x2009;km radius. The study included 115 071 patients aged 18 years or older (mean age, 67 years; 28% women) who were discharged with a diagnosis of AMI during the study period. An autoregressive integrated moving average (ARIMA) model was applied to each hospital, and a meta-analysis was conducted to consolidate the estimates of the association between PM<sub>2.5</sub> levels and variations in AMI hospital admissions. The association between PM<sub>2.5</sub> pollution and in-hospital AMI mortality was analyzed using logistic regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Maximum 3-day average PM<sub>2.5</sub> levels exceeding 10&#x2009;&#x3bc;g/m<sup>3</sup> were associated with an additional 21.9 AMI hospital admissions per 1000 (95%CI, 9.1-34.8; P&#x2009;&lt;&#x2009;.001). Furthermore, PM<sub>2.5</sub> levels above 25&#x2009;&#x3bc;g/m<sup>3</sup> (3-day moving average) were associated with an increased risk of in-hospital mortality due to AMI (OR, 1.14; 95%CI, 1.07-1.23; P&#x2009;&lt;&#x2009;.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study identifies a significant association between elevated PM<sub>2.5</sub> levels and increased hospital admissions and in-hospital mortality due to AMI in Spain, highlighting the importance of reducing air pollution as a critical factor in cardiovascular health. Full English text available from: www.revespcardiol.org/en.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Sociedad Espa&#xf1;ola de Cardiolog&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Campuzano</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario Fundaci&#xf3;n Alcorc&#xf3;n, Alcorc&#xf3;n, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfa;&#xf1;ez</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Cl&#xed;nico Universitario de Valencia, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez</LastName><ForeName>Violeta</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario 12 de Octubre, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Doblas</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario Virgen de la Victoria, M&#xe1;laga, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrarte</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital General Universitario de Alicante, Alicante, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cequier</LastName><ForeName>&#xc1;ngel</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Blanca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Programas SEC/FEC, Sociedad Espa&#xf1;ola de Cardiolog&#xed;a, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Instituto para la Mejora de la Asistencia Sanitaria (IMAS), Madrid, Espa&#xf1;a; Servicio de Medicina Preventiva, &#xc1;rea Sanitaria de Santiago y Barbanza, Instituto de Investigaciones Sanitarias de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, A Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prado</LastName><ForeName>N&#xe1;yade</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Instituto para la Mejora de la Asistencia Sanitaria (IMAS), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosillo</LastName><ForeName>Nicol&#xe1;s</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Instituto para la Mejora de la Asistencia Sanitaria (IMAS), Madrid, Espa&#xf1;a; Servicio de Medicina Preventiva, Hospital Universitario 12 de Octubre, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luis Bernal</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Instituto para la Mejora de la Asistencia Sanitaria (IMAS), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Instituto para la Mejora de la Asistencia Sanitaria (IMAS), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Sanitas Hospitales para la investigaci&#xf3;n e innovaci&#xf3;n m&#xe9;dica, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba&#xf1;eras</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Cardiolog&#xed;a, Hospital Universitari Vall d'Hebron, Barcelona, Espa&#xf1;a; Vall d'Hebron Institut de Recerca (VHIR), Universidad Aut&#xf3;noma de Barcelona, Barcelona, Espa&#xf1;a; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Espa&#xf1;a. Electronic address: jordi.baneras@vallhebron.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Cardiol (Engl Ed)</MedlineTA><NlmUniqueID>101587954</NlmUniqueID><ISSNLinking>1885-5857</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Contaminaci&#xf3;n ambiental</Keyword><Keyword MajorTopicYN="N">Environmental pollution</Keyword><Keyword MajorTopicYN="N">Infarto agudo de miocardio</Keyword><Keyword MajorTopicYN="N">PM2,5</Keyword><Keyword MajorTopicYN="N">PM2.5</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840676</ArticleId><ArticleId IdType="doi">10.1016/j.rec.2025.06.011</ArticleId><ArticleId IdType="pii">S1885-5857(25)00221-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40847485</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Using Machine Learning to Risk Stratify Emergency Department Patients With Chest Pain but No Acute Myocardial Infarction: A&#xa0;Multicenter Retrospective Analysis.</ArticleTitle><Pagination><StartPage>e041915</StartPage><MedlinePgn>e041915</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.125.041915</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to develop a machine learning-based model to predict the risk of major adverse cardiac events (MACE) in patients presenting to the emergency department (ED) with chest pain, for whom acute myocardial infarction was excluded after serial high-sensitivity cardiac troponin testing.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective analysis included adult patients presenting with chest pain at 5 study hospitals between 2021 and 2024 in Texas. Patients diagnosed with acute myocardial infarction during the index visit were excluded. The primary outcome was the occurrence of 30-day MACE, defined as myocardial infarction or all-cause mortality within 30&#x2009;days of the index ED visit. A long short-term memory algorithm was used to develop the prediction model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The analysis included 14&#x2009;177 patients with a median age of 49.7&#x2009;years, 41.2% of whom were men. A total of 535 patients (3.8%) had at least 1 high-sensitivity cardiac troponin level above the 99th percentile. Thirty-nine patients (0.3%) experienced 30-day MACE, including 15 (0.1%) with myocardial infarction and 24 (0.2%) with all-cause mortality. The long short-term memory model demonstrated excellent performance in predicting 30-day MACE (area under the receiver operating characteristic curve [AUC], 0.884 [95% CI, 0.815-0.941]), myocardial infarction (AUC, 0.963 [95% CI, 0.926-0.993]), and all-cause mortality (AUC, 0.849 [95% CI, 0.698-0.948]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The long short-term memory model accurately predicted 30-day MACE in ED patients presenting with chest pain and no acute myocardial infarction, using patient demographics, vital signs at ED presentation, electrocardiographic findings, and serial high-sensitivity cardiac troponin levels measured at flexible time points within 24&#x2009;hours of ED arrival.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Eric H</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0002-6731-6304</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine Baylor Scott and White All Saints Medical Center Fort Worth TX USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tsung-Chien</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0003-2729-7142</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, College of Medicine National Taiwan University Taipei Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine National Taiwan University Hospital Taipei Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Yong-Tai</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Graduate Institute of Electrical Engineering National Taiwan University Taipei Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Fan-Ya</ForeName><Initials>FY</Initials><Identifier Source="ORCID">0000-0003-1149-423X</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine National Taiwan University Hospital Taipei Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamada</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine Baylor Scott and White All Saints Medical Center Fort Worth TX USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Jaydeep</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0003-2900-3459</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology Baylor Scott and White All Saints Medical Center Fort Worth TX USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shori</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine Baylor Scott and White All Saints Medical Center Fort Worth TX USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danley</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1415-6746</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology Baylor Scott and White All Saints Medical Center Fort Worth TX USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shedd</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4000-0374</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine Baylor Scott and White All Saints Medical Center Fort Worth TX USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhakta</LastName><ForeName>Toral</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine Baylor Scott and White All Saints Medical Center Fort Worth TX USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Chu-Lin</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0003-4639-1513</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, College of Medicine National Taiwan University Taipei Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine National Taiwan University Hospital Taipei Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chih-Hung</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0003-0802-7825</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, College of Medicine National Taiwan University Taipei Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine National Taiwan University Hospital Taipei Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine National Taiwan University Hospital Yunlin Branch Douliu Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Hung-Yu</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0002-3116-306X</Identifier><AffiliationInfo><Affiliation>Department of Electrical Engineering and Graduate Institute of Communications Engineering National Taiwan University Taipei Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">chest pain</Keyword><Keyword MajorTopicYN="N">deep learning</Keyword><Keyword MajorTopicYN="N">emergency department</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">major adverse cardiac events</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>1</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40847485</ArticleId><ArticleId IdType="doi">10.1161/JAHA.125.041915</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40839161</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-187X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>American journal of cardiovascular drugs : drugs, devices, and other interventions</Title><ISOAbbreviation>Am J Cardiovasc Drugs</ISOAbbreviation></Journal><ArticleTitle>SGLT2 Inhibitors and Improved Survival in Patients with Diabetes and Acute Myocardial Infarction: Evidence from an Electronic Health Record-Based Cohort Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40256-025-00759-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Emerging evidence suggests that sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce cardiovascular events in patients with diabetes mellitus (DM) after acute myocardial infarction (AMI), but evidence in Asian populations remains limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We assessed the impact of SGLT2 inhibitors on in-hospital, 30-day, and 30-day to 1-year mortality in a Northern Chinese real-world cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An electronic health record-based cohort was constructed from the Tianjin Health and Medical Data Platform from January 2013 to December 2022. Statistical analyses, including Kaplan-Meier survival analysis, multivariable regression analysis, and propensity score matching, were undertaken to evaluate the impact of SGLT2 inhibitors on in-hospital, 30-day, and 1-year mortality rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 23,486 patients with both AMI and DM were included. Patients treated with SGLT2 inhibitors (n = 5053) were younger (64.2 vs 67.2 years) and had a higher frequency of dyslipidemia (26.4% vs 18.5%) and history of percutaneous coronary intervention (17.1% vs 15.3%) than those who did not receive them. After multivariable adjustment, the use of SGLT2 inhibitors showed a lower mortality rate during hospitalization (odds ratio 0.44; 95% confidence interval [CI] 0.33-0.58), at 30 days (hazard ratio 0.44; 95% CI 0.36-0.53), and at 30 days to 1 year (hazard ratio 0.86; 95% CI 0.73-1.00). These findings were further supported by propensity score matching and subgroup analyses, which consistently confirmed the reduction in mortality across all three time points.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In a real-world electronic health record-based cohort in China, this study confirmed a mortality benefit with the use of SGLT2 inhibitors in patients with combined DM and AMI. Further studies are needed to validate these benefits across broader populations.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yu</LastName><ForeName>Xuefang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Hangkuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Guoyan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Xilong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Shiyang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China. cardio-yq@tmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Pengfei</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0006-7812-833X</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China. spf2022@tmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82270349</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>72304205</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>72274133</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>TJYXZDXK-069C</GrantID><Agency>Tianjin Key Medical Discipline (Specialty) Construction Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Am J Cardiovasc Drugs</MedlineTA><NlmUniqueID>100967755</NlmUniqueID><ISSNLinking>1175-3277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declarations. Funding: This study was supported by the National Natural Science Foundation of China (72304205, 82270349, 72274133 and 82000338), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-069C). Conflicts of interest: Xuefang Yu, Liang Zhao, Hangkuan Liu, Xin Zhou, Guoyan Zhao, Zhiqiang Zhang, Xilong Qian, Bin Sun, Shiyang Fang, Qing Yang, Pengfei Sun have no relevant financial or non-financial interests to disclose. Ethics approval: This study received approval from the Tianjin Municipal Health Commission and conforms to ethical guidelines from the Tianjin Medical University General Hospital Ethical Committee (IRB2024-YX-338-01). Consent to participate: Considering the retrospective nature of the research and the lack of direct patient interaction or privacy breaches, informed consent was deemed unnecessary. Consent to publish: Not applicable. Data availability: Data may be obtained from a third party and are not publicly available. The data that support the findings of this study are available from Tianjin Municipal Health Commission, but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. However, data are available from the authors upon reasonable request and with permission of the Tianjin Municipal Health Commission. Code availability: All statistical analyses were conducted using R software (version 4.1.3, http://www.R-project.org ). Author contributions: Xuefang Yu, Pengfei Sun, and Qing Yang designed the study. Guoyan Zhao, Zhiqiang Zhang, Bin Sun, and Xilong Qian extracted the dataset and performed statistical analysis. Xuefang Yu wrote the first draft. Liang Zhao, Hangkuan Liu, and Xin Zhou prepared the figures and tables, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839161</ArticleId><ArticleId IdType="doi">10.1007/s40256-025-00759-4</ArticleId><ArticleId IdType="pii">10.1007/s40256-025-00759-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeFilippis AP, Chapman AR, Mills NL, et al. Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury. Circulation. 2019;140(20):1661&#x2013;78. https://doi.org/10.1161/CIRCULATIONAHA.119.040631 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.040631</ArticleId><ArticleId IdType="pubmed">31416350</ArticleId><ArticleId IdType="pmc">6855329</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauerman HL, Ibanez B. The edge of time in acute myocardial infarction. J Am Coll Cardiol. 2021;77(15):1871&#x2013;4. https://doi.org/10.1016/j.jacc.2021.03.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.03.003</ArticleId><ArticleId IdType="pubmed">33858623</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155&#x2013;65. https://doi.org/10.1056/NEJMoa0908610 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908610</ArticleId><ArticleId IdType="pubmed">20558366</ArticleId></ArticleIdList></Reference><Reference><Citation>Udell JA, Jones WS, Petrie MC, et al. Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week. J Am Coll Cardiol. 2022;79(20):2058&#x2013;68. https://doi.org/10.1016/j.jacc.2022.03.353 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.03.353</ArticleId><ArticleId IdType="pubmed">35589167</ArticleId></ArticleIdList></Reference><Reference><Citation>von Lewinski D, Benedikt M, Tripolt N, Wallner M, Sourij H, Kolesnik E. Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction? Kardiol Pol. 2021;79(5):503&#x2013;9. https://doi.org/10.33963/KP.15969 .</Citation><ArticleIdList><ArticleId IdType="doi">10.33963/KP.15969</ArticleId></ArticleIdList></Reference><Reference><Citation>Idowu A, Adebolu O, Wattanachayakul P, et al. Cardiovascular outcomes of sodium-glucose co-transporter 2 inhibitors use after myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024;49(8): 102648. https://doi.org/10.1016/j.cpcardiol.2024.102648 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2024.102648</ArticleId><ArticleId IdType="pubmed">38759767</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden K, Mailey J, Kearney A, Menown IBA. Advances in clinical cardiology 2019: a summary of key clinical trials. Adv Ther. 2020;37(6):2620&#x2013;45. https://doi.org/10.1007/s12325-020-01355-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-020-01355-5</ArticleId><ArticleId IdType="pubmed">32361851</ArticleId><ArticleId IdType="pmc">7467440</ArticleId></ArticleIdList></Reference><Reference><Citation>Moady G, Ben Gal T, Atar S. Sodium-glucose co-transporter 2 inhibitors in heart failure-current evidence in special populations. Life (Basel). 2023;13(6): 1256. https://doi.org/10.3390/life13061256 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13061256</ArticleId><ArticleId IdType="pubmed">37374037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe9;n HC, Mohammad MA, Jernberg T, James S, Oldgren J, Erlinge D. SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART. Lancet Reg Health. 2024;45: 101032. https://doi.org/10.1016/j.lanepe.2024.101032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2024.101032</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolisso P, Bergamaschi L, Gragnano F, et al. Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry. Pharmacol Res. 2023;187: 106597. https://doi.org/10.1016/j.phrs.2022.106597 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106597</ArticleId><ArticleId IdType="pubmed">36470546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun P, Liu WN, Qian X, et al. Age-specific prognosis of acute and steady minor elevations in cardiac troponin among non-acute myocardial infarction inpatients: a large real-world cohort study. Heart. 2025;111(11):513&#x2013;21. https://doi.org/10.1136/heartjnl-2024-325079 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2024-325079</ArticleId><ArticleId IdType="pubmed">39819612</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai TY, Lin JF, Tu YK, et al. Validation of ICD-10-CM diagnostic codes for identifying patients with ST-elevation and non-ST-elevation myocardial infarction in a national health insurance claims database. Clin Epidemiol. 2023;15:1027&#x2013;39. https://doi.org/10.2147/CLEP.S431231 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S431231</ArticleId><ArticleId IdType="pubmed">37868152</ArticleId><ArticleId IdType="pmc">10590151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun P, Li J, Fang W, et al. Effectiveness of chest pain centre accreditation on the management of acute coronary syndrome: a retrospective study using a national database. BMJ Qual Saf. 2021;30(11):867&#x2013;75. https://doi.org/10.1136/bmjqs-2020-011491 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjqs-2020-011491</ArticleId><ArticleId IdType="pubmed">33443197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul P, Federspiel JJ, Dai X, et al. Association of inpatient vs outpatient onset of ST-elevation myocardial infarction with treatment and clinical outcomes. JAMA. 2014;312(19):1999&#x2013;2007. https://doi.org/10.1001/jama.2014.15236 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.15236</ArticleId><ArticleId IdType="pubmed">25399275</ArticleId><ArticleId IdType="pmc">4266685</ArticleId></ArticleIdList></Reference><Reference><Citation>Stekhoven DJ, B&#xfc;hlmann P. MissForest&#x2014;non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28(1):112&#x2013;8. https://doi.org/10.1093/bioinformatics/btr597 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr597</ArticleId><ArticleId IdType="pubmed">22039212</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao SG, Lin Y, Kang DD, et al. Missing value imputation in high-dimensional phenomic data: imputable or not, and how? BMC Bioinform. 2014;15(1): 346. https://doi.org/10.1186/s12859-014-0346-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-014-0346-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43(27):2549&#x2013;61. https://doi.org/10.1093/eurheartj/ehac223 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac223</ArticleId><ArticleId IdType="pubmed">35511857</ArticleId><ArticleId IdType="pmc">9336586</ArticleId></ArticleIdList></Reference><Reference><Citation>Desta L, Jernberg T, Spaak J, Hofman-Bang C, Persson H. Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: a Swedish nationwide observational study. Int J Cardiol. 2017;248:221&#x2013;6. https://doi.org/10.1016/j.ijcard.2017.05.086 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2017.05.086</ArticleId><ArticleId IdType="pubmed">28579167</ArticleId></ArticleIdList></Reference><Reference><Citation>von Lewinski D, Kolesnik E, Tripolt NJ, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421&#x2013;32. https://doi.org/10.1093/eurheartj/ehac494 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac494</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413&#x2013;24. https://doi.org/10.1056/NEJMoa2022190 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022190</ArticleId><ArticleId IdType="pubmed">32865377</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995&#x2013;2008. https://doi.org/10.1056/NEJMoa1911303 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1911303</ArticleId><ArticleId IdType="pubmed">31535829</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington J, Butler J. Heart failure after myocardial infarction: glass emptier than full. Eur J Heart Fail. 2023;25(8):1225&#x2013;7. https://doi.org/10.1002/ejhf.2961 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2961</ArticleId><ArticleId IdType="pubmed">37462280</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752&#x2013;72. https://doi.org/10.1161/CIRCULATIONAHA.116.021887 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.021887</ArticleId><ArticleId IdType="pubmed">27470878</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolisso P, Bergamaschi L, Santulli G, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21(1):77. https://doi.org/10.1186/s12933-022-01506-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01506-8</ArticleId><ArticleId IdType="pubmed">35570280</ArticleId><ArticleId IdType="pmc">9107763</ArticleId></ArticleIdList></Reference><Reference><Citation>Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81(25):2377&#x2013;87. https://doi.org/10.1016/j.jacc.2023.04.034 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.04.034</ArticleId><ArticleId IdType="pubmed">37344038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall ME, Vaduganathan M, Khan MS, et al. Reductions in heart failure hospitalizations during the COVID-19 pandemic. J Card Fail. 2020;26(6):462&#x2013;3. https://doi.org/10.1016/j.cardfail.2020.05.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2020.05.005</ArticleId><ArticleId IdType="pubmed">32405232</ArticleId><ArticleId IdType="pmc">7219367</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc Res. 2022;118(10):2231&#x2013;52. https://doi.org/10.1093/cvr/cvab271 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab271</ArticleId><ArticleId IdType="pubmed">34390570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulsin GS, Graham-Brown MPM, Squire IB, Davies MJ, McCann GP. Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart. 2022;108(1):16&#x2013;21. https://doi.org/10.1136/heartjnl-2021-319185 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2021-319185</ArticleId><ArticleId IdType="pubmed">33972360</ArticleId></ArticleIdList></Reference><Reference><Citation>James S, Erlinge D, Storey RF, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3(2): EVIDoa2300286. https://doi.org/10.1056/EVIDoa2300286 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2300286</ArticleId><ArticleId IdType="pubmed">38320489</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler J, Jones WS, Udell JA, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390(16):1455&#x2013;66. https://doi.org/10.1056/NEJMoa2314051 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2314051</ArticleId><ArticleId IdType="pubmed">38587237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99. https://doi.org/10.1186/s12933-019-0903-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-019-0903-4</ArticleId><ArticleId IdType="pubmed">31382965</ArticleId><ArticleId IdType="pmc">6683461</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846128</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Reply to comment on "Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevation myocardial infarction" by Poller et al.</ArticleTitle><Pagination><StartPage>133801</StartPage><MedlinePgn>133801</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2025.133801</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(25)00844-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poller</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sahlgrenska University Hospital/S, Gothenburg, Sweden; Department of Clinical Physiology, Sahlgrenska University Hospital/S, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sweden. Electronic address: angela.poller@vgregion.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bech-Hanssen</LastName><ForeName>Odd</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Physiology, Sahlgrenska University Hospital/S, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redfors</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sahlgrenska University Hospital/S, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sweden; Clinical Trial Centre, Cardiovascular Research Foundation, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Echocardiography</Keyword><Keyword MajorTopicYN="N">Global strain</Keyword><Keyword MajorTopicYN="N">ST-elevation myocardial infarction</Keyword><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword></KeywordList><CoiStatement>Declaration of competing interest None to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846128</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2025.133801</ArticleId><ArticleId IdType="pii">S0167-5273(25)00844-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40842747</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Elevation Myocardial Infarction and the Impact of Impella: A Retrospective Single-Center Study.</ArticleTitle><Pagination><StartPage>e88394</StartPage><MedlinePgn>e88394</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e88394</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.88394</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">&#xa0;ST-segment elevation myocardial infarction (STEMI) often requires urgent revascularization, with percutaneous coronary intervention (PCI) as the primary strategy. However, coronary artery bypass grafting (CABG) remains essential in cases where PCI is either unfeasible or fails. Emergency CABG for STEMI is associated with high operative risk and poor outcomes, especially in hemodynamically unstable patients. The Impella device (Abiomed Inc., Danvers, MA)&#xa0;provides percutaneous mechanical circulatory support (MCS), which stabilizes hemodynamics, enhances end-organ perfusion, and facilitates myocardial recovery through left ventricular unloading. These effects may allow for clinical stabilization before surgery, thereby reducing the need for emergency CABG and improving surgical outcomes. This study aimed to evaluate the outcomes of CABG for STEMI and to assess how the introduction of Impella influenced its indications, timing, and patient selection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">&#xa0;We conducted a retrospective analysis of 59 consecutive patients with STEMI who underwent CABG between 2012 and 2023. Clinical data were obtained from the institutional electronic medical records for all patients included in this study. Patients were classified as requiring emergency, urgent, or elective procedures. Clinical and procedural data were compared before and after the introduction of Impella in 2019.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">&#xa0;The hospital mortality occurred in one patient (1.7%), including one patient (3.3%) among emergent cases. Postoperative complications occurred in 13 patients (43.3%) of emergency cases, five patients (27.8%) of urgent cases, and none of the elective cases. Sepsis and acute kidney injury were the most common complications. The length of stay in the intensive care unit was significantly longer for emergent cases than for urgent and elective cases. CABG for STEMI was performed in 49 cases before the introduction of Impella and in 10 cases afterward. This led to a decrease in the rate of CABG performed for STEMI from 11.2% to 4.3%. Although the difference was not statistically significant, the proportion of emergency CABG decreased from 53.1% to 40%, while urgent CABG increased from 26.5% to 50%, suggesting a trend toward surgical stabilization. Regarding the use of MCS, the rate increased from 53.1% (26 patients) before Impella introduction to 70% (seven patients) after, with Impella used in 20% (two patients) of the latter group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">&#xa0;CABG remains a viable option for patients with high-risk STEMI. Observations suggest that the use of Impella may be linked to a shift in CABG indications, from unsuitable PCI&#xa0;to failed PCI, and a tendency toward less emergent surgical timing.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Takagi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Kazuyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shojima</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kono</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaima</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saku</LastName><ForeName>Kosuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Maki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibata</LastName><ForeName>Tatushiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanai</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsushima</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishikido</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashida</LastName><ForeName>Miyu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamakawa</LastName><ForeName>Rei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mine</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shintani</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takaseya</LastName><ForeName>Tohru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arinaga</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukumoto</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tayama</LastName><ForeName>Eiki</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kurume University, Kurume, JPN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronary artery bypass grafting</Keyword><Keyword MajorTopicYN="N">impella</Keyword><Keyword MajorTopicYN="N">institutional outcome</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">st-elevation myocardial infarction</Keyword></KeywordList><CoiStatement>Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. The Ethical Committee of Kurume University issued approval 21001. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40842747</ArticleId><ArticleId IdType="pmc">PMC12365362</ArticleId><ArticleId IdType="doi">10.7759/cureus.88394</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Kimura K, Kimura T, Ishihara M, et al. Circ J. 2019;83:1085&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">30930428</ArticleId></ArticleIdList></Reference><Reference><Citation>2023 ESC guidelines for the management of acute coronary syndromes. Byrne RA, Rossello X, Coughlan JJ, et al. Eur Heart J. 2023;44:3720&#x2013;3826.</Citation><ArticleIdList><ArticleId IdType="pubmed">38206306</ArticleId></ArticleIdList></Reference><Reference><Citation>Utilization, characteristics, and in-hospital outcomes of coronary artery bypass grafting in patients with ST-segment-elevation myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the guidelines. Pi Y, Roe MT, Holmes DN, et al. Circ Cardiovasc Qual Outcomes. 2017;10:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">28794118</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock. Smilowitz NR, Alviar CL, Katz SD, Hochman JS. Am Heart J. 2020;226:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442583</ArticleId><ArticleId IdType="pubmed">32278440</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronary artery bypass grafting within 30 days of an acute myocardial infarction. Kaul TK, Fields BL, Riggins L, et al. Ann Thorac Surg. 1995;59:1169&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">7733715</ArticleId></ArticleIdList></Reference><Reference><Citation>Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. Weiss ES, Chang DD, Joyce DL, Nwakanma LU, Yuh DD. J Thorac Cardiovasc Surg. 2008;135:503-11, 511.e1-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329460</ArticleId></ArticleIdList></Reference><Reference><Citation>Outcome of stable patients with acute myocardial infarction and coronary artery bypass surgery within 48 hours: a single-center, retrospective experience. Grothusen C, Friedrich C, Loehr J, et al. J Am Heart Assoc. 2017;6:5498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5721822</ArticleId><ArticleId IdType="pubmed">28974496</ArticleId></ArticleIdList></Reference><Reference><Citation>Timing of coronary artery bypass grafting after acute myocardial infarction may not influence mortality and readmissions. Bianco V, Kilic A, Gleason TG, Aranda-Michel E, Wang Y, Navid F, Sultan I. J Thorac Cardiovasc Surg. 2021;161:2056&#x2013;2064.</Citation><ArticleIdList><ArticleId IdType="pubmed">31952832</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. White HD, Assmann SF, Sanborn TA, et al. Circulation. 2005;112:1992&#x2013;2001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186436</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. Shah M, Patnaik S, Patel B, et al. Clin Res Cardiol. 2018;107:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">29134345</ArticleId></ArticleIdList></Reference><Reference><Citation>Contemporary trends in use of mechanical circulatory support in patients with acute MI and cardiogenic shock. Helgestad OK, Josiassen J, Hassager C, et al. Open Heart. 2020;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059524</ArticleId><ArticleId IdType="pubmed">32201591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanical pre-conditioning with acute circulatory support before reperfusion limits infarct size in acute myocardial infarction. Kapur NK, Qiao X, Paruchuri V, et al. JACC Heart Fail. 2015;3:873&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">26541785</ArticleId></ArticleIdList></Reference><Reference><Citation>Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: rationale and design of the STEMI-DTU randomized pivotal trial. Kapur NK, Kim RJ, Moses JW, et al. Am Heart J. 2022;254:122&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">36058253</ArticleId></ArticleIdList></Reference><Reference><Citation>Microaxial flow pump or standard care in infarct-related cardiogenic shock. M&#xf8;ller JE, Engstr&#xf8;m T, Jensen LO, et al. N Engl J Med. 2024;390:1382&#x2013;1393.</Citation><ArticleIdList><ArticleId IdType="pubmed">38587239</ArticleId></ArticleIdList></Reference><Reference><Citation>Characteristics and predictors of mortality in patients with cardiovascular shock in Japan - results from the Japanese Circulation Society Cardiovascular Shock registry. Ueki Y, Mohri M, Matoba T, et al. Circ J. 2016;80:852&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">27001192</ArticleId></ArticleIdList></Reference><Reference><Citation>Short-term outcomes of Impella support in Japanese patients with cardiogenic shock due to acute myocardial infarction - Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) Ikeda Y, Ako J, Toda K, et al. Circ J. 2023;87:588&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">36682787</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term outcomes of extent of revascularization in complex high risk and indicated patients undergoing Impella-protected percutaneous coronary intervention: report from the Roma-Verona registry. Burzotta F, Russo G, Ribichini F, et al. J Interv Cardiol. 2019;2019:5243913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6739781</ArticleId><ArticleId IdType="pubmed">31772533</ArticleId></ArticleIdList></Reference><Reference><Citation>Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices. O'Neill WW, Anderson M, Burkhoff D, et al. Am Heart J. 2022;248:139&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">35192839</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics and in-hospital outcomes of patients with cardiogenic shock undergoing coronary artery bypass surgery: insights from the Society of Thoracic Surgeons National Cardiac Database. Mehta RH, Grab JD, O'Brien SM, Glower DD, Haan CK, Gammie JS, Peterson ED. Circulation. 2008;117:876&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">18250266</ArticleId></ArticleIdList></Reference><Reference><Citation>Re-evaluating the role of CABG in acute coronary syndromes. Farmer D, Jimenez E. Curr Cardiol Rep. 2020;22:148.</Citation><ArticleIdList><ArticleId IdType="pubmed">32944807</ArticleId></ArticleIdList></Reference><Reference><Citation>Optimal timing of coronary artery bypass grafting in acute myocardial infarction. Caceres M, Weiman DS. Ann Thorac Surg. 2013;95:365&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">23200230</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics and outcomes of patients with myocardial infarction and cardiogenic shock undergoing coronary artery bypass surgery: data from the Society of Thoracic Surgeons National Database. Acharya D, Gulack BC, Loyaga-Rendon RY, et al. Ann Thorac Surg. 2016;101:558&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5142520</ArticleId><ArticleId IdType="pubmed">26718859</ArticleId></ArticleIdList></Reference><Reference><Citation>Temporary circulatory support with surgically implanted microaxial pumps in postcardiotomy cardiogenic shock following coronary artery bypass surgery. Sommer W, Arif R, Kremer J, et al. JTCVS Open. 2023;15:252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10556953</ArticleId><ArticleId IdType="pubmed">37808068</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronary artery bypass graft surgery in patients with acute coronary syndromes after primary percutaneous coronary intervention: a current report from the North-Rhine Westphalia surgical myocardial infarction registry. Thielmann M, Wendt D, Slottosch I, et al. J Am Heart Assoc. 2021;10:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8649544</ArticleId><ArticleId IdType="pubmed">34514809</ArticleId></ArticleIdList></Reference><Reference><Citation>The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction. Burgess SN, French JK, Nguyen TL, et al. Am Heart J. 2018;205:31&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">30153623</ArticleId></ArticleIdList></Reference><Reference><Citation>Identification of candidates for coronary artery bypass grafting admitted with STEMI and multivessel disease. Rodr&#xed;guez-Olivares R, L&#xf3;pez-Men&#xe9;ndez J, Barca LV, Hycka JM, Hern&#xe1;ndez-Antol&#xed;n R, Rodr&#xed;guez-Roda Stuart J, Zamorano G&#xf3;mez JL. Cardiovasc Revasc Med. 2018;19:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29934066</ArticleId></ArticleIdList></Reference><Reference><Citation>A patient with extensive ST elevation myocardial infarction who underwent emergent Impella CP&#xae; assisted off-pump coronary artery bypass without mechanical complication. Machii Y, Sezai A, Hayashi Y, Harada A, Kamata K, Eguchi N, Tanaka M. J Cardiol Cases. 2024;29:104&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10927439</ArticleId><ArticleId IdType="pubmed">38481636</ArticleId></ArticleIdList></Reference><Reference><Citation>Staged revascularization and multi-modal mechanical circulatory supports in a patient with severe cardiogenic shock due to acute-on-chronic coronary syndrome. Horimoto M, Tsutsui M, Mochizuki N, et al. J Surg Case Rep. 2023;2023:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10663061</ArticleId><ArticleId IdType="pubmed">38026743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40845475</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1980-5322</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Clinics (Sao Paulo, Brazil)</Title><ISOAbbreviation>Clinics (Sao Paulo)</ISOAbbreviation></Journal><ArticleTitle>Assessment of oxidative stress and trace element dynamics in acute myocardial infarction and heart failure: a focus on zinc, copper, and thiol dynamics.</ArticleTitle><Pagination><StartPage>100755</StartPage><MedlinePgn>100755</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinsp.2025.100755</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1807-5932(25)00174-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute Myocardial Infarction (AMI) and Heart Failure (HF) are the leading global causes of death from Cardiovascular Diseases (CVD). This study aimed to investigate the association of serum Zinc (Zn), Copper (Cu), and thiol levels with CVD and new potential biomarkers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study included serum samples from 150 participants, including 50 AMI patients, 50 HF patients, and 50 healthy individuals. Oxidative stress, trace elements (Cu and Zn), and thiol levels were investigated by automated kits in AMI and HF patients compared to the control group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">T-thiol, N-thiol and Cu levels were higher in the AMI group than in the control group (p &lt; 0.05, p &lt; 0.01, p &lt; 0.01, respectively). Cu and Zn levels were higher in the HF group compared to the control group (p &lt; 0.001, p &lt; 0.01, respectively). Compared to the HF group, T-thiol (p &lt; 0.05), N-thiol (p &lt; 0.05), and Zn (p &lt; 0.001) levels were higher in the AMI group. By ROC analysis, Zn, Cu and thiol levels showed moderate discriminative power, emphasizing their candidacy as biomarkers.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite the limitations of age-related variations and sample size, this study pioneers the comparative analysis of AMI and HF, contributing to the elucidation of the complex connections between Zn, Cu and thiol levels in cardiovascular pathologies. It increases the importance of Zn, Cu and thiol levels in CVD's status, necessitating further research on this topic with refined methodologies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cimen</LastName><ForeName>Yasin Ali</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey. Electronic address: ycimen1@bezmialem.edu.tr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taslidere</LastName><ForeName>Bahadir</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarikaya</LastName><ForeName>Ufuk</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demirel</LastName><ForeName>Metin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acikgoz</LastName><ForeName>Nusret</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selek</LastName><ForeName>Sahabettin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clinics (Sao Paulo)</MedlineTA><NlmUniqueID>101244734</NlmUniqueID><ISSNLinking>1807-5932</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction (AMI)</Keyword><Keyword MajorTopicYN="N">Copper (Cu)</Keyword><Keyword MajorTopicYN="N">Heart failure (HF)</Keyword><Keyword MajorTopicYN="N">Oxidative Stress</Keyword><Keyword MajorTopicYN="N">Thiols</Keyword><Keyword MajorTopicYN="N">Zinc (Zn)</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845475</ArticleId><ArticleId IdType="doi">10.1016/j.clinsp.2025.100755</ArticleId><ArticleId IdType="pii">S1807-5932(25)00174-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40833236</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-2586</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of magnetic resonance imaging : JMRI</Title><ISOAbbreviation>J Magn Reson Imaging</ISOAbbreviation></Journal><ArticleTitle>Editorial for "Atrioventricular Coupling Index: A Novel Approach to Risk-Stratification for Major Adverse Cardiovascular Events in Patients With ST-Elevation Myocardial Infarction".</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmri.70090</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5589-8792</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Pneumology, University Medical Center G&#xf6;ttingen, Georg-August University and German Center for Cardiovascular Research (DZHK), Partner Site Lower-Saxony, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Torben</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0505-2582</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Pneumology, University Medical Center G&#xf6;ttingen, Georg-August University and German Center for Cardiovascular Research (DZHK), Partner Site Lower-Saxony, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Magn Reson Imaging</MedlineTA><NlmUniqueID>9105850</NlmUniqueID><ISSNLinking>1053-1807</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40833236</ArticleId><ArticleId IdType="doi">10.1002/jmri.70090</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>T. Pezel, B. A. Venkatesh, H. D. De Vasconcellos, et&#xa0;al., &#x201c;Left Atrioventricular Coupling Index as a Prognostic Marker of Cardiovascular Events: The MESA Study,&#x201d; Hypertension 78 (2021): 661&#x2013;671.</Citation></Reference><Reference><Citation>T. Lange, S. J. Backhaus, A. Schulz, et&#xa0;al., &#x201c;Cardiovascular Magnetic Resonance&#x2010;Derived Left Atrioventricular Coupling Index and Major Adverse Cardiac Events in Patients Following Acute Myocardial Infarction,&#x201d; Journal of Cardiovascular Magnetic Resonance 25 (2023): 24.</Citation></Reference><Reference><Citation>S. J. Backhaus, T. Lange, A. Schulz, et&#xa0;al., &#x201c;Cardiovascular Magnetic Resonance Rest and Exercise&#x2010;Stress Left Atrioventricular Coupling Index to Detect Diastolic Dysfunction,&#x201d; American Journal of Physiology. Heart and Circulatory Physiology 324 (2023): H686&#x2013;H695.</Citation></Reference><Reference><Citation>G. Kasa, A. Teis, M. De Raffele, et&#xa0;al., &#x201c;Prognostic Value of Left Atrioventricular Coupling Index in Heart Failure,&#x201d; European Heart Journal Cardiovascular Imaging 26 (2025): 610&#x2013;617.</Citation></Reference><Reference><Citation>T. Pezel, P. Garot, S. Toupin, et&#xa0;al., &#x201c;AI&#x2010;Based Fully Automated Left Atrioventricular Coupling Index as a Prognostic Marker in Patients Undergoing Stress CMR,&#x201d; JACC: Cardiovascular Imaging 16 (2023): 1288&#x2013;1302.</Citation></Reference><Reference><Citation>L.&#x2010;M. Wu, J.&#x2010;P. Wu, Y. Zhao, et&#xa0;al., &#x201c;Atrioventricular Coupling Index: A Novel Approach to Risk&#x2010;Stratification for Major Adverse Cardiovascular Events in Patients With ST&#x2010;Elevation Myocardial Infarction,&#x201d; Journal of Magnetic Resonance Imaging JMRI&#x2010;25&#x2010;0798.</Citation></Reference><Reference><Citation>S. Qin, L. Zhang, M. Ji, et&#xa0;al., &#x201c;Clinical Utility of Atrioventricular Coupling Index in Cardiovascular Disease,&#x201d; Journal of the American Heart Association 14 (2025): e041392.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40834426</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-5049</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of cardiovascular nursing</Title><ISOAbbreviation>J Cardiovasc Nurs</ISOAbbreviation></Journal><ArticleTitle>The Impact of Nurse-Led Peer Support Interventions on Psychological Status and Quality of Life After Acute Myocardial Infarction Stent Implantation in China.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCN.0000000000001247</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with acute myocardial infarction (AMI) often experience psychological distress and reduced quality of life after stent implantation. In this study, our aim was to evaluate the effectiveness of a nurse-led peer support intervention on the psychological status and quality of life of patients with AMI post stent implantation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this randomized controlled trial, 200 patients with AMI who underwent stent implantation were randomly assigned to either a nurse-led peer support intervention group (n = 100) or a standard care control group (n = 100). The intervention consisted of weekly 90-minute group sessions facilitated by trained nurses and peer supporters for 12 weeks. Psychological status was assessed using the Hospital Anxiety and Depression Scale and the Perceived Stress Scale. Quality of life was measured using the Short Form-36 (SF-36) questionnaire. Assessments were conducted at baseline and 12 weeks post intervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the control group, individuals in the intervention group showed significantly lower anxiety (mean difference, -2.5; 95% confidence interval [CI], -3.2 to -1.8; P &lt; .001) and depression (mean difference, -2.1; 95% CI, -2.8 to -1.4; P &lt; .001) scores at 12 weeks. Perceived stress levels were also significantly reduced in the intervention group (mean difference, -3.7; 95% CI, -4.5 to -2.9; P &lt; .001). Quality of life scores improved significantly across all domains of the Short Form-36 in the intervention group, with the most notable improvements in emotional well-being (mean difference, 10.2; 95% CI, 7.1-13.3; P &lt; .001) and social functioning (mean difference, 9.8; 95% CI, 6.7-12.9; P &lt; .001). Medication adherence and perceived social support also improved significantly in the intervention group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Nurse-led peer support interventions significantly improve psychological status and quality of life in patients with AMI after stent implantation. These findings suggest that incorporating such interventions into standard care could enhance postoperative recovery and long-term outcomes for individuals with AMI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Xiaohong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qin</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Hongmei</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Nurs</MedlineTA><NlmUniqueID>8703516</NlmUniqueID><ISSNLinking>0889-4655</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">nurse-led intervention</Keyword><Keyword MajorTopicYN="N">peer support</Keyword><Keyword MajorTopicYN="N">psychological status</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">stent implantation</Keyword></KeywordList><CoiStatement>The authors have no funding or conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>17</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40834426</ArticleId><ArticleId IdType="doi">10.1097/JCN.0000000000001247</ArticleId><ArticleId IdType="pii">00005082-990000000-00330</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Published June 11, 2023. Accessed October 15, 2024.</Citation></Reference><Reference><Citation>Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824&#x2013;835.</Citation></Reference><Reference><Citation>Vaccarino V, Badimon L, Bremner JD, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687&#x2013;1696.</Citation></Reference><Reference><Citation>Albus C, Waller C, Fritzsche K, et al. Significance of psychosocial factors in cardiology: update 2018: position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175&#x2013;1196.</Citation></Reference><Reference><Citation>Wu M, Zhu Y, Lv J, et al. Association of anxiety with cardiovascular disease in a Chinese cohort of 0.5 million adults. J Affect Disord. 2022;315:291&#x2013;296.</Citation></Reference><Reference><Citation>Erickson KI, Stillman CM, Ballard RM, et al. Physical activity, cognition, and brain outcomes: a review of the 2018 physical activity guidelines. Med Sci Sports Exerc. 2019;51(6):1242&#x2013;1251.</Citation></Reference><Reference><Citation>Llewellyn-Beardsley J, Rennick-Egglestone S, Bradstreet S, et al. Not the story you want? Assessing the fit of a conceptual framework characterising mental health recovery narratives. Soc Psychiatry Psychiatr Epidemiol. 2020;55:295&#x2013;308.</Citation></Reference><Reference><Citation>He X, Li J, Wang B, et al. Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine. 2017;55(3):712&#x2013;731.</Citation></Reference><Reference><Citation>Devlin JW, Skrobik Y, G&#xe9;linas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825&#x2013;e873.</Citation></Reference><Reference><Citation>K&#xf6;hler AK, Tingstr&#xf6;m P, Jaarsma T, Nilsson S. Patient empowerment and general self-efficacy in patients with coronary heart disease: a cross-sectional study. BMC Fam Pract. 2018;19(1):76.</Citation></Reference><Reference><Citation>Rashidi A, Kaistha P, Whitehead L, Robinson S. Factors that influence adherence to treatment plans amongst people living with cardiovascular disease: a review of published qualitative research studies. Int J Nurs Stud. 2020;110:103727.</Citation></Reference><Reference><Citation>Santiago de Ara&#xfa;jo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to promote patient utilisation of cardiac rehabilitation. Cochrane Database Syst Rev. 2019;2(2):CD007131.</Citation></Reference><Reference><Citation>Supervia M, Turk-Adawi K, Lopez-Jimenez F, et al. Nature of cardiac rehabilitation around the globe. EClinicalMedicine. 2019;13:46&#x2013;56.</Citation></Reference><Reference><Citation>Pesah E, Turk-Adawi K, Supervia M, et al. Cardiac rehabilitation delivery in low/middle-income countries. Heart. 2019;105(23):1806&#x2013;1812.</Citation></Reference><Reference><Citation>Gary RA, Paul S, Corwin E, et al. Exercise and cognitive training intervention improves self-care, quality of life and functional capacity in persons with heart failure. J Appl Gerontol. 2022;41(2):486&#x2013;495.</Citation></Reference><Reference><Citation>McConnell MV, Turakhia MP, Harrington RA, King AC, Ashley EA. Mobile health advances in physical activity, fitness, and atrial fibrillation: moving hearts. J Am Coll Cardiol. 2018;71(23):2691&#x2013;2701.</Citation></Reference><Reference><Citation>Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anxiety in heart failure: a review. Harv Rev Psychiatry. 2018;26(4):175&#x2013;184.</Citation></Reference><Reference><Citation>Chindhy S, Taub PR, Lavie CJ, et al. Current challenges in cardiac rehabilitation: strategies to overcome social factors and attendance barriers. Expert Rev Cardiovasc Ther. 2020;18(11):777&#x2013;789.</Citation></Reference><Reference><Citation>Haff N, Sreedhara SK, Wood W, et al. Testing interventions to reduce clinical inertia in the treatment of hypertension: rationale and design of a pragmatic randomized controlled trial. Am Heart J. 2024;268:18&#x2013;28.</Citation></Reference><Reference><Citation>Pietrzykowski &#x141;, Michalski P, Kosobucka A, et al. Medication adherence and its determinants in patients after myocardial infarction. Sci Rep. 2020;10(1):12028.</Citation></Reference><Reference><Citation>Xia N, Li H. Loneliness, social isolation, and cardiovascular health. Antioxid Redox Signal. 2018;28(9):837&#x2013;851.</Citation></Reference><Reference><Citation>Ng SX, Wang W, Shen Q, et al. The effectiveness of preoperative education interventions on improving perioperative outcomes of adult patients undergoing cardiac surgery: a systematic review and meta-analysis. Eur J Cardiovasc Nurs. 2022;21(6):521&#x2013;536.</Citation></Reference><Reference><Citation>Conway-Phillips R, Dagadu H, Motley D, et al. Qualitative evidence for Resilience, Stress, and Ethnicity (RiSE): a program to address race-based stress among Black women at risk for cardiovascular disease. Complement Ther Med. 2020;48:102277.</Citation></Reference><Reference><Citation>Emmons-Bell S, Johnson C, Roth G. Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022;108(17):1351&#x2013;1360.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40836409</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>162</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>PENG-based self-powered transcutaneous auricular vagus nerve stimulation attenuated myocardial infarction-induced heart-brain remodeling via ameliorating the neuroinflammatory response in central amygdala.</ArticleTitle><Pagination><StartPage>115085</StartPage><MedlinePgn>115085</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2025.115085</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(25)01075-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myocardial infarction (MI) is responsible for the majority of deaths worldwide and depression can intensify the detrimental cycle of heart-brain remodeling after MI. Transcutaneous auricular vagus nerve stimulation (taVNS) is an effective non-invasive neuromodulation strategy for treating depression and cardiovascular disease (CVD). Piezoelectric nanogenerators (PENGs) can convert the mechanical energy of organism into electrical energy to achieve self-powering. Self-powered vagal neuromodulation based on PENGs have been used for neural stimulation and CVD treatment. We aim to determine the interaction between heart and central amygdala (CeA), integrate self-powered PENG technology into taVNS system and explore the effects and underlying mechanisms of taVNS on heart-CeA remodeling after MI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Neural tracing and chemogenetic technologies were used to confirm the heart-CeA connectivity. A four-weeks taVNS treatment was promoted after MI induction in male Sprague-Dawley rats. Then, depression-like behaviors and cardiac remodeling were evaluated. Besides, neuronal activity and neuroinflammation levels were assessed and the underlying mechanisms were elucidated. The self-powered PENG technology was integrated into the taVNS system and its neuromodulation effectiveness was evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MI increased neuronal activity in the CeA and depression-like behaviors, and over-activation of the CeA led to cardiac dysfunction, resulting in malignant feedback. taVNS attenuated MI-induced "heart-CeA" remodeling, improved cardiac function, and reduced depression-like behaviors by ameliorating the neuroinflammatory response via MLCK pathway in the CeA. In addition, the self-powered PENG-based system enabled effective transcutaneous neuromodulation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PENG-based self-powered taVNS holds potential for heart-brain neuromodulation, offering a synergistic strategy for treating cardiac and mental co-morbidities after MI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Jiaming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhihao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Wuhan No.1 Hospital, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zihan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Wuping</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Changyi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Siyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Xinrui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yueyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaoya</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuanzheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Henan Province Engineering Research Center of Smart Micro-Nano Sensing Technology and Application, Kaifeng 475004, PR China; School of Physics and Electronics, Henan University, Kaifeng 475004, PR China. Electronic address: zhangyz0926@henu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China. Electronic address: Liping-Zhou@whu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Autonomic Nervous System Modulation, Wuhan 430060, China; Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430060, China; Institute of Molecular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China. Electronic address: hong-jiang@whu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055536" MajorTopicYN="Y">Vagus Nerve Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004561" MajorTopicYN="Y">Transcutaneous Electric Nerve Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066274" MajorTopicYN="Y">Central Amygdaloid Nucleus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="Y">Neuroinflammatory Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020257" MajorTopicYN="N">Ventricular Remodeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Heart-brain remodeling</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Vagus nerve stimulation</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>1</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40836409</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2025.115085</ArticleId><ArticleId IdType="pii">S1567-5769(25)01075-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40832644</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2753-4294</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>BMJ public health</Title><ISOAbbreviation>BMJ Public Health</ISOAbbreviation></Journal><ArticleTitle>Variation in coronary revascularisation and mortality after myocardial infarction across three public health insurance schemes in Thailand: an observational analysis from nationwide claims data.</ArticleTitle><Pagination><StartPage>e001264</StartPage><MedlinePgn>e001264</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e001264</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjph-2024-001264</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Evidence on the impact of diverse healthcare insurance arrangements on healthcare variation is limited in low-income and middle-income countries. In Thailand, the Civil Servant Medical Benefit Scheme (CSMBS), Social Health Insurance (SHI) and Universal Coverage Scheme (UCS) have different provider choice and reimbursement arrangements and cover different populations. We explored to what extent use of revascularisation in patients with ST elevation myocardial infarction (STEMI) varied by insurance scheme.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We used claims data, including all admissions for patients with STEMI between 2015 and 2020. Outcomes were any type of revascularisation, primary percutaneous coronary intervention (PPCI) and mortality. Regression models were used to estimate absolute differences (ADs) by scheme, adjusted for age, sex, comorbidities and admission year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 98&#x2009;142 patients, 75.7% were covered by UCS, 13.3% by CSMBS and 11.0% by SHI. Overall, 76.3% underwent revascularisation and 53.8% received PPCI. Mortality rates were 13.2% in-hospital and 20.7% at 180 days. Compared with UCS, use of revascularisation was slightly higher with CSMBS and slightly lower with SHI (AD: CSMBS 1.3% (95% CI -0.2 to 2.8), SHI -0.8% (-2.6 to 1.0), p=0.0264) and use of PPCI was slightly higher with CSMBS and SHI (AD: CSMBS 2.4% (-0.3 to 5.2), SHI 5.2% (3.1 to 7.2), p&lt;0.0001)). CSMBS and SHI-insured patients had lower mortality compared with UCS (AD for in-hospital: CSMBS -1.3% (-2.1 to -0.5), SHI -0.9% (-1.8 to -0.1), p&lt;0.0001; AD for 180-day mortality: CSMBS -4.5% (-5.3 to -3.6), SHI -1.9% (-3.0 to -0.8), p&lt;0.0001). Effects of insurance scheme varied by hospital type for all outcomes (p for interaction&lt;0.0001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Three-quarters of patients with STEMI received coronary revascularisation, suggesting potential undertreatment. We identified relatively small differences in access to revascularisation by insurance scheme which are unlikely to explain the lower mortality with CSMBS and SHI. Claims data can be used to assess the impact of insurance on access to effective treatments.</AbstractText><CopyrightInformation>Copyright &#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Witthayapipopsakul</LastName><ForeName>Woranan</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-1817-8264</Identifier><AffiliationInfo><Affiliation>Health Services Research &amp; Policy, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Health Policy Program Foundation, Nonthaburi, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anupraiwan</LastName><ForeName>Orawan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Central Chest Institute of Thailand, Nonthaburi, Nonthaburi, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veerakul</LastName><ForeName>Gumpanart</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bangkok Heart Hospital, Bangkok, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurol-Urganci</LastName><ForeName>Ipek</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Health Services Research &amp; Policy, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Meulen</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Health Services Research &amp; Policy, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Public Health</MedlineTA><NlmUniqueID>9918697578906676</NlmUniqueID><ISSNLinking>2753-4294</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular Diseases</Keyword><Keyword MajorTopicYN="N">Cross-Sectional Studies</Keyword><Keyword MajorTopicYN="N">Emergencies</Keyword><Keyword MajorTopicYN="N">Public Health</Keyword></KeywordList><CoiStatement>The principal investigator of this study is affiliated with the London School of Hygiene &amp; Tropical Medicine and the International Health Policy Foundation Thailand.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40832644</ArticleId><ArticleId IdType="pmc">PMC12359411</ArticleId><ArticleId IdType="doi">10.1136/bmjph-2024-001264</ArticleId><ArticleId IdType="pii">bmjph-2024-001264</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sundmacher L, Busse R. Geographic variation in health care&#x2014;A special issue on the 40th anniversary of &#x201c;Small area variation in health care delivery. Health Policy. 2014;114:3&#x2013;4. doi: 10.1016/j.healthpol.2013.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2013.11.011</ArticleId><ArticleId IdType="pubmed">24373551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg JE. Forty years of unwarranted variation&#x2014;And still counting. Health Policy. 2014;114:1&#x2013;2. doi: 10.1016/j.healthpol.2013.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2013.11.010</ArticleId><ArticleId IdType="pubmed">24373550</ArticleId></ArticleIdList></Reference><Reference><Citation>Corallo AN, Croxford R, Goodman DC, et al. A systematic review of medical practice variation in OECD countries. Health Policy. 2014;114:5&#x2013;14. doi: 10.1016/j.healthpol.2013.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2013.08.002</ArticleId><ArticleId IdType="pubmed">24054709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YY, Kim AM, Kang M, et al. Health atlas as a policy tool: how to investigate geographic variation and utilize the information for decision-making. 2015.</Citation></Reference><Reference><Citation>Mercuri M, Gafni A. Medical practice variations: what the literature tells us (or does not) about what are warranted and unwarranted variations. J Eval Clin Pract. 2011;17:671&#x2013;7. doi: 10.1111/j.1365-2753.2011.01689.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2753.2011.01689.x</ArticleId><ArticleId IdType="pubmed">21501341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulyte A, Wei W, Dressel H, et al. Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines. PLoS One. 2020;15:e0231409. doi: 10.1371/journal.pone.0231409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0231409</ArticleId><ArticleId IdType="pmc">PMC7162274</ArticleId><ArticleId IdType="pubmed">32298325</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison R, Manias E, Mears S, et al. Addressing unwarranted clinical variation: A rapid review of current evidence. J Eval Clin Pract. 2019;25:53&#x2013;65. doi: 10.1111/jep.12930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jep.12930</ArticleId><ArticleId IdType="pubmed">29766616</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirunrassamee S, Ratanawijitrasin S. Does your health care depend on how your insurer pays providers? Variation in utilization and outcomes in Thailand. Int J Health Care Finance Econ. 2009;9:153&#x2013;68. doi: 10.1007/s10754-009-9062-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10754-009-9062-6</ArticleId><ArticleId IdType="pubmed">19396629</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Wang J, King M, et al. Rural&#x2013;urban disparities in the utilization of mental health inpatient services in China: the role of health insurance. Int J Health Econ Manag . 2018;18:377&#x2013;93. doi: 10.1007/s10754-018-9238-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10754-018-9238-z</ArticleId><ArticleId IdType="pmc">PMC6223725</ArticleId><ArticleId IdType="pubmed">29589249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulyanto J, Kunst AE, Kringos DS. Geographical inequalities in healthcare utilisation and the contribution of compositional factors: A multilevel analysis of 497 districts in Indonesia. Health Place. 2019;60 doi: 10.1016/j.healthplace.2019.102236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthplace.2019.102236</ArticleId><ArticleId IdType="pubmed">31778844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazungu JS, Barasa EW, Obadha M, et al. What characteristics of provider payment mechanisms influence health care providers&#x2019; behaviour? A literature review. Int J Health Plann Manage. 2018;33:e892&#x2013;905. doi: 10.1002/hpm.2565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hpm.2565</ArticleId><ArticleId IdType="pmc">PMC7611391</ArticleId><ArticleId IdType="pubmed">29984422</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Zhang W. The impacts of health insurance on health care utilization among the older people in China. Soc Sci Med. 2013;85:59&#x2013;65. doi: 10.1016/j.socscimed.2013.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2013.02.037</ArticleId><ArticleId IdType="pubmed">23540367</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H, Meng Q, Rizzo JA. Do Different Health Insurance Plans in China Create Disparities in Health Care Utilization and Expenditures. Int J Appl Econ. 2014;11:1&#x2013;18.</Citation></Reference><Reference><Citation>Suriyawongpaisal P, Aekplakorn W, Tansirisithikul R. Does harmonization of payment mechanisms enhance equitable health outcomes in delivery of emergency medical services in Thailand? Health Policy Plan. 2015;30:1342&#x2013;9. doi: 10.1093/heapol/czv005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/heapol/czv005</ArticleId><ArticleId IdType="pubmed">25797471</ArticleId></ArticleIdList></Reference><Reference><Citation>Thammatacharee J. Variations in the performance of three public insurance schemes in Thailand. London School of Hygiene &amp; Tropical Medicine. 2009 doi: 10.17037/PUBS.04646540.</Citation><ArticleIdList><ArticleId IdType="doi">10.17037/PUBS.04646540</ArticleId></ArticleIdList></Reference><Reference><Citation>Limwattananon C, Limwattananon S, Sakulpanit T, et al. Different provider payment methods: variation in clinical practice, lessons from Thailand n.d.</Citation></Reference><Reference><Citation>The Center for the Evaluative Clinical Sciences . Effective care, The Dartmouth atlas project. Illinois; 2007.</Citation></Reference><Reference><Citation>Burden of Disease Research Program Thailand . Nonthaburi: 2021. Causes of death among Thai population 2017-2019.</Citation></Reference><Reference><Citation>Nonthaburi: International Health Policy Program, Ministry of Public Health; 2017. Burden of disease and injury of Thai population in 2014.</Citation></Reference><Reference><Citation>National Health Security Office  Statistics of provincial population by insurance schemes 2021.  [01-Mar-2021]. https://ucinfo.nhso.go.th/ucinfo/RptRegisPop-3 Available. Accessed.</Citation></Reference><Reference><Citation>Tangcharoensathien V, Witthayapipopsakul W, Panichkriangkrai W, et al. Health systems development in Thailand: a solid platform for successful implementation of universal health coverage. Lancet. 2018;391:1205&#x2013;23. doi: 10.1016/S0140-6736(18)30198-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30198-3</ArticleId><ArticleId IdType="pubmed">29397200</ArticleId></ArticleIdList></Reference><Reference><Citation>Vongmongkol V, Viriyathorn S, Wanwong Y, et al. Annual prevalence of unmet healthcare need in Thailand: evidence from national household surveys between 2011 and 2019. Int J Equity Health. 2021;20:244. doi: 10.1186/s12939-021-01578-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12939-021-01578-0</ArticleId><ArticleId IdType="pmc">PMC8588591</ArticleId><ArticleId IdType="pubmed">34772404</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongudomsuk P, Srithamrongsawat S, Patcharanarumol W, et al. The Kingdom of Thailand health system review. WHO Press; 2015.</Citation></Reference><Reference><Citation>Suriyawongpaisal P, Atiksawedparit P, Srithamrongsawad S, et al. Closing the Equity Gap of Access to Emergency Departments of Private Hospitals in Thailand. Emerg Med Int. 2018;2018:6470319. doi: 10.1155/2018/6470319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6470319</ArticleId><ArticleId IdType="pmc">PMC6178173</ArticleId><ArticleId IdType="pubmed">30356396</ArticleId></ArticleIdList></Reference><Reference><Citation>Executive summary: the universal coverage for emergency patients (UCEP)</Citation></Reference><Reference><Citation>Medical Committees under the Social Security Act  Announcement of medical committees under the social security act on reimbursement rates for non-occupational illnessess.  [05-Mar-2023]. https://www.krisdika.go.th/librarian/getfile?sysid=776025&amp;ext=htm Available. Accessed.</Citation></Reference><Reference><Citation>National Health Security Office . Bangkok: National Health Security Office (NHSO); 2020. The universal coverage scheme&#x2019;s fund management fiscal year 2021.</Citation></Reference><Reference><Citation>The Comptroller General&#x2019;s Department  Ministry of finance announcement on payment rates of medical devices (version 2) 2022. https://w1.med.cmu.ac.th/finance/wp-content/uploads/2022/09/&#xe1b;&#xe23;&#xe30;&#xe40;&#xe20;&#xe17;&#xe41;&#xe25;&#xe30;&#xe2d;&#xe31;&#xe15;&#xe23;&#xe32;&#xe04;&#xe48;&#xe32;&#xe2d;&#xe27;&#xe31;&#xe22;&#xe27;&#xe30;&#xe40;&#xe17;&#xe35;&#xe22;&#xe21;&#xe41;&#xe25;&#xe30;&#xe2d;&#xe38;&#xe1b;&#xe01;&#xe23;&#xe13;&#xe4c;&#xe43;.pdf Available.</Citation></Reference><Reference><Citation>National Health Security Office . Bangkok: 2019. The universal coverage scheme&#x2019;s fund management 2020.</Citation></Reference><Reference><Citation>Medical committee under social security act 1990. Reimbursement regulations and rates for non-occupational illnesses. 2016</Citation></Reference><Reference><Citation>Channoi T. Provider payment methods for public insurance schemes: an approach towards harmonisation of insurance schemes. 2013.</Citation></Reference><Reference><Citation>The Strategy and Planning Division . Nonthaburi: 2020. Report on public health resource 2020 .</Citation></Reference><Reference><Citation>Ministry of Public Health. The Heart Association of Thailand under the Royal Patronage of H.M. the King. The Cardiovascular Intervention Association of Thailand . Bangkok: The Heart Association of Thailand under the Royal Patronage of H.M. the King; 2020. Thai acute coronary syndromes guidelines 2020.</Citation></Reference><Reference><Citation>National Health Security Office  NHSO registered health facility database.  [06-Feb-2023]. https://reghosp.nhso.go.th/hospital_search/index.xhtml Available. Accessed.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  ICD - ICD-10 - international classification of diseases, Tenth revision.  [02-May-2023];2021  https://www.cdc.gov/nchs/icd/icd10.htm Available. accessed.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  ICD - ICD-9-CM - International classification of diseases, Ninth revision, clinical modification.  [02-May-2023];2021  https://www.cdc.gov/nchs/icd/icd9cm.htm Available. accessed.</Citation></Reference><Reference><Citation>Naimi AI, Whitcomb BW. Estimating Risk Ratios and Risk Differences Using Regression. Am J Epidemiol. 2020;189:508&#x2013;10. doi: 10.1093/aje/kwaa044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwaa044</ArticleId><ArticleId IdType="pubmed">32219364</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H-Y. Statistical notes for clinical researchers: Risk difference, risk ratio, and odds ratio. Restor Dent Endod. 2017;42:72&#x2013;6. doi: 10.5395/rde.2017.42.1.72.</Citation><ArticleIdList><ArticleId IdType="doi">10.5395/rde.2017.42.1.72</ArticleId><ArticleId IdType="pmc">PMC5300861</ArticleId><ArticleId IdType="pubmed">28194368</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage JN, Meulen JH. Identifying co-morbidity in surgical patients using administrative data with the royal college of surgeons charlson score. 2010. Available.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.6930</ArticleId><ArticleId IdType="pubmed">20306528</ArticleId></ArticleIdList></Reference><Reference><Citation>StataCorp LLC  Stata | Explore our products.  [02-May-2023]. https://www.stata.com/products/ Available. Accessed.</Citation></Reference><Reference><Citation>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18&#x2013;114. doi: 10.1161/CIR.0000000000001038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001038</ArticleId><ArticleId IdType="pubmed">34882435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg JE. Time to tackle unwarranted variations in practice. BMJ. 2011;342:d1513. doi: 10.1136/bmj.d1513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d1513</ArticleId><ArticleId IdType="pubmed">21415111</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallabhajosyula S, Patlolla SH, Dunlay SM, et al. Regional Variation in the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock in the United States. Circ: Heart Failure. 2020;13 doi: 10.1161/CIRCHEARTFAILURE.119.006661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.119.006661</ArticleId><ArticleId IdType="pmc">PMC7027926</ArticleId><ArticleId IdType="pubmed">32059628</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukel TA, Lucas FL, Wennberg DE. Long-term Outcomes of Regional Variations in Intensity of Invasive vs Medical Management of Medicare Patients With Acute Myocardial Infarction. JAMA. 2005;293:1329. doi: 10.1001/jama.293.11.1329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.293.11.1329</ArticleId><ArticleId IdType="pmc">PMC1459288</ArticleId><ArticleId IdType="pubmed">15769966</ArticleId></ArticleIdList></Reference><Reference><Citation>Limwattananon C, Jaratpatthararoj J, Thungthong J, et al. Access to reperfusion therapy and mortality outcomes in patients with ST-segment elevation myocardial infarction under universal health coverage in Thailand. BMC Cardiovasc Disord. 2020;20:121. doi: 10.1186/s12872-020-01379-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-020-01379-3</ArticleId><ArticleId IdType="pmc">PMC7060593</ArticleId><ArticleId IdType="pubmed">32143572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Public Health T  In-hospital mortality rate of STEMI patients 2021.  [08-Jan-2023]. http://healthkpi.moph.go.th/kpi2/kpi/index2/?kpi_year=2563 Available. Accessed.</Citation></Reference><Reference><Citation>Srimahachota S, Boonyaratavej S, Kanjanavanit R, et al. Thai Registry in Acute Coronary Syndrome (TRACS)--an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year. J Med Assoc Thai. 2012;95:508&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">22612004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LY, Warren-Gash C, Smeeth L, et al. Data resource profile: the National Health Insurance Research Database (NHIRD) Epidemiol Health. 2018;40:e2018062. doi: 10.4178/epih.e2018062.</Citation><ArticleIdList><ArticleId IdType="doi">10.4178/epih.e2018062</ArticleId><ArticleId IdType="pmc">PMC6367203</ArticleId><ArticleId IdType="pubmed">30727703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JA, Yoon S, Kim LY, et al. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data. J Korean Med Sci. 2017;32:718&#x2013;28. doi: 10.3346/jkms.2017.32.5.718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2017.32.5.718</ArticleId><ArticleId IdType="pmc">PMC5383602</ArticleId><ArticleId IdType="pubmed">28378543</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837323</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2229-5097</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Surgical neurology international</Title><ISOAbbreviation>Surg Neurol Int</ISOAbbreviation></Journal><ArticleTitle>Delayed presentation of esophageal perforation from anterior cervical discectomy and fusion hardware failure in a patient presenting with non-ST-elevation myocardial infarction: An illustrative technical note.</ArticleTitle><Pagination><StartPage>299</StartPage><MedlinePgn>299</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">299</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.25259/SNI_242_2025</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">A 69-year-old male, who underwent a C5-T1 ACDF 5-years prior to arrival, presented with a ventral pharyngeal abscess and esophageal perforation warranting major gastro-esophageal surgery and instrumentation removal.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The case of a patient who underwent a C5-T1 ACDF five years ago was reviewed. A review of past reports of cases of patients who experienced esophageal erosion or perforation following ACDF was conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At the age of 69, the patient acutely developed disorientation/agitation and urinary/fecal incontinence. Lab studies showed leukocytosis, an elevated creatine phosphokinase (CPK), and lactic acidosis, while the EKG confirmed a non-ST-elevation myocardial infarction (NSTEMI) with increased troponins. An esophagram revealed esophageal perforation, and a prevertebral C5-C6 abscess, and neck/thoracic CT studies documented 8-9 mm anterior displacement of the right inferior C7 screw with extravasation extending inferiorly into the mediastinum. Surgery consisted of an esophagogastroduodenoscopy, gastric/jejunal tube placement, left neck exploration, and dissection of the esophagus off the anterior instrumentation that was subsequently removed. Despite emergent surgical intervention, the patient expired 5 days postoperatively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Neurosurgical follow-up is warranted in ACDF patients who newly present with findings indicative of with anterior retropharyngeal abscess or esophageal perforation.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Surgical Neurology International.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lackland</LastName><ForeName>Tyler Nicole</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Saint Louis University, St. Louis, Missouri, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Mayur</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Saint Louis University, St. Louis, Missouri, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botterbush</LastName><ForeName>Kathleen Suzann</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Saint Louis University, St. Louis, Missouri, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Platz</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Saint Louis University, St. Louis, Missouri, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avila</LastName><ForeName>Mauricio J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Saint Louis University, St. Louis, Missouri, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Neurol Int</MedlineTA><NlmUniqueID>101535836</NlmUniqueID><ISSNLinking>2152-7806</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anterior cervical discectomy and fusion</Keyword><Keyword MajorTopicYN="N">Computed tomography</Keyword><Keyword MajorTopicYN="N">Dysphagia</Keyword><Keyword MajorTopicYN="N">Esophagram</Keyword><Keyword MajorTopicYN="N">Esophagus perforation</Keyword><Keyword MajorTopicYN="N">Expiration</Keyword><Keyword MajorTopicYN="N">Hardware failure</Keyword><Keyword MajorTopicYN="N">Prevertebral infection</Keyword><Keyword MajorTopicYN="N">Retropharyngeal abscess</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837323</ArticleId><ArticleId IdType="pmc">PMC12361707</ArticleId><ArticleId IdType="doi">10.25259/SNI_242_2025</ArticleId><ArticleId IdType="pii">10.25259/SNI_242_2025</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amhaz HH, Kuo R, Vaidya R, Orlewicz MS. Esophageal perforation following cervical spine surgery: A review with considerations in airway management. Int J Crit Illn Inj Sci. 2013;3:276&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891196</ArticleId><ArticleId IdType="pubmed">24459627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershman SH, Kunkle WA, Kelly MP, Buchowski JM, Ray WZ, Bumpass DB, et al. Esophageal perforation following anterior cervical spine surgery: Case report and review of the literature. Glob Spine J. 2017;7(1 Suppl):28S&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5400185</ArticleId><ArticleId IdType="pubmed">28451488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassem MM, Wallen JM.  StatPearls. StatPearls Publishing; 2024. Esophageal perforation and tears. Available from:  https://www.ncbi.nlm.nih.gov/books/nbk532298 [Last accessed on 2024 Nov 23]</Citation><ArticleIdList><ArticleId IdType="pubmed">30335331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TS, Appelbaum EN, Sheen D, Han R, Wie B. Esophageal perforation due to anterior cervical spine hardware placement: Case series. Int J Otolaryngol. 2019;2019:7682654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6614980</ArticleId><ArticleId IdType="pubmed">31341480</ArticleId></ArticleIdList></Reference><Reference><Citation>Leven D, Meaike J, Radcliff K, Qureshi S. Cervical disc replacement surgery: Indications, technique, and technical pearls. Curr Rev Musculoskelet Med. 2017;10:160&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435629</ArticleId><ArticleId IdType="pubmed">28493215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning X, Wen Y, Xiao-Jian Y, Bin N, De-Yu C, Jian-Ru X, et al. Anterior cervical locking plate-related complications; prevention and treatment recommendations. Int Orthop. 2008;32:649&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2551717</ArticleId><ArticleId IdType="pubmed">17497150</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaker H, Elsayed H, Whittle I, Hussein S, Shackcloth M. The influence of the &#x2018;golden 24h rule&#x2019; on the prognosis of oesophageal perforation in the modern era. Eur J Cardiothorac Surg. 2010;38:216&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304664</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;reide JA, Viste A. Esophageal perforation: Diagnostic work-up and clinical decision-making in the first 24 hours. Scand J Trauma Resusc Emerg Med. 2011;19:66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219576</ArticleId><ArticleId IdType="pubmed">22035338</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahanda AT, Pennicooke B, Ray WZ, Hacker CD, Kelly MP, Dorward IG, et al. Pharyngoesophageal damage from hardware extrusion at an average of 7.5 years after anterior cervical diskectomy and fusion: A case series, discussion of risk factors, and guide for management. World Neurosurg. 2022;160:e189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">34990840</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakko P, Rontal M, Park D. Delayed esophageal perforation diagnosed 12 years after anterior cervical diskectomy and fusion: A case report and review of current literature. JAAOS Glob Res Rev. 2022;6:e22.00080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9575766</ArticleId><ArticleId IdType="pubmed">36227832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40848227</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1826-6983</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>La Radiologia medica</Title><ISOAbbreviation>Radiol Med</ISOAbbreviation></Journal><ArticleTitle>Residual myocardial hyperemia in regadenoson stress/rest quantitative perfusion cardiac magnetic resonance.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11547-025-02062-3</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study sought to investigate the presence of residual myocardial hyperemia on the recovery phase in patients undergoing stress CMR.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Fifty patients with clinical indication for stress CMR underwent quantitative perfusion imaging in resting conditions, after regadenoson-induced hyperemia (400 mcg, 5&#xa0;mL), and 10&#xa0;min after recovery with euphylline. Studies showing hypoperfusion due to ischemia and/or prior myocardial infarction were excluded. Global myocardial blood flow during rest (MBF<sub>rest</sub>), stress (MBF<sub>stress</sub>) and recovery (MBF<sub>recovery</sub>) and MPR indices (MPR<sub>stress/rest</sub> and MPR<sub>stress/recovery</sub>) were calculated using automated pixel-wise quantitative myocardial perfusion mapping.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 30 patients (22 males, mean age of 62.7&#x2009;&#xb1;&#x2009;1&#xa0;years) were included in the analysis. Global MBF<sub>rest</sub> and MBF<sub>stress</sub> were 0.83&#x2009;&#xb1;&#x2009;0.2&#xa0;mL/g/min and 2.1&#x2009;&#xb1;&#x2009;0.6&#xa0;mL/g/min, respectively. After recovery with euphylline, myocardial perfusion did not return to the resting values (MBF<sub>recovery</sub> of 0.92&#x2009;&#xb1;&#x2009;0.3&#xa0;mL/g/min) and statistically differed from MBF<sub>rest</sub> (p&#x2009;&lt;&#x2009;0.01), suggesting residual myocardial hyperemia. This resulted in an abnormally low MPR<sub>stress/recovery</sub> (2.43&#x2009;&#xb1;&#x2009;0.7) with respect to MPR<sub>stress/rest</sub> (2.56&#x2009;&#xb1;&#x2009;0.7) (p&#x2009;=&#x2009;0.03). A linear mixed-effects model accounting for repeated measures revealed statistically significant group differences over time in global MBF (mean difference 0.1, 95% CI 0.02-0.17, p&#x2009;=&#x2009;0.01) and global MPR (mean difference -0.13, 95% CI -0.25 to -0.02, p&#x2009;=&#x2009;0.02).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite the use of euphylline to counteract the vasodilator effect, MBF does not completely revert to resting values and MBF<sub>recovery</sub> cannot be used as a substitute for MBF<sub>rest</sub> when regadenoson is used. Consequently, a rest/stress protocol is advised for quantitative CMR perfusion to obtain accurate MBF and MPR parameters.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bastarrika</LastName><ForeName>Gorka</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9493-6907</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Clinica Universidad de Navarra, Pamplona, Spain. bastarrika@unav.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdiSNA), Pamplona, Spain. bastarrika@unav.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezponda</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Clinica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;iz-S&#xe1;enz-Diez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidorreta</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Siemens Healthineers, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochoa Gonz&#xe1;lez</LastName><ForeName>Amaia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavira</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salterain</LastName><ForeName>Nahikari</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Radiol Med</MedlineTA><NlmUniqueID>0177625</NlmUniqueID><ISSNLinking>0033-8362</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac magnetic resonance</Keyword><Keyword MajorTopicYN="N">Coronary artery disease</Keyword><Keyword MajorTopicYN="N">Perfusion</Keyword><Keyword MajorTopicYN="N">Vasodilator</Keyword></KeywordList><CoiStatement>Declarations. Conflicts of interest: The authors have no relevant financial or nonfinancial interests to disclose regarding this manuscript. Human and animal rights The Ethics and research committee with medicines of the Foral Community of Navarra approved the study protocol (EO_2021/24), which was performed in accordance with Royal Decree 957/2020 and Declaration of Helsinki. Informed consent Written informed consent to participate in the study was obtained from all patients except two, who were excluded.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40848227</ArticleId><ArticleId IdType="doi">10.1007/s11547-025-02062-3</ArticleId><ArticleId IdType="pii">10.1007/s11547-025-02062-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Winchester DE, Maron DJ, Blankstein R, Chang IC, Kirtane AJ, Kwong RY, Pellikka PA, Prutkin JM, Russell R, Sandhu AT (2023) ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 multimodality appropriate use criteria for the detection and risk assessment of chronic coronary disease. J Am Coll Cardiol 81:2445&#x2013;2467</Citation><ArticleIdList><ArticleId IdType="pubmed">37245131</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai AE, Schulz-Menger J, Shah DJ et al (2023) Stress perfusion cardiac magnetic resonance vs SPECT imaging for detection of coronary artery disease. J Am Coll Cardiol 82:1828&#x2013;1838</Citation><ArticleIdList><ArticleId IdType="pubmed">37914512</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwitter J, Wacker CM, Wilke N et al (2013) MR-IMPACT II: magnetic resonance imaging for myocardial perfusion assessment in coronary artery disease trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative. Eur Heart J 34:775&#x2013;781</Citation><ArticleIdList><ArticleId IdType="pubmed">22390914</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel E, Greenwood JP, McCann GP et al (2019) Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med 380:2418&#x2013;2428</Citation><ArticleIdList><ArticleId IdType="pubmed">31216398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer CM, Barkhausen J, Bucciarelli-ducci C, Flamm SD, Kim RJ (2020) Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 22:17</Citation><ArticleIdList><ArticleId IdType="pubmed">32089132</ArticleId><ArticleId IdType="pmc">7038611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhave NM, Freed BH, Yodwut C, Kolanczyk D, Dill K, Lang RM, Mor-Avi V, Patel AR (2012) Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson. J Cardiovasc Magn Reson 14:89</Citation><ArticleIdList><ArticleId IdType="pubmed">23272658</ArticleId><ArticleId IdType="pmc">3552720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordini FE, Haddad T, Hsu LY, Kellman P, Lowrey TB, Aletras AH, Bandettini WP, Arai AE (2014) Diagnostic accuracy of stress perfusion CMR in comparison with quantitative coronary angiography: fully quantitative, semiquantitative, and qualitative assessment. JACC Cardiovasc Imaging 7:14&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">24433707</ArticleId><ArticleId IdType="pmc">4186701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M, Xue H (2017) Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. J Cardiovasc Magn Reson 19:43</Citation><ArticleIdList><ArticleId IdType="pubmed">28385161</ArticleId><ArticleId IdType="pmc">5383963</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai AE, Schulz-Menger J, Berman D et al (2020) Gadobutrol-enhanced cardiac magnetic resonance imaging for detection of coronary artery disease. J Am Coll Cardiol 76:1536&#x2013;1547</Citation><ArticleIdList><ArticleId IdType="pubmed">32972530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundley WG, Bluemke D, Bogaert JG et al (2009) Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson 11:5</Citation><ArticleIdList><ArticleId IdType="pubmed">19257889</ArticleId><ArticleId IdType="pmc">2662831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotecha T, Martinez-Naharro A, Boldrini M et al (2019) Automated pixel-wise quantitative myocardial perfusion mapping by CMR to detect obstructive coronary artery disease and coronary microvascular dysfunction: validation against invasive coronary physiology. JACC Cardiovasc Imaging 12:1958&#x2013;1969</Citation><ArticleIdList><ArticleId IdType="pubmed">30772231</ArticleId><ArticleId IdType="pmc">8414332</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen MS, S&#xf8;rensen TS (2013) Gadgetron: an open source framework for medical image reconstruction. Magn Reson Med 69:1768&#x2013;1776</Citation><ArticleIdList><ArticleId IdType="pubmed">22791598</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Taljaard M, Van Den Heuvel ER, Levine MAH, Cook DJ, Wells GA, Devereaux PJ, Thabane L (2017) An introduction to multiplicity issues in clinical trials: The what, why, when and how. Int J Epidemiol 46:746&#x2013;756</Citation><ArticleIdList><ArticleId IdType="pubmed">28025257</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasu S, Bandettini WP, Hsu LY, Kellman P, Leung S, Mancini C, Shanbhag SM, Wilson J, Booker OJ, Arai AE (2013) Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 15:85</Citation><ArticleIdList><ArticleId IdType="pubmed">24063278</ArticleId><ArticleId IdType="pmc">3851492</ArticleId></ArticleIdList></Reference><Reference><Citation>Monmeneu Menadas JV, Garc&#xed;a Gonzalez MP, Lopez-Lereu MP, Higueras Ortega L, Maceira Gonzalez AM (2022) Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: data from a multicentre prospective registry. Int J Cardiovasc Imaging 38:195&#x2013;209</Citation><ArticleIdList><ArticleId IdType="pubmed">34331614</ArticleId></ArticleIdList></Reference><Reference><Citation>Baritussio A, Scatteia A, Dellegrottaglie S, Bucciarelli-Ducci C (2021) Evidence and applicability of stress cardiovascular magnetic resonance in detecting coronary artery disease: state of the art. J Clin Med 10:3279</Citation><ArticleIdList><ArticleId IdType="pubmed">34362063</ArticleId><ArticleId IdType="pmc">8347143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacif MS, Arai AE, Lima JAC, Bluemke DA (2012) Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines. J Cardiovasc Magn Reson 14:18</Citation><ArticleIdList><ArticleId IdType="pubmed">22376193</ArticleId><ArticleId IdType="pmc">3305456</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong EYS, Wang H, Leung KHG et al (2024) Comparison of dual bolus versus dual sequence techniques for determining myocardial blood flow and myocardial perfusion reserve by cardiac magnetic resonance stress perfusion: from the automated quantitative analysis of myocardial perfusion cardiac magnetic resonance consortium. J Cardiovasc Magn Reson 26:101085</Citation><ArticleIdList><ArticleId IdType="pubmed">39154806</ArticleId><ArticleId IdType="pmc">11422560</ArticleId></ArticleIdList></Reference><Reference><Citation>Abidov A, Dilsizian V, Doukky R et al (2018) Aminophylline shortage and current recommendations for reversal of vasodilator stress: an ASNC information statement endorsed by SCMR. J Cardiovasc Magn Reson 20:87</Citation><ArticleIdList><ArticleId IdType="pubmed">30567577</ArticleId><ArticleId IdType="pmc">6300896</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman H, Scannell CM, Demir OM, Ryan M, McConkey H, Ellis H, Masci PG, Perera D, Chiribiri A (2021) High-resolution cardiac magnetic resonance imaging techniques for the identification of coronary microvascular dysfunction. JACC Cardiovasc Imaging 14:978&#x2013;986</Citation><ArticleIdList><ArticleId IdType="pubmed">33248969</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotecha T, Chacko L, Chehab O et al (2020) Assessment of multivessel coronary artery disease using cardiovascular magnetic resonance pixelwise quantitative perfusion mapping. JACC Cardiovasc Imaging 13:2546&#x2013;2557</Citation><ArticleIdList><ArticleId IdType="pubmed">33011115</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott KD, Seraphim A, Augusto JB et al (2020) The prognostic significance of quantitative myocardial perfusion: an artificial intelligence-based approach using perfusion mapping. Circulation 141:1282&#x2013;1291</Citation><ArticleIdList><ArticleId IdType="pubmed">32078380</ArticleId><ArticleId IdType="pmc">7176346</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs M, Benovoy M, Chang LC, Corcoran D, Berry C, Arai AE, Hsu LY (2021) Automated segmental analysis of fully quantitative myocardial blood flow maps by first-pass perfusion cardiovascular magnetic resonance. IEEE Access 9:52796&#x2013;52811</Citation><ArticleIdList><ArticleId IdType="pubmed">33996344</ArticleId><ArticleId IdType="pmc">8117952</ArticleId></ArticleIdList></Reference><Reference><Citation>Seraphim A, Dowsing B, Rathod KS et al (2022) Quantitative myocardial perfusion predicts outcomes in patients with prior surgical revascularization. J Am Coll Cardiol 79:1141&#x2013;1151</Citation><ArticleIdList><ArticleId IdType="pubmed">35331408</ArticleId><ArticleId IdType="pmc">9034686</ArticleId></ArticleIdList></Reference><Reference><Citation>Engblom H, Xue H, Akil S et al (2017) Fully quantitative cardiovascular magnetic resonance myocardial perfusion ready for clinical use: a comparison between cardiovascular magnetic resonance imaging and positron emission tomography. J Cardiovasc Magn Reson 19:78</Citation><ArticleIdList><ArticleId IdType="pubmed">29047385</ArticleId><ArticleId IdType="pmc">5648469</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846132</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9319</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Microvascular research</Title><ISOAbbreviation>Microvasc Res</ISOAbbreviation></Journal><ArticleTitle>Assessing coronary microvascular dysfunction in refractory no-reflow: Insights from dynamic myocardial perfusion scintigraphy and cardiac MRI.</ArticleTitle><Pagination><StartPage>104862</StartPage><MedlinePgn>104862</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mvr.2025.104862</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0026-2862(25)00081-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Refractory no-reflow correlates with worse outcomes, including larger infarct sizes, impaired ventricular function, and higher mortality rates, despite advances in percutaneous coronary intervention (PCI). Microvascular obstruction (MVO) and increased left ventricular end-diastolic pressure (LVEDP) are implicated in the pathogenesis, potentially exacerbating ischemic injury and limiting myocardial recovery. While pressure-wire-derived indices such as the Index of Microcirculatory Resistance (IMR) have been validated against MRI-defined MVO in STEMI populations, their invasive nature and procedural complexity limit broad adoption. In contrast, combining dynamic SPECT and cardiac MRI enables a comprehensive non-invasive functional-structural evaluation of coronary microvascular function in refractory no-reflow.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study is a post hoc analysis of a larger randomized controlled trial (RCT) evaluating the efficacy and safety of intracoronary epinephrine in patients with refractory no-reflow post-PCI (ClinicalTrials.govNCT04573751). We evaluated global coronary flow metrics (RMBF, SMBF, gRFI) derived from SPECT and assessed structural mark-ers of microvascular injury (infarct size, MVO) on MRI. Echocardiographic estimations of LVEDP were also analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Dynamic SPECT revealed suboptimal stress myocardial blood flow in most patients, highlighting microvascular impairment. Elevated estimated LVEDP was significantly cor-related with indexed MVO (rs&#x202f;=&#x202f;0.678, p&#x202f;=&#x202f;0.001). Traditional flow reserve metrics showed lim-ited sensitivity, whereas global relative flow increase (gRFI) showed a statistically significant correlation with MVO, highlighting its added value in detecting stress-induced perfusion abnormalities. Given the small sample and potential outlier influence, this observation should be considered hypothesis-generating.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings support that functional impairments-particularly elevated LVEDP and reduced gRFI-are associated with refractory no-reflow. In particular, gRFI may serve as a promising non-invasive marker of microvascular dysfunction, complementing structural imaging. None-theless, further validation in larger cohorts is needed. This study advocates for refined multimod-al imaging strategies and tailored therapeutic approaches targeting dynamic microvascular dis-turbances to improve outcomes in refractory no-reflow.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dil</LastName><ForeName>Stanislav</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. Electronic address: dil.stanislav@mail.ru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryabov</LastName><ForeName>Vyacheslav</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maslov</LastName><ForeName>Leonid</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochula</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochula</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kercheva</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zavadovsky</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vyshlov</LastName><ForeName>Evgeny</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04573751</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microvasc Res</MedlineTA><NlmUniqueID>0165035</NlmUniqueID><ISSNLinking>0026-2862</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac MRI</Keyword><Keyword MajorTopicYN="N">Dynamic SPECT</Keyword><Keyword MajorTopicYN="N">Microvascular obstruction</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Refractory no-reflow phenomenon</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work described in this article. The work was carried out without the involvement of grants or financial support from public, non-profit and commercial organizations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846132</ArticleId><ArticleId IdType="doi">10.1016/j.mvr.2025.104862</ArticleId><ArticleId IdType="pii">S0026-2862(25)00081-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40836312</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-783X</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>Quercetin improves myocardial ischemia-reperfusion injury by regulating macrophage M2 polarization through Bcl-2/Beclin-1 complex.</ArticleTitle><Pagination><StartPage>780</StartPage><MedlinePgn>780</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">780</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40001-025-03077-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myocardial ischemia-reperfusion injury (MIRI) is a common pathological phenomenon during the treatment of acute myocardial infarction. Recent studies suggest that macrophage polarization plays a crucial role in MIRI progression. However, whether quercetin mitigates MIRI by modulating macrophage polarization and the underlying molecular mechanisms remain unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The protective effects of quercetin against MIRI were assessed using TTC-Evans blue staining, echocardiography, and myocardial enzyme assays. Histological changes, including myocardial fibrosis, were evaluated via HE and Masson staining. Western blot, qPCR, and immunofluorescence were performed to analyze macrophage M1/M2 polarization. Additionally, co-immunoprecipitation (Co-IP) assays were conducted to determine whether quercetin regulates M2 polarization through autophagy modulation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Quercetin significantly reduced infarct size, improved cardiac function, and alleviated inflammation and myocardial fibrosis in a dose-dependent manner. Western blot and immunofluorescence analyses showed that quercetin downregulated M1 markers while upregulating M2 markers and enhancing IL-10 secretion. In vitro experiments further confirmed that quercetin promoted M2 macrophage polarization under H/R conditions, thereby attenuating cardiomyocyte injury through a paracrine mechanism. Mechanistically, quercetin facilitated autophagic flux by reducing the binding affinity between Bcl-2 and Beclin-1, leading to enhanced M2 macrophage polarization, an effect partially reversed by 3-MA.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study provides the first evidence that quercetin exerts cardioprotective effects in MIRI by promoting M2 macrophage polarization. Furthermore, it elucidates a novel molecular mechanism in which quercetin regulates autophagy to drive M2 polarization, offering experimental support for quercetin as a potential therapeutic strategy for MIRI.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Sailing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Lishui Central Hospital and the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China. hsl15157813202@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Lingchun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Lishui Central Hospital and the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China. lvlingchun@medmail.com.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Wuming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Lishui Central Hospital and the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Lishui Central Hospital and the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LLSSY24H020003</GrantID><Agency>Natural Science Foundation of Zhejiang Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9IKM0I5T1E</RegistryNumber><NameOfSubstance UI="D011794">Quercetin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071186">Beclin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011794" MajorTopicYN="Y">Quercetin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015428" MajorTopicYN="Y">Myocardial Reperfusion Injury</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071186" MajorTopicYN="Y">Beclin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="Y">Macrophages</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019253" MajorTopicYN="Y">Proto-Oncogene Proteins c-bcl-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autophagy</Keyword><Keyword MajorTopicYN="N">Macrophage polarization</Keyword><Keyword MajorTopicYN="N">Myocardial ischemia&#x2013;reperfusion injury</Keyword><Keyword MajorTopicYN="N">Quercetin</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This experiment was approved by the Animal Ethics Committee of Wenzhou Medical University (ID: xmsq2023-0889). Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>0</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40836312</ArticleId><ArticleId IdType="pmc">PMC12369085</ArticleId><ArticleId IdType="doi">10.1186/s40001-025-03077-2</ArticleId><ArticleId IdType="pii">10.1186/s40001-025-03077-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17(12):773&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">32620851</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson SM, et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol. 2019;73(1):89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">30621955</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann C, et al. Transient inhibition of translation improves cardiac function after ischemia/reperfusion by attenuating the inflammatory response. Circulation. 2024;150(16):1248&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11472906</ArticleId><ArticleId IdType="pubmed">39206545</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, et al. Targeting CaMKII-&#x3b4;9 ameliorates cardiac ischemia/reperfusion injury by inhibiting myocardial inflammation. Circ Res. 2022;130(6):887&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">35152717</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo B, et al. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. 2024;17(1):44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11167803</ArticleId><ArticleId IdType="pubmed">38863020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha W, et al. Astragalus polysaccharide ameliorates vascular endothelial dysfunction by stimulating macrophage M2 polarization via potentiating Nrf2/HO-1 signaling pathway. Phytomedicine. 2023;112: 154667.</Citation><ArticleIdList><ArticleId IdType="pubmed">36842218</ArticleId></ArticleIdList></Reference><Reference><Citation>Strizova Z, et al. M1/M2 macrophages and their overlaps - myth or reality? Clin Sci (Lond). 2023;137(15):1067&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10407193</ArticleId><ArticleId IdType="pubmed">37530555</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, et al. Emodin ameliorates myocardial fibrosis in mice by inactivating the ROS/PI3K/Akt/mTOR axis. Clin Exp Hypertens. 2024;46(1): 2326022.</Citation><ArticleIdList><ArticleId IdType="pubmed">38507311</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. Quercetin improves cerebral ischemia/reperfusion injury by promoting microglia/macrophages M2 polarization via regulating PI3K/Akt/NF-&#x3ba;B signaling pathway. Biomed Pharmacother. 2023;168: 115653.</Citation><ArticleIdList><ArticleId IdType="pubmed">37812891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X, et al. Synthesis and characterization of a novel antioxidant RS4 by esterifying carboxymethyl sweetpotato starch with quercetin. Carbohydr Polym. 2016;152:317&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">27516278</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang GG, et al. Multifunctional low-temperature photothermal nanodrug with in vivo clearance, ROS-scavenging and anti-inflammatory abilities. Biomaterials. 2019;216: 119280.</Citation><ArticleIdList><ArticleId IdType="pubmed">31228705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein SA, et al. Antitumor effects of quercetin and luteolin in A375 cutaneous melanoma cell line are mediated by upregulation of P-ERK, c-Myc, and the upstream GPER. Life (Basel). 2025. 10.3390/life15030417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11943993</ArticleId><ArticleId IdType="pubmed">40141761</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Quercetin down-regulates MCP-1 expression in autoimmune myocarditis via ERK1/2-C/EBP&#x3b2; pathway: an integrative approach using network pharmacology and experimental models. Int Immunopharmacol. 2025;154: 114559.</Citation><ArticleIdList><ArticleId IdType="pubmed">40158430</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong LY, et al. Quercetin attenuates myocardial ischemia-reperfusion injury via downregulation of the HMGB1-TLR4-NF-&#x3ba;B signaling pathway. Am J Transl Res. 2018;10(5):1273&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5992549</ArticleId><ArticleId IdType="pubmed">29887944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandpal A, et al. Amplification of cardioprotective response of remote ischemic preconditioning in rats by Quercetin: potential role of activation of mTOR-dependent autophagy and Nrf2. Cardiovasc Drugs Ther. 2024. 10.1007/s10557-024-07595-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">38916838</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, et al. USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy. Cell Mol Immunol. 2021;18(10):2431&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8484569</ArticleId><ArticleId IdType="pubmed">33097834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, et al. Silica nanocarrier-mediated intracellular delivery of rapamycin promotes autophagy-mediated M2 macrophage polarization to regulate bone regeneration. Mater Today Bio. 2023;20: 100623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10106556</ArticleId><ArticleId IdType="pubmed">37077506</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, et al. Golm1 facilitates the CaO2-DOPC-DSPE200-PEI -CsPbBr 3 QDs -induced apoptotic death of hepatocytes through the stimulation of mitochondrial autophagy and mitochondrial reactive oxygen species production through interactions with P53/Beclin-1/Bcl-2. Chem Biol Interact. 2024;398: 111076.</Citation><ArticleIdList><ArticleId IdType="pubmed">38815669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, et al. Efficacy of the Bushen Jianpi Huoxue Formula on Beclin-1/Bcl-2-mediated autophagy and apoptosis in osteoblasts. Front Pharmacol. 2024;15:1513298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11743543</ArticleId><ArticleId IdType="pubmed">39834809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, et al. Low molecular weight fucoidan induces M2 macrophage polarization to attenuate inflammation through activation of the AMPK/mTOR autophagy pathway. Eur J Pharmacol. 2025;986: 177134.</Citation><ArticleIdList><ArticleId IdType="pubmed">39547407</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, et al. Ginseng exosomes modulate M1/M2 polarisation by activating autophagy and target IKK/I&#x43a;B/NF-&#x3ba;B to alleviate inflammatory bowel disease. J Nanobiotechnology. 2025;23(1):198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11895377</ArticleId><ArticleId IdType="pubmed">40065319</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Li X, Song L. Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway. Pharm Biol. 2020;58(1):655&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470075</ArticleId><ArticleId IdType="pubmed">32649845</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao T, et al. SHEP1 alleviates cardiac ischemia reperfusion injury via targeting G3BP1 to regulate macrophage infiltration and inflammation. Cell Death Dis. 2024;15(12):916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11655884</ArticleId><ArticleId IdType="pubmed">39695094</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, et al. TRIM21 aggravates cardiac injury after myocardial infarction by promoting M1 macrophage polarization. Front Immunol. 2022;13:1053171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9684192</ArticleId><ArticleId IdType="pubmed">36439111</ArticleId></ArticleIdList></Reference><Reference><Citation>de Couto G, et al. Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction. J Clin Invest. 2015;125(8):3147&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4563759</ArticleId><ArticleId IdType="pubmed">26214527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K, Li YY, Jin J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. Signal Transduct Target Ther. 2021;6(1):79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897720</ArticleId><ArticleId IdType="pubmed">33612829</ArticleId></ArticleIdList></Reference><Reference><Citation>Leor J, et al. Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation. 2006;114(1 Suppl):I94-100.</Citation><ArticleIdList><ArticleId IdType="pubmed">16820652</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen JH, et al. Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis. Front Immunol. 2022;13: 946832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9583253</ArticleId><ArticleId IdType="pubmed">36275654</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai E, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16(11):2069&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7595620</ArticleId><ArticleId IdType="pubmed">31920150</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, et al. Taurine antagonizes macrophages M1 polarization by mitophagy-glycolysis switch blockage via dragging SAM-PP2Ac transmethylation. Front Immunol. 2021;12: 648913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8071881</ArticleId><ArticleId IdType="pubmed">33912173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, et al. A new perspective on the therapeutic potential of tumor metastasis: targeting the metabolic interactions between TAMs and tumor cells. Int J Biol Sci. 2024;20(13):5109&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11489172</ArticleId><ArticleId IdType="pubmed">39430253</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan YZ, et al. Structural insights for selective disruption of Beclin 1 binding to Bcl-2. Commun Biol. 2023;6(1):1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10598227</ArticleId><ArticleId IdType="pubmed">37875561</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840792</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2165</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</Title><ISOAbbreviation>Eur J Vasc Endovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Impaired Long Term Survival with Asymptomatic Peri-operative Myocardial Injury following Endovascular Infrarenal Abdominal Aortic Aneurysm Repair: A Retrospective Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1078-5884(25)00792-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejvs.2025.08.034</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Peri-operative myocardial injury (PMI) is characterised by an acute but clinical asymptomatic increase in troponin levels. Its incidence in vascular surgery is underreported. Moreover, the impact of PMI on survival in patients undergoing endovascular aneurysm repair (EVAR), who are particularly at risk owing to their cardiovascular burden, remains unclear. This study aimed to assess the incidence of PMI following infrarenal EVAR and its association with long term mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Pre-operative and consecutive post-operative high sensitivity troponin T (hsTnT) levels were retrospectively analysed from patients who underwent standard infrarenal EVAR in a Dutch tertiary hospital between 2012 and 2022. PMI was defined as a difference of &#x2265; 14 ng/L (&#x394;hsTnT) between pre-operative and post-operative troponin concentrations without clinical features of myocardial ischaemia. Patients with clinically evident myocardial infarction were excluded. The primary outcomes were the incidence of PMI and long term mortality. A secondary outcome was the association between the magnitude of &#x394;hsTnT and long term mortality, irrespective of PMI criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 318 patients were included, with a median follow up of 43 months. PMI occurred in 38 patients (11.9%). Six year risk of mortality was statistically significantly higher in patients with PMI (42.1% vs. 23.6%, adjusted hazard ratio [HR] 2.11, 95% confidence interval [CI] 1.13 - 3.92; p = .019). Age (adjusted HR 1.06, 95% CI 1.02 - 1.09; p &#x2264; .001) and American Society of Anesthesiologist score (adjusted HR 1.82, 95% CI 1.16 - 2.87; p = .009) were independent predictors of mortality. Statin therapy demonstrated protective advantages against mortality (adjusted HR 0.40, 95% CI 0.25 - 0.65; p &lt; .001). Lastly, a significant association between the magnitude of &#x394;hsTnT and long term mortality was found (adjusted HR = 1.016/&#x394; 1 ng/L, 95% CI 1.004 - 1.029; p = .012).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Asymptomatic PMI is relatively common following EVAR and is associated with impaired long term survival. HsTnT is a sensitive marker for identifying cardiac damage in patients undergoing EVAR. Prospective studies may strengthen the evidence of the potential association between PMI and post-EVAR mortality and clarify any benefit from intensified post-operative cardiac care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vecht</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: davidvecht@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Tongeren</LastName><ForeName>Olivier L R M</ForeName><Initials>OLRM</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rastogi</LastName><ForeName>Vinamr</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Lier</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ultee</LastName><ForeName>Klaas H J</ForeName><Initials>KHJ</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoeks</LastName><ForeName>Sanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Mieghem</LastName><ForeName>Nicolos M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blankensteijn</LastName><ForeName>Jan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Amsterdam University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhagen</LastName><ForeName>Hence J M</ForeName><Initials>HJM</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bruin</LastName><ForeName>Jorg L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Vasc Endovasc Surg</MedlineTA><NlmUniqueID>9512728</NlmUniqueID><ISSNLinking>1078-5884</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal aortic aneurysm</Keyword><Keyword MajorTopicYN="N">Endovascular aneurysm repair</Keyword><Keyword MajorTopicYN="N">High sensitivity troponin T</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Peri-operative myocardial injury</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840792</ArticleId><ArticleId IdType="doi">10.1016/j.ejvs.2025.08.034</ArticleId><ArticleId IdType="pii">S1078-5884(25)00792-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40847484</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Ticagrelor Paradox: Systematic Review and Network Meta-Analysis.</ArticleTitle><Pagination><StartPage>e041959</StartPage><MedlinePgn>e041959</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.125.041959</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Based on the landmark PLATO (Platelet Inhibition and Patient Outcomes) and TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction) trials, current guidelines recommend ticagrelor and prasugrel over clopidogrel for acute coronary syndrome. However, subsequent studies have failed to replicate the reported benefits of ticagrelor, raising concerns about the validity of the PLATO trial's findings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Randomized trials published until January 2025 were searched on PubMed and Embase and included if they compared 2 of the 3 standard dual antiplatelet therapies: 12 months aspirin plus clopidogrel, prasugrel, or ticagrelor. We constructed a network with and without PLATO to assess its impact on the synthesized risk estimates on major adverse cardiovascular events, patient mortality, myocardial infarction, and stent thrombosis, as well as major bleeding and major or minor bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve trials, enrolling 52&#x2009;415 patients (clopidogrel: 23&#x2009;557; ticagrelor: 13&#x2009;344, prasugrel: 15&#x2009;514) were included. The analysis with PLATO showed lower hazard ratios for ticagrelor versus clopidogrel&#xa0;than the analysis without PLATO in major adverse cardiovascular events, mortality, myocardial infarction, and bleeding outcomes (e.g., cardiovascular mortality; hazard ratio [HR], 0.83 [95% CI, 0.72-0.96] when PLATO was included; HR, 0.96 [95% CI, 0.73-1.25] when PLATO was excluded). Ticagrelor and prasugrel were associated with higher incidences of major bleeding and major or minor bleeding for analyses including and excluding PLATO, altohugh the point estimates for ticagrelor were lower when PLATO was included.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The pooled estimates with PLATO favored ticagrelor compared with estimates without PLATO in several studied outcomes, potentially suggesting the substantial impacts of PLATO's findings on the pooled risk estimates; therefore, additional evidence may be needed given the large number of patients worldwide treated with dual antiplatelet therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Atsuyuki</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8781-0329</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Mount Sinai Morningside and West Icahn School of Medicine at Mount Sinai New York NY USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aikawa</LastName><ForeName>Tadao</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1786-0176</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2852-2946</Identifier><AffiliationInfo><Affiliation>Department of Real-World Evidence, Graduate School of Medicine University of Tokyo Bunkyo City Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueyama</LastName><ForeName>Hiroki A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Division of Cardiology Emory University School of Medicine Atlanta GA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujisaki</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9204-8551</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Osaka Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoji</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2223-7215</Identifier><AffiliationInfo><Affiliation>Duke Clinical Research Institute Durham NC USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Kaveh</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5676-3099</Identifier><AffiliationInfo><Affiliation>Tehran Heart Center, Cardiovascular Diseases Research Institute Tehran University of Medical Sciences Tehran Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slipczuk</LastName><ForeName>Leandro</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3091-3735</Identifier><AffiliationInfo><Affiliation>Cardiology Division Montefiore Medical Center/Albert Einstein College of Medicine Bronx NY USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briasoulis</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5740-9670</Identifier><AffiliationInfo><Affiliation>Section of Heart Failure University of Iowa Iowa City IA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampaktsis</LastName><ForeName>Polydoros N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Structural and Congenital Center Hackensack University Medical Center Hackensack NJ USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiley</LastName><ForeName>Jose</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9940-0367</Identifier><AffiliationInfo><Affiliation>Section of Cardiology, Department of Medicine Tulane University School of Medicine New Orleans LA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Secemsky</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-3861-3163</Identifier><AffiliationInfo><Affiliation>Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwagami</LastName><ForeName>Masao</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7079-0640</Identifier><AffiliationInfo><Affiliation>Department of Digital Health, Institute of Medicine University of Tsukuba Tsukuba Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsugawa</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1937-4833</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at UCLA Los Angeles CA USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management UCLA Fielding School of Public Health Los Angeles CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2487-8366</Identifier><AffiliationInfo><Affiliation>Division of Cardiology Beth Israel Deaconess Medical Center Boston MA USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Division, Massachusetts General Hospital Harvard Medical School Boston MA USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">dual antiplatelet therapy</Keyword><Keyword MajorTopicYN="N">guideline</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40847484</ArticleId><ArticleId IdType="doi">10.1161/JAHA.125.041959</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846217</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1913</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>The American journal of cardiology</Title><ISOAbbreviation>Am J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Ostial Stent Implantation or Crossover Stenting for Ostial LAD Lesions: The Multicenter CROSS-ANATOLIA Registry.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-9149(25)00483-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjcard.2025.08.023</ELocationID><Abstract><AbstractText>Percutaneous coronary intervention (PCI) for isolated ostial left anterior descending artery (LAD) lesions remains technically difficult. Accurate ostial stenting (AOS) aims to prevent involvement of the left main coronary artery (LMCA), while crossover stenting (COS) ensures complete ostial coverage but may increase procedural complexity. This study aimed to evaluate the long-term outcomes of patients who underwent AOS or COS for ostial LAD disease. From 2014 to 2025, patients who underwent PCI for ostial LAD lesions were retrospectively collected. The primary outcome was major adverse cardiac events (MACE), including cardiac death, target lesion revascularization (TLR), and target vessel myocardial infarction (TVMI). This large-scale multicenter (n=12) observational study included a total of 1,167 consecutive patients [men: 859 (73.6%), mean age: 61.70&#xb1;12.73 years] with ostial LAD lesions who underwent PCI; 590 (50.6%) of the cases were revascularized with AOS, and 577 (49.4%) were treated with COS. The incidences of MACE (18.1 vs. 9.5%, p&lt;0.001), TVMI (9.2 vs. 4.7%, p=0.003), and clinically driven TLR (10.7 vs. 4.2%, p&lt;0.001) were notably higher in the AOS group compared to the COS group. Treatment (AOS) (HR:2.469, p&lt;0.001), chronic kidney disease (HR:1.832, p=0.003), reduced LVEF (HR:1.016, p=0.042), SYNTAX score (HR:1.089, p&lt;0.001), lack of intravascular imaging (HR: 1.451, p=0.049), direct stenting (HR:2.171, p=0.001), stent length (HR:1.036, p=0.001) were found to be independent predictors of MACE. In conclusion, this non-randomized study suggests that COS was associated with better long-term MACE, TVMI, and clinically driven TLR rates compared with AOS in patients with ostial LAD disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan&#x131;k</LastName><ForeName>Veysel Ozan</ForeName><Initials>VO</Initials><AffiliationInfo><Affiliation>Ankara Etlik City Hospital, Department of Cardiology, Ankara, T&#xfc;rkiye. Electronic address: drozantanik@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;ner</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serin</LastName><ForeName>Ebru</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Health Science University, Sisli Hamidiye Etfal Training and Research Hospital, Department of Cardiology, Istanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;al&#x131;k</LastName><ForeName>Ali Nazmi</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Health Science University, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deniz</LastName><ForeName>Furkan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Health Science University, Bagcilar Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdo&#x11f;an</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ankara Bilkent City Hospital, Department of Cardiology, Ankara, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asil</LastName><ForeName>Serkan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Health Science University, Gulhane Training and Research Hospital, Department of Cardiology, Ankara, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba&#x15f;kurt</LastName><ForeName>Ahmet An&#x131;l</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Bakircay University, &#xc7;igli Training and Research Hospital, Department of Cardiology, Izmir, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markirt</LastName><ForeName>Sezer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Adiyaman Training and Research Hospital, Department of Cardiology, Adiyaman, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkan</LastName><ForeName>Semih</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Basaksehir Cam and Sakura City Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arslan</LastName><ForeName>Enes</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Yalova Training and Research Hospital, Department of Cardiology, Yalova, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kara</LastName><ForeName>Faruk</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Health Science University, Ahi Evran Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Trabzon, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;k</LastName><ForeName>Saner Bahad&#x131;r</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Ankara Etlik City Hospital, Department of Cardiology, Ankara, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;ebi</LastName><ForeName>&#xd6;zge</ForeName><Initials>&#xd6;</Initials><AffiliationInfo><Affiliation>Health Science University, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#x131;rm&#x131;z&#x131;g&#xfc;l</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ankara Bilkent City Hospital, Department of Cardiology, Ankara, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf6;nmez</LastName><ForeName>Onur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Health Science University, Gulhane Training and Research Hospital, Department of Cardiology, Ankara, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uzun</LastName><ForeName>Fatih</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;izgici</LastName><ForeName>Ahmet Ya&#x15f;ar</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedir</LastName><ForeName>Fatih Furkan</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x15e;im&#x15f;ek</LastName><ForeName>Ayb&#xfc;ke</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zt&#xfc;rk</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;k&#xe7;e</LastName><ForeName>Kaan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do&#x11f;an</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;ilo&#x11f;lu</LastName><ForeName>Koray</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akt&#xfc;rk</LastName><ForeName>Faruk</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Health Science University, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tunca</LastName><ForeName>&#xc7;a&#x11f;atay</ForeName><Initials>&#xc7;</Initials><AffiliationInfo><Affiliation>Ankara Etlik City Hospital, Department of Cardiology, Ankara, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbu&#x11f;a</LastName><ForeName>K&#xfc;r&#x15f;at</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ankara Etlik City Hospital, Department of Cardiology, Ankara, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balc&#x131;</LastName><ForeName>Mustafa M&#xfc;cahit</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Ankara Etlik City Hospital, Department of Cardiology, Ankara, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keskin</LastName><ForeName>Kudret</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Health Science University, Sisli Hamidiye Etfal Training and Research Hospital, Department of Cardiology, Istanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;rdal</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Science University, Sisli Hamidiye Etfal Training and Research Hospital, Department of Cardiology, Istanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arslanhan</LastName><ForeName>Aylin &#x15e;afak</ForeName><Initials>A&#x15e;</Initials><AffiliationInfo><Affiliation>Health Science University, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durak</LastName><ForeName>Furkan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Health Science University, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karaer</LastName><ForeName>Ey&#xfc;p</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Health Science University, Bagcilar Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x15e;ahin</LastName><ForeName>&#x130;rfan</ForeName><Initials>&#x130;</Initials><AffiliationInfo><Affiliation>Health Science University, Bagcilar Training and Research Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;ksoylu</LastName><ForeName>G&#xfc;nsel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ankara Bilkent City Hospital, Department of Cardiology, Ankara, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Y&#xfc;ksel</LastName><ForeName>Uygar &#xc7;a&#x11f;da&#x15f;</ForeName><Initials>U&#xc7;</Initials><AffiliationInfo><Affiliation>Health Science University, Gulhane Training and Research Hospital, Department of Cardiology, Ankara, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akman</LastName><ForeName>Cemalettin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Adiyaman Training and Research Hospital, Department of Cardiology, Adiyaman, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozanalp</LastName><ForeName>Cemal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Basaksehir Cam and Sakura City Hospital, Department of Cardiology, Istanbul, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zlek</LastName><ForeName>B&#xfc;lent</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mugla Sitki Kocman University, School of Medicine, Department of Cardiology, Mugla, Turkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Cardiol</MedlineTA><NlmUniqueID>0207277</NlmUniqueID><ISSNLinking>0002-9149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Accurate ostial stenting</Keyword><Keyword MajorTopicYN="N">crossover stenting</Keyword><Keyword MajorTopicYN="N">major adverse cardiac events</Keyword><Keyword MajorTopicYN="N">ostial LAD lesion</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846217</ArticleId><ArticleId IdType="doi">10.1016/j.amjcard.2025.08.023</ArticleId><ArticleId IdType="pii">S0002-9149(25)00483-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846354</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Impact of Anabolic-Androgenic Steroids on Coronary Artery Disease: Insights From Optical Coherence Tomography.</ArticleTitle><Pagination><StartPage>104662</StartPage><MedlinePgn>104662</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104662</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01442-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Anabolic-androgenic steroids (AAS), synthetic derivatives of testosterone, are misused by athletes to enhance performance despite known cardiovascular risks including dyslipidemia, hypertension, and acute myocardial infarction.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 30-year-old male with a history of AAS abuse presented with acute chest pain and was diagnosed with non-ST elevation myocardial infarction. Coronary angiography revealed intimal hyperplasia, plaque erosion, and thrombus formation in the proximal left anterior descending artery, confirmed by optical coherence tomography. He was managed with glycoprotein IIb/IIIa inhibitors, anticoagulation, and triple therapy (aspirin, clopidogrel, apixaban) and was shifted to dual therapy post discharge.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Literature links AAS abuse to atherogenic, thrombogenic, and vasospastic mechanisms, increasing coronary artery disease risks. This case highlights AAS-induced coronary pathology in a young patient, emphasizing the need for awareness among athletes and clinicians to prevent life-threatening outcomes.</AbstractText><AbstractText Label="TAKE-HOME MESSAGE" NlmCategory="CONCLUSIONS">AAS abuse can cause severe coronary artery disease. Education is critical to mitigate cardiovascular risks in young athletes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdelsamie</LastName><ForeName>Ahmed Hegazi</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Cardiology Department, Mouwasat Hospital Dammam, Dammam, Saudi Arabia. Electronic address: doc.hegazi@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelhadi</LastName><ForeName>Hani Omar</ForeName><Initials>HO</Initials><AffiliationInfo><Affiliation>Cardiology Department, Mouwasat Hospital Dammam, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anabolic-androgenic steroids</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and food and drug administration guidelines, including patient consent where appropriate.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846354</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104662</ArticleId><ArticleId IdType="pii">S2666-0849(25)01442-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40845923</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4995</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of controlled release : official journal of the Controlled Release Society</Title><ISOAbbreviation>J Control Release</ISOAbbreviation></Journal><ArticleTitle>Sorbitol-responsive in situ gel improves rat ischemic hearts: Supporting mesenchymal stem cell survival and enhancing paracrine effect.</ArticleTitle><Pagination><StartPage>114148</StartPage><MedlinePgn>114148</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jconrel.2025.114148</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-3659(25)00759-X</ELocationID><Abstract><AbstractText>Mesenchymal stem cells (MSCs) repair damaged myocardium by secreting biological factors and have shown only modest therapeutic efficacy in clinical trials. We recently developed a sorbitol-responsive in situ gelling material (SRG) solution, which increases viscosity by diffusing out pre-added sorbitol upon contact with heart tissue without external stimulation. Here, this study demonstrates that intramyocardial injection of MSC-loaded SRG (MSC/SRG) improves cardiac function and facilitates tissue repair following acute myocardial ischemia in rats, and the underlying mechanisms are elucidated. MSC/SRG is more effective than either MSC or SRG alone in preventing cardiac dysfunction and fibrotic remodeling while stimulating angiogenesis. The optimized SRG consists of 25&#x202f;mg/mL boronic acid group-bearing polymer, 10&#x202f;mg/mL polyvinyl alcohol, and 5&#x202f;mg/mL sorbitol, which prolongs MSC survival and enhances their paracrine function in in vitro and in vivo assays. Sorbitol supplementation increases MSC proliferation, modulates cytokine secretion from MSCs in a concentration-dependent manner, and promotes angiogenesis in vitro. These findings suggest that the sorbitol in SRG supports MSC survival and enhances MSC paracrine activity. The SRG may facilitate the therapeutic potential of MSC and hydrogel-based interventions for myocardial ischemia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Hue Thi</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe Shim-machi, Suita, Osaka 564-8565, Japan; Department of Physiology, Hanoi Medical University, Hanoi 10000, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahara</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe Shim-machi, Suita, Osaka 564-8565, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagasaki</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka 558-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaoka</LastName><ForeName>Tetsuji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe Shim-machi, Suita, Osaka 564-8565, Japan; Department of Clinical Engineering, Faculty of Health Sciences, Komatsu University, He 14-1, Mukai-motoori-machi, Komatsu, Ishikawa 923-0961, Japan. Electronic address: tetsuji.yamaoka@komatsu-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Control Release</MedlineTA><NlmUniqueID>8607908</NlmUniqueID><ISSNLinking>0168-3659</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiogenesis</Keyword><Keyword MajorTopicYN="N">In situ gelling material</Keyword><Keyword MajorTopicYN="N">Mesenchymal stem cell</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Sorbitol</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845923</ArticleId><ArticleId IdType="doi">10.1016/j.jconrel.2025.114148</ArticleId><ArticleId IdType="pii">S0168-3659(25)00759-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40845836</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2817-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>JMIR AI</Title><ISOAbbreviation>JMIR AI</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of the GPT-4o Model in Interpreting Electrocardiogram Images for Cardiac Diagnostics: Diagnostic Accuracy Study.</ArticleTitle><Pagination><StartPage>e74426</StartPage><MedlinePgn>e74426</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2196/74426</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Recent progress has demonstrated the potential of deep learning models in analyzing electrocardiogram (ECG) pathologies. However, this method is intricate, expensive to develop, and designed for specific purposes. Large language models show promise in medical image interpretation, and yet their effectiveness in ECG analysis remains understudied. Generative Pretrained Transformer 4 Omni (GPT-4o), a multimodal artificial intelligence model, capable of processing images and text without task-specific training, may offer an accessible alternative.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aimed to evaluate GPT-4o's effectiveness in interpreting 12-lead ECGs, assessing classification accuracy, and exploring methods to enhance its performance.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 6 common ECG diagnoses were evaluated: normal ECG, ST-segment elevation myocardial infarction, atrial fibrillation, right bundle branch block, left bundle branch block, and paced rhythm, with 30 normal ECGs and 10 of each abnormal pattern, totaling 80 cases. Deidentified ECGs were analyzed using OpenAI's GPT-4o. Our study used both zero-shot and few-shot learning methodologies to investigate three main scenarios: (1) ECG image recognition, (2) binary classification of normal versus abnormal ECGs, and (3) multiclass classification into 6 categories.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The model excelled in recognizing ECG images, achieving an accuracy of 100%. In the classification of normal or abnormal ECG cases, the few-shot learning approach improved GPT-4o's accuracy by 30% from the baseline, reaching 83% (95% CI 81.8%-84.6%). However, multiclass classification for a specific pathology remained limited, achieving only 41% accuracy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">GPT-4o effectively differentiates normal from abnormal ECGs, suggesting its potential as an accessible artificial intelligence-assisted triage tool. Although limited in diagnosing specific cardiac conditions, GPT-4o's capability to interpret ECG images without specialized training highlights its potential for preliminary ECG interpretation in clinical and remote settings.</AbstractText><CopyrightInformation>&#xa9; Haya Engelstein, Roni Ramon Gonen, Avi Sabbag, Eyal Klang, Karin Sudri, Michal Cohen-Shelly, Israel Barbash. Originally published in JMIR AI (https://ai.jmir.org).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Engelstein</LastName><ForeName>Haya</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0005-6721-5158</Identifier><AffiliationInfo><Affiliation>Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ramon-Gonen</LastName><ForeName>Roni</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2529-1567</Identifier><AffiliationInfo><Affiliation>The Graduate School of Business Administration, Information Systems Program, Bar-Ilan University, Max and Anna Webb St, Ramat Gan, 5290002, Israel, 972 3-531-8910.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbag</LastName><ForeName>Avi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4295-6679</Identifier><AffiliationInfo><Affiliation>Davidai Arrhythmia Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klang</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4567-3108</Identifier><AffiliationInfo><Affiliation>Division of Data-Driven and Digital Medicine (D3M), Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles Bronfman Institute of Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudri</LastName><ForeName>Karin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5118-8619</Identifier><AffiliationInfo><Affiliation>Sheba ARC, Sagol Big Data and AI Hub, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cohen-Shelly</LastName><ForeName>Michal</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0007-6532-9252</Identifier><AffiliationInfo><Affiliation>Sheba ARC, Sagol Big Data and AI Hub, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Barbash</LastName><ForeName>Israel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7416-5989</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interventional Cardiology Unit, Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR AI</MedlineTA><NlmUniqueID>9918645789006676</NlmUniqueID><ISSNLinking>2817-1705</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LLMs</Keyword><Keyword MajorTopicYN="N">artificial intelligence</Keyword><Keyword MajorTopicYN="N">cardiology</Keyword><Keyword MajorTopicYN="N">decision support systems</Keyword><Keyword MajorTopicYN="N">electrocardiogram</Keyword><Keyword MajorTopicYN="N">large language models</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>18</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845836</ArticleId><ArticleId IdType="doi">10.2196/74426</ArticleId><ArticleId IdType="pii">v4i1e74426</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40844465</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1897-4279</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Kardiologia polska</Title><ISOAbbreviation>Kardiol Pol</ISOAbbreviation></Journal><ArticleTitle>Diabetes: At what resting heart rate does the risk of cardiovascular events increase?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.33963/v.phj.108166</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Elevated resting heart rate (RHR) is associated with an increased risk of cardiovascular (CV) events, including myocardial infarction, stroke, and CV mortality. Despite current guidelines suggesting an RHR threshold of 80 bpm for heightened risk and potential therapeutic intervention, evidence supporting this cutoff remains inconclusive.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To assess the relationship between RHR and CV risk in individuals with diabetes mellitus (DM) and identify an RHR threshold above which CV risk significantly increases.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">A post hoc analysis was conducted using data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD-BP) trial, which included 4733 participants with DM. Baseline RHR were used to stratify patients into RHR categories. Cox proportional hazards models, including restricted cubic splines and segmented regression, were used to evaluate the relationship between RHR and a composite CV endpoint (nonfatal myocardial infarction, nonfatal stroke, or all-cause death), as well as secondary endpoints (CV death, myocardial infarction, and stroke).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher RHR was associated with increased CV risk, with a nonlinear relationship observed. Segmented regression identified an RHR threshold of 77 (7.4) bpm, above which the risk of CV events increased significantly. Stroke risk was most strongly associated with elevated RHR, while myocardial infarction exhibited a linear relationship with RHR.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that an RHR threshold of approximately 77 bpm may better define increased CV risk in patients with DM compared to the previously proposed 80 bpm cut-off. These results may inform clinical decision-making regarding RHR-lowering interventions in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sobieraj</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Disease, Hypertension and Vascular Diseases, Medical University of Warsaw, Warszawa, Poland. piotr.sobieraj@wum.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>Jacek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Disease, Hypertension and Vascular Diseases, Medical University of Warsaw, Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Si&#x144;ski</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Disease, Hypertension and Vascular Diseases, Medical University of Warsaw, Warszawa, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Kardiol Pol</MedlineTA><NlmUniqueID>0376352</NlmUniqueID><ISSNLinking>0022-9032</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular prevention</Keyword><Keyword MajorTopicYN="N">cardiovascular risk</Keyword><Keyword MajorTopicYN="N">heart rate</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>10</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844465</ArticleId><ArticleId IdType="doi">10.33963/v.phj.108166</ArticleId><ArticleId IdType="pii">VM/OJS/J/108166</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40844863</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2575-3126</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>A&amp;A practice</Title><ISOAbbreviation>A A Pract</ISOAbbreviation></Journal><ArticleTitle>Association Between Postoperative Acute Kidney Injury and Long-Term Mortality in Patients Undergoing Major Abdominal Surgery: A Cohort-Based Study.</ArticleTitle><Pagination><StartPage>e02038</StartPage><MedlinePgn>e02038</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1213/XAA.0000000000002038</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute kidney injury (AKI) is a frequent complication after major surgery and has significant implications for long-term outcomes. This study aimed to evaluate the incidence and impact of postoperative AKI (PO-AKI) in adults who underwent major abdominal surgeries in 2019 at Hospital Cl&#xed;nico de la Universidad de Chile. The primary focus was on the association between PO-AKI and 2-year mortality, along with other postoperative complications and hospital-related outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A descriptive observational study was conducted with approval from the Local Ethical Committee. Patients aged 18 years and older who underwent major abdominal surgeries were included, excluding those with incomplete records or preoperative renal failure. Data were collected from electronic medical records (TiCares) and included demographics, comorbidities, and surgical details. Postoperative complications, including PO-AKI [defined by kidney disease: improving global outcomes (KDIGO) criteria or clinical diagnosis], in-hospital myocardial infarction, pulmonary thrombosis, pneumonia, sepsis, in-hospital mortality, and 2 years mortality, were recorded. The primary outcome was 2-year mortality, while secondary outcomes included in-hospital mortality and hospital stay length. Multivariable analysis was used to explore the relationship between PO-AKI and these outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 214 patients analyzed, PO-AKI occurred in 13.6% of patients and was associated with advanced age (P = .003), high American Society of Anesthesiologists physical status (ASA-PS) scores (P = .02, between ASA-PS 1-2 vs 3-higher), and longer surgical durations (mean [standard deviation {SD}] 282.6 [144.3] vs 227.4 [108.5] min; P = .02). Individual preoperative creatinine and baseline renal function did not significantly differ between those with and without PO-AKI (P = .82 and P = .22, respectively). PO-AKI was associated with a relative risk of 1.4 [95% confidence interval [CI], 1.2-1.8] for 2-year mortality and stayed in the hospital twice as long as those without PO-AKI (median (min - max) 14 (2-67) vs 7 (0-53) P &lt; .0001). Multivariate analysis identified PO-AKI (odds ratio [OR] = 4.1 [95% CI, 2.5-6.5]; P = .003) as an independent predictor of 2-year mortality. Overall, 20.1% of the cohort died within 2 years, and 3.7% experienced in-hospital mortality. Additional complications included sepsis (12.6%), pulmonary thromboembolism (3.7%), and pneumonia (2.8%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PO-AKI was found to be an independent predictor of 2-year mortality. These findings highlight postoperative renal function impairment as a key marker of poor long-term prognosis. Acute renal deterioration may reflect systemic damage from surgery and/or increased vulnerability in this population, underscoring the need for targeted preventive strategies and early interventions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 International Anesthesia Research Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>C&#xe9;sped</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Escuela de Medicina, Facultad de Medicina, Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Medicina Perioperatoria, Hospital Cl&#xed;nico de la Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Cl&#xed;nica Avanzada (CICA), Facultad de Medicina, Hospital Cl&#xed;nico de la Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ega&#xf1;a</LastName><ForeName>Jos&#xe9; I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Medicina Perioperatoria, Hospital Cl&#xed;nico de la Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Maza</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Medicina Perioperatoria, Hospital Cl&#xed;nico de la Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toro</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Cl&#xed;nica Avanzada (CICA), Facultad de Medicina, Hospital Cl&#xed;nico de la Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Secci&#xf3;n de Nefrolog&#xed;a, Departamento de Medicina, Hospital Cl&#xed;nico Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penna</LastName><ForeName>Antonello</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Medicina Perioperatoria, Hospital Cl&#xed;nico de la Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Cl&#xed;nica Avanzada (CICA), Facultad de Medicina, Hospital Cl&#xed;nico de la Universidad de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>A A Pract</MedlineTA><NlmUniqueID>101714112</NlmUniqueID><ISSNLinking>2575-3126</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000005" MajorTopicYN="Y">Abdomen</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002677" MajorTopicYN="N" Type="Geographic">Chile</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844863</ArticleId><ArticleId IdType="doi">10.1213/XAA.0000000000002038</ArticleId><ArticleId IdType="pii">02054229-202508000-00019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179&#x2013;c184.</Citation></Reference><Reference><Citation>Levey AS, James MT. Acute Kidney Injury. Ann Intern Med. 2017;167:ITC66&#x2013;ITC80.</Citation></Reference><Reference><Citation>Bihorac A, Yavas S, Subbiah S, et al. Long-term risk of mortality and acute kidney injury during hospitalization after major surgery. Ann Surg. 2009;249:851&#x2013;858.</Citation></Reference><Reference><Citation>Grams ME, Sang Y, Coresh J, et al. Acute kidney injury after major surgery: a retrospective analysis of veterans health administration data. Am J Kidney Dis. 2016;67:872&#x2013;880.</Citation></Reference><Reference><Citation>Gameiro J, Fonseca JA, Neves M, Jorge S, Lopes JA. Acute kidney injury in major abdominal surgery: incidence, risk factors, pathogenesis and outcomes. Ann Intensive Care. 2018;8:22.</Citation></Reference><Reference><Citation>Peerapornratana S, Manrique-Caballero CL, Gomez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology. Kidney Int. 2019;96:1083&#x2013;1099.</Citation></Reference><Reference><Citation>Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41:1411&#x2013;1423.</Citation></Reference><Reference><Citation>Thakar CV. Perioperative acute kidney injury. Adv Chronic Kidney Dis. 2013;20:67&#x2013;75.</Citation></Reference><Reference><Citation>Uchino S, Kellum JA, Bellomo R, et al.; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813&#x2013;818.</Citation></Reference><Reference><Citation>Sutherland L, Hittesdorf E, Yoh N, Lai T, Mechling A, Wagener G. Acute kidney injury after cardiac surgery: a comparison of different definitions. Nephrology (Carlton). 2020;25:212&#x2013;218.</Citation></Reference><Reference><Citation>Prowle JR, Forni LG, Bell M, et al. Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative. Nat Rev Nephrol. 2021;17:605&#x2013;618.</Citation></Reference><Reference><Citation>Teixeira C, Rosa R, Rodrigues N, et al. Acute kidney injury after major abdominal surgery: a retrospective cohort analysis. Crit Care Res Pract. 2014;2014:132175.</Citation></Reference><Reference><Citation>Calvert S, Shaw A. Perioperative acute kidney injury. Perioper Med (Lond). 2012;1:6.</Citation></Reference><Reference><Citation>Chronopoulos A, Cruz DN, Ronco C. Hospital-acquired acute kidney injury in the elderly. Nat Rev Nephrol. 2010;6:141&#x2013;149.</Citation></Reference><Reference><Citation>Darmon M, Ostermann M, Cerda J, et al. Diagnostic work-up and specific causes of acute kidney injury. Intensive Care Med. 2017;43:829&#x2013;840.</Citation></Reference><Reference><Citation>Sear JW. Kidney dysfunction in the postoperative period. Br J Anaesth. 2005;95:20&#x2013;32.</Citation></Reference><Reference><Citation>Cho E, Kim SC, Kim MG, Jo SK, Cho WY, Kim HK. The incidence and risk factors of acute kidney injury after hepatobiliary surgery: a prospective observational study. BMC Nephrol. 2014;15:169.</Citation></Reference><Reference><Citation>Ryden L, Sartipy U, Evans M, Holzmann MJ. Acute kidney injury after coronary artery bypass grafting and long-term risk of end-stage renal disease. Circulation. 2014;130:2005&#x2013;2011.</Citation></Reference><Reference><Citation>Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16:3365&#x2013;3370.</Citation></Reference><Reference><Citation>Inker LA, Eneanya ND, Coresh J, et al.; Chronic Kidney Disease Epidemiology Collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385:1737&#x2013;1749.</Citation></Reference><Reference><Citation>Biteker M, Dayan A, Tekkesin AI, et al. Incidence, risk factors, and outcomes of perioperative acute kidney injury in noncardiac and nonvascular surgery. Am J Surg. 2014;207:53&#x2013;59.</Citation></Reference><Reference><Citation>Erdost HA, Ozkardesler S, Akan M, et al. Comparison of the RIFLE, AKIN, and KDIGO diagnostic classifications for acute renal injury in patients undergoing liver transplantation. Transplant Proc. 2016;48:2112&#x2013;2118.</Citation></Reference><Reference><Citation>Rodrigues FB, Bruetto RG, Torres US, Otaviano AP, Zanetta DM, Burdmann EA. Incidence and mortality of acute kidney injury after myocardial infarction: a comparison between KDIGO and RIFLE criteria. PLoS One. 2013;8:e69998.</Citation></Reference><Reference><Citation>Luo X, Jiang L, Du B, Wen Y, Wang M, Xi X; Beijing Acute Kidney Injury Trial (BAKIT) workgroup. A comparison of different diagnostic criteria of acute kidney injury in critically ill patients. Crit Care. 2014;18:R144.</Citation></Reference><Reference><Citation>Long TE, Helgason D, Helgadottir S, et al. Acute kidney injury after abdominal surgery: incidence, risk factors, and outcome. Anesth Analg. 2016;122:1912&#x2013;1920.</Citation></Reference><Reference><Citation>Rossouw E, Chetty S. Acute kidney injury after major non-cardiac surgery: Incidence and risk factors. S Afr Med J. Mar 22023;113:135&#x2013;140.</Citation></Reference><Reference><Citation>O&#x2019;Connor ME, Kirwan CJ, Pearse RM, Prowle JR. Incidence and associations of acute kidney injury after major abdominal surgery. Intensive Care Med. 2016;42:521&#x2013;530.</Citation></Reference><Reference><Citation>Wu QF, Xing MW, Hu WJ, et al. Acute kidney injury and 3-year mortality in elderly patients after non-cardiac surgery. Front Med (Lausanne). 2022;9:779754.</Citation></Reference><Reference><Citation>Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43:1551&#x2013;1561.</Citation></Reference><Reference><Citation>Chaudery H, MacDonald N, Ahmad T, et al.; International Surgical Outcomes Study (ISOS) Group. Acute kidney injury and risk of death after elective surgery: prospective analysis of data from an international cohort study. Anesth Analg. 2019;128:1022&#x2013;1029.</Citation></Reference><Reference><Citation>Gesualdo L, Grandaliano G, Mascia L, Pertosa G, Schena FP. Acute renal failure in critically ill patients. Intensive Care Med. 1999;25:1188&#x2013;1190.</Citation></Reference><Reference><Citation>Romagnoli S, Zagli G, Tuccinardi G, et al. Postoperative acute kidney injury in high-risk patients undergoing major abdominal surgery. J Crit Care. 2016;35:120&#x2013;125.</Citation></Reference><Reference><Citation>Zarbock A, Weiss R, Albert F, et al.; EPIS-AKI Investigators. Epidemiology of surgery associated acute kidney injury (EPIS-AKI): a prospective international observational multi-center clinical study. Intensive Care Med. 2023;49:1441&#x2013;1455.</Citation></Reference><Reference><Citation>Li S, Wang S, Priyanka P, Kellum JA. Acute kidney injury in critically ill patients after noncardiac major surgery: early versus late onset. Crit Care Med. 2019;47:e437&#x2013;e444.</Citation></Reference><Reference><Citation>Sung HM, Oh AR, Jung M, et al. Association between postoperative acute kidney injury and mortality after plastic and reconstructive surgery. Sci Rep. 2022;12:20050.</Citation></Reference><Reference><Citation>French WB, Shah PR, Fatani YI, et al. Mortality and costs associated with acute kidney injury following major elective, non-cardiac surgery. J Clin Anesth. 2022;82:110933.</Citation></Reference><Reference><Citation>O&#x2019;Connor ME, Hewson RW, Kirwan CJ, Ackland GL, Pearse RM, Prowle JR. Acute kidney injury and mortality 1 year after major non-cardiac surgery. Br J Surg. 2017;104:868&#x2013;876.</Citation></Reference><Reference><Citation>Ozrazgat-Baslanti T, Thottakkara P, Huber M, et al. Acute and chronic kidney disease and cardiovascular mortality after major surgery. Ann Surg. 2016;264:987&#x2013;996.</Citation></Reference><Reference><Citation>Ferreiro A, Lombardi R. Acute kidney injury after cardiac surgery is associated with mid-term but not long-term mortality: a cohort-based study. PLoS One. 2017;12:e0181158.</Citation></Reference><Reference><Citation>Gumbert SD, Kork F, Jackson ML, et al. Perioperative acute kidney injury. Anesthesiology. 2020;132:180&#x2013;204.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40844997</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Ischemic duration determines extent of cardiac remodeling, and both early and delayed reperfusion prevent fatal cardiac rupture: Model comparison.</ArticleTitle><Pagination><StartPage>e0328001</StartPage><MedlinePgn>e0328001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0328001</ELocationID><Abstract><AbstractText>High incidence of cardiac rupture in murine myocardial infarction (MI) model leads to a substantial loss before the study end-point. Selecting animal models with varying degrees of injury for different research purposes is crucial for cardiovascular research. Male C57 mice were subjected to ischemia/reperfusion (I/R) or permanent occlusion (MI) injury. The incidence of cardiac rupture, degree of myocardial injury, inflammatory responses, left ventricular (LV) remodeling and infarct myocardium healing were examined. Compared to MI mice, early reperfusion (1, 2 and 4h I/R) completely prevented cardiac rupture, while delayed reperfusion (12h and 24h I/R) significantly reduced incidence of cardiac rupture to 5.7% and 8.6%, respectively. In the acute phase, prolonged ischemia increased infarct size, myocyte apoptosis, and both systemic and regional inflammatory responses. These changes correspond to enhanced MMP-9 activity and a weakening of the tensile strength of the infarcted myocardium. Following ischemic insult, early reperfusion was associated with less extent of myocardial injury, inflammatory response and adverse cardiac remodeling, whereas, delayed reperfusion and MI groups exhibited severe myocardial damage and remodeling. Furthermore, both early and delayed reperfusion were associated with increased infiltration of type 2 macrophages and proliferation of endothelial cells during the early healing phase, thereby facilitating healing of the infarct myocardium. Delayed reperfusion resulted in a comparable and substantial degree of cardiac remodeling but with a lower risk of cardiac rupture in comparison with MI model. This feature makes it a feasible model for cardiac ischemia research.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, First Affiliated Hospital, Clinical Medical Research Institute of Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruze</LastName><ForeName>Amanguli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, First Affiliated Hospital, Clinical Medical Research Institute of Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Guo-Li</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Cardiology, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, First Affiliated Hospital, Clinical Medical Research Institute of Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gai</LastName><ForeName>Min-Tao</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Cardiology, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, First Affiliated Hospital, Clinical Medical Research Institute of Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Cardiovascular Disease, Urumqi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, First Affiliated Hospital, Clinical Medical Research Institute of Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Laboratory, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xiao-Ming</ForeName><Initials>XM</Initials><Identifier Source="ORCID">0009-0007-3510-3105</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asian, First Affiliated Hospital, Clinical Medical Research Institute of Xinjiang Medical University, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Medical Animal Model Research, Urumqi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Cardiovascular Disease, Urumqi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020257" MajorTopicYN="Y">Ventricular Remodeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015428" MajorTopicYN="Y">Myocardial Reperfusion Injury</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006341" MajorTopicYN="Y">Heart Rupture</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015425" MajorTopicYN="Y">Myocardial Reperfusion</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844997</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0328001</ArticleId><ArticleId IdType="pii">PONE-D-24-55939</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40845148</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Repair versus Replacement in mitral valve papillary muscle rupture: a multicenter study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ezaf284</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ejcts/ezaf284</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Papillary muscle rupture (PMR) is a rare but potentially fatal mechanical complication after acute myocardial infarction (AMI). Despite surgery is considered the gold-standard treatment for post-AMI PMR, the optimal surgical strategy remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from post-AMI PMR patients submitted to MVR or MVr surgery in the period between 2001 and 2019, from 20 international centers, were collected in the CAUTION study database. In-hospital, and long-term post-discharge mortality were the end-points. Multivariable logistic regression model was used to determine mortality independent factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patient cohort available included 218 patients. MVR was the most frequent type of surgery (81.6%). Complete PMR was more common in MVR group (71.9%, p&#x2009;=&#x2009;0.008), while partial PMR was more frequent in MVr patients (75%, p&#x2009;=&#x2009;0.008). In-hospital mortality rate was 25.8% in MVR subgroup and 20% in MVr subjects (p&#x2009;=&#x2009;0.440). In MVR subgroup, concomitant CABG was associated with lower in-hospital mortality (n&#x2009;=&#x2009;20/96, 21%) than no concomitant CABG (31.7%, p&#x2009;=&#x2009;0.035). Survival at 1,3,5 and 10 years was 59.3%, 55.9%,53.1%,46.9% in MVR group and 59.9%,56.8%,54.1% and 43.2% in MVr patients, respectively, with no statistical differences (p&#x2009;=&#x2009;0.474). Patients underwent MVr surgery 1,3,5 and 10 years survival was 79.8%, 75.4%, 68.5% and 37.5% when CABG revascularization is performed, while no CABG survival was 16.7%, 16.7%, 8.3% and 8.3% (p&#x2009;&lt;&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MVR is the mostly performed in complete post-AMI PMR and MVr in partial PMR. No differences were observed regarding in-hospital and long-term mortality in the two surgical groups, and no independent factors were associated with overall mortality. Concomitant CABG was associated to higher in-hospital survival.</AbstractText><AbstractText Label="CLINICAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">Clinicaltrials.gov, NCT03848429.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Massimi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Department, Santa Maria Hospital, Terni, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matteucci</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Surgery Unit ASST Sette Laghi Circolo Hospital, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Bonis</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, San Raffaele University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalewski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formica</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Cardiac Surgery Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Medicine Department, University of Salento, Lecce, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Claudio Francesco</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sponga</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic Department, University Hospital of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vendramin</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiothoracic Department, University Hospital of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiac Surgery, University Hospital, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcetta</LastName><ForeName>Giosu&#xe8;</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Section of Cardiac Surgery, University Hospital, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trumello</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, San Raffaele University Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrozzini</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischlein</LastName><ForeName>Theodor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Paracelsus Medical University, Cardiovascular Center, Germany, Klinikum N&#xfc;rnberg, Nuremberg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troise</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Poliambulanza Foundation Hospital, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dato</LastName><ForeName>Guglielmo Actis</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Department, Mauriziano Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Alessandro</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, Cardiac Surgery Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nia</LastName><ForeName>Peyman Sardari</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lodo</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Department, Mauriziano Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Poliambulanza Foundation Hospital, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Shabir Hussain</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Cardiovascular and Thoracic Surgery Department, King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scrofani</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Policlinico Milano Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binaco</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Policlinico Milano Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalisnik</LastName><ForeName>Jurij Matija</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Paracelsus Medical University, Cardiovascular Center, Germany, Klinikum N&#xfc;rnberg, Nuremberg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dell'Uomo</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Department, Santa Maria Hospital, Terni, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettinari</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Ziekenhuis Oost-Limburg, Genk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thielmann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, West-German Heart Center, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyns</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khouqeer</LastName><ForeName>Fareed A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fino</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musazzi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiac Surgery Unit ASST Sette Laghi Circolo Hospital, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalowka</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deja</LastName><ForeName>Marek A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisani</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Santa Maria della Misericordia Hospital, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batko</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Thoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAROL-Cardiothoracic Anatomy Research Operative Lab, Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borghetti</LastName><ForeName>Valentino</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiothoracic and Vascular Department, Santa Maria Hospital, Terni, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronco</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, Niguarda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Mauro</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03848429</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">mitral valve</Keyword><Keyword MajorTopicYN="N">mitral valve repair</Keyword><Keyword MajorTopicYN="N">mitral valve replacement</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">papillary muscle rupture</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>14</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845148</ArticleId><ArticleId IdType="doi">10.1093/ejcts/ezaf284</ArticleId><ArticleId IdType="pii">8239958</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40845727</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1484</ISSN><JournalIssue CitedMedium="Internet"><Volume>409</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Atherosclerosis</Title><ISOAbbreviation>Atherosclerosis</ISOAbbreviation></Journal><ArticleTitle>Antiplatelet therapy with clopidogrel versus aspirin in atherosclerotic cardiovascular disease: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>120478</StartPage><MedlinePgn>120478</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.atherosclerosis.2025.120478</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9150(25)01376-0</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Whether single antiplatelet therapy (SAPT) with clopidogrel offers superior ischemic efficacy and a more favourable bleeding profile than aspirin in atherosclerotic cardiovascular disease is unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search on the main databases Medline, Web of Science, and Embase until April 21, 2024 was performed. Only randomized trials were eligible for this analysis. As primary endpoint we analyzed major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction (MI) and non-fatal stroke. As secondary endpoints we investigated the individual primary endpoints as well as the rate of total and severe bleeding events. The analysis was carried out using the odds ratio (OR) as outcome measure. Due to the expected heterogeneity across studies, a random-effects model was fitted to the data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 6 randomized trials comprising 33,508 patients (16,824 on clopidogrel, 16,684 on aspirin) were analyzed. Clopidogrel as compared to aspirin significantly reduced MACE (OR 0.85 [95 %CI 0.77-0.94], p&#xa0;&lt;&#xa0;0.001, I<sup>2</sup>&#xa0;=&#xa0;26&#xa0;%). The reduction was driven by a decrease in non-fatal MI (OR 0.73 [95 %CI 0.60-0.90], p&#xa0;=&#xa0;0.01, I<sup>2</sup>&#xa0;=&#xa0;28&#xa0;%) and stroke (OR 0.86 [95 %CI 0.74-1.00], p&#xa0;=&#xa0;0.05, I<sup>2</sup>&#xa0;=&#xa0;8&#xa0;%), without increasing the rates of total (OR 1.04 [95 %CI 0.83-1.31], p&#xa0;=&#xa0;0.73, I<sup>2</sup>&#xa0;=&#xa0;72&#xa0;%) or severe bleeding (OR 0.89 [95 %CI 0.83-1.18], p&#xa0;=&#xa0;0.43, I<sup>2</sup>&#xa0;=&#xa0;50&#xa0;%). No effect on all-cause mortality was detectable (OR 0.96 [95 %CI 0.87-1.06], p&#xa0;=&#xa0;0.41, I<sup>2</sup>&#xa0;=&#xa0;0&#xa0;%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In patients with atherosclerotic cardiovascular disease, SAPT with clopidogrel is associated with lower MACE rates as compared to aspirin without increasing the risk of bleeding.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tscharre</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cardiology and Nephrology, Landesklinikum Wiener Neustadt, Austria; Institute of Vascular Medicine and Cardiac Electrophysiology, Karl Landsteiner Society, St. P&#xf6;lten, Austria; Department of Medicine, Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutschlechner</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology and Intensive Care Medicine, Landesklinikum Mistelbach-G&#xe4;nserndorf, Mistelbach, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sigmund Freud University, Medical School, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gremmel</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology and Intensive Care Medicine, Landesklinikum Mistelbach-G&#xe4;nserndorf, Mistelbach, Austria; Institute of Cardiovascular Pharmacotherapy and Interventional Cardiology, Karl Landsteiner Society, St. P&#xf6;lten, Austria; Karl Landsteiner University of Health Sciences, Krems, Austria. Electronic address: thomas.gremmel@mistelbach.lknoe.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Atherosclerosis</MedlineTA><NlmUniqueID>0242543</NlmUniqueID><ISSNLinking>0021-9150</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aspirin</Keyword><Keyword MajorTopicYN="N">Atherosclerotic cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Clopidogrel</Keyword><Keyword MajorTopicYN="N">Monotherapy</Keyword><Keyword MajorTopicYN="N">Secondary prevention</Keyword><Keyword MajorTopicYN="N">Single antiplatelet therapy</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Thomas Gremmel reports a relationship with AstraZeneca, Amgen, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Novartis, and Pfizer that includes: consulting or advisory and speaking and lecture fees. Thomas Gremmel reports a relationship with Boehringer-Ingelheim, Bristol Myers Squibb, Medtronic and Abbott that includes: funding grants. Kurt Huber reports a relationship with AstraZeneca, Bayer, and Daiichi Sankyo that includes: consulting or advisory and speaking and lecture fees. For the other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>18</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40845727</ArticleId><ArticleId IdType="doi">10.1016/j.atherosclerosis.2025.120478</ArticleId><ArticleId IdType="pii">S0021-9150(25)01376-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846126</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Reply to improving reproducibility and pathophysiological understanding in strain imaging: Reflections on Takotsubo versus STEMI.</ArticleTitle><Pagination><StartPage>133780</StartPage><MedlinePgn>133780</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2025.133780</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(25)00823-X</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poller</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sahlgrenska University Hospital/S, Gothenburg, Sweden; Department of Clinical Physiology, Sahlgrenska University Hospital/S, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg. Electronic address: angela.poller@vgregion.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bech-Hanssen</LastName><ForeName>Odd</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Physiology, Sahlgrenska University Hospital/S, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redfors</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sahlgrenska University Hospital/S, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg; Clinical Trial Centre, Cardiovascular Research Foundation, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">Echocardiography</Keyword><Keyword MajorTopicYN="N">Global strain</Keyword><Keyword MajorTopicYN="N">ST-elevation myocardial infarction</Keyword><Keyword MajorTopicYN="N">Takotsubo syndrome</Keyword></KeywordList><CoiStatement>Declaration of competing interest None to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846126</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2025.133780</ArticleId><ArticleId IdType="pii">S0167-5273(25)00823-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40841605</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2261</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC cardiovascular disorders</Title><ISOAbbreviation>BMC Cardiovasc Disord</ISOAbbreviation></Journal><ArticleTitle>Long-term risk of stroke after acute coronary syndrome: the ABC-10* study on heart disease.</ArticleTitle><Pagination><StartPage>623</StartPage><MedlinePgn>623</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">623</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12872-025-05040-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies link myocardial infarction to increased stroke risk. This long-term prospective study examines stroke incidence and stroke-related mortality in acute coronary syndrome (ACS) patients, identifying risk factors and geographic disparities.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled 535 ACS patients admitted to hospitals across three provinces in the Veneto region of Italy. Patients' residences were classified into three urban and three rural areas in each province. Patients were followed prospectively for 24 years or until death. Survival analysis was conducted using uni- and Multivariable Cox regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients, except for three, completed the follow-up, totaling 6.151 person-years. During follow-up, 84 patients experienced a stroke, with 85% being ischemic and 15% hemorrhagic, proving fatal in 43 cases. The stroke incidence rate was 14/1.000 person-years. Older age (HR 1.84; 95% CI 1.30-2.60), atrial fibrillation (AF) (HR 2.64; 95% CI 1.49-4.67), and a higher albumin-to-creatinine ratio (ACR) tertile (HR 1.38; 95% CI 1.04-1.83) were independent predictors of overall stroke risk, while higher estimated glomerular filtration rate tertile (eGFR) (HR 0.71; 95% CI 0.53-0.95) was independent predictor a lower risk. A sub-analysis revealed older age (HR 2.67; 95% CI 1.60-4.45) and AF (HR 2.95; 95% CI 1.38-6.32) as independent predictors of fatal stroke. Unexpectedly, we observed a higher fatal stroke risk in urban areas (HR 1.89; 95% CI 1.03-3.48) and southern provinces (HR 1.71; 95% CI 1.15-2.53).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This long-term cohort study reinforces the role of established clinical predictors (age, AF, renal function) in post-ACS stroke risk and highlights novel geographic disparities in fatal stroke outcomes. These findings support the integration of geographic and clinical risk stratification in long-term secondary prevention strategies.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahmoud</LastName><ForeName>Heba T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>The ABC Study on Heart Disease Foundation-ONLUS, Conegliano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Minia University, Minia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordiano</LastName><ForeName>Rocco</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Adria General Hospital, Adria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merotto</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The ABC Study on Heart Disease Foundation-ONLUS, Conegliano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dario</LastName><ForeName>Mattia Ludovico</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>The ABC Study on Heart Disease Foundation-ONLUS, Conegliano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavuto</LastName><ForeName>Fiorella</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The ABC Study on Heart Disease Foundation-ONLUS, Conegliano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berton</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The ABC Study on Heart Disease Foundation-ONLUS, Conegliano, Italy. giubeste@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Act no. 748, Venice, May 14, 2015, grant number 2987929</GrantID><Agency>Grant from the Veneto Region in Italy</Agency><Country/></Grant><Grant><GrantID>Act no. 748, Venice, May 14, 2015, grant number 2987929</GrantID><Agency>Grant from the Veneto Region in Italy</Agency><Country/></Grant><Grant><GrantID>Act no. 748, Venice, May 14, 2015, grant number 2987929</GrantID><Agency>Grant from the Veneto Region in Italy</Agency><Country/></Grant><Grant><GrantID>Act no. 748, Venice, May 14, 2015, grant number 2987929</GrantID><Agency>Grant from the Veneto Region in Italy</Agency><Country/></Grant><Grant><GrantID>Act no. 748, Venice, May 14, 2015, grant number 2987929</GrantID><Agency>Grant from the Veneto Region in Italy</Agency><Country/></Grant><Grant><GrantID>Act no. 748, Venice, May 14, 2015, grant number 2987929</GrantID><Agency>Grant from the Veneto Region in Italy</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cardiovasc Disord</MedlineTA><NlmUniqueID>100968539</NlmUniqueID><ISSNLinking>1471-2261</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054058" MajorTopicYN="Y">Acute Coronary Syndrome</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014504" MajorTopicYN="N">Urban Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012423" MajorTopicYN="N">Rural Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000083302" MajorTopicYN="Y">Hemorrhagic Stroke</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054624" MajorTopicYN="N">Health Status Disparities</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">Fatal stroke</Keyword><Keyword MajorTopicYN="N">Follow-up studies</Keyword><Keyword MajorTopicYN="N">Geographic difference</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword><Keyword MajorTopicYN="N">Urban-rural</Keyword></KeywordList><CoiStatement>Declarations. Ethical approval: The study protocol adhered to the Declaration of Helsinki and received approval from the ethics committee of Adria, Bassano, Conegliano hospitals. Consent for publication: Not applicable. Informed consent: Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>16</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841605</ArticleId><ArticleId IdType="doi">10.1186/s12872-025-05040-9</ArticleId><ArticleId IdType="pii">10.1186/s12872-025-05040-9</ArticleId><ArticleId IdType="pmc">PMC12369170</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Organization WH. Global health estimates 2020: deaths by cause, age, sex, by country and by region, 2000&#x2013;2019. In. Switzerland: WHO Geneva; 2020.</Citation></Reference><Reference><Citation>Ferreira JP, Girerd N, Gregson J, Latar I, Sharma A, Pfeffer MA, McMurray JJ, Abdul-Rahim AH, Pitt B, Dickstein K. Stroke risk in patients with reduced ejection fraction after myocardial infarction without atrial fibrillation. J Am Coll Cardiol. 2018;71(7):727&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">29447733</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt BJ, Ballman KV, Brown RD Jr., Meverden RA, Jacobsen SJ, Roger VL. The incidence of stroke after myocardial infarction: a meta-analysis. Am J Med. 2006;119(4):e354351&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">16564779</ArticleId></ArticleIdList></Reference><Reference><Citation>Budaj A, Flasinska K, Gore JM, Anderson FA Jr., Dabbous OH, Spencer FA, Goldberg RJ, Fox KA, Investigators G. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a global registry of acute coronary events. Circulation. 2005;111(24):3242&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956123</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin L, Mehta SR, Zhao F, Pogue J, Budaj A, Hunt D, Yusuf S. Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome: a study involving&#x2009;&gt;&#x2009;18 000 patients. Circulation. 2001;104(3):269&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11457743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurskainen M, Tynkkynen J, Eskola M, Hernesniemi J. Incidence of stroke and mortality due to stroke after acute coronary syndrome. J Stroke Cerebrovasc Dis. 2022;31(12):106842. 10.1016/j.jstrokecerebrovasdis.2022.106842. Epub 2022 Oct 26. PMID: 36309003.</Citation><ArticleIdList><ArticleId IdType="pubmed">36309003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternak RC, Braunwald E, Sobel BE. Acute myocardial infarction. In: <i>Heart Disease: A Textbook of Cardiovascular Medicine</i> 5th edn. Edited by Braunwald E. Philadelphia: WB Saunders; 1997: 1198&#x2013;&#x2009;1191 1207.</Citation></Reference><Reference><Citation>Berton G, Mahmoud HT, Palmieri R, Cavuto F, Cordiano R, Lorenzon E, Bagato F. Risk of malignancy long after acute coronary syndrome in selected urban and rural areas and comparison with smoking risk: the ABC-7* study on Heart Disease. <i>Cardio-oncology</i> 2021, 7(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7903679</ArticleId><ArticleId IdType="pubmed">33627190</ArticleId></ArticleIdList></Reference><Reference><Citation>Regione del Veneto. Italy&#x2013; Rural Development Programme (Regional): Veneto 2014&#x2013;2020. Capitolo 8; 289:306. Available at: https://sharing.regione.veneto.it/index.php/s/spp32HQLZcANrLm. Accessed June 2025.</Citation></Reference><Reference><Citation>Population, Family. http://statistica.regione.veneto.it/banche_dati_societa_popolazione.jsp</Citation></Reference><Reference><Citation>Berton G, Cordiano R, Cavuto F, Giacomini G, De Toni R, Palatini P. Predictors of ten-year event-free survival in patients with acute myocardial infarction (from the adria, bassano, conegliano, and Padova hospitals [ABC] study on myocardial infarction). Am J Cardiol. 2012;109(7):966&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">22221943</ArticleId></ArticleIdList></Reference><Reference><Citation>Berton G, Citro T, Palmieri R, Petucco S, De Toni R, Palatini P. Albumin excretion rate increases during acute myocardial infarction and strongly predicts early mortality. Circulation. 1997;96(10):3338&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9396425</ArticleId></ArticleIdList></Reference><Reference><Citation>Berton G, Cordiano R, Palmieri R, De Toni R, Guarnieri GL, Palatini P. Albumin excretion in diabetic patients in the setting of acute myocardial infarction: association with 3-year mortality. Diabetologia. 2004;47(9):1511&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322753</ArticleId></ArticleIdList></Reference><Reference><Citation>Farooq MU, Chaudhry AH, Amin K, Majid A. The WHO STEPwise approach to stroke surveillance. J Coll Physicians Surg Pak. 2008;18(10):665.</Citation><ArticleIdList><ArticleId IdType="pubmed">18940134</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741409</ArticleId><ArticleId IdType="pubmed">26858290</ArticleId></ArticleIdList></Reference><Reference><Citation>Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, Abbasifard M, Abbasi-Kangevari M, Abd-Allah F, Abedi V. Global, regional, and National burden of stroke and its risk factors, 1990&#x2013;2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2021;20(10):795&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443449</ArticleId><ArticleId IdType="pubmed">34487721</ArticleId></ArticleIdList></Reference><Reference><Citation>Budaj A, Flasinska K, Gore JM, Anderson FA Jr, Dabbous OH, Spencer FA, Goldberg RJ, Fox KA. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a global registry of acute coronary events. Circulation. 2005;111(24):3242&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956123</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha MJ, Lee H, Kim Y, Nam H, Heo J. The association between asymptomatic coronary artery disease and CHADS 2 and CHA 2 DS 2-VAS c scores in patients with stroke. Eur J Neurol. 2013;20(9):1256&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23560528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30(9):1038&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">19109347</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C-H, Hung W-T, Huang W-C, Jheng Y-C, Lai W-Y, Lin Y-Y, Lin T-W, Lin K-C, Cheng C-C, Kuo F-Y. The risk of stroke after acute myocardial infarction in patients with and without atrial fibrillation: A nationwide cohort study. J Chin Med Assoc. 2021;84(12):1126&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">34898532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang CN, Gislason GH, Greve AM, Bang CA, Lilja A, Torp-Pedersen C, Andersen PK, K&#xf8;ber L, Devereux RB, Wachtell K. New&#x2010;Onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89 703 patients with Long&#x2010;Term Follow&#x2010;Up: A nationwide study. J Am Heart Assoc. 2014;3(1):e000382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959680</ArticleId><ArticleId IdType="pubmed">24449803</ArticleId></ArticleIdList></Reference><Reference><Citation>Mace-Brickman T, Eddeen AB, Carrero J-J, Mark PB, Molnar AO, Lam NN, Zimmerman D, Harel Z, Sood MM. The risk of stroke and stroke type in patients with atrial fibrillation and chronic kidney disease. Can J Kidney Health Dis. 2019;6:2054358119892372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893926</ArticleId><ArticleId IdType="pubmed">31839975</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Saver JL, Chang K-H, Liao H-W, Chang S-C, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ. 2010;341:c4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948650</ArticleId><ArticleId IdType="pubmed">20884696</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam study. Stroke. 2007;38(12):3127&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">17962600</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y. Heart disease and stroke statistics&#x2014;2022 update: a report from the American heart association. Circulation. 2022;145(8):e153&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">35078371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J-C. Geographic determinants of stroke mortality: role of ambient air pollution. In., vol. 41: Am Heart Assoc; 2010: 839&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879336</ArticleId><ArticleId IdType="pubmed">20339123</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard G. Rural-urban differences in stroke risk. Prev Med. 2021;152:106661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8545748</ArticleId><ArticleId IdType="pubmed">34087323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846605</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8422</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>J Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>Association Between COVID-19 Infection and Postoperative Outcomes Following Coronary Artery Bypass Grafting: A Retrospective Cohort Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1053-0770(25)00612-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.jvca.2025.07.022</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the association between preoperative Coronavirus disease 2019 (COVID-19) infection and complications in patients undergoing coronary artery bypass grafting (CABG), focusing on the timing of infection.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A retrospective cohort study using the National Covid Cohort Collaborative (N3C) database SETTING: Multi-institutional data from the National COVID Cohort Collaborative, representing diverse US healthcare settings PARTICIPANTS: Adult patients undergoing CABG during the COVID-19 pandemic, identified through CPT codes. COVID-19 infection timing was stratified into 3 groups: 0 to 2 weeks, 2 to 6 weeks, and 6 to 12 weeks before surgery. Outcomes were analyzed based on the timing of COVID-19 infection and compared to patients without a history of COVID-19.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">No direct interventions were performed. Outcomes were analyzed based on the timing of COVID-19 infection.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Postoperative complications were assessed using International Classification of Disease, Tenth Revision codes, including venous thromboembolism (VTE), sepsis, acute kidney injury, surgical site infection, acute myocardial infarction (AMI), 30-day mortality, and 1-year mortality. For COVID-19 infection occurring within 0 to 2 weeks before surgery, significantly increased odds were observed for VTE (odds ratio [OR], 2.29; 95% confidence interval [CI], 1.36-3.59]; p = 0.001), sepsis (OR, 1.74; 95% CI, 1.01-2.81; p = 0.032), 30-day mortality (OR, 3.60; 95% CI, 2.32-5.35; p &lt; 0.0001), and 1-year mortality (OR, 3.10; 95% CI, 2.24-4.21; p &lt; 0.0001), with no significant associations for surgical site infection (OR, .94; 95% CI, 0.48-1.64; p = 0.849), or AMI (OR, 1.21; 95% CI, 0.84-1.69; p = 0.274) compared to COVID-19-negative patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">COVID-19 infection within 2 weeks before CABG is associated with a significantly increased risk of complications. Further research is needed to understand the mechanisms and optimize care for these patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoang</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY. Electronic address: henry.hoang@mountsinai.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romanelli</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY. Electronic address: eromanel@montefiore.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borngaesser</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY. Electronic address: felix.borngaesser1@uni-oldenburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karaye</LastName><ForeName>Ibraheem M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY. Electronic address: ikaraye@montefiore.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derose</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tufail</LastName><ForeName>Bilal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY. Electronic address: btufail@montefiore.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogoy</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY. Electronic address: dnogoy@montefiore.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eikermann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leff</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY. Electronic address: JLEFF@montefiore.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C Consortium</CollectiveName><AffiliationInfo><Affiliation>Department of Anesthesiology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9110208</NlmUniqueID><ISSNLinking>1053-0770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CABG</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">complications</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">perioperative</Keyword><Keyword MajorTopicYN="N">postoperative</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>21</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846605</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2025.07.022</ArticleId><ArticleId IdType="pii">S1053-0770(25)00612-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846359</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>An Atypical Left Ventricular Pseudoaneurysm Managed Conservatively.</ArticleTitle><Pagination><StartPage>104664</StartPage><MedlinePgn>104664</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104664</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01444-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Left ventricle (LV) pseudoaneurysms pose a serious and life-threatening complication of myocardial infarction.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">We present a case of a thrombosed LV pseudoaneurysm with clot extension into the LV cavity in an asymptomatic 62-year-old man presenting with nonsecific symptoms. Multimodal imaging was undertaken to confirm the diagnosis. Owing to the chronicity of the pseudoaneurysm, the patient was managed conservatively.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This case illustrates an alternative management approach in a clinical scenario with a paucity of data and no clear guidelines.</AbstractText><AbstractText Label="TAKE-HOME MESSAGES" NlmCategory="CONCLUSIONS">Multimodal imaging is critical to distinguish LV pseudoaneurysms from true aneurysms, particularly in atypical locations, as accurate diagnosis directly affects management decisions. Although surgical repair remains the standard treatment for LV pseudoaneurysms, select chronic cases may be candidates for conservative management. Long-term follow-up data is needed to validate this approach.</AbstractText><CopyrightInformation>Crown Copyright &#xa9; 2025. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Travis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia. Electronic address: travis.chong@health.wa.gov.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Aswin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia; University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajwani</LastName><ForeName>Adil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Curtin University, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Best</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac magnetic resonance</Keyword><Keyword MajorTopicYN="N">cardiomypathy</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">imaging</Keyword><Keyword MajorTopicYN="N">reduced ejection fraction</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846359</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104664</ArticleId><ArticleId IdType="pii">S2666-0849(25)01444-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40846381</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JACC. Case reports</Title><ISOAbbreviation>JACC Case Rep</ISOAbbreviation></Journal><ArticleTitle>Arrhythmogenic Isolated Right Coronary Vasospasm.</ArticleTitle><Pagination><StartPage>104681</StartPage><MedlinePgn>104681</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccas.2025.104681</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0849(25)01461-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Coronary vasomotion disorders, although prevalent among patients with ischemia, remain poorly understood given limited use of invasive functional testing.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">Presented here is a case of isolated severe right-coronary-artery vasospasm with acetylcholine reactivity testing resulting in ventricular arrhythmias.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Determining the type of coronary vasomotion disorder is important for providing the appropriate treatment; therefore, performing invasive functional testing is critical. Although isolated right-coronary-artery vasospasm is rare, if vasospastic angina is of high suspicion, evaluating the right coronary artery is necessary.</AbstractText><AbstractText Label="TAKE-HOME MESSAGES" NlmCategory="CONCLUSIONS">Vasospastic angina can occur in any phase of coronary atherosclerotic disease and result in myocardial infarction or sudden cardiac death. Vasomotor disorders can involve variable regions and combinations of microvascular and epicardial coronary arteries. A comprehensive diagnosis of vasomotor disorders is only possible with reactivity testing, with isolation of both right and left coronary arteries when indicated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kendall</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilkens</LastName><ForeName>Blair</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solis</LastName><ForeName>Joaquin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kieu</LastName><ForeName>Andy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jan</LastName><ForeName>M Fuad</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddadian</LastName><ForeName>Babak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA. Electronic address: babak.haddadian@aah.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JACC Case Rep</MedlineTA><NlmUniqueID>101757292</NlmUniqueID><ISSNLinking>2666-0849</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Prinzmetal</Keyword><Keyword MajorTopicYN="N">acetylcholine</Keyword><Keyword MajorTopicYN="N">microvascular</Keyword><Keyword MajorTopicYN="N">nonobstructive coronary artery disease</Keyword><Keyword MajorTopicYN="N">vasospasm</Keyword><Keyword MajorTopicYN="N">vasospastic</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846381</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2025.104681</ArticleId><ArticleId IdType="pii">S2666-0849(25)01461-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40846582</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1444-2892</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Heart, lung &amp; circulation</Title><ISOAbbreviation>Heart Lung Circ</ISOAbbreviation></Journal><ArticleTitle>Subtle ECG, but Significant Angiographic Change: Aslanger's Pattern, a Newly Described STEMI - Equivalent.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1443-9506(25)00437-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hlc.2025.04.090</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barlow</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Orange Health Service, Orange, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Harry C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Orange Health Service, Orange, NSW, Australia; Department of Cardiology, Concord Repatriation General Hospital, Concord, NSW, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. Electronic address: harry.lowe@health.nsw.gov.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Heart Lung Circ</MedlineTA><NlmUniqueID>100963739</NlmUniqueID><ISSNLinking>1443-9506</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECG</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Reperfusion</Keyword><Keyword MajorTopicYN="N">STEMI</Keyword></KeywordList><CoiStatement>Declaration of Competing Interests The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>21</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846582</ArticleId><ArticleId IdType="doi">10.1016/j.hlc.2025.04.090</ArticleId><ArticleId IdType="pii">S1443-9506(25)00437-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40847431</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2057-3804</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Cardio-oncology (London, England)</Title><ISOAbbreviation>Cardiooncology</ISOAbbreviation></Journal><ArticleTitle>Revolutionizing cardiac fibrosis treatment: the potential of personalized CAR T-cell therapy.</ArticleTitle><Pagination><StartPage>76</StartPage><MedlinePgn>76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40959-025-00367-w</ELocationID><Abstract><AbstractText>Cardiac fibrosis, a condition characterized by the deposition of excess collagen in the cardiac tissue, is a major complication of various cardiovascular diseases, including myocardial infarction, hypertension, and different types of cardiomyopathies. CAR T-cell therapy, a form of immunotherapy that involves the genetic modification of T cells to recognize and target specific antigens, has shown promise in the treatment of various cancers and autoimmune diseases. The rationale behind using CAR T-cell therapy to treat cardiac fibrosis lies in the fact that fibrosis is often driven by the activation of pro-fibrotic immune cells, such as myofibroblasts. By targeting these pro-fibrotic cells with CAR T-cells, it may be possible to reduce the severity of cardiac fibrosis. Enhancing CAR T-cell therapy through innovative nanoparticle delivery systems provides a comprehensive approach to treating cardiac fibrosis, with experimental evidence indicating potential in reducing fibrosis and improving cardiac function. Despite these benefits, significant challenges such as cardiotoxicity and cardiovascular complications remain. Therefore, this review explores the molecular mechanisms underlying cardiac fibrosis and the effects of CAR T-cell therapy on the heart, elucidating both its antifibrotic properties and associated cardiotoxic effects based on findings from recent studies.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taherkhani</LastName><ForeName>Soroush</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honardoost</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardio-oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. Honardoost.m@iums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dokhani</LastName><ForeName>Negar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardio-oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janzadeh</LastName><ForeName>Atousa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuromusculoskeletal Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiooncology</MedlineTA><NlmUniqueID>101689938</NlmUniqueID><ISSNLinking>2057-3804</ISSNLinking></MedlineJournalInfo><CoiStatement>Declarations. Ethical approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40847431</ArticleId><ArticleId IdType="doi">10.1186/s40959-025-00367-w</ArticleId><ArticleId IdType="pii">10.1186/s40959-025-00367-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71:549&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">23649149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinderer S, Schenke-Layland K. Cardiac fibrosis&#x2013;a short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019;146:77&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">31158407</ArticleId></ArticleIdList></Reference><Reference><Citation>Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circul Res. 2016;118(6):1021&#x2013;40.</Citation></Reference><Reference><Citation>Ma ZG, Yuan YP, Wu HM, Zhang X, Tang QZ. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018;14(12):1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">30416379</ArticleId><ArticleId IdType="pmc">6216032</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Translational Res. 2019;209:121&#x2013;37.</Citation></Reference><Reference><Citation>Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010;225(3):631&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20635395</ArticleId><ArticleId IdType="pmc">3098503</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangogiannis NG. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019;65:70&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">30056242</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama K, Imanaka-Yoshida K. The pathogenesis of cardiac fibrosis: a review of recent progress. Int J Mol Sci. 2022;23(5):2617.</Citation><ArticleIdList><ArticleId IdType="pubmed">35269759</ArticleId><ArticleId IdType="pmc">8910720</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Z, Guan J. Antifibrotic therapies to control cardiac fibrosis. Biomaterials Res. 2016;20(1):13.</Citation></Reference><Reference><Citation>Leask A. Getting to the heart of the matter: new insights into cardiac fibrosis. Circul Res. 2015;116(7):1269&#x2013;76.</Citation></Reference><Reference><Citation>Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol. 2018;68:490&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">29371055</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MN, Kiriazis H, Gao XM, Du XJ. Cardiac fibrosis and arrhythmogenesis. Compr Physiol. 2011;7(3):1009&#x2013;49.</Citation></Reference><Reference><Citation>Sohns C, Marrouche NF. Atrial fibrillation and cardiac fibrosis. Eur Heart J. 2020;41(10):1123&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">31713590</ArticleId></ArticleIdList></Reference><Reference><Citation>Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction&#x2014;from repair and remodeling to regeneration. Cell Tissue Res. 2016;365:563&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">27324127</ArticleId><ArticleId IdType="pmc">5010608</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Epstein JA. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573(7774):430&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">31511695</ArticleId><ArticleId IdType="pmc">6752964</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnozzi RJ, Johansen AK, Molkentin JD. CARdiac immunotherapy: T cells engineered to treat the fibrotic heart. Mol Therapy. 2019;27(11):1869&#x2013;71.</Citation></Reference><Reference><Citation>Vagnozzi RJ, McKinsey TA. T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR. Cell Stem Cell. 2022;29(3):352&#x2013;4.</Citation></Reference><Reference><Citation>Liu M, de Juan Abad BL, Cheng K. Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies. Adv Drug Deliv Rev. 2021;173:504&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">33831476</ArticleId><ArticleId IdType="pmc">8299409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikane S, Arioka M, Takahashi-Yanaga F. Promising small molecule anti-fibrotic agents: newly developed or repositioned drugs targeting myofibroblast transdifferentiation. Biochem Pharmacol. 2023;214:115663.</Citation></Reference><Reference><Citation>Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019;20(1):205.</Citation></Reference><Reference><Citation>Liuzzo G, Patrono C. In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure. 2002</Citation></Reference><Reference><Citation>Zhang Q, Dai J, Liu T, Rao W, Li D, Gu Z, Hou X. Targeting cardiac fibrosis with chimeric antigen Receptor-Engineered cells. Mol Cell Biochem. 2024;1&#x2013;14.</Citation></Reference><Reference><Citation>Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573(7774):430&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">31511695</ArticleId><ArticleId IdType="pmc">6752964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer-Curriu G, Soler-Botija C, Charvatova S, Motais B, Roura S, Galvez-Monton C, Mongui&#xf3;-Tortajada M, Iborra-Egea O, Emdin M, Lup&#xf3;n J, Aimo A. Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy. Biomed Pharmacother. 2023;158:114061.</Citation><ArticleIdList><ArticleId IdType="pubmed">36495661</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Sosinowski T, Cox AR, Cepeda JR, Sekhar NS, Hartig SM, Miao D, Yu L, Pietropaolo M, Davidson HW. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II: peptide complex modulate the progression of autoimmune diabetes. J Autoimmun. 2019;96:50&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30122420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi V, Maleki AJ, Nazari M, Siahmansouri A, Moradi A, Elahi R, Esmaeilzadeh A. Chimeric antigen receptor (CAR)-based cell therapy for type 1 diabetes mellitus (T1DM); current progress and future approaches. Stem Cell Reviews Rep. 2024;20(3):585&#x2013;600.</Citation></Reference><Reference><Citation>Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xu H. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">39013470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao TA, Chen YY. T cells to fix a broken heart. Science. 2022;375(6576):23&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">34990255</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NP, Doukas PG, Gordon LI, Akhter N. Cardiovascular toxicities of CAR T-cell therapy. Curr Oncol Rep. 2021;23:1&#x2013;0.</Citation></Reference><Reference><Citation>Bertaud A, Joshkon A, Heim X, Bachelier R, Bardin N, Leroyer AS, Blot-Chabaud M. Signaling pathways and potential therapeutic strategies in cardiac fibrosis. Int J Mol Sci. 2023;24(2):1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">36675283</ArticleId><ArticleId IdType="pmc">9866199</ArticleId></ArticleIdList></Reference><Reference><Citation>Eijgenraam TR, Sillj&#xe9; HH, de Boer RA. Current Understanding of fibrosis in genetic cardiomyopathies. Trends Cardiovasc Med. 2020;30(6):353&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">31585768</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowling RT, Kupsky D, Kahn AM, Daniels LB, Greenberg BH. Mechanisms of cardiac collagen deposition in experimental models and human disease. Translational Res. 2019;209:138&#x2013;55.</Citation></Reference><Reference><Citation>Qin W, Cao L, Massey IY. Role of PI3K/Akt signaling pathway in cardiac fibrosis. Mol Cell Biochem. 2021;476(11):4045&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">34244974</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao H, Yang JJ, Shi KH, Li J. Wnt signaling pathway in cardiac fibrosis: new insights and directions. Metabolism. 2016;65(2):30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">26773927</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumori A. Nuclear factor-&#x3ba;B is a prime candidate for the diagnosis and control of inflammatory cardiovascular disease. Eur Cardiol Rev. 2023;18:e40. Article e40 View in Scopus.</Citation></Reference><Reference><Citation>Yousefi F, Shabaninejad Z, Vakili S, Derakhshan M, Movahedpour A, Dabiri H, Hamblin MR. TGF-&#x3b2; and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus. Cell Communication Signal. 2020;18:1&#x2013;16.</Citation></Reference><Reference><Citation>Delaunay M, Osman H, Kaiser S, Diviani D. The role of Cyclic AMP signaling in cardiac fibrosis. Cells. 2019;9(1):69.</Citation><ArticleIdList><ArticleId IdType="pubmed">31888098</ArticleId><ArticleId IdType="pmc">7016856</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguado-Alvaro LP, Garitano N, Pelacho B. Fibroblast diversity and epigenetic regulation in cardiac fibrosis. Int J Mol Sci. 2024;25(11):6004.</Citation><ArticleIdList><ArticleId IdType="pubmed">38892192</ArticleId><ArticleId IdType="pmc">11172550</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Wang LY, Liu ZQ, Jiang D, Wu SY, Guo YQ, Zhang DY. TNAP Inhibition attenuates cardiac fibrosis induced by myocardial infarction through deactivating TGF-&#x3b2;1/Smads and activating P53 signaling pathways. Cell Death Dis. 2020;11(1):44.</Citation><ArticleIdList><ArticleId IdType="pubmed">31969558</ArticleId><ArticleId IdType="pmc">6976710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna A, Humeres C, Frangogiannis NG. The role of Smad signaling cascades in cardiac fibrosis. Cell Signal. 2021;77:109826.</Citation><ArticleIdList><ArticleId IdType="pubmed">33160018</ArticleId></ArticleIdList></Reference><Reference><Citation>Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H. Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on TGF-&#x3b2; signaling. Front Cardiovasc Med. 2020;7:34.</Citation><ArticleIdList><ArticleId IdType="pubmed">32211422</ArticleId><ArticleId IdType="pmc">7075814</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhu H, Su Z, Sun C, Yin J, Yuan H, Xu H. IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKC&#x3b2;/Erk1/2/NF-&#x3ba;B-dependent signaling pathway. Int Immunol. 2012;24(10):605&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">22531062</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabani M, Dutta D, Ambale-Venkatesh B, Post WS, Taylor KD, Rich SS, Lima JA. Rare genetic variants associated with myocardial fibrosis: multi-ethnic study of atherosclerosis. Front Cardiovasc Med. 2022;9:804788.</Citation><ArticleIdList><ArticleId IdType="pubmed">35265679</ArticleId><ArticleId IdType="pmc">8899004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sygitowicz G, Maciejak-Jastrz&#x119;bska A, Sitkiewicz D. A review of the molecular mechanisms underlying cardiac fibrosis and atrial fibrillation. J Clin Med. 2021;10(19):4430.</Citation><ArticleIdList><ArticleId IdType="pubmed">34640448</ArticleId><ArticleId IdType="pmc">8509789</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabani M, Wang M, Jenkins GD, Rotter JI, Rich SS, Batzler A, Pereira NL. Myocardial fibrosis and cardiomyopathy risk: A genetic link in the MESA. Circulation: Heart Fail 2023;16(9):e010262.</Citation></Reference><Reference><Citation>Li X, Li L, Lei W, Chua HZ, Li Z, Huang X, Zhang H. Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms. Biomed Pharmacother. 2021;142:111979.</Citation></Reference><Reference><Citation>Skarp S, Doedens A, Holmstr&#xf6;m L, Izzi V, Saarim&#xe4;ki S, Sliz E, Junttila J. Novel genetic variants associated with primary myocardial fibrosis in sudden cardiac death victims. J Cardiovasc Transl Res. 2024;1&#x2013;11.</Citation></Reference><Reference><Citation>Nauffal V, Di Achille P, Klarqvist MD, Cunningham JW, Hill MC, Pirruccello JP, Lubitz SA. Genetics of myocardial interstitial fibrosis in the human heart and association with disease. Nat Genet. 2023;55(5):777&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">37081215</ArticleId><ArticleId IdType="pmc">11107861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Translational Res. 2014;164(4):323&#x2013;35.</Citation></Reference><Reference><Citation>Lu L, Guo J, Hua Y, Huang K, Magaye R, Cornell J, Wang BH. Cardiac fibrosis in the ageing heart: contributors and mechanisms. Clin Exp Pharmacol Physiol. 2017;44:55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28316086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Weinheimer C, Courtois M, Kovacs A, Zhang CE, Cheng AM, Muslin AJ. The role of the Grb2&#x2013;p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Investig. 2003;111(6):833&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639989</ArticleId><ArticleId IdType="pmc">153766</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Wu Z, Yang K, Han Y, Chen Y, Zhao W, Jin W. BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway. Am J Physiol Heart Circ Physiol. 2019;316(1):H61&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30359076</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimaldi V, De Pascale MR, Zullo A, Soricelli A, Infante T, Mancini FP, Napoli C. Evidence of epigenetic tags in cardiac fibrosis. J Cardiol. 2017;69(2):401&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27863907</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Zhu S, Liu Q, Wei J, Jin Y, Wang X, Zhang L. Polystyrene microplastics cause cardiac fibrosis by activating Wnt/&#x3b2;-catenin signaling pathway and promoting cardiomyocyte apoptosis in rats. Environ Pollut. 2020;265:115025.</Citation><ArticleIdList><ArticleId IdType="pubmed">32806417</ArticleId></ArticleIdList></Reference><Reference><Citation>Improta-Caria AC, Rodrigues LF, Joaquim VHA, De Sousa RAL, Fernandes T, Oliveira EM. MicroRNAs regulating signaling pathways in cardiac fibrosis: potential role of the exercise training. Am J Physiol Heart Circ Physiol. 2024;326(3):H497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">38063810</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Zhang Y. Metformin attenuates cardiac fibrosis by inhibiting the TGF&#x3b2;1&#x2013;Smad3 signalling pathway. Cardiovascular Res. 2010;87(3):504&#x2013;13.</Citation></Reference><Reference><Citation>Zhao J, Chen Y, Chen Q, Hong T, Zhong Z, He J, Ni C. Curcumin ameliorates cardiac fibrosis by regulating macrophage-fibroblast crosstalk via IL18-P-SMAD2/3 signaling pathway Inhibition. Front Pharmacol. 2022;12:784041.</Citation><ArticleIdList><ArticleId IdType="pubmed">35115932</ArticleId><ArticleId IdType="pmc">8804383</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-&#x3b2;) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract. 2017;133:124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">28934669</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng X, Wang L, Wen X, Gao L, Li G, Chang G, et al. TNAP is a novel regulator of cardiac fibrosis after myocardial infarction by mediating TGF-&#x3b2;/Smads and ERK1/2 signaling pathways. EBioMedicine 2021;67.</Citation></Reference><Reference><Citation>Li R, Frangogiannis NG. Integrins in cardiac fibrosis. J Mol Cell Cardiol. 2022;172:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">35872324</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X, Jiang YN, Wang WJ, Zhang J, Shang DS, Sun CB, Zhang Y. Comprehensive circrna expression profile and construction of circrna-related CeRNA network in cardiac fibrosis. Biomed Pharmacother. 2020;125:109944.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann C, M&#xfc;ller F, Distler JH, Gy&#xf6;rfi AH, V&#xf6;lkl S, Aigner M, Schett G. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82(8):1117&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">37147112</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalal PJ, Patel NP, Feinstein MJ, Akhter N. Adverse cardiac effects of car t-cell therapy: characteristics, surveillance, management, and future research directions. Technol Cancer Res Treat. 2022;21:15330338221132927.</Citation><ArticleIdList><ArticleId IdType="pubmed">36254553</ArticleId><ArticleId IdType="pmc">9580078</ArticleId></ArticleIdList></Reference><Reference><Citation>Amrute JM, Luo X, Penna V, Yang S, Yamawaki T, Hayat S, et al. Targeting immune&#x2013;fibroblast cell communication in heart failure. Nature 2024;1 -11.</Citation></Reference><Reference><Citation>Ananthakrishnan A. The potential of immunotherapy treatments to facilitate post-cardiac injury recovery. J High School Sci. 2022;6(4).</Citation></Reference><Reference><Citation>Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, et al. Cardiovascular toxicities of immune therapies for cancer&#x2013;a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2024.</Citation></Reference><Reference><Citation>Amrute JM, Luo X, Penna V, Bredemeyer A, Yamawaki T, Heo GS. Targeting the immune-fibrosis axis in myocardial infarction and heart failure. bioRxiv. 2022;2022-10.</Citation></Reference><Reference><Citation>Tillmanns J, Weiglein JM, Neuser J, Fraccarollo D, Galuppo P, K&#xf6;nig T, Diekmann J, Ross T, Bengel FM, Bauersachs J, Derlin T. Circulating soluble fibroblast activation protein (FAP) levels are independent of cardiac and extra-cardiac FAP expression determined by targeted molecular imaging in patients with myocardial FAP activation. Int J Cardiol. 2024;406:132044.</Citation><ArticleIdList><ArticleId IdType="pubmed">38614364</ArticleId></ArticleIdList></Reference><Reference><Citation>Korell, F., Entenmann, L., Romann, S., Giannitsis, E., Schmitt, A., M&#xfc;ller-Tidow,C., &#x2026; Lehmann, L. H. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. EClinicalMedicine, 69.</Citation></Reference><Reference><Citation>Spoladore R, Falasconi G, Fiore G, Di Maio S, Preda A, Slavich M, Fragasso G. Cardiac fibrosis: emerging agents in preclinical and clinical development. Expert Opin Investig Drugs. 2021;30(2):153&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">33356660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JY, Wang L. CAR-T cell therapy: where are we now, and where are we heading? Blood Sci. 2023;5(04):237&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">37941917</ArticleId><ArticleId IdType="pmc">10629745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg IE, Galindo-Feria AS, Horuluoglu B. CD19-targeting CAR T-cell therapy for antisynthetase syndrome. JAMA. 2023;329(24):2130&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">37367988</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengel, F., Epstein, J. A., Gropler, R., Haberkorn, U., Kramann, R., Lavine, K.,&#x2026; Wu, H. Linking immune modulation to cardiac fibrosis. Nature Cardiovascular Research, 2024;3(4), 414&#x2013;419.</Citation></Reference><Reference><Citation>Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, Henderson JM, Ebert BL, Humphreys BD. Perivascular Gli1&#x2009;+&#x2009;progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 2015;16(1):51&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25465115</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24579088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule&#x2013;gated chimeric receptor. Science. 2015;350(6258):aab4077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26405231</ArticleId><ArticleId IdType="pmc">4721629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmievskaya E, Valiullina A, Ganeeva I, Petukhov A, Rizvanov A, Bulatov E. Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections. Biomedicines. 2021;9(1):59.</Citation><ArticleIdList><ArticleId IdType="pubmed">33435454</ArticleId><ArticleId IdType="pmc">7827151</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Xiao Y, Lyu J, Jing D, Liu L, Fu Y, Zhang C. The expanded application of CAR-T cell therapy for the treatment of multiple non-tumoral diseases. Protein Cell. 2024;15(9):633&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">38146589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Dai J, Liu T, Rao W, Li D, Gu Z, Huang L, Wang J, Hou X. Targeting cardiac fibrosis with chimeric antigen Receptor-Engineered cells. Molecular and cellular biochemistry. Oct. 2024;26:1&#x2013;4.</Citation></Reference><Reference><Citation>Dai H, Zhu C, Huai Q, Xu W, Zhu J, Zhang X, Wang H. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J Hepatol. 2024;80(6):913&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">38340812</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15e;ahin A, Babayev H, G&#xfc;l M. FAP-targeted CAR T-cell therapy: A promising approach for the treatment of peyronie&#x2019;s disease. Med Hypotheses. 2023;178:111130.</Citation></Reference><Reference><Citation>Globerson Levin A, Rivi&#xe8;re I, Eshhar Z, Sadelain M. CAR T cells: Building on the CD19 paradigm. Eur J Immunol. 2021;51(9):2151&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">34196410</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S, Eom GH. Chimeric antigen receptor T cell therapy: a novel modality for immune modulation. Chonnam Med J. 2020;56(1):6&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32021836</ArticleId><ArticleId IdType="pmc">6976774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye B, Hu Y, Zhang M, Huang H. Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy. Zhejiang Da Xue Xue bao. Yi Xue ban&#x2009;=&#x2009;journal of Zhejiang university. Med Sci. 2022;51(2):185&#x2013;91.</Citation></Reference><Reference><Citation>Huang S, de Jong D, P Das J, S Widemon R, Braumuller B, Paily J, M Capaccione K. Imaging the side effects of CAR T cell therapy: a primer for the practicing radiologist. Acad Radiol. 2023;30(11):2712&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">37394411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun MY, Li W, Chen W. Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023. Hum Vaccines Immunotherapeutics. 2023;19(2):2251839.</Citation></Reference><Reference><Citation>Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.</Citation><ArticleIdList><ArticleId IdType="pubmed">37256141</ArticleId><ArticleId IdType="pmc">10225594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardin B, Epstein JA. Emerging mRNA therapies for cardiac fibrosis. Am J Physiology-Cell Physiol. 2024;326(1):C107&#x2013;11.</Citation></Reference><Reference><Citation>Massaro M, Wu S, Baudo G, Liu H, Collum S, Lee H, Blanco E. Lipid nanoparticle-mediated mRNA delivery in lung fibrosis. Eur J Pharm Sci. 2023;183:106370.</Citation><ArticleIdList><ArticleId IdType="pubmed">36642345</ArticleId><ArticleId IdType="pmc">10898324</ArticleId></ArticleIdList></Reference><Reference><Citation>Soroudi S, Jaafari MR, Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy. J Controlled Release. 2024;372:113&#x2013;40.</Citation></Reference><Reference><Citation>Evers, M. J., Du, W., Yang, Q., Kooijmans, S. A., Vink, A., van Steenbergen, M.,&#x2026; Schiffelers, R. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles. Journal of Controlled Release, 2022;343, 207&#x2013;216.</Citation></Reference><Reference><Citation>Wang QZ, Wang ZM, Huang ZY, Ge JB. Direct in vivo cardiac reprogramming with circular RNA of single transcription factor delivered by fibroblast-targeting lipid nanoparticles. Eur Heart J. 2024;45(Supplement1):ehae666&#x2013;3734.</Citation></Reference><Reference><Citation>Labonia MCI, Senti ME, van der Kraak PH, Brans MAD, Dokter I, Streef TJ, Vader P. Cardiac delivery of modified mRNA using lipid nanoparticles: cellular targets and biodistribution after intramyocardial administration. J Controlled Release. 2024;369:734&#x2013;45.</Citation></Reference><Reference><Citation>Cheng M, Yu X, Qi S, Yang K, Lu M, Cao F, Yu G. (2024). Development of organ targeting lipid nanoparticles with low immunogenicity and their application in the treatment of pulmonary fibrosis. Angew Chem, 136(44), e202407398.</Citation></Reference><Reference><Citation>Mainkar G, Yoo J, Zak MZ, Kurian AA, Adjmi M, Zangi L. Specific modified mRNA translation system (SMRTS) for the Attenuation of pulmonary fibrosis. A68. Unveiling novel avenues in ipf therapies. American Thoracic Society; 2024;A2468-A2468.</Citation></Reference><Reference><Citation>Zhu D, Liu S, Huang K, Li J, Mei X, Li Z, Cheng K. Intrapericardial long non-coding RNA&#x2013;Tcf21 antisense RNA inducing demethylation administration promotes cardiac repair. Eur Heart J. 2023;44(19):1748&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">36916305</ArticleId><ArticleId IdType="pmc">10411945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartneck M. Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis. Adv Drug Deliv Rev. 2021;173:70&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">33774114</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington J, Pachauri M, Ali H, Giacca M. RNA interference therapeutics for cardiac regeneration. Curr Opin Genet Dev. 2021;70:48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">34098251</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wu M, Guo H. Modified mRNA as a treatment for myocardial infarction. Int J Mol Sci. 2023;24(5):4737.</Citation><ArticleIdList><ArticleId IdType="pubmed">36902165</ArticleId><ArticleId IdType="pmc">10003380</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratton MS, McKinsey TA. Epigenetic regulation of cardiac fibrosis. J Mol Cell Cardiol. 2016;92:206&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">26876451</ArticleId><ArticleId IdType="pmc">4987078</ArticleId></ArticleIdList></Reference><Reference><Citation>Felisbino MB, McKinsey TA. Epigenetics in cardiac fibrosis: emphasis on inflammation and fibroblast activation. JACC: Basic Translational Sci. 2018;3(5):704&#x2013;15.</Citation></Reference><Reference><Citation>Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, Aguilar B, Qi Y, Ann DK, Starr R, Urak R. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">30890531</ArticleId><ArticleId IdType="pmc">6687561</ArticleId></ArticleIdList></Reference><Reference><Citation>Catino AB. Cytokines are at the heart of it: cytokine release syndrome underlies cardiovascular effects of CAR T cell. Cardio Oncol. 2020;2(2):204&#x2013;6.</Citation></Reference><Reference><Citation>Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep. 2018;20:1&#x2013;7.</Citation></Reference><Reference><Citation>Simbaqueba CC, Aponte MP, Kim P, Deswal A, Palaskas NL, Iliescu C, Lopez-Mattei J. Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias. J Immunotherapy Precision Oncol. 2020;3(3):113&#x2013;20.</Citation></Reference><Reference><Citation>Dal&#x2019;bo N, Patel R, Parikh R, Shah SP, Guha A, Dani SS, Ganatra S. Cardiotoxicity of contemporary anticancer immunotherapy. Curr Treat Options Cardiovasc Med. 2020;22:1&#x2013;15.</Citation></Reference><Reference><Citation>Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A. Cardiotoxicity of T-cell antineoplastic therapies: JACC: cardiooncology primer. Cardio Oncol. 2022;4(5):616&#x2013;23.</Citation></Reference><Reference><Citation>Yamauchi-Takihara K. gp130-mediated pathway and heart failure. Future Cardiol. 2008;4(4):427&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19804322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregolin CS, do Nascimento M, de Souza SL, Mota GA, Bomfim GF, Luvizotto RD, Sugizaki MM, Bazan SG, de Campos DH, Dias MC, Correa CR. Myocardial dysfunction in cirrhotic cardiomyopathy is associated with alterations of phospholamban phosphorylation and IL-6 levels. Arch Med Res. 2021;52(3):284&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">33220932</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal A, Farooque U, Gillies E, Hassell L. T-cell therapy-mediated myocarditis secondary to cytokine release syndrome. Cureus, 2020;12(8).</Citation></Reference><Reference><Citation>Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity associated with anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy: recognition, risk factors, and management. Diseases. 2021;9(1):20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33802788</ArticleId><ArticleId IdType="pmc">8006027</ArticleId></ArticleIdList></Reference><Reference><Citation>Maleki S, Esmaeili Z, Seighali N, Shafiee A, Namin SM, Zavareh MAT, Hosseini K. Cardiac adverse events after chimeric antigen receptor (CAR) T cell therapies: an updated systematic review and meta-analysis. Cardio-Oncology. 2024;10(1):52.</Citation><ArticleIdList><ArticleId IdType="pubmed">39164789</ArticleId><ArticleId IdType="pmc">11334556</ArticleId></ArticleIdList></Reference><Reference><Citation>Tvedt THA, Vo AK, Bruserud &#xd8;, Reikvam H. Cytokine release syndrome in the immunotherapy of hematological malignancies: the biology behind and possible clinical consequences. J Clin Med. 2021;10(21):5190.</Citation><ArticleIdList><ArticleId IdType="pubmed">34768710</ArticleId><ArticleId IdType="pmc">8585070</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito, R., Fedele, T., Orefice, S., Cuomo, V., Prastaro, M., Canonico, M. E.,&#x2026; Esposito, G. An emergent form of cardiotoxicity: acute myocarditis induced by immune checkpoint inhibitors. Biomolecules, 2021;11(6), 785.</Citation></Reference><Reference><Citation>Galani J, Gupta T, Waheed N, Sennhauser S, Abdou M. Cytokine release syndrome mediated myocarditis: a rare complication of chimeric antigen receptor T-cell therapy. J Card Fail. 2024;30(1):255.</Citation></Reference><Reference><Citation>Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns,B., &#x2026; Thavendiranathan, P. Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal, 2022;43, 4229&#x2013;4361.</Citation></Reference><Reference><Citation>Quagliariello, V., Paccone, A., Iovine, M., Cavalcanti, E., Berretta, M., Maurea,C., &#x2026; Maurea, N. Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19. European Review for Medical &amp; Pharmacological Sciences, 2021;25(21).</Citation></Reference><Reference><Citation>Haybar H, Shahrabi S, Zayeri ZD, Pezeshki S. Strategies to increase cardioprotection through cardioprotective chemokines in chemotherapy-induced cardiotoxicity. Int J Cardiol. 2018;269:276&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">30054148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of immune therapy. Cardiol Clin. 2019;37(4):385&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">31587780</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilli M, Viscovo M, Felici T, Maggio L, Ballacci F, Carella G, Minotti G. Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study. Cardio-Oncology. 2024;10(1):18.</Citation><ArticleIdList><ArticleId IdType="pubmed">38532515</ArticleId><ArticleId IdType="pmc">10967131</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein-Merlob AF, Rothberg MV, Ribas A, Yang EH. Cardiotoxicities of novel cancer immunotherapies. Heart. 2021;107(21):1694&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">33722826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C, Mousavi N, Park JH, Perales MA, Ryan TD. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC Council perspectives. J Am Coll Cardiol. 2019;74(25):3153&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">31856973</ArticleId><ArticleId IdType="pmc">8211027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels. J Clin Oncol. 2017;35:1803&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">28291388</ArticleId><ArticleId IdType="pmc">5455597</ArticleId></ArticleIdList></Reference><Reference><Citation>Totzeck M, Michel L, Lin Y, Herrmann J, Rassaf T. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022;43(20):1928&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">35257157</ArticleId><ArticleId IdType="pmc">9123242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazetto RA, Monteiro SO, Bulh&#xf5;es E, Defante ML, Antunes VL, Balieiro CC, Feitoza L, Ferreira AL, Carvalho AM, Guida C. The cardiotoxic effects of CAR-T cell therapy: an updated systematic review and meta&#x2010;analysis. Eur J Haematol. 2024;113(6):798&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">39171519</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NP, Dalal PJ, Meng Z, Baldridge AS, Cascino GJ, Sunderraj A, Sinha A, Karmali R, Feinstein MJ, Akhter N. Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy. Eur J Haematol. 2024;112(1):102&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">37649240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell therapy&#x2013;related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? Cardio Oncol. 2020;2(1):97&#x2013;109.</Citation></Reference><Reference><Citation>Patel NP, Doukas PG, Gordon LI, Akhter N. Cardiovascular toxicities of CAR T-cell therapy. Curr Oncol Rep. 2021;23:1&#x2013;10.</Citation></Reference><Reference><Citation>Lipe, D. N., Rajha, E., Wechsler, A. H., Gaeta, S., Palaskas, N. L., Alhajji, Z.,&#x2026; Chaftari, P. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. The American Journal of Emergency Medicine, 2021;50, 51&#x2013;58.</Citation></Reference><Reference><Citation>Hanna, K. S., Kaur, H., Alazzeh, M. S., Thandavaram, A., Channar, A., Purohit, A.,&#x2026; Mohammed, L. Cardiotoxicity associated with chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies: A systematic review. Cureus, 2022;14(8).</Citation></Reference><Reference><Citation>Koch, C., Montrasio, G., Scherr, B. F., Schimmer, R., Matter, C. M., B&#xfc;hler, K. P.,&#x2026; M&#xfc;ller, A. M. (2022). Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells. Cardio Oncology, 4(5), 708&#x2013;712.</Citation></Reference><Reference><Citation>Mazetto, R. A., Monteiro, S. O., Bulh&#xf5;es, E., Defante, M. L., Antunes, V. L., Balieiro,C. C. A., &#x2026; Guida, C. The cardiotoxic effects of CAR-T cell therapy: An updated systematic review and meta&#x2010;analysis. European Journal of Haematology.</Citation></Reference><Reference><Citation>Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular effects of CAR T cell therapy: a retrospective study. Cardio Oncol. 2020;2(2):193&#x2013;203.</Citation></Reference><Reference><Citation>Patel M, Hudson O, Han J, Kondapalli L, Arora G, Hawi R, Lenneman C. Update on immunotherapy cardiotoxicity: checkpoint inhibitors, CAR T, and beyond. Curr Treat Options Oncol. 2023;24(11):1489&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">37624557</ArticleId></ArticleIdList></Reference><Reference><Citation>Montisci A, Vietri MT, Palmieri V, Sala S, Donatelli F, Napoli C. Cardiac toxicity associated with cancer immunotherapy and biological drugs. Cancers. 2021;13(19):4797.</Citation><ArticleIdList><ArticleId IdType="pubmed">34638281</ArticleId><ArticleId IdType="pmc">8508330</ArticleId></ArticleIdList></Reference><Reference><Citation>Nenna A, Carpenito M, Chello C, Nappi P, Annibali O, Vincenzi B, Nappi F. Cardiotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy: pathophysiology,clinical implications, and echocardiographic assessment. Int J Mol Sci. 2022;23(15):8242.</Citation><ArticleIdList><ArticleId IdType="pubmed">35897819</ArticleId><ArticleId IdType="pmc">9368621</ArticleId></ArticleIdList></Reference><Reference><Citation>Maleki, S., Esmaeili, Z., Seighali, N., Shafiee, A., Namin, S. M., Zavareh, M. A.T., &#x2026; Hosseini, K. (2024). Cardiac adverse events after Chimeric Antigen Receptor(CAR) T cell therapies: an updated systematic review and meta-analysis. Cardio-Oncology,10(1), 52.</Citation></Reference><Reference><Citation>Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Reviews Cardiol. 2020;17(8):474&#x2013;502.</Citation></Reference><Reference><Citation>Karthikeyan B, Sunder SS, Puzanov I, Olejniczak SH, Pokharel S, Sharma UC. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers. Commun Med. 2024;4(1):116.</Citation><ArticleIdList><ArticleId IdType="pubmed">38871977</ArticleId><ArticleId IdType="pmc">11176393</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilli M, Maggio L, Tinti L, Lamendola P, Lanza GA, Crea F, Lombardo A. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. Front Cardiovasc Med. 2023;10:1090103.</Citation><ArticleIdList><ArticleId IdType="pubmed">36895831</ArticleId><ArticleId IdType="pmc">9988907</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari B, Ghahri-Saremi N, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Epigenetic strategies to boost CAR T cell therapy. Mol Ther. 2021;29(9):2640&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">34365035</ArticleId><ArticleId IdType="pmc">8417511</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40846933</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Examining the relationship between oral health indicators, obesity, and Xerostomia in older adults.</ArticleTitle><Pagination><StartPage>2901</StartPage><MedlinePgn>2901</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-025-23892-w</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVE" NlmCategory="OBJECTIVE">Obesity is becoming a hot topic for people and governments around the world, with many countries even considering it an epidemic. A group of researchers has made new findings about the link between obesity and oral health, making the issue even more sensitive than before. According to the findings, clear signs of periodontal disease are seen in people with a body mass index (BMI) above 30. Also, xerostomia is actually a subset of oral health that can significantly affect various aspects of oral health. Saliva plays an important role in maintaining oral health by keeping your mouth moist, cleaning your teeth, and fighting bacteria. Therefore, this study aimed to explore the association between obesity indicators, general oral health variables, and xerostomia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional study involved 439 adults aged 50 years or older. Data were collected using a structured questionnaire consisting of five sections: (I) demographic information, (II) oral health (issues such as loose teeth, tooth loss, use of dentures/implants, bleeding gums - self based on reported questionnaires and dental examination), (III) general health, (IV) overweight and/or obesity ( based on BMI- Height and weight measurement by a final year dental student), and (V) xerostomia (self-reported questionnaires). Statistical analysis was performed using the SPSS 24 software, with methods including T-test, Kruskal-Wallis, ANOVA, Chi-Square test, Pearson correlation coefficient, and logistic regression. A significance level of P&#x2009;&lt;&#x2009;0.05 was set for analyzing relationships.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 312 female and 127 male participants. The average age, body mass index (BMI kg/m<sup>2</sup>) and waist-to-height ratio (WHtR- cm/cm) of the group were 67.8&#x2009;&#xb1;&#x2009;11.5 years, 24.4&#x2009;&#xb1;&#x2009;2.1&#xa0;kg/m&#xb2;, and 0.54&#x2009;&#xb1;&#x2009;0.4, respectively. The mean of the xerostomia questionnaire XI was 33.21&#x2009;&#xb1;&#x2009;6.56. Regarding xerostomia (self-reported questionnaires), 21.8% of respondents reported mild symptoms, 11.4% moderate symptoms, and 6.4% severe symptoms. The prevalence of xerostomia was highest in the age group of 80 years or older. People with tooth mobility reported more xerostomia than patients without tooth mobility. 41.5% vs. 27.2% (P&#x2009;=&#x2009;0.01). Xerostomia was reported statistically significantly more frequently in patients with hypertension (P&#x2009;=&#x2009;0.01), diabetes (P&#x2009;=&#x2009;0.04), and myocardial infarction (P&#x2009;=&#x2009;0.01). Patients who reported good general health had significantly less xerostomia than patients with bad general health (P&#x2009;=&#x2009;0.04). In this study, BMI and WHtR had no significant relationship with xerostomia (P&#x2009;=&#x2009;0.61, 0.24, respectively). However, a statistically significant association was found between WHtR and BMI with the number of missing teeth, i.e., the higher the tooth loss, the lower the BMI and WHtR (P&#x2009;=&#x2009;0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study concludes that the prevalence of xerostomia is 39.6%, as reported by participants. Age emerged as a critical factor influencing this condition, while BMI and WHtR showed no direct relationship with xerostomia itself but were significantly related to tooth loss patterns. Notably, the highest prevalence of xerostomia was observed in patients with pulmonary disease (Asthma and respiratory allergies, COPD (Chronic Obstructive Pulmonary Disease).</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rezvaninejad</LastName><ForeName>Raziyehsadat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Kerman Social Determinants on Oral Health Research Center, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeinali</LastName><ForeName>Mahdie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oral Medicine, School of Dentistry, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatemi</LastName><ForeName>Amirreza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dentist, Kerman Social Determinants on Oral Health Research Center, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashemipour</LastName><ForeName>Maryam Alsadat</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Kerman Social Determinants on Oral Health Research Center, Kerman University of Medical Sciences, Kerman, Iran. m.s.hashemipour@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014987" MajorTopicYN="Y">Xerostomia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009909" MajorTopicYN="Y">Oral Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="Y">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006305" MajorTopicYN="Y">Health Status Indicators</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Elderly</Keyword><Keyword MajorTopicYN="N">General health</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">Oral health</Keyword><Keyword MajorTopicYN="N">Xerostomia</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This research was approved by the Ethics Committee of Kerman University of Medical Sciences and its Research Deputy Office. All experimental protocols were conducted according to relevant guidelines and regulations, including the Declaration of Helsinki. Verbal informed consent was obtained from all participants after a detailed explanation of the study objectives was provided by the researchers. Confidentiality regarding participant information is strictly maintained. The authors extend their gratitude to the Vice Deputy of Research at Kerman University of Medical Sciences for financial support (Registration No. 401000591). This project received ethics approval under code IR.KMU.REC.1401.445. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40846933</ArticleId><ArticleId IdType="doi">10.1186/s12889-025-23892-w</ArticleId><ArticleId IdType="pii">10.1186/s12889-025-23892-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pedersen A, S&#xf8;rensen CE, Proctor GB, Carpenter GH. Salivary functions in mastication, taste and textural perception, swallowing and initial digestion. Oral Dis. 2018;24(8):1399&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">29645367</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya A, Chandra S, Singh A, Raj V, Gupta B. Salivary glucose levels and oral candidal carriage in type 2 diabetics. J Oral Biol Craniofac Res. 2018;8(3):158&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30191100</ArticleId><ArticleId IdType="pmc">6107908</ArticleId></ArticleIdList></Reference><Reference><Citation>Papandreou A, Mahony A, Breaks A, Absoud M, Fairhurst C. Comparative efficacy and side effect profiles of interventions for pediatric saliva control: A cohort study. J Pediatr. 2024;265:113803.</Citation><ArticleIdList><ArticleId IdType="pubmed">37898423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar Z, Davarmanesh M, Zahed M, Salehi S. Evaluating the etiologies of burning mouth symptom in patients of Shiraz dental school from 2007 to 2015. Iran Red Crescent Med J. 2017;19(4):e42675.</Citation></Reference><Reference><Citation>Dreyer NS, Lynggaard CD, Jakobsen KK, Pedersen AML, von Buchwald C, Gr&#xf8;nh&#xf8;j C. [Xerostomia] Ugeskr Laeger. 2021;183(27):V11200814.</Citation><ArticleIdList><ArticleId IdType="pubmed">34219641</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatchala Rani RM, Kumar D, Dheer SS, Pathania AS, Dasara MR, Kaur N. Stress depression and anxiety with Xerostomia among young Indian adults. Bioinformation. 2023;19(13):1365&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">38415029</ArticleId><ArticleId IdType="pmc">10895538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Liu Z. Saliva biomarkers in oral disease. Clin Chim Acta. 2023;548:117503.</Citation><ArticleIdList><ArticleId IdType="pubmed">37536520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluijpers NRF, Delli K, De Wolff L, Stel AJ, Spijkervet FKL, Kroese FGM, et al. Longitudinal evaluation of major salivary gland functioning in sj&#xf6;gren&#x2019;s disease patients in a prospective standard-of-care cohort. Clin Exp Rheumatol. 2023;41(12):2474&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">38149509</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho HN, Dos Santos YL, Bernardino &#xcd;M, de Lima KC, Granville-Garcia AF. Melo de Brito Costa EM. Accuracy of a questionnaire on Xerostomia as a screening tool for hyposalivation. Int Dent J. 2020;70(6):427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">32830311</ArticleId><ArticleId IdType="pmc">9379185</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonpanao P, Janebodin K, Namvichaisirikul N, Thongjit S, Jitprasertwong P. The prevalence of Xerostomia in older Thai individuals with type II diabetes mellitus and its association with type of toothpaste and oral functions: A Cross-Sectional study using questionnaires. Geriatr (Basel). 2023;8(4):76.</Citation></Reference><Reference><Citation>Jamieson LM, Thomson WM, Xerostomia. Its prevalence and associations in the adult Australian population. Aust Dent J. 2020;65:67&#x2013;70.</Citation></Reference><Reference><Citation>Barancheshme F, Philibert J, Noam-Amar N, Gerchman Y, Barbeau B. Assessment of saliva interference with UV-based disinfection technologies. J Photochem Photobiol B. 2021;217:112168.</Citation><ArticleIdList><ArticleId IdType="pubmed">33714723</ArticleId><ArticleId IdType="pmc">8614578</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi E, Jung D. Factors influencing oral health-Related quality of life in older adults in rural areas: oral dryness and oral health knowledge and behavior. Int J Environ Res Public Health. 2021;18(8):4295.</Citation><ArticleIdList><ArticleId IdType="pubmed">33919539</ArticleId><ArticleId IdType="pmc">8073921</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S, Kim Y, Min S, Song M, Son S, Lee S. Taste sensitivity of elderly people is associated with quality of life and inadequate dietary intake. Nutrients. 2021;13(5):1693.</Citation><ArticleIdList><ArticleId IdType="pubmed">34067560</ArticleId><ArticleId IdType="pmc">8155931</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferizi L, Bimbashi V, Kelmendi J. Association between metabolic control and oral health in children with type 1 diabetes mellitus. BMC Oral Health. 2022;22(1):502.</Citation><ArticleIdList><ArticleId IdType="pubmed">36384715</ArticleId><ArticleId IdType="pmc">9670584</ArticleId></ArticleIdList></Reference><Reference><Citation>Abidin ZZ, Halim RA, Noor E, Nor NSM, Nazari NSM, Zaini AA, Azizi NZ, Soelar SA. Knowledge and perception of bidirectional relationship between periodontal disease and type 1 diabetes mellitus: A questionnaire study. J Int Soc Prev Community Dent. 2023;13(5):416&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">38124724</ArticleId><ArticleId IdType="pmc">10729881</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicembrini I, Serni L, Monami M, Caliri M, Barbato L, Cairo F, Mannucci E. Type 1 diabetes and periodontitis: prevalence and periodontal destruction-a systematic review. Acta Diabetol. 2020;57(12):1405&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">32318875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Pintor RM, Casanas E, Gonzalez-Serrano J. Xerostomia, Hyposalivation, and Salivary Flow in Diabetes Patients. J Diabetes Res. 2016;2016:1&#x2013;15.</Citation></Reference><Reference><Citation>Lima DLF, Carneiro SDRM, Barbosa FTS. Salivary flow and Xerostomia in older patients with type 2 diabetes mellitus. PLoS ONE. 2017;12:e0180891.</Citation><ArticleIdList><ArticleId IdType="pubmed">28767676</ArticleId><ArticleId IdType="pmc">5540406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornari CB, Bergonci D, Stein CB, Agostini BA, Rigo L. Prevalence of Xerostomia and its association with systemic diseases and medications in the elderly: a cross-sectional study. Sao Paulo Med J. 2021;139(4):380&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34190871</ArticleId><ArticleId IdType="pmc">9615591</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Meulen AI, Neis EPJG, de Nijs EJM, Coenegracht BJEG, Stoppelenburg A, van den Beuken-van Everdingen MHJ, van der Linden YM. Dry mouth in patients with a life-limiting condition or frailty: a study protocol for two intervention studies and a nested qualitative sub-study (the dry mOuth project, DROP). BMC Palliat Care. 2023;22(1):120.</Citation><ArticleIdList><ArticleId IdType="pubmed">37612654</ArticleId><ArticleId IdType="pmc">10463805</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalak P, Polak-Szl&#xf3;sarczyk P, Dyduch-Dudek W, Zarzecka-Francica E, Styrna M, Czekaj &#x141;, et al. Oral health of elderly people in institutionalized care and Three-Month rehabilitation programme in Southern poland: A Case-Control study. Int J Environ Res Public Health. 2022;19(9):4994.</Citation><ArticleIdList><ArticleId IdType="pubmed">35564391</ArticleId><ArticleId IdType="pmc">9105158</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Gonz&#xe1;lez A, Su&#xe1;rez-Quintanilla JA, Otero-Rey E, Blanco-Carri&#xf3;n A, G&#xf3;mez-Garc&#xed;a FJ, G&#xe1;ndara-Vila P, et al. Association between xerostomia, oral and general health, and obesity in adults. A cross-sectional pilot study. Med Oral Patol Oral Cir Bucal. 2021;26(6):e762&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34023839</ArticleId><ArticleId IdType="pmc">8601639</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento GG, Leite FRM, Concei&#xe7;&#xe3;o DA, Ferr&#xfa;a CP, Singh A, Demarco FF. Is there a relationship between obesity and tooth loss and edentulism? A systematic review and meta-analysis. Obes Rev. 2016;17:587&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">27125768</ArticleId></ArticleIdList></Reference><Reference><Citation>Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20:12.</Citation><ArticleIdList><ArticleId IdType="pubmed">29480368</ArticleId><ArticleId IdType="pmc">5866840</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Say&#xe1;ns M, Gonz&#xe1;lez-Juanatey JR, Lorenzo-Pouso AI, Chamorro-Petronacci C, Blanco-Carri&#xf3;n A, Marichalar-Mend&#xed;a X, et al. Metabolic syndrome and masticatory hypofunction: a cross-sectional study. Odontology. 2020;23:54&#x2013;62.</Citation></Reference><Reference><Citation>Ohara Y, Kawai H, Shirobe M, Iwasaki M, Motokawa K, Edahiro A, et al. Association between dry mouth and physical frailty among community-dwelling older adults in japan: the Otassha study. Gerodontol. 2022;39:41&#x2013;8.</Citation></Reference><Reference><Citation>Pina GDMS, Mota Carvalho R, Silva BSDF, Almeida FT. Prevalence of hyposalivation in older people: A systematic review and meta-analysis. Gerodontol. 2020;37:317&#x2013;31.</Citation></Reference><Reference><Citation>Negreiros Filho ZV, Silva NCD, F&#xe9; RASS, Louren&#xe7;o MAG, Pazinatto RB, Cabral AEA, Melo LA. Lifestyles associated with complete tooth loss in elderly people in brazil, 2019. Epidemiol Serv Saude. 2025;34:e20240614.</Citation><ArticleIdList><ArticleId IdType="pubmed">40366955</ArticleId></ArticleIdList></Reference><Reference><Citation>Indrapriyadharshini K, Julius A, Karthikeyan GR, AartiNisha V, Vishnuprasad S. Awareness and practice of oral complications due to diabetes mellitus among diabetes patients at Chengalpattu district, india: A cross-sectional study. J Oral Health Oral Epidemiol. 2023;12(2):65&#x2013;70.</Citation></Reference><Reference><Citation>Hijjaw O, Alawneh M, Ojjoh K, Abuasbeh H, Alkilany A, Qasem N, et al. Correlation between Xerostomia index, clinical oral dry&#xac;ness scale, and ESSPRI with different hyposalivation tests. Open Access Rheumatology: Res Reviews. 2019;11:11&#x2013;8.</Citation></Reference><Reference><Citation>Erhamza TS, Almaz ME, Tulumbaci F. Relationship between body mass index and halitosis amongst late adolescents. Selcuk Dent J. 2021;8:95&#x2013;100.</Citation></Reference><Reference><Citation>Johansson A, Johansson A, Unell L, Ekb&#xe4;ck G, Ordell S, Carlsson GE. Self-reported dry mouth in 50- to 80-year-old swedes: longitudinal and cross-sectional population studies. J Oral Rehabil. 2020;47:246&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">31444791</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamani G, Zarei MR, Mehrabani M, Nakhaee N, Kalaghchi B, Aghili M, et al. Assessment of systemic effects of ginger on salivation in patients with post-radiotherapy Xerostomia. J Oral Health Oral Epidemiol. 2017;6(3):130&#x2013;7.</Citation></Reference><Reference><Citation>Storbeck T, Qian F, Marek C, CaplanD. Marchini L. Dose-dependent association between Xerostomia and number of medications among older adults. Spec Care Dent. 2022;42:225&#x2013;31.</Citation></Reference><Reference><Citation>Padros-Auge J, Nouhaila Z, Miquel C, Morales-Vigo A, Sebasti&#xe9;n C, Laurine P. Diagnostic criteria for bruxism: A scoping review. J Oral Health Oral Epidemiol. 2023;12(3):98&#x2013;104.</Citation></Reference><Reference><Citation>Khongsirisombat N, Kiattavorncharoen S, Thanakun S. Increased oral dryness and negative oral health-related quality of life in older people with overweight or obesity. Dent J. 2022;10:231.</Citation></Reference><Reference><Citation>T&#xf4;rres LHN, De Marchi RJ, Hilgert JB, Hugo FN, Ismail AI, Antunes JLF, et al. Oral health and obesity in Brazilian elders: A longitudinal study. Community Dent Oral Epidemiol. 2020;48:540&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32786084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Izumi N, Funayama S, Nohno K, Katsura K, Kaneko N, Inoue M. Characteristics of medication-induced Xerostomia and effect of treatment. PLoS ONE. 2023;18(1):e0280224.</Citation><ArticleIdList><ArticleId IdType="pubmed">36634078</ArticleId><ArticleId IdType="pmc">9836311</ArticleId></ArticleIdList></Reference><Reference><Citation>Islas-Granillo H, Borges-Yanez A, Fernandez-Barrera MA, et al. Relationship of hyposalivation and Xerostomia in Mexican elderly with socioeconomic, sociodemographic and dental factors. Sci Rep. 2017;7:40686.</Citation><ArticleIdList><ArticleId IdType="pubmed">28094800</ArticleId><ArticleId IdType="pmc">5240562</ArticleId></ArticleIdList></Reference><Reference><Citation>Niklander S, Veas L, Barrera C. Risk factors, hyposalivation and impact of Xerostomia on oral health-related quality of life. Braz Oral Res. 2017;31:e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">28099580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorathy I, Siva R, Chacko R, Sebastian T, Abdulrahma I. Prevalence of oral problems among patients with type II diabetes mellitus in the selected urban area of vellore city, Tamil Nadu. Indian J Cont Nurs Edu. 2022;23(1):76.</Citation></Reference><Reference><Citation>Verhulst MJL, Loos BG, Gerdes VEA, Teeuw WJ. Evaluating all potential oral complications of diabetes mellitus. Front Endocrinol (Lausanne). 2019;10:56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30962800</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquezin MCS, Chaves-J&#xfa;nior SC, Rasera I Jr, Pacheco ERP, Gavi&#xe3;o MBD, Lamy E, Castelo PM. Oral health and nutritional characteristics of adults with morbid obesity: a multivariate analysis. Front Nutr. 2020;7:589510.</Citation><ArticleIdList><ArticleId IdType="pubmed">33330590</ArticleId><ArticleId IdType="pmc">7714904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40847509</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Consistency and Risk Stratification Performance of 4 Society for Cardiovascular Angiography and Interventions SHOCK Stage Definitions: A Retrospective Study.</ArticleTitle><Pagination><StartPage>e041340</StartPage><MedlinePgn>e041340</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.125.041340</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiogenic shock (CS) is a critical condition associated with high mortality rates, making prompt diagnosis essential for timely interventions that may improve patient outcomes. The Society for Cardiovascular Angiography and Interventions (SCAI) SHOCK Stage Classification is a validated tool for assessing CS and predicting patient outcomes. Here, we evaluated how different parameter definitions affect SCAI stage adjudication, hypothesizing that variations may influence stage determination and the overall assessment of CS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All patients diagnosed with CS or conditions leading to CS at the University Medical Center Mannheim, Germany, from January 2018 to June 2022 were included in the study. SCAI SHOCK stages were assigned retrospectively on the basis of 4 previously published studies. The distribution of SCAI SHOCK stages, outcomes, classification concordance, and predictive performance were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From January 2018 to June 2022, we identified 1303 patients on the basis of <i>International Classification of Diseases</i>, <i>Tenth Revision</i> (<i>ICD-10</i>) codes. Of these, 1281 patients (98.2%) were classified into SCAI SHOCK stages according to all 4 classification frameworks. While the assignment of SCAI SHOCK stages and associated mortality rates varied among the frameworks, Kendall's W indicated moderate to strong overall classification agreement (W=0.70). There was no significant difference in predictive performance for in-hospital death.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study demonstrates a moderate to strong concordance and comparable prognostic performance across different SCAI SHOCK Stage Classification frameworks in evaluating patients with CS. Despite differences in stage assignments, all frameworks effectively stratified patients by clinical severity. Comparable stage assignment in retrospective studies requires further standardization of the SCAI SHOCK Stage Classification system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becher</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7670-757X</Identifier><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Leonie</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0007-1286-1835</Identifier><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Britsch</LastName><ForeName>Markward</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0004-7257-6057</Identifier><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Medical Center Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DKFZ Hector Cancer Institute, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mannheim Institute for Intelligent Systems in Medicine (MIISM), Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HMS Analytical Software GmbH Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muschko</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>SAP Deutschland SE &amp; Co. KG Department of Mobile User Experience (UX)/EMEA Walldorf Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langer</LastName><ForeName>Harald F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindner</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helbing</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jabbour</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duerschmied</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5249-4012</Identifier><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Britsch</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0001-2212-4114</Identifier><AffiliationInfo><Affiliation>Cardiology, Haemostaseology, and Medical Intensive Care, Medical Centre Mannheim, Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Center for AngioScience (ECAS), German Centre for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, and Centre for Cardiovascular Acute Medicine Mannheim (ZKAM), Medical Centre Mannheim and Medical Faculty Mannheim Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University Heidelberg Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SCAI</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">death</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40847509</ArticleId><ArticleId IdType="doi">10.1161/JAHA.125.041340</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40847512</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Impact of Baseline Cardiogenic Shock Severity on Outcomes in Patients Treated With Impella Device.</ArticleTitle><Pagination><StartPage>e043266</StartPage><MedlinePgn>e043266</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.125.043266</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Risk stratification of patients with cardiogenic shock (CS) is of considerable importance. We aimed to test the utility of the Society for Cardiovascular Angiography and Intervention shock staging system recently refined by the CS Working Group in an Asian population and to investigate its association with in-hospital adverse events.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From the Japanese nationwide registry of Impella, the patients with CS who successfully received Impella support between February 2020 and December 2023 were included and assigned to any stage according to the CS Working Group-refined Society for Cardiovascular Angiography and Intervention staging system. We set the primary end point as in-hospital death and explored it within each stage, with stage B as a reference.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 4643 patients were analyzed (median age, 69&#x2009;years; women, 23.3%; CS due to acute myocardial infarction, 61.7%), and 122, 588, 1905, and 2058 patients were in stages B, C, D, and E, respectively. After adjustment with potential confounders, stage C had no significant difference in in-hospital death (odds ratio, 1.12 [95% CI, 0.69-1.80]; <i>P</i>=0.653). However, with adjusted analysis, stages D and E had a significantly higher rate of in-hospital death (stage D: odds ratio, 2.41 [95% CI, 1.55-3.77]; <i>P</i>&lt;0.001; stage E: odds ratio, 4.90 [95% CI, 3.14-7.66]; <i>P</i>&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The CS Working Group-refined Society for Cardiovascular Angiography and Intervention staging system at baseline has a satisfactory association with in-hospital death in the more progressive stage; however, the system seems to have a lower power in the earlier phase of CS. Further investigation is warranted to establish a more accurate staging system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4677-2829</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Tokushima Red Cross Hospital Tokushima Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosokawa</LastName><ForeName>Shinobu</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0000-9612-6078</Identifier><AffiliationInfo><Affiliation>Department of Cardiology Tokushima Red Cross Hospital Tokushima Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sata</LastName><ForeName>Masataka</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8036-7501</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology Tokushima Red Cross Hospital Tokushima Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>J&#x2010;PVAD Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Impella</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">percutaneous ventricular assist device</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>1</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40847512</ArticleId><ArticleId IdType="doi">10.1161/JAHA.125.043266</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40847662</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2796</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of internal medicine</Title><ISOAbbreviation>J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.70012</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Type 2 diabetes mellitus (T2DM) and gout are associated with an increased risk of cardiovascular events. Despite the approval for the secondary prevention of cardiovascular diseases by the United States Food and Drug Administration in 2023, evidence regarding the effectiveness of colchicine among T2DM population remains limited.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We aimed to evaluate the association between the use of colchicine and the risk of major adverse cardiovascular events (MACE) among patients with gout and T2DM.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a nationwide, population-based cohort study with active comparator, new-user design using nationwide claims data of South Korea (2010-2022). Patients with T2DM and gout who initiated colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) from 2011 to 2022 were included. The primary outcome was MACE (myocardial infarction, ischemic stroke, and cardiovascular death). Secondary outcomes were each individual components of primary outcome and hospitalization due to heart failure. As-treated approach with 30-day grace period was applied.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Before propensity score (PS) matching, 13,019 colchicine users and 111,594 NSAIDs users were included in the study cohort (mean age, 65.5 vs. 62.9; 35.0% vs. 29.8% female). After 1:2 PS matching, 12,908 colchicine users and 25,816 NSAIDs users remained (mean age, 65.7 vs. 65.7 years; 35.2% vs. 35.1% female). The PS-matched hazard ratio for MACE was 0.94 (95% confidence interval 0.65-1.36), and all secondary outcomes also resulted in null findings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Use of colchicine does not significantly reduce the risk of MACE compared with NSAIDs in a real-world population with T2DM and gout in South Korea between 2011 and 2022.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Journal of Internal Medicine published by John Wiley &amp; Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Minjeong</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Yongtai</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3303-7881</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bea</LastName><ForeName>Sungho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Wonkyoung</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sung Kweon</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Seungho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yoosoo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6945-9050</Identifier><AffiliationInfo><Affiliation>Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Ju-Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0003-1010-7525</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Samsung Advanced Institute for Health Sciences &amp; Technology, Sungkyunkwan University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Ministry of Food and Drug Safety</Agency><Country/></Grant><Grant><Agency>National Research Foundation of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intern Med</MedlineTA><NlmUniqueID>8904841</NlmUniqueID><ISSNLinking>0954-6820</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword><Keyword MajorTopicYN="N">cardiovascular events</Keyword><Keyword MajorTopicYN="N">colchicine</Keyword><Keyword MajorTopicYN="N">gout</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>23</Day><Hour>4</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40847662</ArticleId><ArticleId IdType="doi">10.1111/joim.70012</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metab Clin North Am. 2021;50:337&#x2013;355.</Citation></Reference><Reference><Citation>Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380&#x2013;390.</Citation></Reference><Reference><Citation>Collier A, Stirling A, Cameron L, Hair M, Crosbie D. Gout and diabetes: a common combination. Postgrad Med J. 2016;92:372&#x2013;378.</Citation></Reference><Reference><Citation>Cho J, Dalbeth N, Petrov MS. Relationship between gout and diabetes mellitus after acute pancreatitis: a nationwide cohort study. J Rheumatol. 2020;47:917&#x2013;923.</Citation></Reference><Reference><Citation>Borghi C, Agabiti&#x2010;Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, et&#xa0;al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1&#x2013;11.</Citation></Reference><Reference><Citation>Kim SC, Liu J, Solomon DH. Risk of incident diabetes in patients with gout: a cohort study. Arthritis Rheumatol. 2015;67:273&#x2013;280.</Citation></Reference><Reference><Citation>Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et&#xa0;al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119:154766.</Citation></Reference><Reference><Citation>Singh JA, Ramachandaran R, Yu S, Yang S, Xie F, Yun H, et&#xa0;al. Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study. Arthritis Res Ther. 2017;19:228.</Citation></Reference><Reference><Citation>Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21:21.</Citation></Reference><Reference><Citation>Lee JJ, Lee JiS, Chung MK, Ahn JK, Choi H&#x2010;J, Hong S&#x2010;J, et&#xa0;al. Korean guidelines for the management of gout. J Rheum Dis. 2023;30:141&#x2013;150.</Citation></Reference><Reference><Citation>Agepha Pharma. LODOCO (colchicine) tablets, for oral use, NDA 215727. Agepha Pharma. 2023; Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215727s000lbl.pdf.</Citation></Reference><Reference><Citation>Nidorf SM, Fiolet ATL, Eikelboom JW, Schut A, Opstal TSJ, Bax WA, et&#xa0;al. The effect of low&#x2010;dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46&#x2013;56.</Citation></Reference><Reference><Citation>Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et&#xa0;al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838&#x2013;1847.</Citation></Reference><Reference><Citation>Roubille F, Bouabdallaoui N, Kouz S, Waters DD, Diaz R, Maggioni AP, et&#xa0;al. Low&#x2010;dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467&#x2013;470.</Citation></Reference><Reference><Citation>Tardif J&#x2010;C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et&#xa0;al. Efficacy and safety of low&#x2010;dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497&#x2013;2505.</Citation></Reference><Reference><Citation>FitzGerald JD, Dalbeth N, Mikuls T, Brignardello&#x2010;Petersen R, Guyatt G, Abeles AM, et&#xa0;al. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Rheumatol. 2020;72:879&#x2013;895.</Citation></Reference><Reference><Citation>Qaseem A, Harris RP, Forciea MA, Clinical Guidelines Committee of the American College of Physicians, Denberg TD, Barry MJ, et&#xa0;al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:58&#x2013;68.</Citation></Reference><Reference><Citation>Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta&#xf1;eda&#x2010;Sanabria J, et&#xa0;al. 2016 updated EULAR evidence&#x2010;based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29&#x2013;42.</Citation></Reference><Reference><Citation>Park J, Kwon S, Choi E&#x2010;K, Choi Y&#x2010;J, Lee E, Choe W, et&#xa0;al. Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database. International Journal of Arrhythmia. 2019;20:5.</Citation></Reference><Reference><Citation>Kim D, Yang P&#x2010;S, You SC, Sung J&#x2010;H, Jang E, Yu HT, et&#xa0;al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021;373:n991.</Citation></Reference><Reference><Citation>Curtis JR, Yamaoka K, Chen Yi&#x2010;H, Bhatt DL, Gunay LM, Sugiyama N, et&#xa0;al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open&#x2010;label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82:331&#x2013;343.</Citation></Reference><Reference><Citation>Bouabdallaoui N, Tardif J&#x2010;C, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et&#xa0;al. Time&#x2010;to&#x2010;treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41:4092&#x2013;4099.</Citation></Reference><Reference><Citation>Li J, Meng X, Shi F&#x2010;D, Jing J, Gu H&#x2010;Q, Jin A, et&#xa0;al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE&#x2010;3): multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024;385:e079061.</Citation></Reference><Reference><Citation>Jolly SS, d'Entremont M&#x2010;A, Lee SF, Mian R, Tyrwhitt J, Kedev S, et&#xa0;al. Colchicine in acute myocardial infarction. N Engl J Med. 2025;392:633&#x2013;642.</Citation></Reference><Reference><Citation>Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75:1674&#x2013;1679.</Citation></Reference><Reference><Citation>Roddy E, Bajpai R, Forrester H, Partington RJ, Mallen CD, Clarson LE, et&#xa0;al. Safety of colchicine and NSAID prophylaxis when initiating urate&#x2010;lowering therapy for gout: propensity score&#x2010;matched cohort studies in the UK Clinical Practice Research Datalink. Ann Rheum Dis. 2023;82:1618&#x2013;1625.</Citation></Reference><Reference><Citation>Yeh JJ, Kuo IL, Yip HT, Hsueh MY, Hsu CY, Kao CH. Effects of colchicine use on ischemic and hemorrhagic stroke risk in diabetic patients with and without gout. Sci Rep. 2022;12:9195.</Citation></Reference><Reference><Citation>Shah B, Toprover M, Crittenden DB, Jeurling S, Pike VC, Krasnokutsky S, et&#xa0;al. Colchicine use and incident coronary artery disease in male patients with gout. Can J Cardiol. 2020;36:1722&#x2013;1728.</Citation></Reference><Reference><Citation>Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et&#xa0;al. Colchicine in cardiovascular disease: in&#x2010;depth review. Circulation. 2022;145:61&#x2013;78.</Citation></Reference><Reference><Citation>Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA. 2022;328:440&#x2013;450.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40839301</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1615-2573</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Heart and vessels</Title><ISOAbbreviation>Heart Vessels</ISOAbbreviation></Journal><ArticleTitle>Long-term outcome of tailored antithrombotic therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a 5-year retrospective cohort study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00380-025-02584-w</ELocationID><Abstract><AbstractText>Dual antiplatelet therapy is the standard therapy for the secondary prevention of acute and chronic coronary syndromes in patients undergoing percutaneous coronary intervention&#xa0;(PCI). The introduction of more potent antiplatelet agents and understanding of prognostic implications associated with bleeding have led to a substantial evolution in antiplatelet treatment regimens over the past decades. Several investigations have been conducted to better stratify patients undergoing PCI according to their ischemic and bleeding risks and to optimize antithrombotic regimens accordingly. One of the available strategies involves using platelet aggregation tests to determine the most suitable antiplatelet agent to combine with aspirin. Our aim was to evaluate the role of platelet function tests&#xa0;(PFT) in clinical practice in choosing dual antiplatelet therapy for patients undergoing PCI: in this study, we compared the impact on ischemic and hemorrhagic cardiovascular events in a 5&#xa0;year follow-up between patients treated according to standard guidelines and those treated with a platelet function test guided approach. This study included 490 patients with acute or chronic coronary syndrome who underwent percutaneous angioplasty between 2013 and 2016 and were subsequently treated with dual antiplatelet therapy. Patients whose treatment strategy was based on PFT&#xa0;were 68.4% (n&#x2009;=&#x2009;335), while others received standard therapy. The primary endpoint of the study was to assess the incidence of net adverse clinical events (NACE), defined as a composite of all-cause mortality, myocardial infarction, stroke, or major bleeding, according to the BARC scale. Follow-up was conducted 5&#xa0;years after angioplasty by telephone contact or by consulting patients' medical records. Heart failure and stable angina were considered as secondary endpoints. From the univariate analysis, the incidence of NACE was significantly lower in patients who received tailored therapy (33.7% vs. 43.9% in the non-tailored group, p&#x2009;=&#x2009;0.02). In addition, results showed that total length of implanted stents and left main coronary disease were independent risk factors for net adverse clinical events (NACE). Similarly, an initial diagnosis of N-STEMI or unstable angina was associated with an increased risk of adverse events during follow-up. In patients undergoing PCI, a tailored antithrombotic approach guided by PFT appears safe and effective, may represent a feasible strategy in contemporary practice and should be considered in case of high bleeding risk.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cecchi</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>General Cardiology Unit, Department of Cardiac Thoracic and Vascular Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Granchietti</LastName><ForeName>Andrea Grasso</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0009-0007-5087-6122</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Largo Brambilla 3, Florence, Italy. andrea.grasso@unifi.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Cardiology Unit, Department of Cardiac Thoracic and Vascular Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. andrea.grasso@unifi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assenza</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Largo Brambilla 3, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanizzi</LastName><ForeName>Angela Ilaria</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Largo Brambilla 3, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garofalo</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Largo Brambilla 3, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Muro</LastName><ForeName>Francesca Maria</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Salerno, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitiello</LastName><ForeName>Veronica Speranza</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Largo Brambilla 3, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losanno</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Largo Brambilla 3, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caciolli</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Cardiology Unit, Department of Cardiac Thoracic and Vascular Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piazzai</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Largo Brambilla 3, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiostri</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, School of Human and Health Science, Largo Brambilla 3, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcucci</LastName><ForeName>Rossella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Atherothrombotic Disease, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Heart Vessels</MedlineTA><NlmUniqueID>8511258</NlmUniqueID><ISSNLinking>0910-8327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dual antiplatelet therapy</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">Platelet function test</Keyword><Keyword MajorTopicYN="N">Tailored antithrombotic therapy</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>11</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839301</ArticleId><ArticleId IdType="doi">10.1007/s00380-025-02584-w</ArticleId><ArticleId IdType="pii">10.1007/s00380-025-02584-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matsuura Y, Moribayashi K, Kaikita K (2022) Optimal Antithrombotic therapy in patients undergoing percutaneous coronary intervention: a focused review on high bleeding risk. J Atheroscler Thromb 29(10):1409&#x2013;1420</Citation><ArticleIdList><ArticleId IdType="pubmed">35934784</ArticleId><ArticleId IdType="pmc">9529379</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbing D, Byrne RA, Kastrati A (2011) Role of platelet function testing in clinical practice: current concepts and future perspectives. Curr Drug Targets 12(12):1836&#x2013;1847</Citation><ArticleIdList><ArticleId IdType="pubmed">21718234</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;pke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, W&#xf6;hrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Fl&#xfc;gel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, M&#xf6;llmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Sch&#xfc;hlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, T&#xf6;lg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, ISAR-REACT 5 Trial Investigators (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381(16):1524&#x2013;1534</Citation><ArticleIdList><ArticleId IdType="pubmed">31475799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators PLATO, Freij A, Thors&#xe9;n M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045&#x2013;1057</Citation><ArticleIdList><ArticleId IdType="pubmed">19717846</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon HY, Lee N, Seong JM, Gwak HS (2020) Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis. Br J Clin Pharmacol 86(8):1489&#x2013;1498</Citation><ArticleIdList><ArticleId IdType="pubmed">32320492</ArticleId><ArticleId IdType="pmc">7373703</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfredsson J, Omar K, Csog J, Venetsanos D, Janzon M, Ekstedt M (2020) Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients - a real life cohort study of two treatment strategies. Int J Cardiol Heart Vasc 12(27):100495</Citation></Reference><Reference><Citation>Angiolillo DJ (2011) Applying platelet function testing in clinical practice: what are the unmet needs? JAMA 306(11):1260&#x2013;1261</Citation><ArticleIdList><ArticleId IdType="pubmed">21934063</ArticleId></ArticleIdList></Reference><Reference><Citation>Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van&#x2019;t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM (2019) A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 381(17):1621&#x2013;1631</Citation><ArticleIdList><ArticleId IdType="pubmed">31479209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA, Working Group on On-Treatment Platelet Reactivity (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62(24):2261&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pubmed">24076493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchi E, Marcucci R, Chiostri M, Mecarocci V, Spini V, Innocenti L, Calabretta R, Cordisco A, Romano SM, Abbate R, Gensini GF, Giglioli C (2015) Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. Intern Emerg Med 10(7):805&#x2013;814</Citation><ArticleIdList><ArticleId IdType="pubmed">25944129</ArticleId></ArticleIdList></Reference><Reference><Citation>De Gregorio MG, Marcucci R, Migliorini A, Gori AM, Giusti B, Vergara R, Paniccia R, Carrabba N, Marchionni N, Valenti R (2020) Clinical implications of &#x201c;tailored&#x201d; antiplatelet therapy in patients with chronic total occlusion. J Am Heart Assoc 9(4):e014676</Citation><ArticleIdList><ArticleId IdType="pubmed">32067582</ArticleId><ArticleId IdType="pmc">7070214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123(23):2736&#x2013;2747</Citation><ArticleIdList><ArticleId IdType="pubmed">21670242</ArticleId></ArticleIdList></Reference><Reference><Citation>Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabat&#xe9; M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryd&#xe9;n L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J 34(38):2949&#x2013;3003</Citation></Reference><Reference><Citation>Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 32(23):2999&#x2013;3054</Citation><ArticleIdList><ArticleId IdType="pubmed">21873419</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ (2019) Updated expert consensus statement on platelet function and genetic testing for guiding P2Y<sub>12</sub> receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 12(16):1521&#x2013;1537</Citation><ArticleIdList><ArticleId IdType="pubmed">31202949</ArticleId></ArticleIdList></Reference><Reference><Citation>Capodanno D, Angiolillo DJ (2023) Personalised antiplatelet therapies for coronary artery disease: what the future holds. Eur Heart J 44(32):3059&#x2013;3072</Citation><ArticleIdList><ArticleId IdType="pubmed">37345589</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Kom&#xf3;csi A, D&#xe9;zsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ, Koltowski L, Mehilli J, Huczek Z, Massberg S, TROPICAL-ACS Investigators (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 390(10104):1747&#x2013;1757</Citation><ArticleIdList><ArticleId IdType="pubmed">28855078</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, J&#xfc;ni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B, ESC Scientific Document Group (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 44(38):3720&#x2013;3826 (Erratum in: Eur Heart J. 2024 Apr 1; 45(13): 1145)</Citation><ArticleIdList><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HS, Kang J, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Rhew JY, Chun KJ, Lim YH, Bong JM, Bae JW, Lee BK, Park KW, HOST-REDUCE-POLYTECH-ACS investigators (2020) Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 396(10257):1079&#x2013;1089</Citation><ArticleIdList><ArticleId IdType="pubmed">32882163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim CJ, Park MW, Kim MC, Choo EH, Hwang BH, Lee KY, Choi YS, Kim HY, Yoo KD, Jeon DS, Shin ES, Jeong YH, Seung KB, Jeong MH, Yim HW, Ahn Y, Chang K, TALOS-AMI investigators (2021) Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet 398(10308):1305&#x2013;1316</Citation><ArticleIdList><ArticleId IdType="pubmed">34627490</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Li M, Liu J, Xie L, Li J, Liu Y, Niu C, Xiao D, Li J, Zhang L (2024) Risk factors and incidence for in-stent restenosis with drug-eluting stent: a systematic review and meta-analysis. Rev Cardiovasc Med 25(12):458</Citation><ArticleIdList><ArticleId IdType="pubmed">39742219</ArticleId><ArticleId IdType="pmc">11683691</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D&#x2019;Ascenzo F, Kimura T, Briguori C, Sabat&#xe8; M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW (2012) Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 379(9824):1393&#x2013;1402</Citation><ArticleIdList><ArticleId IdType="pubmed">22445239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri L, O&#x2019;Malley AJ, Cutlip DE, Ho KK, Popma JJ, Chauhan MS, Baim DS, Cohen DJ, Kuntz RE (2004) Effects of stent length and lesion length on coronary restenosis. Am J Cardiol 93(11):1340&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">15165911</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarsini R, Fezzi S, Leone AM, De Maria GL, Pighi M, Marcoli M, Tavella D, Pesarini G, Banning AP, Barbato E, Wijns W, Ribichini FL (2022) Functional patterns of coronary disease: diffuse, focal, and serial lesions. JACC Cardiovasc Interv 15(21):2174&#x2013;2191</Citation><ArticleIdList><ArticleId IdType="pubmed">36357022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangalore S, Spertus JA, Stevens SR, Jones PG, Mancini GBJ, Leipsic J, Reynolds HR, Budoff MJ, Hague CJ, Min JK, Boden WE, O&#x2019;Brien SM, Harrington RA, Berger JS, Senior R, Peteiro J, Pandit N, Bershtein L, de Belder MA, Szwed H, Doerr R, Monti L, Alfakih K, Hochman JS, Maron DJ, ISCHEMIA Research Group (2022) Outcomes with intermediate left main disease: analysis from the ISCHEMIA trial. Circ Cardiovasc Interv 15(4):e010925</Citation><ArticleIdList><ArticleId IdType="pubmed">35411785</ArticleId><ArticleId IdType="pmc">11863176</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, St&#xe5;hle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW, SYNTAX Investigators (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961&#x2013;72 (Erratum in: N Engl J Med. 2013 Feb 7;368(6):584. PMID: 19228612)</Citation><ArticleIdList><ArticleId IdType="pubmed">19228612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Qiu M, Qi J, Li J, Wang H, Li Y, Han Y (2015) Impact of anemia on long-term ischemic events and bleeding events in patients undergoing percutaneous coronary intervention: a system review and meta-analysis. J Thorac Dis 7(11):2041&#x2013;2052</Citation><ArticleIdList><ArticleId IdType="pubmed">26716044</ArticleId><ArticleId IdType="pmc">4669281</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilgrim T, Vetterli F, Kalesan B, Stefanini GG, R&#xe4;ber L, Stortecky S, Gloekler S, Binder RK, Wenaweser P, Moschovitis A, Khattab AA, Buellesfeld L, Zwahlen M, Meier B, J&#xfc;ni P, Windecker S (2012) The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents. Circ Cardiovasc Interv 5(2):202&#x2013;210</Citation><ArticleIdList><ArticleId IdType="pubmed">22456025</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, Peterson N, Ramsey G, Rao SV, Roback JD, Shander A, Tobian AA (2016) Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 316(19):2025&#x2013;2035</Citation><ArticleIdList><ArticleId IdType="pubmed">27732721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunadian V, Mehran R, Lincoff AM, Feit F, Manoukian SV, Hamon M, Cox DA, Dangas GD, Stone GW (2014) Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the acute catheterization and urgent intervention triage strategy trial). Am J Cardiol 114(12):1823&#x2013;1829</Citation><ArticleIdList><ArticleId IdType="pubmed">25438908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohansal E, Jamalkhani S, Hosseinpour A, Yousefimoghaddam F, Askarinejad A, Hekmat E, Jolfayi AG, Attar A (2025) Invasive versus conservative strategies for non-ST-elevation acute coronary syndrome in the elderly: an updated systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 25(1):96</Citation><ArticleIdList><ArticleId IdType="pubmed">39939951</ArticleId><ArticleId IdType="pmc">11823017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair H, Batty JA, Qiu W, Kunadian V (2016) Engaging older patients in cardiovascular research: observational analysis of the ICON-1 study. Open Heart 3(2):e000436</Citation><ArticleIdList><ArticleId IdType="pubmed">27547431</ArticleId><ArticleId IdType="pmc">4975868</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA, GRACE and GRACE2 Investigators (2010) The global registry of acute coronary events, 1999 to 2009&#x2013;GRACE. Heart 96(14):1095&#x2013;101</Citation><ArticleIdList><ArticleId IdType="pubmed">20511625</ArticleId></ArticleIdList></Reference><Reference><Citation>Aradi D, Gross L, Trenk D, Geisler T, Merkely B, Kiss RG, Kom&#xf3;csi A, D&#xe9;zsi CA, Ruzsa Z, Ungi I, Rizas KD, May AE, M&#xfc;gge A, Zeiher AM, Holdt L, Huber K, Neumann FJ, Koltowski L, Huczek Z, Hadamitzky M, Massberg S, Sibbing D (2019) Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. Eur Heart J 40(24):1942&#x2013;1951</Citation><ArticleIdList><ArticleId IdType="pubmed">31226213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez J, Mark J, Duarte GJ, Shaban M, Sosa F, Mishra R, Jain S, Tran A, Khizar A, Karpel D, Acosta G, Rodriguez-Guerra M (2023) Role of genetic polymorphisms in clopidogrel response variability: a systematic review. Open Heart 10(2):e002436</Citation><ArticleIdList><ArticleId IdType="pubmed">37963685</ArticleId><ArticleId IdType="pmc">10649851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, D&#x17e;av&#xed;k V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM (2019) Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 381(21):2032&#x2013;2042</Citation><ArticleIdList><ArticleId IdType="pubmed">31556978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim SH, Jeong JO, Bae JH, Kim BO, Cho JH, Suh IW, Kim DI, Park HK, Park JS, Choi WG, Lee WS, Kim J, Choi KH, Park TK, Lee JM, Yang JH, Choi JH, Choi SH, Gwon HC, SMART-DATE investigators (2018) 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 391(10127):1274&#x2013;1284</Citation><ArticleIdList><ArticleId IdType="pubmed">29544699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40839904</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort.</ArticleTitle><Pagination><StartPage>102068</StartPage><MedlinePgn>102068</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2025.102068</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2772-963X(25)00493-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chronic kidney disease (CKD) is a risk-enhancing factor for cardiovascular disease (CVD) and is associated with higher lipoprotein(a) (Lp[a]) levels. While aspirin may reduce Lp(a)-related prothrombotic risk, the role of primary prevention aspirin for persons with CKD and elevated Lp(a) is unclear.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of the study was to assess the association of aspirin use with cardiovascular, renal, and bleeding outcomes stratified by Lp(a) level among individuals with CKD without clinical CVD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">There were 2,552 participants without clinical CVD in the Chronic Renal Insufficiency Cohort. Lp(a) was measured at baseline and not reported to clinicians. Aspirin use was self-reported and longitudinally assessed at each follow-up visit. Cox proportional hazards regression assessed the association of aspirin use with myocardial infarction (MI), stroke, end-stage renal disease (ESRD), and major bleeding events, stratified by Lp(a) &#x2265;50 vs &lt;50 mg/dL.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean age was 55.8 years, 48% were women, 34% reported aspirin use at baseline, 27% had Lp(a) &#x2265;50 mg/dL, and mean estimated glomerular filtration rate was 47 mL/min/1.73 m<sup>2</sup>. Over a median follow-up of 15.7 years, aspirin use was associated with a 38% lower risk of MI (HR: 0.62; 95% CI: 0.42-0.91) and a 28% lower risk of ESRD (HR: 0.72; 95% CI: 0.59-0.89) among individuals with Lp(a) &#x2265;50 but not Lp(a) &lt; 50 mg/dL (MI, HR: 1.38; 95% CI: 1.07-1.77; ESRD, HR: 0.98; 95% CI: 0.84-1.15). Aspirin use was not significantly associated with stroke or major bleeding in either Lp(a) group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Individuals with CKD and elevated Lp(a) without clinical CVD may derive net benefit from low-dose aspirin for the primary prevention of MI and ESRD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Razavi</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: acrazav@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sha</LastName><ForeName>Daohang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dzaye</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Harpreet S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsimikas</LastName><ForeName>Sotirios</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lash</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, University of Illinois Chicago College of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kansal</LastName><ForeName>Mayank</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, University of Illinois Chicago College of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rincon-Choles</LastName><ForeName>Hernan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Kidney Medicine, Medical Specialties Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaccarino</LastName><ForeName>Viola</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Terry A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Lipid Clinic and Cardiovascular Risk Reduction Program, Emory Department of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budoff</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Lundquist Institute, Harbor-UCLA Medical Center, Torrance, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blumenthal</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whelton</LastName><ForeName>Seamus P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Laurence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blaha</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CRIC Study Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aspirin</Keyword><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">chronic kidney disease</Keyword><Keyword MajorTopicYN="N">lipoprotein(a)</Keyword></KeywordList><CoiStatement>Funding support and author disclosures Funding for the CRIC study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATSUL1TR000003, Johns Hopkins UniversityUL1 TR-000424, University of MarylandGCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, Kaiser Permanente NIH/NCRR UCSF-CTSI UL1 RR-024131, Department of Internal Medicine, University of New Mexico School of Medicine Albuquerque, NM R01DK119199. Dr Razavi is supported by the National Heart, Lung, and Blood Institute Grant L30HL175751. A full list of participating CRIC investigators and institutions can be found at http://www.cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study. A portion of the data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Amanda H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Appel</LastName><ForeName>Lawrence J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Debbie L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dember</LastName><ForeName>Laura M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Go</LastName><ForeName>Alan S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Pandurago S</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Vallabh O</ForeName><Initials>VO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Unruh</LastName><ForeName>Mark L</ForeName><Initials>ML</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>17</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839904</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2025.102068</ArticleId><ArticleId IdType="pii">S2772-963X(25)00493-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840186</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8430</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of electrocardiology</Title><ISOAbbreviation>J Electrocardiol</ISOAbbreviation></Journal><ArticleTitle>"Acute coronary syndrome with atypical ST segment elevation may underlie multivessel coronary artery disease".</ArticleTitle><Pagination><StartPage>154099</StartPage><MedlinePgn>154099</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jelectrocard.2025.154099</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-0736(25)00227-4</ELocationID><Abstract><AbstractText>In rare cases of acute coronary syndrome, atypical, single lead ST elevation with or without associated ST depression and negative T waves in many leads may underlie multivessel coronary disease. We report the case of elderly man admitted for. syncope followed by epigastric pain, increased hs-TnI peak values and more pronounced ST-segment elevation in V3 than other leads. Coronary angiography showed multi-vessel coronary artery disease and the patient underwent coronary angioplasty.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Correale</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiothoracic Department, Policlinico Riuniti University Hospital, Foggia, Italy. Electronic address: michele.correale@libero.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucci</LastName><ForeName>Maria Luigia</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Electronic address: maria.tucci@unifg.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furore</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Electronic address: andrea_furore.549330@unifg.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbonara</LastName><ForeName>Michelangelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruscino</LastName><ForeName>Giannicola</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggiero</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiothoracic Department, Policlinico Riuniti University Hospital, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacoviello</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunetti</LastName><ForeName>Natale Daniele</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Electronic address: natale.brunetti@unifg.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Electrocardiol</MedlineTA><NlmUniqueID>0153605</NlmUniqueID><ISSNLinking>0022-0736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">Atypical electrocardiogram</Keyword><Keyword MajorTopicYN="N">Multivessel coronary artery disease</Keyword><Keyword MajorTopicYN="N">ST-elevation acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">syncope</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors have no relevant financial or non-financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>18</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840186</ArticleId><ArticleId IdType="doi">10.1016/j.jelectrocard.2025.154099</ArticleId><ArticleId IdType="pii">S0022-0736(25)00227-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40839563</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>8</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Improvement in risk prediction for patients with atrial fibrillation and intermediate-risk CHA2DS2-VASc score utilizing highly sensitive cardiac troponin T.</ArticleTitle><Pagination><StartPage>e0330164</StartPage><MedlinePgn>e0330164</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0330164</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0330164</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Guidelines of the European Society of Cardiology recommend a clinical risk assessment for patients with atrial fibrillation (AF). However, scores such as the CHA2DS2-VASc score show only a modest performance for prediction of adverse endpoints.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective single-center all-comer study uses data from the Heidelberg Registry of Atrial Fibrillation of 9,995 patients with non-valvular AF presenting to the emergency department (ED) of the University Hospital of Heidelberg from June 2009 until March 2020. Per CHA2DS2-VASc, risk was classified as low (0 point in men,&#x2009;&#x2264;&#x2009;1 point in females), intermediate, or high (&#x2265;2 points in men and &#x2265;3 points in females). The predictive performance of the CHA2DS2-VASc score, with and without highly sensitive cardiac troponin T (hs-cTnT), was evaluated for a composite endpoint comprising stroke, myocardial infarction (MI) or all-cause mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Performance of the CHA2DS2-VASc score for the prediction of the composite endpoint was poor Area under the curve (AUC): 0.648 (95%CI: 0.638-0.657) particularly in patients at intermediate-risk AUC: 0.542 (95%CI: 0.508-0.575). Adding hs-cTnT improved discrimination substantially in intermediate-risk patients (AUC: 0.778, 95% CI: 0.748-0.805). Notably, no events occurred in intermediate-risk patients with undetectable hs-cTnT (&lt;5&#x2009;ng/L).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In patients with AF at intermediate thromboembolic risk, the addition of hs-cTnT to the CHA&#x2082;DS&#x2082;-VASc score enhances prediction of adverse cardiovascular outcomes. Hs-cTnT may help identify patients who could benefit from anticoagulation, while also identifying a low-risk subgroup unlikely to experience events.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Salbach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salbach</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1799-545X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildirim</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milles</LastName><ForeName>Barbara Ruth</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0009-0004-4602-5489</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hund</LastName><ForeName>Hauke</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller-Hennessen</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katus</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannitsis</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020107">Troponin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020107" MajorTopicYN="Y">Troponin T</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>MMH received research funding from BRAHMS, Thermo Fisher Scientific and Roche Diagnostics. EG received honoraria for lectures from Roche Diagnostics, AstraZeneca, Bayer, Daiichi-Sankyo, Lilly Eli Deutschland. He serves as a consultant for Roche Diagnostics, BRAHMS, Thermo Fisher Scientific, Boehringer Ingelheim and has received research funding from BRAHMS, Thermo Fisher Scientific, Roche Diagnostics, Bayer Vital and Daiichi Sankyo. NF has received speaker honoraria from Daiichi Sankyo, Astra Zeneca, Boehringer Ingelheim and Bayer Vital. He serves as a consultant for CMS. BRM, received research funding from Daiichi Sankyo. There are no disclosures for MY, HH, HK and CS. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839563</ArticleId><ArticleId IdType="pmc">PMC12370022</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0330164</ArticleId><ArticleId IdType="pii">PONE-D-24-53160</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983&#x2013;8. doi: 10.1161/01.str.22.8.983</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.22.8.983</ArticleId><ArticleId IdType="pubmed">1866765</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56&#x2013;528. doi: 10.1161/CIR.0000000000000659</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000659</ArticleId><ArticleId IdType="pubmed">30700139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019&#x2013;26. doi: 10.1056/NEJMoa022913</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa022913</ArticleId><ArticleId IdType="pubmed">12968085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bode W, Ptaszek LM. Management of Atrial Fibrillation in the Emergency Department. Curr Cardiol Rep. 2021;23(12):179. doi: 10.1007/s11886-021-01611-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-021-01611-2</ArticleId><ArticleId IdType="pubmed">34657210</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh A, Iglesias M, Khanna R, Beaulieu T. Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation. Heart Rhythm O2. 2022;3(5):577&#x2013;86. doi: 10.1016/j.hroo.2022.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hroo.2022.07.010</ArticleId><ArticleId IdType="pmc">PMC9626881</ArticleId><ArticleId IdType="pubmed">36340482</ArticleId></ArticleIdList></Reference><Reference><Citation>Milman B, Burns BD. Atrial fibrillation: an approach to diagnosis and management in the emergency department. Emerg Med Pract. 2021;23(5):1&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">33885254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr&#xf6;m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373&#x2013;498. doi: 10.1093/eurheartj/ehaa612</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa612</ArticleId><ArticleId IdType="pubmed">32860505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorog DA, Gue YX, Chao T-F, Fauchier L, Ferreiro JL, Huber K, et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace. 2022;24(11):1844&#x2013;71. doi: 10.1093/europace/euac020</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac020</ArticleId><ArticleId IdType="pmc">PMC11636575</ArticleId><ArticleId IdType="pubmed">35323922</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Oldgren J, Lindb&#xe4;ck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387(10035):2302&#x2013;11. doi: 10.1016/S0140-6736(16)00741-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00741-8</ArticleId><ArticleId IdType="pubmed">27056738</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395&#x2013;401. doi: 10.1016/j.jacc.2011.03.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2011.03.031</ArticleId><ArticleId IdType="pmc">PMC3175766</ArticleId><ArticleId IdType="pubmed">21757117</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258&#x2013;64. doi: 10.1093/eurheartj/ehv476</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv476</ArticleId><ArticleId IdType="pmc">PMC4670965</ArticleId><ArticleId IdType="pubmed">26424865</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox KAA, Lucas JE, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. doi: 10.1136/bmjopen-2017-017157</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-017157</ArticleId><ArticleId IdType="pmc">PMC5778339</ArticleId><ArticleId IdType="pubmed">29273652</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314&#x2013;414. doi: 10.1093/eurheartj/ehae176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae176</ArticleId><ArticleId IdType="pubmed">39210723</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, et al. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019;139(6):760&#x2013;71. doi: 10.1161/CIRCULATIONAHA.118.038312</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.038312</ArticleId><ArticleId IdType="pmc">PMC6363338</ArticleId><ArticleId IdType="pubmed">30586727</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg DD, Ruff CT, Morrow DA. Biomarkers for Risk Assessment in Atrial Fibrillation. Clin Chem. 2021;67(1):87&#x2013;95. doi: 10.1093/clinchem/hvaa298</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/hvaa298</ArticleId><ArticleId IdType="pubmed">33313695</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Oldgren J, Siegbahn A, Wallentin L. Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. Clin Chem. 2017;63(1):152&#x2013;64. doi: 10.1373/clinchem.2016.255182</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2016.255182</ArticleId><ArticleId IdType="pubmed">27811208</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildirim M, Salbach C, Reich C, Milles BR, Biener M, Frey N, et al. Comparison of the clinical chemistry score to other biomarker algorithms for rapid rule-out of acute myocardial infarction and risk stratification in patients with suspected acute coronary syndrome. Int J Cardiol. 2024;400:131815. doi: 10.1016/j.ijcard.2024.131815</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2024.131815</ArticleId><ArticleId IdType="pubmed">38278492</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildirim M, Reich C, Salbach C, Biener M, Mueller-Hennessen M, S&#xf6;rensen NA, et al. Identification of patients with suspected NSTE-ACS in the observe zone: evaluating GRACE 1.0 score and a biomarker panel for risk stratification and management optimization. Clin Res Cardiol. 2025;114(6):783&#x2013;95. doi: 10.1007/s00392-025-02642-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-025-02642-3</ArticleId><ArticleId IdType="pmc">PMC12089253</ArticleId><ArticleId IdType="pubmed">40227426</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin SY, Han S-J, Kim J-S, Im SI, Shim J, Ahn J, et al. Identification of Markers Associated With Development of Stroke in &#x201c;Clinically Low-Risk&#x201d; Atrial Fibrillation Patients. J Am Heart Assoc. 2019;8(21):e012697. doi: 10.1161/JAHA.119.012697</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.012697</ArticleId><ArticleId IdType="pmc">PMC6898804</ArticleId><ArticleId IdType="pubmed">31668140</ArticleId></ArticleIdList></Reference><Reference><Citation>Salbach C, Yildirim M, Hund H, Biener M, Mueller-Hennessen M, Frey N, et al. Design, rationale and initial findings from the Heidelberg Registry of Atrial Fibrillation on 10,222 patients with atrial fibrillation presenting to an emergency department over an 11-year period. Manuscript submitted for publication; 2024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11179873</ArticleId><ArticleId IdType="pubmed">38639359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip GYH, Collet JP, Caterina R de, Fauchier L, Lane DA, Larsen TB, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci&#xf3;n Card&#xed;aca y Electrofisiolog&#xed;a (SOLEACE). Europace. 2017;19(11):1757&#x2013;8. doi: 10.1093/europace/eux240</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eux240</ArticleId><ArticleId IdType="pubmed">29096024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263&#x2013;72. doi: 10.1378/chest.09-1584</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-1584</ArticleId><ArticleId IdType="pubmed">19762550</ArticleId></ArticleIdList></Reference><Reference><Citation>Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics. 1995;51(4):1469&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">8589234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29&#x2013;36. doi: 10.1148/radiology.143.1.7063747</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.143.1.7063747</ArticleId><ArticleId IdType="pubmed">7063747</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839&#x2013;43. doi: 10.1148/radiology.148.3.6878708</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.148.3.6878708</ArticleId><ArticleId IdType="pubmed">6878708</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencina MJ, D&#x2019;Agostino RB Sr, D&#x2019;Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157&#x2013;72; discussion 207-12. doi: 10.1002/sim.2929</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2929</ArticleId><ArticleId IdType="pubmed">17569110</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J-Y, Zhang A-D, Lu H-Y, Guo J, Wang F-F, Li Z-C. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol. 2013;10(3):258&#x2013;66. doi: 10.3969/j.issn.1671-5411.2013.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1671-5411.2013.03.004</ArticleId><ArticleId IdType="pmc">PMC3796700</ArticleId><ArticleId IdType="pubmed">24133514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hioki H, Miura T, Miyashita Y, Motoki H, Shimada K, Kobayashi M, et al. Risk stratification using the CHA2DS2-VASc score in patients with coronary heart disease undergoing percutaneous coronary intervention; sub-analysis of SHINANO registry. Int J Cardiol Heart Vasc. 2015;7:76&#x2013;81. doi: 10.1016/j.ijcha.2015.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2015.02.007</ArticleId><ArticleId IdType="pmc">PMC5497243</ArticleId><ArticleId IdType="pubmed">28785649</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen J, Tonkin A, Varigos J, Fonguh S, Berkowitz SD, Yusuf S, et al. CHA2DS2-VASc and CHADS2 scores for risk stratification of major adverse cardiovascular events in the COMPASS trial. European Heart Journal. 2020;41(Supplement_2). doi: 10.1093/ehjci/ehaa946.2906</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/ehaa946.2906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-K, Hung C-S, Huang C-C, Chen Y-H, Chuang P-Y, Yu J-Y, et al. Use of the CHA2DS2-VASc Score for Risk Stratification of Hospital Admissions Among Patients With Cardiovascular Diseases Receiving a Fourth-Generation Synchronous Telehealth Program: Retrospective Cohort Study. J Med Internet Res. 2019;21(1):e12790. doi: 10.2196/12790</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/12790</ArticleId><ArticleId IdType="pmc">PMC6374726</ArticleId><ArticleId IdType="pubmed">30702437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B-Y, Lin F-Y, Ku M-S, Wang Y-H, Lee K-Y, Ho S-W. CHA2DS2-VASc Score for Major Adverse Cardiovascular Events Stratification in Patients with Pneumonia with and without Atrial Fibrillation. J Clin Med. 2021;10(18):4093. doi: 10.3390/jcm10184093</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10184093</ArticleId><ArticleId IdType="pmc">PMC8466520</ArticleId><ArticleId IdType="pubmed">34575202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y-T, Chang F-L, Li P-H, Lu W-C, Chiu C-S. Assessing the Suitability of CHA2DS2-VASc for Predicting Adverse Limb Events and Cardiovascular Outcomes in Peripheral Artery Disease Patients with Percutaneous Transluminal Angioplasty: A Retrospective Cohort Study. Biomedicines. 2024;12(6):1374. doi: 10.3390/biomedicines12061374</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12061374</ArticleId><ArticleId IdType="pmc">PMC11202305</ArticleId><ArticleId IdType="pubmed">38927581</ArticleId></ArticleIdList></Reference><Reference><Citation>Champsi A, Mobley AR, Subramanian A, Nirantharakumar K, Wang X, Shukla D, et al. Gender and contemporary risk of adverse events in atrial fibrillation. Eur Heart J. 2024;45(36):3707&#x2013;17. doi: 10.1093/eurheartj/ehae539</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae539</ArticleId><ArticleId IdType="pmc">PMC11439109</ArticleId><ArticleId IdType="pubmed">39217497</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura H, Providencia R, Finan C, Schmidt AF, Lip GYH. Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?. Europace. 2024;26(11):euae280. doi: 10.1093/europace/euae280</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euae280</ArticleId><ArticleId IdType="pmc">PMC11574618</ArticleId><ArticleId IdType="pubmed">39522169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip GYH, Proietti M, Potpara T, Mansour M, Savelieva I, Tse HF, et al. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace. 2023;25(9):euad226. doi: 10.1093/europace/euad226</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad226</ArticleId><ArticleId IdType="pmc">PMC10451006</ArticleId><ArticleId IdType="pubmed">37622590</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735&#x2013;49. doi: 10.1001/jama.2016.3775</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.3775</ArticleId><ArticleId IdType="pmc">PMC5408574</ArticleId><ArticleId IdType="pubmed">27022822</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa F, van Klaveren D, James S, Heg D, R&#xe4;ber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025&#x2013;34. doi: 10.1016/S0140-6736(17)30397-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30397-5</ArticleId><ArticleId IdType="pubmed">28290994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueki Y, B&#xe4;r S, Losdat S, Otsuka T, Zanchin C, Zanchin T, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention. 2020;16(5):371&#x2013;9. doi: 10.4244/EIJ-D-20-00052</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-D-20-00052</ArticleId><ArticleId IdType="pubmed">32065586</ArticleId></ArticleIdList></Reference><Reference><Citation>Brabrand M, Lassen AT, Knudsen T, Hallas J. Seven-day mortality can be predicted in medical patients by blood pressure, age, respiratory rate, loss of independence, and peripheral oxygen saturation (the PARIS score): a prospective cohort study with external validation. PLoS One. 2015;10(4):e0122480. doi: 10.1371/journal.pone.0122480</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0122480</ArticleId><ArticleId IdType="pmc">PMC4395094</ArticleId><ArticleId IdType="pubmed">25867881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125(13):1605&#x2013;16. doi: 10.1161/CIRCULATIONAHA.111.038729</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.038729</ArticleId><ArticleId IdType="pubmed">22374183</ArticleId></ArticleIdList></Reference><Reference><Citation>Provid&#xea;ncia R, Paiva L, Barra S. Risk stratification of patients with atrial fibrillation: Biomarkers and other future perspectives. World J Cardiol. 2012;4(6):195&#x2013;200. doi: 10.4330/wjc.v4.i6.195</Citation><ArticleIdList><ArticleId IdType="doi">10.4330/wjc.v4.i6.195</ArticleId><ArticleId IdType="pmc">PMC3386309</ArticleId><ArticleId IdType="pubmed">22761972</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840206</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-1787</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>JACC. Heart failure</Title><ISOAbbreviation>JACC Heart Fail</ISOAbbreviation></Journal><ArticleTitle>CSWG-SCAI Stages Combined With Machine Learning-Based Phenotypes for Serial Risk Stratification in Cardiogenic Shock.</ArticleTitle><Pagination><StartPage>102611</StartPage><MedlinePgn>102611</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jchf.2025.102611</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-1779(25)00539-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiogenic shock (CS) severity can be defined by the SCAI (Society for Cardiovascular Angiography and Interventions) stages (A to E), or machine learning-based phenotypes (I: noncongested, II: cardiorenal, III: cardiometabolic).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aims to evaluate sequential applicability and prognostic relevance of combining SCAI stages and ML-based phenotypes for risk stratification of patients with CS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The authors retrospectively applied both classification systems at 6- to 12-hour intervals for the first 72 hours to patients from the multicenter CSWG (Cardiogenic Shock Working Group) registry. The primary outcome was in-hospital mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 7,716 CS patients were included (admission CSWG-SCAI stages A to E: n = 1,526, n = 1,602, n = 838, n = 2,445, and n = 1,305, respectively; phenotypes I to III: n = 2,963, n = 3,266, n = 1,487, respectively). Within 6 hours from admission, CSWG-SCAI stages and phenotypes changed in 78% and 77% of patients, respectively, then remained relatively unchanged throughout the first 72 hours. Combining ML-based phenotypes with CSWG-SCAI stages to subclassify patients improved risk stratification (mortality for stages C-I: 12%-14%, C-II: 22%-26%, D-I: 21%-23%, D-II: 31%-34%, and D-III: 37%-40%). Admission phenotypes II and III strongly increased the odds of CS progression from stages A-C to D-E or death within 72 hours of admission (phenotype II: OR: 1.2 [95% CI: 0.99-1.39]; P = 0.051; phenotype III: OR: 11.4 [95% CI: 3.50-36.95]; P &lt; 0.0001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Most patients with CS reached phenotype I and stage D within 6 hours after admission. Combining ML-based phenotypes with CSWG-SCAI staging may facilitate the transition from typical treatment intensity-based approaches to mechanistic classification that reflects the heterogeneity within CS populations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zweck</LastName><ForeName>Elric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA; Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Duesseldorf, Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ton</LastName><ForeName>Van-Khue</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanwar</LastName><ForeName>Manreet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical City Healthcare, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Borui</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Shashank S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Inova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez-Montfort</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Baylor Scott and White Health, Advanced Heart Failure Program Clinic, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garan</LastName><ForeName>A Reshad</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Inova Schar Heart and Vascular Institute, Inova Fairfax Campus, Falls Church, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blumer</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Inova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataria</LastName><ForeName>Rachna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Brown University Health Cardiovascular Institute, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polzin</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Duesseldorf, Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkhoff</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Foundation, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapur</LastName><ForeName>Navin K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>The CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA. Electronic address: Nkapur@tuftsmedicalcenter.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CSWG Academic Research Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Heart Fail</MedlineTA><NlmUniqueID>101598241</NlmUniqueID><ISSNLinking>2213-1779</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">artificial intelligence</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">phenotypes</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The work of Dr Zweck is supported by grants from the German Research Foundation (DFG, grant numbers 527448911, 493659010). Dr Zweck has received a travel grant and speaker honoraria from Abiomed. Dr Kanwar has received consultant fees from Abbott, Abiomed, and CorWave; and has served as speaker for Abiomed. Dr Abraham is an employee of Edwards Lifesciences; and has received honoraria from Abbott, Abiomed, and Ancora. Dr Li has served as consultant for Abiomed. Dr Lundgren has served as speaker for Abbott. Dr Nathan has served as consultant for Medtronic, Inc, Merit Medical, Getinge, Terumo, and Zoll. Dr Hall was a consultant and advisory board member for Abbott, Natera, CareDx, and CVRx. Dr Farr has served on the TransMedics and Natera steering committees. Dr Bezerra was a consultant and part of Speaker Bureau for Abbott, Abiomed, and Medtronic. Dr Mahr was a consultant for Abbott, Abiomed, and Endotronix. Dr Polzin has received research grant and speaker honoraria from Abiomed. Dr Burkhoff served as a consultant to Boston Scientific, Medtronic, and TherOx. Dr Kapur is an employee of Johnson and Johnson, MedTech; and has served as a consultant for Abiomed Grant Support, Abbott, Abiomed, Boston Scientific, Getinge, LivaNova, Teleflex, and Zoll. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Hickey</LastName><ForeName>Gavin W</ForeName><Initials>GW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahuja</LastName><ForeName>Mohit</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lundgren</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nathan</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vorovich</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Shelley</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khalife</LastName><ForeName>Wissam</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartzman</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ju</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vishnevsky</LastName><ForeName>Oleg Alec</ForeName><Initials>OA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fried</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farr</LastName><ForeName>Mary Jane</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mishkin</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>I-Hui</ForeName><Initials>IH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ilonze</LastName><ForeName>Onyedika</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arias</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakata</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marbach</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bezerra</LastName><ForeName>Hiram</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gage</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wald</LastName><ForeName>Joyce</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Sunu</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kochar</LastName><ForeName>Ajar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vallabhajosyula</LastName><ForeName>Saraschandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahr</LastName><ForeName>Claudius</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rahman</LastName><ForeName>Faisal</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masoumi</LastName><ForeName>Amirali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gohar</LastName><ForeName>Salman</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>John</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kong</LastName><ForeName>Qiuyue</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sangal</LastName><ForeName>Paavni</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walec</LastName><ForeName>Karol D</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zazzali</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harwani</LastName><ForeName>Neil M</ForeName><Initials>NM</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>18</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840206</ArticleId><ArticleId IdType="doi">10.1016/j.jchf.2025.102611</ArticleId><ArticleId IdType="pii">S2213-1779(25)00539-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840218</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3181</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Annales de cardiologie et d'angeiologie</Title><ISOAbbreviation>Ann Cardiol Angeiol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Seniors and coronary calcified lesions].</ArticleTitle><Pagination><StartPage>101926</StartPage><MedlinePgn>101926</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ancard.2025.101926</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0003-3928(25)00065-4</ELocationID><Abstract><AbstractText>Coronary artery calcification is highly prevalent in elderly patients and poses significant challenges during percutaneous coronary intervention (PCI). We report the case of an 86-year-old man admitted for ST-elevation myocardial infarction. Coronary angiography revealed triple-vessel disease with an acute coronary artery occlusion, a long, heavily calcified proximal-to-mid left anterior descending artery stenosis, and a severely calcified proximal circumflex lesion. PCI revascularization was performed in 3 steps: primary PCI of the right coronary artery initially, then 3 days after, PCI of the circumflex artery using rotational atherectomy, scoring balloon dilation, and intravascular lithotripsy. Then, at Day 15, PCI of the left anterior descending artery with orbital atherectomy finished complete revascularization. This case underscores the importance of a comprehensive geriatric assessment-particularly frailty and physiological age-before selecting a revascularization strategy requiring the use of specific tools as advanced plaque-modification techniques and intravascular imaging, without any restriction according to age.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El Marzouki</LastName><ForeName>Ikram</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institut Cardio Vasculaire, Groupe Hospitalier Mutualiste de Grenoble, 8 rue du Dr Calmette, 38000 Grenoble, France. Electronic address: ikram034@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsegu</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Groupe Hospitalier Mutualiste de Grenoble, 8 rue du Dr Calmette, 38000 Grenoble, France. Electronic address: jacquesmonsegu@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>S&#xe9;niors et l&#xe9;sions coronaires calcifi&#xe9;es.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Cardiol Angeiol (Paris)</MedlineTA><NlmUniqueID>0142167</NlmUniqueID><ISSNLinking>0003-3928</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Calcified coronary lesions</Keyword><Keyword MajorTopicYN="N">Elderly patients</Keyword><Keyword MajorTopicYN="N">Intravascular imaging</Keyword><Keyword MajorTopicYN="N">Intravascular lithotripsy</Keyword><Keyword MajorTopicYN="N">Orbital atherectomy</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">Rotational atherectomy</Keyword></KeywordList><CoiStatement>Conflits d'int&#xe9;r&#xea;ts Aucun conflit d'int&#xe9;r&#xea;t en rapport avec le texte.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>18</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840218</ArticleId><ArticleId IdType="doi">10.1016/j.ancard.2025.101926</ArticleId><ArticleId IdType="pii">S0003-3928(25)00065-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40841105</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2666-0873</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JACC. CardioOncology</Title><ISOAbbreviation>JACC CardioOncol</ISOAbbreviation></Journal><ArticleTitle>Cancer Development in Atherosclerotic Cardiovascular Disease: JACC: CardioOncology Short-Form Primer.</ArticleTitle><Pagination><StartPage>514</StartPage><EndPage>517</EndPage><MedlinePgn>514-517</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaccao.2025.05.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-0873(25)00254-6</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dalman</LastName><ForeName>Jessie M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA; University of Michigan Medical School, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Kathryn J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA; Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA. Electronic address: kathryn.moore@nyulangone.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC CardioOncol</MedlineTA><NlmUniqueID>101761697</NlmUniqueID><ISSNLinking>2666-0873</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atherosclerosis</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">epigenetics</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">neoplasm</Keyword><Keyword MajorTopicYN="N">reverse cardio-oncology</Keyword><Keyword MajorTopicYN="N">tumor</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The authors were supported by grants from the Sarnoff Cardiovascular Research Foundation (to Ms Dalman) and the National Institutes of Health (R01HL172335, R01HL172365, and P01HL131481 to Dr Moore). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841105</ArticleId><ArticleId IdType="doi">10.1016/j.jaccao.2025.05.016</ArticleId><ArticleId IdType="pii">S2666-0873(25)00254-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40841145</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-3003</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>The European respiratory journal</Title><ISOAbbreviation>Eur Respir J</ISOAbbreviation></Journal><ArticleTitle>MACE or Death Risk in Obstructive Sleep Apnoea and the Effect of Positive Airway Pressure.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2500519</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1183/13993003.00519-2025</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Evidence regarding the efficacy of positive airway pressure (PAP) therapy in reducing the risks of non-fatal major cardiovascular events (NF-MACE) and mortality in patients with obstructive sleep apnoea (OSA) remains controversial.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aims to quantify the impact of PAP therapy on these risks and develop a predictive risk estimator.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multicentre, observational, prospective study involving 5358 individuals diagnosed with OSA, with a median follow-up of 14&#x2005;years (IQR 10-15&#x2005;years). We derived and validated a risk estimator of NF-MACE (including myocardial infarction, stroke, revascularisation procedures, and congestive heart failure) and all-cause mortality, incorporating PAP adherence alongside clinical and sleep-related data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The cohort's mean (sd) for age was 55&#xb1;11&#x2005;years, the Body Mass Index 32.0&#xb1;5.4&#x2005;Kg&#xb7;m<sup>-2</sup>, and an apnoea-hypopnea index (AHI) of 35 (&#xb1;22) events/hour; 26% were females, and 1467 (37%) were PAP adherent. Over the follow-up period, 754 participants experienced NF-MACE, while 858 deaths were recorded. Significant predictors included prior cardiovascular events, non-HDL cholesterol &#x2265;200&#x2005;mg&#xb7;dL<sup>-1</sup>, COPD diagnosis, AHI &gt;30 events/hr, and age &gt;60&#x2005;years. PAP adherence was protective (OR 0.46; 95% CI: 0.38 to 0.56), and the absolute risk reduction varied depending on the baseline risk (median of 16%, IQR 12-18). The risk estimator yielded an AUROC of 0.75 and a Brier score of 0.17, with 64% sensitivity and 75% specificity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PAP therapy is associated with long-term risk reduction of NF-MACE and mortality in OSA patients, while the developed risk estimator enhances clinical decision-making regarding therapy initiation.</AbstractText><CopyrightInformation>Copyright &#xa9;The authors 2025. For reproduction rights and permissions contact permissions@ersnet.org.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Divo</LastName><ForeName>Miguel J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0770-7653</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA mdivo@bwh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Foundation, Wellesley, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Garcia</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-7321-1891</Identifier><AffiliationInfo><Affiliation>Respiratory Department, Polytechnic and University Hospital la Fe, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Invertigaci&#xf3;n Biomedica en Red, Instituto Carlos III, Ministry of Health, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pneumology, "Marques de Valdecilla" University Hospital, University of Cantabria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Research Marqu&#xe9;s de Valdecilla (IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos-Rodriguez</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centro Invertigaci&#xf3;n Biomedica en Red, Instituto Carlos III, Ministry of Health, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Department, Hospital Universitario Valme, and Instituto de Biomedicina de Sevilla, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloberes</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centro Invertigaci&#xf3;n Biomedica en Red, Instituto Carlos III, Ministry of Health, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Department, Hospital Universitario Vall de Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin-Oto</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory Department, Hospital Clinico Universitario, Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sleep Research Program, IIS-Arag&#xf3;n, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forner</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro Invertigaci&#xf3;n Biomedica en Red, Instituto Carlos III, Ministry of Health, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sleep Research Program, IIS-Arag&#xf3;n, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz-Rubio</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centro Invertigaci&#xf3;n Biomedica en Red, Instituto Carlos III, Ministry of Health, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sleep Research Program, IIS-Arag&#xf3;n, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieto</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sleep Research Program, IIS-Arag&#xf3;n, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celli</LastName><ForeName>Bartolome R</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-7266-8371</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Foundation, Wellesley, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Bartolome Celli and Dr. Jose M. Marin are both senior co-authors.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-9096-2294</Identifier><AffiliationInfo><Affiliation>Centro Invertigaci&#xf3;n Biomedica en Red, Instituto Carlos III, Ministry of Health, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sleep Research Program, IIS-Arag&#xf3;n, Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Department, Hospital Universitario Miguel Servet &amp; Department of Medicine, University of Zaragoza, Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Bartolome Celli and Dr. Jose M. Marin are both senior co-authors.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Spanish Sleep Network</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Respir J</MedlineTA><NlmUniqueID>8803460</NlmUniqueID><ISSNLinking>0903-1936</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841145</ArticleId><ArticleId IdType="doi">10.1183/13993003.00519-2025</ArticleId><ArticleId IdType="pii">13993003.00519-2025</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40840987</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Association between adjusted atherogenic index of plasma and major adverse cardiovascular events after percutaneous coronary intervention in patients with STEMI: a prospective observational study in China.</ArticleTitle><Pagination><StartPage>e096065</StartPage><MedlinePgn>e096065</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-096065</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The atherogenic index of plasma (AIP) has been reported as a biomarker for cardiovascular disease risks and clinical outcomes. However, few studies have investigated the relationship between the AIP and major adverse cardiovascular events (MACEs) after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective observational study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Data were collected from consecutive patients with STEMI who received PCI at Fuyang People's Hospital from January 2023 to March 2024.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 334 patients with STEMI who underwent PCI. The adjusted AIP (aAIP) was calculated using the following formula: aAIP=log ((triglyceride/high-density lipoprotein cholesterol &#xd7; 100). The patient population was divided into four groups based on the aAIP quartiles.</AbstractText><AbstractText Label="PRIMARY AND SECONDARY OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome was MACEs, and the secondary outcomes included all-cause mortality, all-cause readmission and unplanned readmission as individual endpoints.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 334 eligible patients, 68 (20.36%) experienced MACEs during a median follow-up of 8.70 months. After adjusting for confounders, continuous aAIP was positively correlated with MACEs in all three models. Patients in Q3 and Q4 had significantly higher MACE risks than Q1 (p&lt;0.001 for each model), but no difference was observed between Q1 and Q2 (p&gt;0.05 for each model). Compared with Q1, Q4 had significantly increased all-cause mortality risk (Model 2: HR=12.72, 95%&#x2009;CI 1.39 to 76.44 and Model 3: HR=16.18, 95%&#x2009;CI 1.66 to 117.50). All-cause readmission risk was also higher in Q3 and Q4 (Model 3: Q3: HR=2.242, 95%&#x2009;CI 1.043 to 4.818, p=0.039 and Q4: HR=5.378, 95%&#x2009;CI 2.557 to 11.314, p&lt;0.001). Kaplan-Meier curves showed that higher aAIP was associated with increased risks of MACEs, all-cause readmission and unplanned readmission (all log-rank p&lt;0.0001), but not all-cause mortality (log-rank p=0.1534). No significant interactions between subgroups and the aAIP were observed (p&gt;0.05 for interaction).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Higher aAIP was significantly associated with increased risks of MACEs, all-cause readmission and unplanned readmission.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0005-4029-4693</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Fuyang People's Hospital, Fuyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Xiaowu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-6954-598X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Laboratory, The Second People's Hospital of Fuyang, Fuyang Clinical College of Infectious Diseases, Anhui Medical University, Fuyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhenfeng</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0002-8945-916X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Fuyang People's Hospital, Fuyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0002-4230-2042</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Fuyang People's Hospital, Fuyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M A</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0007-1797-4791</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fuyang People's Hospital, Fuyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yongkai</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0001-6951-059X</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Fuyang People's Hospital, Fuyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0005-1666-0307</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Fuyang People's Hospital, Fuyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guangli</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0008-2986-9259</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Fuyang People's Hospital, Fuyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaojuan</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-9215-5733</Identifier><AffiliationInfo><Affiliation>Department of Academic Affairs, Fuyang People's Hospital, Fuyang, China wxj0037@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="Y">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="Y">Cholesterol, HDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronary intervention</Keyword><Keyword MajorTopicYN="N">Death, Sudden, Cardiac</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840987</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-096065</ArticleId><ArticleId IdType="pii">bmjopen-2024-096065</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40840836</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-8584</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Journal of molecular and cellular cardiology</Title><ISOAbbreviation>J Mol Cell Cardiol</ISOAbbreviation></Journal><ArticleTitle>A brief history of circadian time in the heart.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0022-2828(25)00146-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yjmcc.2025.08.005</ELocationID><Abstract><AbstractText>This review tracks the discovery of circadian biology in cardiovascular science, starting with early clinical observations of daily changes in heart rate, blood pressure, and cardiovascular events. These patterns suggested that time of day matters, but it was not until the past two decades that the mechanisms and knowledge translation of these rhythms were uncovered. We describe the heart's intrinsic circadian properties and importantly how this leads to regulation of cardiac gene and protein expression, neuroendocrine and vascular rhythms, metabolism, cellular electrophysiology, and cell signaling pathways. Next, we explore emerging themes, including the impact of circadian timing on ischemic injury, cardiac aging, and trends in circadian desynchrony, sex, and interorgan crosstalk. Building on these discoveries, circadian medicine is beginning to reshape clinical care including timing of surgery, chronotherapies, biomarkers, ICU design, novel molecular drugs targeting the circadian clock, the role of the microbiome and time restricted eating, the new field of rest, and the concept of One Health and applications to veterinary medicine. Looking ahead we address new frontiers such as epigenetics, gene editing, and spaceflight. Together, these advances offer a roadmap for how circadian rhythms can be harnessed to improve cardiovascular health and disease outcomes, supporting longer and healthier lives.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Martin E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanna</LastName><ForeName>Vanya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre for Cardiovascular Investigations, Department of Biomedical Science, University of Guelph, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metcalfe</LastName><ForeName>Mallory</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Cardiovascular Investigations, Department of Biomedical Science, University of Guelph, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rameshkumar</LastName><ForeName>Niruththaan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Cardiovascular Investigations, Department of Biomedical Science, University of Guelph, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harington</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Cardiovascular Investigations, Department of Biomedical Science, University of Guelph, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Leo H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Centre for Cardiovascular Investigations, Department of Biomedical Science, University of Guelph, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doost</LastName><ForeName>Janan Shoja</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Centre for Cardiovascular Investigations, Department of Biomedical Science, University of Guelph, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taegtmeyer</LastName><ForeName>Heinrich</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>McGovern Medical School, The University of Texas Health Science Center at Houston, Department of Internal Medicine, Division of Cardiology, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Tami A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Centre for Cardiovascular Investigations, Department of Biomedical Science, University of Guelph, Ontario, Canada. Electronic address: tmartino@uoguelph.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Mol Cell Cardiol</MedlineTA><NlmUniqueID>0262322</NlmUniqueID><ISSNLinking>0022-2828</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac</Keyword><Keyword MajorTopicYN="N">Cardiovascular</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Chronotherapy</Keyword><Keyword MajorTopicYN="N">Circadian medicine</Keyword><Keyword MajorTopicYN="N">Desynchrony</Keyword><Keyword MajorTopicYN="N">Diurnal</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>19</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40840836</ArticleId><ArticleId IdType="doi">10.1016/j.yjmcc.2025.08.005</ArticleId><ArticleId IdType="pii">S0022-2828(25)00146-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40843738</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2076-3271</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Medical sciences (Basel, Switzerland)</Title><ISOAbbreviation>Med Sci (Basel)</ISOAbbreviation></Journal><ArticleTitle>Risk Stratification in Acute Coronary Syndromes: The Systemic Immune-Inflammation Index as Prognostic Marker.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medsci13030116</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">Inflammation plays a key role in acute coronary syndromes (ACS). The systemic immune-inflammation index (SII), which integrates immune and inflammatory markers, may serve as a valuable prognostic tool. This study aimed to evaluate the utility of SII as a short-term predictor of mortality and major adverse cardiovascular and cerebral events (MACCE) in ACS patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis was conducted on 964 ACS patients admitted in 2023. SII was calculated from admission hematological parameters. Primary and secondary outcomes were 30-day mortality and MACCE, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SII levels differed significantly across ACS subtypes (<i>p</i> &lt; 0.001), highest in ST-segment elevation myocardial infarction (STEMI) and lowest in unstable angina. SII was markedly higher in deceased patients (2003.79 &#xb1; 1601.17) vs. survivors (722.04 &#xb1; 837.25; <i>p</i> &lt; 0.001) and remained an independent predictor of mortality (OR = 1.038, <i>p</i> &lt; 0.001). Similarly, SII was elevated in MACCE cases (1717 &#xb1; 1611.32) vs. non-MACCE (664.68 &#xb1; 713.11; <i>p</i> &lt; 0.001) and remained predictive in multivariate analysis (OR = 1.080, <i>p</i> &lt; 0.001). Predictive accuracy for MACCE was moderate (AUC = 0.762), improved when combined with GRACE 2, especially in specificity (<i>p</i> = 0.07). In STEMI, SII had excellent accuracy (AUC = 0.874), outperforming neutrophil-lymphocyte ratio and C-reactive protein. SII rose at 24 h and declined at 48 h in STEMI, with a slower decline in MACCE patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SII proved to be a cost-effective biomarker reflecting inflammation, immunity, and thrombosis. Elevated SII predicted short-term MACCE and mortality in ACS, with improved prognostic power when combined with GRACE 2. Persistent elevation may signal ongoing inflammation and increased MACCE risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Babes</LastName><ForeName>Elena Emilia</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radu</LastName><ForeName>Andrei-Flavius</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-7625-8177</Identifier><AffiliationInfo><Affiliation>Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psycho-Neurosciences and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cretu</LastName><ForeName>Noemi Adaus</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bungau</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaconu</LastName><ForeName>Camelia Cristina</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-6837-260X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila Bucharest, 050474 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Romanian Scientists, 050085 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tit</LastName><ForeName>Delia Mirela</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-0296-6592</Identifier><AffiliationInfo><Affiliation>Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babes</LastName><ForeName>Victor Vlad</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Med Sci (Basel)</MedlineTA><NlmUniqueID>101629322</NlmUniqueID><ISSNLinking>2076-3271</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054058" MajorTopicYN="Y">Acute Coronary Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NSTEMI</Keyword><Keyword MajorTopicYN="N">STEMI</Keyword><Keyword MajorTopicYN="N">acute coronary syndromes</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">major adverse cardiac and cerebrovascular events</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">systemic immune-inflammation index</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843738</ArticleId><ArticleId IdType="doi">10.3390/medsci13030116</ArticleId><ArticleId IdType="pii">medsci13030116</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40843768</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2076-3271</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Medical sciences (Basel, Switzerland)</Title><ISOAbbreviation>Med Sci (Basel)</ISOAbbreviation></Journal><ArticleTitle>Health-Related Quality-of-Life Measures in Patients with Heart Failure Cardiogenic Shock Following Axillary Mechanical Circulatory Support.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">146</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medsci13030146</ELocationID><Abstract><AbstractText><b>Background:</b> Patients with end-stage heart failure-related cardiogenic shock (HF-CS) are conclusively associated with a poor health-related quality of life (HRQL). Axillary mechanical circulatory support (aMCS), such as the Impella 5.5, is increasingly used in this population and may improve HRQL during hospitalization by providing enhanced left ventricular unloading. We aimed to assess changes in HRQL between admission and two weeks after Impella 5.5 placement in patients with HF-CS, using the Kansas City Cardiomyopathy Questionnaire (KCCQ). <b>Methods:</b> We conducted a prospective longitudinal analysis on patients with the Impella 5.5 between May 2023 and July 2023. Participants completed the condensed KCCQ-12 at admission and again two weeks post-implantation. Changes in the scores were evaluated using the Wilcoxon signed-rank test. <b>Results:</b> Fifteen patients were enrolled. The median age was 59 years (50-63), and the median ejection fraction at implantation was 20% (15-30). On admission, most patients reported an overall HRQL of poor-to-fair (46.7%) according to the summary KCCQ-12 score. The median overall summary score increased significantly after Impella 5.5 support (50.52 vs. 28.13, <i>p</i> = 0.005). Symptom frequency (70.83 vs. 43.75, <i>p</i> = 0.009) and quality-of-life (50.00 vs. 12.50, <i>p</i> = 0.023) domains improved significantly, while physical limitation showed a positive trend and social limitation remained unchanged. These HRQL improvements occurred alongside a significant shift toward lower SCAI shock stages, marked increases in cardiac output and cardiac index, and no escalation in vasoactive-inotropic requirements. <b>Conclusions:</b> Impella 5.5 support in HF-CS patients was associated with early and clinically meaningful improvements in HRQL, particularly in symptom frequency and quality of life, during the critical pre-transplant or recovery period. These findings suggest that the Impella 5.5 may provide both physiological and patient-perceived benefits in this high-risk population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mautong</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Health, Universidad Esp&#xed;ritu Santo-Ecuador, Samborond&#xf3;n 092301, Guayas, Ecuador.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>John H. Stroger Jr. Hospital of Cook County, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Aarti</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0006-2502-6153</Identifier><AffiliationInfo><Affiliation>Division of Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Shriya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>St. Elizabeth Medical Center, Boston, MA 02135, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Jose</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8616-6321</Identifier><AffiliationInfo><Affiliation>Division of Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leoni</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7820-3842</Identifier><AffiliationInfo><Affiliation>Division of Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0921-1416</Identifier><AffiliationInfo><Affiliation>Division of Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Med Sci (Basel)</MedlineTA><NlmUniqueID>101629322</NlmUniqueID><ISSNLinking>2076-3271</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">KCCQ</Keyword><Keyword MajorTopicYN="N">KCCQ-12</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">the Impella</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843768</ArticleId><ArticleId IdType="doi">10.3390/medsci13030146</ArticleId><ArticleId IdType="pii">medsci13030146</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40841929</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2261</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC cardiovascular disorders</Title><ISOAbbreviation>BMC Cardiovasc Disord</ISOAbbreviation></Journal><ArticleTitle>Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.</ArticleTitle><Pagination><StartPage>625</StartPage><MedlinePgn>625</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12872-025-05022-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ischemic heart disease (IHD) continues to be the foremost contributor to global morbidity and mortality. This analysis aims to report an updated assessment of prevalence, deaths, and disability-adjusted life years (DALYs) due to IHD and its attributable risk factors in 204 countries and territories from 1990 to 2021, by age, sex, and socio-demographic index (SDI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This analysis used data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. IHD was defined as acute myocardial infarction, chronic stable angina, chronic IHD, and heart failure due to IHD. Major indicators used in this study were prevalence, death and DALYs. All estimates were reported as absolute counts and age-standardized rates per 100,000 population, along with their 95% uncertainty intervals (UIs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Globally, IHD accounted for 254.3 (95%UI: 221.4 to 295.5) million prevalent cases, 9.0 (95%UI: 8.3 to 9.5) million deaths and 188.4 (95%UI: 177.0 to 198.1) million DALYs in 2021. There was a noticeable decline in the global age-standardized death rate (ASDR) [-31.6% (95%UI: -34.9 to -28.3)] and age-standardized DALYs (ASRDALYs) [-28.8% (95%UI: -32.5 to -25.2)] from 1990 to 2021, with an estimated annual percentage change of -1.3 (95%CI: -1.34 to -1.26) and -&#x2009;1.2 (95%CI: -1.25 to -1.16), respectively. In 2021, the global prevalence, death, and DALY rates of IHD were higher among males across all age groups, while death and DALY rates reaching a peak in the oldest group for both sexes. Regionally, we found a nonlinear but negative association between age-standardized prevalence rate (ASPR) and SDI. Nationally, similar negative associations were observed between ASRDALYs and SDI. High systolic blood pressure and high low-density lipoprotein cholesterol were the factors contributing most to the deaths and DALYs due to IHD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite declining global age-standardized death and DALYs rates of IHD, sustained multilevel prevention strategies remain essential. This requires population-wide risk factor reduction, targeted interventions for high-risk populations, and strengthened community healthcare networks to ensure accessible, guideline-based management.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Leyuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Yanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China. gongyanjun@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cardiovasc Disord</MedlineTA><NlmUniqueID>100968539</NlmUniqueID><ISSNLinking>1471-2261</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071219" MajorTopicYN="N">Global Burden of Disease</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017202" MajorTopicYN="Y">Myocardial Ischemia</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087509" MajorTopicYN="N">Disability-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">GBD 2021</Keyword><Keyword MajorTopicYN="N">Ischemic heart disease</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Ethical approval and informed consent were not required because the GBD study is publicly available and no identifable information was included in the analyses. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>7</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>7</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841929</ArticleId><ArticleId IdType="doi">10.1186/s12872-025-05022-x</ArticleId><ArticleId IdType="pii">10.1186/s12872-025-05022-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from world health organisation and united nations. Int J Cardiol. 2013;168(2):934&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23218570</ArticleId><ArticleId IdType="pmc">3819990</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990&#x2013;2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982&#x2013;3021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33309175</ArticleId><ArticleId IdType="pmc">7755038</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990&#x2013;2021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2100&#x2013;32.</Citation></Reference><Reference><Citation>GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990&#x2013;2021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2133&#x2013;61.</Citation></Reference><Reference><Citation>GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990&#x2013;2021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2162&#x2013;203.</Citation></Reference><Reference><Citation>Wang W, Hu M, Liu H, et al. Global burden of disease study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metab. 2021;33(10):1943&#x2013;e19562.</Citation><ArticleIdList><ArticleId IdType="pubmed">34478633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kibel A, Lukinac AM, Dambic V, Juric I, Selthofer-Relatic K. Oxidative stress in ischemic heart disease. Oxid Med Cell Longev. 2020;2020:6627144.</Citation><ArticleIdList><ArticleId IdType="pubmed">33456670</ArticleId><ArticleId IdType="pmc">7785350</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Leyte DJ, Zepeda-Garc&#xed;a O, Dom&#xed;nguez-P&#xe9;rez M, Gonz&#xe1;lez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850.</Citation><ArticleIdList><ArticleId IdType="pubmed">33917744</ArticleId><ArticleId IdType="pmc">8068178</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019;124(1):150&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30605419</ArticleId><ArticleId IdType="pmc">6447371</ArticleId></ArticleIdList></Reference><Reference><Citation>Safiri S, Karamzad N, Singh K, et al. Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019. Eur J Prev Cardiol. 2022;29(2):420&#x2013;431.</Citation></Reference><Reference><Citation>Makuvire TT, Latif Z, Kumar P, Samad Z, Warraich HJ. Trends in ischemic heart disease among females in low-and middle-income countries from 1990 to 2019. Int J Cardiol. 2023;388:131113.</Citation><ArticleIdList><ArticleId IdType="pubmed">37295502</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhang J. Disease burden and risk factors of ischemic heart disease in China during 1990&#x2013;2019 based on the global burden of disease 2019 report: A systematic analysis. Front Public Health. 2022;10:973317.</Citation><ArticleIdList><ArticleId IdType="pubmed">36408039</ArticleId><ArticleId IdType="pmc">9670122</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei D, Xiao W, Zhou L, Guo J, Lu W, Wang Y. Age-Period-Cohort analysis of ischemic heart disease morbidity and mortality in china, 1990&#x2013;2019. Circ J. 2022;86(9):1437&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">35569970</ArticleId></ArticleIdList></Reference><Reference><Citation>Avan A, Aamodt AH, Selbaek G, et al. Decreasing incidence of stroke, ischaemic heart disease and dementia in norway, 1990&#x2013;2019, a global burden of disease study: an opportunity. Eur J Neurol. 2023;30(8):2267&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">37154405</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan R, Tong Z, Chen JX, Wang Y, Zhou YF. Global burden of ischemic heart disease in adolescents and young adults, 1990&#x2013;2019. Am J Prev Med. 2024;66(5):751&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">38104848</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet. 2016;388(10062):e19&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">27371184</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray CJ, Acharya AK. Understanding dalys (disability-adjusted life years). J Health Econ. 1997;16(6):703&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10176780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankey BF, Ries LA, Kosary CL, et al. Partitioning linear trends in age-adjusted rates. Cancer Causes Control. 2000;11(1):31&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10680727</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Mortality Collaborators. Global, regional, and National under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970&#x2013;2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1084&#x2013;150.</Citation></Reference><Reference><Citation>Barquera S, Pedroza-Tob&#xed;as A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">26135634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">32690910</ArticleId><ArticleId IdType="pmc">7370876</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22(2):77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">34912108</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MK, Zidar DA, Bristow MR, et al. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res. 2021;128(8):1214&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">33856918</ArticleId><ArticleId IdType="pmc">8048382</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I, Fonseca-Rodr&#xed;guez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398(10300):599&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">34332652</ArticleId><ArticleId IdType="pmc">8321431</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Glenn S, Sy L, et al. Impact of the COVID-19 pandemic on health care utilization in a large integrated health care system: retrospective cohort study. J Med Internet Res. 2021;23(4):e26558.</Citation><ArticleIdList><ArticleId IdType="pubmed">33882020</ArticleId><ArticleId IdType="pmc">8086778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosik J, Clowse MEB, Overton R, et al. Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care. Am Heart J. 2021;231:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">33137309</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida C, Honda H, Otsuka Y, et al. Impact of lifestyle changes on body weight gain during nationwide lockdown due to COVID-19 pandemic. J Clin Med. 2025;14(7):2242.</Citation><ArticleIdList><ArticleId IdType="pubmed">40217694</ArticleId><ArticleId IdType="pmc">11989682</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman Y, van Rijn BB, Ten Haaf ME, Boersma E, Peters SA. Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis. 2015;241(1):211&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25670232</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13&#x2013;27.</Citation></Reference><Reference><Citation>Mateos JT, Fern&#xe1;ndez-S&#xe1;ez J, Marcos-Marcos J, et al. Gender equality and the global gender gap in life expectancy: an exploratory analysis of 152 countries. Int J Health Policy Manag. 2022;11(6):740&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33059429</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">24002282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallal PC, Andersen LB, Bull FC, et al. Lancet physical activity series working group. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380(9838):247&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">22818937</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayaraghavan K, Brown A. South Asian ancestry as a risk enhancer for ASCVD: Merits and challenges. J Clin Lipidol. 2019;13(4):522&#x2013;524. https://doi.org/10.1016/j.jacl.2019.04.009 . Epub 2019 Apr 30.</Citation></Reference><Reference><Citation>Shi H, Xia Y, Cheng Y, et al. Global burden of ischemic heart disease from 2022 to 2050: projections of incidence, prevalence, deaths, and disability-adjusted life years. Eur Heart J Qual Care Clin Outcomes. 2024;25:qcae049.</Citation></Reference><Reference><Citation>NCD Countdown 2030 collaborators. NCD countdown 2030: worldwide trends in non-communicable disease mortality and progress towards sustainable development goal target 3.4. Lancet. 2018;392(10152):1072&#x2013;88.</Citation></Reference><Reference><Citation>Prabhakaran D, Anand S, Watkins DA, et al. Cardiovascular, respiratory, and related disorders: Key Messages and Essential Interventions to Address Their Burden in Low- and Middle-Income Countries. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors. Cardiovascular, respiratory, and related disorders. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017. Nov 17. Chapter 1.</Citation></Reference><Reference><Citation>Wang Y, Li Q, Bi L, Wang B, Lv T, Zhang P. Global trends in the burden of ischemic heart disease based on the global burden of disease study 2021: the role of metabolic risk factors. BMC Public Health. 2025;25(1):310.</Citation><ArticleIdList><ArticleId IdType="pubmed">39856644</ArticleId><ArticleId IdType="pmc">11763131</ArticleId></ArticleIdList></Reference><Reference><Citation>An JQ, Jia YZ, Shi XH, et al. Global burden, trends and inequalities for ischaemic heart disease attributable to high fasting plasma glucose, high low-density lipoprotein cholesterol and high systolic blood pressure, 1990&#x2013;2021: an analysis of the global burden of disease study 2021. Diabetes Obes Metab. 2025;27(4):2070&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">39962724</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Li Q, Bi L, Wang B, Lv T, Zhang P. Global trends in the burden of ischemic heart disease attributable to smoking from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021. Tob Induc Dis. 2025;23. https://doi.org/10.18332/tid/199931 .</Citation></Reference><Reference><Citation>Zhang Y, Wu J, Wang N, et al. Global burden and national health inequity of ischemic heart disease attributed to kidney dysfunction from 1990 to 2021: Findings from the global burden of disease study 2021. Atherosclerosis. 2025;405:119140. https://doi.org/10.1016/j.atherosclerosis.2025.119140 . Epub 2025 Feb 26.</Citation></Reference><Reference><Citation>Gupta R, Wood DA. Primary prevention of ischaemic heart disease: populations, individuals, and health professionals. Lancet. 2019;394(10199):685&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">31448740</ArticleId></ArticleIdList></Reference><Reference><Citation>Authors/Task Force Members, Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention &amp; rehabilitation (EACPR). Atherosclerosis. 2016;252:207&#x2013;74.</Citation></Reference><Reference><Citation>Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">30879355</ArticleId><ArticleId IdType="pmc">7734661</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan MS, Freiberg MS, Greevy RA Jr, Kundu S, Vasan RS, Tindle HA. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019;322(7):642&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">31429895</ArticleId><ArticleId IdType="pmc">6704757</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan S, Brauer M, Bhatnagar A, et al. Personal-Level protective actions against particulate matter air pollution exposure: A scientific statement from the American heart association. Circulation. 2020;142(23):e411&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33150789</ArticleId></ArticleIdList></Reference><Reference><Citation>Shupler M, Hystad P, Gustafson P, et al. Household, community, Sub-National and Country-level predictors of primary cooking fuel switching in nine countries from the PURE study. Environ Res Lett. 2019;14(8):085006.</Citation><ArticleIdList><ArticleId IdType="pubmed">33777170</ArticleId><ArticleId IdType="pmc">7995525</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Z, He Q, Lin HM, et al. Exploring uncertainty of the change from ICD-9 to ICD-10 on acute mortality effects of air pollution. Environ Int. 2008;34(2):248&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17854896</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelson KA, Dart AH, Bachur RG, Mahajan P, Finkelstein JA. Measuring complications of serious pediatric emergencies using ICD-10. Health Serv Res. 2021;56(2):225&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">33374034</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40841853</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-6049</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Renal failure</Title><ISOAbbreviation>Ren Fail</ISOAbbreviation></Journal><ArticleTitle>Dose-dependent renoprotective effects of sacubitril/valsartan in heart failure: a retrospective study.</ArticleTitle><Pagination><StartPage>2538830</StartPage><MedlinePgn>2538830</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2025.2538830</ELocationID><Abstract><AbstractText>To evaluate the dose-dependent renoprotective effects of sacubitril/valsartan in heart failure patients. This retrospective observational study included patients with heart failure (Stage B or higher, B-type natriuretic peptide (BNP) &gt;100&#x2009;pg/mL or N-terminal proBNP &gt;300&#x2009;pg/mL) who initiated sacubitril/valsartan (SV) treatment. Patients were classified by final SV daily dose (50, 100, 200, or 400&#x2009;mg) at 18&#x2009;months. Factors associated with eGFR changes were identified using multiple regression analysis. A total of 157 patients (mean age 74.8-77.9&#x2009;years, 64.3% male) were stratified by daily SV dosage groups (50&#x2009;mg, <i>n</i>&#x2009;=&#x2009;20; 100&#x2009;mg, <i>n</i>&#x2009;=&#x2009;46; 200&#x2009;mg, <i>n</i>&#x2009;=&#x2009;62; 400&#x2009;mg, <i>n</i>&#x2009;=&#x2009;29). Baseline characteristics were similar across groups for eGFR, heart failure stage, diabetes history, myocardial infarction, atrial fibrillation, proteinuria, and use of most heart failure medications. However, hypertension prevalence and systolic blood pressure differed significantly between groups (<i>p</i>&#x2009;&lt;&#x2009;0.05). One-way ANOVA revealed significant dose-dependent differences in eGFR changes among SV dosage groups (<i>p</i>&#x2009;&lt;&#x2009;0.05). In the final multiple linear regression model, SV dosage (<i>p</i>&#x2009;&lt;&#x2009;0.05) was a significant factor associated with eGFR changes, with proteinuria showing a trend toward significance. Sex and BNP levels &#x2265;400&#x2009;pg/dL were not significant. Sensitivity analysis converting SV dosage to a categorical variable confirmed these findings. Stratification by proteinuria status demonstrated dose-dependent relationships in both proteinuria-positive and proteinuria-negative subgroups, with more pronounced dose dependency in the proteinuria-positive group (<i>p</i>&#x2009;&lt;&#x2009;0.001). SV exhibits dose-dependent renoprotective effects in heart failure patients. Optimizing SV dosage may be beneficial for heart failure patients with concurrent kidney dysfunction, especially those with proteinuria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Kochi Medical School Hospital, Kochi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Aichi Medical University, Nagakute, Aichi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AISAN Clinic, Tsushima, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasukawa</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oonishi</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamada</LastName><ForeName>Yukihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Kochi Medical School Hospital, Kochi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ren Fail</MedlineTA><NlmUniqueID>8701128</NlmUniqueID><ISSNLinking>0886-022X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000613">Aminobutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>80M03YXJ7I</RegistryNumber><NameOfSubstance UI="D000068756">Valsartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>WB8FT61183</RegistryNumber><NameOfSubstance UI="C549068">sacubitril and valsartan sodium hydrate drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000613" MajorTopicYN="Y">Aminobutyrates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068756" MajorTopicYN="Y">Valsartan</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="Y">Tetrazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="Y">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">angiotensin receptor neprilysin inhibitor</Keyword><Keyword MajorTopicYN="N">cardiorenal syndrome</Keyword><Keyword MajorTopicYN="N">proteinuria</Keyword><Keyword MajorTopicYN="N">renal protection</Keyword><Keyword MajorTopicYN="N">sacubitril/valsartan</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841853</ArticleId><ArticleId IdType="doi">10.1080/0886022X.2025.2538830</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40841572</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Integrative Mendelian randomization and multi-omics analysis identifies anti-allergic drug targets associated with cardiovascular disease risk.</ArticleTitle><Pagination><StartPage>30783</StartPage><MedlinePgn>30783</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-15331-y</ELocationID><Abstract><AbstractText>Cardiovascular diseases (CVDs) are major global health threats. This study explores links between anti-allergic drugs and CVD risk, providing valuable insights for clinical pharmacotherapy. Mendelian randomization (MR) analyses were performed on 139 eQTLs for anti-allergic drugs in coronary artery disease (CAD), heart failure (HF), myocardial infarction (MI), and atrial fibrillation (AF) cohorts, with validation in independent cohorts. Sensitivity analyses, transcriptomics analysis, enrichment analysis, and molecular docking were performed to evaluate the robustness of causality, potential pathways and binding affinity. Furthermore, the FAERS database evaluated the cardiovascular adverse events associated with prednisone in combination with cardiovascular drugs. Among the 11 anti-allergic drug targets significantly linked to CVDs, KAT2A inversely correlated with CAD risk, BAZ2B and CYP2C8 with AF risk, and ITGB2, TG and six other eQTLs were associated with HF risk. Notably, prednisone (targeting ITGB2, TG) and loratadine (targeting TSHR) elevated CVD risk, while zafirlukast (targeting KAT2A, POLB, BAZ2B) reduced it. The progression of CVDs may be influenced by the formation of neutrophil extracellular traps and lipid accumulation, which could potentially be affected by the administration of prednisone and similar medications. Molecular docking revealed a strong binding affinity between the cardiovascular candidate drug quercetin and zafirlukast (POLB). Pharmacovigilance analysis indicated an increased risk of adverse cardiovascular outcomes with the concurrent use of prednisone and cardiovascular drugs. The comprehensive analyses indicate that certain anti-allergic drugs may heighten the risk of CVDs, suggesting caution with medications like prednisone.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lian</LastName><ForeName>Huilin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Dai</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Phase I Clinical Research Center, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Youjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Phase I Clinical Research Center, Xiangya Hospital, Central South University, Changsha, 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ruifang</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Experimental Center, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. 601427@csu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Ren</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. pharmguor@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82073850</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82073850</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82073850</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82073850</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82073850</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82073850</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018926">Anti-Allergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="Y">Mendelian Randomization Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018926" MajorTopicYN="Y">Anti-Allergic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095028" MajorTopicYN="N">Multiomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Expression quantitative trait loci</Keyword><Keyword MajorTopicYN="N">Mendelian randomization</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance analysis</Keyword><Keyword MajorTopicYN="N">Transcriptome analysis</Keyword></KeywordList><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841572</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-15331-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-15331-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990&#x2013;2019: update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982&#x2013;3021 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33309175</ArticleId><ArticleId IdType="pmc">7755038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralapanawa, U. &amp; Sivakanesan, R. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: A narrative review. J. Epidemiol. Glob Health. 11, 169&#x2013;177 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33605111</ArticleId><ArticleId IdType="pmc">8242111</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. Global trends in heart failure from 1990 to 2019: an age-period-cohort analysis from the global burden of disease study. ESC Heart Fail. 11, 3264&#x2013;3278 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38937863</ArticleId><ArticleId IdType="pmc">11424301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanrahan, J. P. et al. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann. Epidemiol. 5, 201&#x2013;209 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7606309</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura, T. et al. A pilot study of Tranilast for cardiomyopathy of muscular dystrophy. Intern. Med. 57, 311&#x2013;318 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29093384</ArticleId></ArticleIdList></Reference><Reference><Citation>Tattersall, M. C. et al. Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis. Arterioscler. Thromb. Vasc Biol. 35, 1520&#x2013;1525 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25908767</ArticleId><ArticleId IdType="pmc">4441553</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Mast cell stabilizer, an anti-allergic drug, reduces ventricular arrhythmia risk via modulation of neuroimmune interaction. Basic. Res. Cardiol. 119, 75&#x2013;91 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38172251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt, A. F. et al. Genetic drug target validation using Mendelian randomisation. Nat. Commun. 11, 3255 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32591531</ArticleId><ArticleId IdType="pmc">7320010</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xf5;sa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat. Genet. 53, 1300&#x2013;1310 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34475573</ArticleId><ArticleId IdType="pmc">8432599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, Y. &amp; Wang, Y. Causal relationship between Antibody-Mediated immune responses of chlamydia trachomatis infection and reproductive tract complications: A bidirectional Mendelian randomization study. Am. J. Reprod. Immunol. 93, e70036 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">39777772</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, Y., Wang, Y. &amp; Shu, W. Immunocyte phenotypes and childhood disease susceptibility: insights from bidirectional Mendelian randomization and implications for Immunomodulatory therapies. Naunyn Schmiedebergs Arch. Pharmacol. https://doi.org/10.1007/s00210-025-04091-1 (2025).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-025-04091-1</ArticleId><ArticleId IdType="pubmed">40488852</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, Y. et al. Integrative genomic and single-cell framework identifies druggable targets for colorectal cancer precision therapy. Front. Immunol. 16, 1604154 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">40496862</ArticleId><ArticleId IdType="pmc">12149120</ArticleId></ArticleIdList></Reference><Reference><Citation>T, W. et al. ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. PubMed (2021).</Citation></Reference><Reference><Citation>Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. &amp; Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672&#x2013;D677 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">39417505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947&#x2013;1951 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31441146</ArticleId><ArticleId IdType="pmc">6798127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. &amp; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27&#x2013;30 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10592173</ArticleId><ArticleId IdType="pmc">102409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, Y. et al. Decoding per- and polyfluoroalkyl substances (PFAS) in hepatocellular carcinoma: a multi-omics and computational toxicology approach. J. Transl Med. 23, 504 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">40317014</ArticleId><ArticleId IdType="pmc">12049027</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo, M. et al. DSigDB: drug signatures database for gene set analysis. Bioinformatics 31, 3069&#x2013;3071 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25990557</ArticleId><ArticleId IdType="pmc">4668778</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. CB-Dock2: improved protein-ligand blind Docking by integrating cavity detection, Docking and homologous template fitting. Nucleic Acids Res. 50, W159&#x2013;W164 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35609983</ArticleId><ArticleId IdType="pmc">9252749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, Y. et al. Environmental triggers and future risk of developing autoimmune diseases: molecular mechanism and network toxicology analysis of bisphenol A. Ecotoxicol. Environ. Saf. 288, 117352 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39550874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, Y. et al. Analysis of toxicity and mechanisms of Busulfan in non-obstructive azoospermia: a genomic and toxicological approach integrating molecular docking, single-cell sequencing, and experimentation in vivo. Ecotoxicol. Environ. Saf. 291, 117878 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">39933234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, Y. et al. Assessing male reproductive toxicity of environmental pollutant di-ethylhexyl phthalate with network toxicology and molecular Docking strategy. Reprod. Toxicol. 130, 108749 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39551107</ArticleId></ArticleIdList></Reference><Reference><Citation>Salpeter, S. R. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging. 21, 405&#x2013;414 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15084142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson, E., Yin, L. &amp; B&#xe4;ck, M. Nationwide cohort study of the leukotriene receptor antagonist Montelukast and incident or recurrent cardiovascular disease. J. Allergy Clin. Immunol. 129, 702&#x2013;707e2 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22244598</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;bel, T. et al. Zafirlukast is a dual modulator of human soluble epoxide hydrolase and peroxisome Proliferator-Activated receptor &#x3b3;. Front. Pharmacol. 10, 263 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30949053</ArticleId><ArticleId IdType="pmc">6435570</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J. et al. GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway. Cell. Death Dis. 13, 421 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35490166</ArticleId><ArticleId IdType="pmc">9056507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen, J., Sheng, X., Chen, T. &amp; Yu, H. Histone acetyltransferase Kat2a regulates ferroptosis via enhancing Tfrc and Hmox1 expression in diabetic cardiomyopathy. Cell. Death Dis. 15, 406 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38858351</ArticleId><ArticleId IdType="pmc">11164963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong, L. et al. Discovery and validation of molecular patterns and immune characteristics in the peripheral blood of ischemic stroke patients. PeerJ 12, e17208 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38650649</ArticleId><ArticleId IdType="pmc">11034498</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. Spatiotemporal gene coexpression and regulation in mouse cardiomyocytes of early cardiac morphogenesis. J. Am. Heart Assoc. 8, e012941 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31322043</ArticleId><ArticleId IdType="pmc">6761639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. M., Wang, G. H., Xu, M. J. &amp; Jin, G. OGG1 prevents atherosclerosis-induced vascular endothelial cell injury through mediating DNA damage repair. Clin. Hemorheol Microcirc. 87, 249&#x2013;261 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38363604</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X. et al. Blocking mitochondrial Cyclophilin D ameliorates TSH-impaired defensive barrier of artery. Redox Biol. 15, 418&#x2013;434 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29353219</ArticleId><ArticleId IdType="pmc">5975066</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, C. et al. Thyrotropin aggravates atherosclerosis by promoting macrophage inflammation in plaques. J. Exp. Med. 216, 1182&#x2013;1198 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30940720</ArticleId><ArticleId IdType="pmc">6504213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, L. et al. Identification of an association between coronary heart disease and ITGB2 methylation in peripheral blood by a case-control study. Clin. Chim. Acta. 552, 117627 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37923103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Lian, Q., Nie, Y. &amp; Zhao, W. Identification of atrial fibrillation-related genes through transcriptome data analysis and Mendelian randomization. Front. Cardiovasc. Med. 11, 1414974 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39055656</ArticleId><ArticleId IdType="pmc">11269132</ArticleId></ArticleIdList></Reference><Reference><Citation>Campi, I. et al. Pulsed intravenous Methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis. Eur. J. Endocrinol. 181, 519&#x2013;524 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31536966</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. et al. CYP2C8 and CYP2J2 gene variations increase the risk of hypertensive intracerebral hemorrhage. J. Stroke Cerebrovasc. Dis. 32, 106974 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36587509</ArticleId></ArticleIdList></Reference><Reference><Citation>Siva, B., Sherin, S., Somabattni, R. A. &amp; Nanjappan, S. K. Integrative CYP450 and network Pharmacology approach for the assessment of corilagin&#x2019;s influence on sitagliptin pharmacokinetics. Biochem. Pharmacol. 237, 116960 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">40287102</ArticleId></ArticleIdList></Reference><Reference><Citation>Frustaci, A. et al. Atrogin-1 pathway activation in Cushing syndrome cardiomyopathy. J. Am. Coll. Cardiol. 67, 116&#x2013;117 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26764074</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams, K. F. et al. A perspective on re-evaluating digoxin&#x2019;s role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. Eur. J. Heart Fail. 16, 483&#x2013;493 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24574198</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40841213</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-2128</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Archives of cardiovascular diseases</Title><ISOAbbreviation>Arch Cardiovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Comparative efficacy and safety of intravascular lithotripsy versus rotational atherectomy in coronary artery calcification: An updated meta-analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1875-2136(25)00407-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acvd.2025.06.075</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The presence of coronary artery calcification during percutaneous coronary intervention is associated with an increased risk of complications and poor outcomes. Comparison of the efficacy and safety of intravascular lithotripsy and rotational atherectomy in coronary artery calcification has always been a topic of debate in the literature.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To present the most recent comparative analysis of these two calcium debulking techniques.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A search was conducted in online databases, including PubMed, Web of Science and the Cochrane Library. We performed a meta-analysis to find the difference between intravascular lithotripsy and rotational atherectomy regarding all-cause death, myocardial infarction, coronary perforation, slow/no-reflow, target vessel revascularization and procedural success. Using a random effects model, the results were reported as risk ratios.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of nine studies with 2203 patients (intravascular lithotripsy, n=1004; rotational atherectomy, n=1199) were selected. Intravascular lithotripsy was associated with a reduced risk of coronary perforation (risk ratio 0.38, 95% confidence interval 0.23-0.62; P=0.0001) and increased procedural success (risk ratio 1.04, 95% confidence interval 1.02-1.06; P=0.0004). There was no significant difference between intravascular lithotripsy and rotational atherectomy in terms of the risk of all cause death, myocardial infarction, target vessel revascularization and slow/no-reflow.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intravascular lithotripsy was associated with a lower risk of coronary perforation and higher procedural success compared with rotational atherectomy in the management of coronary artery calcification. However, no significant differences were observed between intravascular lithotripsy and RA in terms of all-cause death, myocardial infarction, target vessel revascularization and slow/no-reflow. Given the predominance of retrospective studies in the analysis, randomized controlled trials with long-term follow-up are needed to better identify patient populations most likely to benefit, as well as to compare the long-term clinical outcomes of these two plaque modification strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kayani</LastName><ForeName>Abdul Mueez Alam</ForeName><Initials>AMA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, AdventHealth Tampa, Tampa, FL 33613, United States. Electronic address: abdulmueezalam.kayani.md@adventhealth.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umar</LastName><ForeName>Muhammad Faiq</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, AdventHealth Tampa, Tampa, FL 33613, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fretz</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemus-Zamora</LastName><ForeName>Ricky E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alraies</LastName><ForeName>Chadi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cardiovascular Institute, Detroit Medical Center, Wayne State University, Detroit, MI 48201, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Tarique</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Cathay General Hospital, Taipei City 106, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alharbi</LastName><ForeName>Anas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, West Virginia University, Morgantown, WV 26506, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daggubati</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, West Virginia University, Morgantown, WV 26506, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattar</LastName><ForeName>Yasar</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, West Virginia University, Morgantown, WV 26506, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Arch Cardiovasc Dis</MedlineTA><NlmUniqueID>101465655</NlmUniqueID><ISSNLinking>1875-2128</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Calcium modification techniques</Keyword><Keyword MajorTopicYN="N">Coronary artery calcification</Keyword><Keyword MajorTopicYN="N">Intravascular lithotripsy</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">Rotational atherectomy</Keyword></KeywordList><CoiStatement>Disclosure of interest The authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>21</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841213</ArticleId><ArticleId IdType="doi">10.1016/j.acvd.2025.06.075</ArticleId><ArticleId IdType="pii">S1875-2136(25)00407-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40844089</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2038-8306</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>European journal of histochemistry : EJH</Title><ISOAbbreviation>Eur J Histochem</ISOAbbreviation></Journal><ArticleTitle>circRNA-79530 regulates Twist-mediated mitochondrial damage <i>via s</i>ponging miR-214 affecting hypoxia/reoxygenation-induced injury in H9c2 cardiomyocytes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4081/ejh.2025.4230</ELocationID><Abstract><AbstractText>Cardiomyocyte injury related to hypoxia/reoxygenation (H/R) is pivotal in myocardial infarction. The circular RNA circRNA-79530 (circ79530) may play a regulatory role in this process, though its exact function has yet to be elucidated. This research explores the role of circRNA-79530 in H9c2 cells under H/R, with a particular focus on its interactions with miR-214 and the transcription factor Twist. It also examines their subsequent effects on mitochondrial function and oxidative stress. H9c2 cardiomyocytes were subjected to H/R to model myocardial injury. We measured circRNA-79530, miR-214, and Twist levels via RT-qPCR, with Twist protein via Western blotting. ROS levels were quantified using DCFH-DA, and cell viability and injuries were assessed through CCK-8, LDH, SOD, and MDA assays, respectively. Mitochondrial performance was assessed through various methods, including the measurement of mitochondrial membrane potential using JC-1 staining, the quantification of ATP levels, and the examination of the protein levels of mitochondrial complexes, as well as the expression of fusion proteins. Our findings indicated that downregulation of circRNA-79530 modulated miR-214 and Twist expression, influencing mitochondrial dynamics and ROS production. Knockdown of circRNA-79530 improved cell viability, reduced oxidative stress and enhanced mitochondrial function. Additionally, overexpression of miR-214 mitigated Twist expression, further supporting the effect of miR-214 in H/R conditions. circRNA-79530 could worsen oxidative stress and mitochondrial dysfunction, and regulate Twist-mediated mitochondrial damage via sponging miR-214 in H9c2 cells under H/R conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Ziyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenbo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Laboratory, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Yirong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Practice, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Ren</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ju</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xichen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yanping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Yinglu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The 6th Affiliated Hospital of Kunming Medical University, The People's Hospital of Yuxi City.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur J Histochem</MedlineTA><NlmUniqueID>9207930</NlmUniqueID><ISSNLinking>1121-760X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079962">RNA, Circular</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051879">Twist-Related Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C559947">Mirn214 microRNA, rat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079962" MajorTopicYN="Y">RNA, Circular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="Y">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051879" MajorTopicYN="Y">Twist-Related Protein 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015687" MajorTopicYN="N">Cell Hypoxia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="Y">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844089</ArticleId><ArticleId IdType="doi">10.4081/ejh.2025.4230</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843879</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2571-841X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Reports (MDPI)</Title><ISOAbbreviation>Reports (MDPI)</ISOAbbreviation></Journal><ArticleTitle>Fatal Cytokine Collision: HLH-AIHA in Advanced AIDS-Case Report and Literature Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">137</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/reports8030137</ELocationID><Abstract><AbstractText><b>Background and Clinical Significance</b>: Hemophagocytic lymphohistiocytosis (HLH) and autoimmune hemolytic anemia (AIHA) are both life-threatening hematologic syndromes that rarely present together outside of malignancy. Advanced acquired immunodeficiency syndrome (AIDS) creates a milieu of profound immune dysregulation and hyperinflammation, predisposing patients to atypical overlaps of these disorders. <b>Case Presentation</b>: A 30-year-old woman with poorly controlled AIDS presented with three weeks of jaundice, fever, and fatigue. Initial labs revealed pancytopenia, hyperbilirubinemia, and elevated ferritin level. Direct anti-globulin testing confirmed warm AIHA (IgG<sup>+</sup>/C3d<sup>+</sup>) with transient cold agglutinins. Despite intravenous immunoglobulin (IVIG), rituximab, and transfusions, she developed hepatosplenomegaly, extreme hyperferritinemia, and sIL-2R &gt; 10,000 pg/mL, meeting HLH-2004 criteria. Bone marrow biopsy excluded malignancy; further work-up revealed Epstein-Barr virus (EBV) viremia and cytomegalovirus (CMV) reactivation. Dexamethasone plus reduced-dose etoposide transiently reduced soluble interleukin-2 receptor (sIL-2R) but precipitated profound pancytopenia, Acute respiratory distress syndrome (ARDS) from CMV/parainfluenza pneumonia, bilateral deep vein thrombosis (DVT), and an ST-elevation myocardial infarction (STEMI). She ultimately died of hemorrhagic shock after anticoagulation despite maximal supportive measures. <b>Conclusions</b>: This case underscores the diagnostic challenges of HLH-AIHA overlap in AIDS, where cytopenias and hyperferritinemia mask the underlying cytokine storm. Pathogenesis likely involved IL-6/IFN-&#x3b3; overproduction, impaired cytotoxic T-cell function, and molecular mimicry. While etoposide remains a cornerstone of HLH therapy, its myelotoxicity proved catastrophic in this immunocompromised host, highlighting the urgent need for cytokine-targeted agents to mitigate treatment-related mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoyi</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0009-4043-7518</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres Nolasco</LastName><ForeName>Maria Felix</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0002-2402-4301</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wing Fai</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshino</LastName><ForeName>Toru</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1586-2706</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anipindi</LastName><ForeName>Manasa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Reports (MDPI)</MedlineTA><NlmUniqueID>101757880</NlmUniqueID><ISSNLinking>2571-841X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">advanced AIDS</Keyword><Keyword MajorTopicYN="N">autoimmune hemolytic anemia</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">epstein-barr virus</Keyword><Keyword MajorTopicYN="N">etoposide</Keyword><Keyword MajorTopicYN="N">hemophagocytic lymphohistiocytosis</Keyword><Keyword MajorTopicYN="N">hyperferritinemia</Keyword><Keyword MajorTopicYN="N">soluble interleukin-2 receptor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843879</ArticleId><ArticleId IdType="doi">10.3390/reports8030137</ArticleId><ArticleId IdType="pii">reports8030137</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40844176</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1748-1716</ISSN><JournalIssue CitedMedium="Internet"><Volume>241</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta physiologica (Oxford, England)</Title><ISOAbbreviation>Acta Physiol (Oxf)</ISOAbbreviation></Journal><ArticleTitle>NMDA-Type Glutamate Receptor Activation Promotes Ischemic Arrhythmias by Targeting the AKT1-TBX3-Nav1.5 Axis.</ArticleTitle><Pagination><StartPage>e70085</StartPage><MedlinePgn>e70085</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/apha.70085</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study is to determine the possible role of N-methyl-D-aspartate receptor (NMDAR) dysregulation in the ischemic electrical remodeling observed in patients with myocardial infarction (MI) and elucidate the underlying mechanisms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Human heart tissue was obtained from the border of the infarct and remote zones of patients with ischemic heart disease, and mouse heart tissue was obtained from the peri-infarct zone. NMDAR expression was detected using immunofluorescence (IF) and Western blotting (WB). Spontaneous ventricular arrhythmias (VAs) in mice were detected using electrocardiogram backpacks. Electrical remodeling post-MI was detected using patch clamp recordings, quantitative real-time polymerase chain reactions, IF, and WB. Mechanistic studies were performed using bioinformatic analysis, plasmid and small interfering RNA transfection, lentiviral packaging, and site-directed mutagenesis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">NMDAR is highly expressed in patients with ischemic heart disease and mice with MI. NMDAR inhibition reduces the occurrence of VAs. Mechanistically, NMDAR activation promotes electrophysiological remodeling, as characterized by decreased Nav1.5, Kv11.1, Kv4.2, Kv7.1, Kir2.1, and Cav1.2 expression in patients with ischemic heart disease and mice with MI and rescues these ion channels dysregulation in mice with MI to varying degrees by NMDAR inhibition. Decreased Nav1.5 expression and inward sodium current density were attenuated by NMDAR inhibition in primary rat cardiomyocytes. Moreover, NMDAR activation upregulates T-Box Transcription Factor 3 (TBX3) post-translationally, further downregulating Nav1.5 transcriptionally. Furthermore, AKT1 is the predominant isoform in the ventricular myocardium upstream of TBX3 and mediates NMDAR-induced TBX3 upregulation in cardiomyocytes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NMDAR activation contributes to MI-induced VAs by regulating the AKT1-TBX3-Nav1.5 axis, providing novel therapeutic strategies for treating ischemic arrhythmias.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Acta Physiologica published by John Wiley &amp; Sons Ltd on behalf of Scandinavian Physiological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yuxian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Atrial Fibrillation Center, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qinggang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Zewei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Atrial Fibrillation Center, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xingang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Biomedical Engineering &amp; Instrument Science, Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Liangrong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Atrial Fibrillation Center, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81873484</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82000316</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>QZYY-2024-042</GrantID><Agency>Guizhou Province Special Project for Traditional Chinese Medicine and Ethnic Medicine Science and Technology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Physiol (Oxf)</MedlineTA><NlmUniqueID>101262545</NlmUniqueID><ISSNLinking>1748-1708</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062554">NAV1.5 Voltage-Gated Sodium Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568320">SCN5A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="Y">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="Y">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062554" MajorTopicYN="Y">NAV1.5 Voltage-Gated Sodium Channel</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="Y">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017202" MajorTopicYN="Y">Myocardial Ischemia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NMDAR</Keyword><Keyword MajorTopicYN="N">electrophysiological remodeling</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">pseudo&#x2010;phosphorylation</Keyword><Keyword MajorTopicYN="N">ventricular arrhythmias</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40844176</ArticleId><ArticleId IdType="doi">10.1111/apha.70085</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>R. J. Myerburg and M. J. Junttila, &#x201c;Sudden Cardiac Death Caused by Coronary Heart Disease,&#x201d; Circulation 125, no. 8 (2012): 1043&#x2013;1052.</Citation></Reference><Reference><Citation>J. L. Rouleau, M. Talajic, B. Sussex, et&#xa0;al., &#x201c;Myocardial Infarction Patients in the 1990s&#x2014;Their Risk Factors, Stratification and Survival in Canada: The Canadian Assessment of Myocardial Infarction (CAMI) Study,&#x201d; Journal of the American College of Cardiology 27, no. 5 (1996): 1119&#x2013;1127.</Citation></Reference><Reference><Citation>T. Pezawas, A. Diedrich, D. Robertson, et&#xa0;al., &#x201c;Risk of Arrhythmic Death in Ischemic Heart Disease: A Prospective, Controlled, Observer&#x2010;Blind Risk Stratification Over 10&#x2009;Years,&#x201d; European Journal of Clinical Investigation 47, no. 3 (2017): 231&#x2013;240.</Citation></Reference><Reference><Citation>S. Wasson, H. K. Reddy, and M. L. Dohrmann, &#x201c;Current Perspectives of Electrical Remodeling and Its Therapeutic Implications,&#x201d; Journal of Cardiovascular Pharmacology and Therapeutics 9, no. 2 (2004): 129&#x2013;144.</Citation></Reference><Reference><Citation>T. P. Nguyen, Z. Qu, and J. N. Weiss, &#x201c;Cardiac Fibrosis and Arrhythmogenesis: The Road to Repair Is Paved With Perils,&#x201d; Journal of Molecular and Cellular Cardiology 70 (2014): 83&#x2013;91.</Citation></Reference><Reference><Citation>C. Meyer and K. Scherschel, &#x201c;Ventricular Tachycardia in Ischemic Heart Disease: The Sympathetic Heart and Its Scars,&#x201d; American Journal of Physiology. Heart and Circulatory Physiology 312, no. 3 (2017): H549&#x2013;H551.</Citation></Reference><Reference><Citation>A. Kelly, S. Salerno, A. Connolly, et&#xa0;al., &#x201c;Normal Interventricular Differences in Tissue Architecture Underlie Right Ventricular Susceptibility to Conduction Abnormalities in a Mouse Model of Brugada Syndrome,&#x201d; Cardiovascular Research 114, no. 5 (2018): 724&#x2013;736.</Citation></Reference><Reference><Citation>C. A. Remme and C. R. Bezzina, &#x201c;Sodium Channel (Dys)function and Cardiac Arrhythmias,&#x201d; Cardiovascular Therapeutics 28, no. 5 (2010): 287&#x2013;294.</Citation></Reference><Reference><Citation>E. S. Kepenek, E. Ozcinar, E. Tuncay, K. C. Akcali, A. R. Akar, and B. Turan, &#x201c;Differential Expression of Genes Participating in Cardiomyocyte Electrophysiological Remodeling via Membrane Ionic Mechanisms and Ca(2+)&#x2010;Handling in Human Heart Failure,&#x201d; Molecular and Cellular Biochemistry 463, no. 1&#x2013;2 (2020): 33&#x2013;44.</Citation></Reference><Reference><Citation>D. Han, H. Tan, C. Sun, et&#xa0;al., &#x201c;Dysfunctional Nav1.5 Channels due to SCN5A Mutations,&#x201d; Experimental Biology and Medicine (Maywood, N.J.) 243, no. 10 (2018): 852&#x2013;863.</Citation></Reference><Reference><Citation>G. J. Kang, A. Xie, H. Liu, and S. C. Dudley, Jr., &#x201c;MIR448 Antagomir Reduces Arrhythmic Risk After Myocardial Infarction by Upregulating the Cardiac Sodium Channel,&#x201d; JCI Insight 5, no. 23 (2020): e140759.</Citation></Reference><Reference><Citation>C. C. Veerman, A. A. Wilde, and E. M. Lodder, &#x201c;The Cardiac Sodium Channel Gene SCN5A and Its Gene Product NaV1.5: Role in Physiology and Pathophysiology,&#x201d; Gene 573, no. 2 (2015): 177&#x2013;187.</Citation></Reference><Reference><Citation>M. Jiang, C. Cabo, J. Yao, et&#xa0;al., &#x201c;Delayed Rectifier K Currents Have Reduced Amplitudes and Altered Kinetics in Myocytes From Infarcted Canine Ventricle,&#x201d; Cardiovascular Research 48, no. 1 (2000): 34&#x2013;43.</Citation></Reference><Reference><Citation>M. Liu, H. Liu, P. Parthiban, et&#xa0;al., &#x201c;Inhibition of the Unfolded Protein Response Reduces Arrhythmia Risk After Myocardial Infarction,&#x201d; Journal of Clinical Investigation 131, no. 18 (2021): e147836.</Citation></Reference><Reference><Citation>J. Li, Z. Y. Ma, Y. F. Cui, et&#xa0;al., &#x201c;Cardiac&#x2010;Specific Deletion of BRG1 Ameliorates Ventricular Arrhythmia in Mice With Myocardial Infarction,&#x201d; Acta Pharmacologica Sinica 45, no. 3 (2024): 517&#x2013;530.</Citation></Reference><Reference><Citation>X. Li, W. Chu, J. Liu, et&#xa0;al., &#x201c;Antiarrhythmic Properties of Long&#x2010;Term Treatment With Matrine in Arrhythmic Rat Induced by Coronary Ligation,&#x201d; Biological &amp; Pharmaceutical Bulletin 32, no. 9 (2009): 1521&#x2013;1526.</Citation></Reference><Reference><Citation>T. Chen, B. Kong, W. Shuai, Y. Gong, J. Zhang, and H. Huang, &#x201c;Vericiguat Alleviates Ventricular Remodeling and Arrhythmias in Mouse Models of Myocardial Infarction via CaMKII Signaling,&#x201d; Life Sciences 334 (2023): 122184.</Citation></Reference><Reference><Citation>Y. Fo, C. Zhang, X. Chen, et&#xa0;al., &#x201c;Chronic Sigma&#x2010;1 Receptor Activation Ameliorates Ventricular Remodeling and Decreases Susceptibility to Ventricular Arrhythmias After Myocardial Infarction in Rats,&#x201d; European Journal of Pharmacology 889 (2020): 173614.</Citation></Reference><Reference><Citation>H. Hu, M. Jiang, Y. Cao, et&#xa0;al., &#x201c;HuR Regulates Phospholamban Expression in Isoproterenol&#x2010;Induced Cardiac Remodelling,&#x201d; Cardiovascular Research 116, no. 5 (2020): 944&#x2013;955.</Citation></Reference><Reference><Citation>S. F. Traynelis, L. P. Wollmuth, C. J. Mcbain, et&#xa0;al., &#x201c;Glutamate Receptor Ion Channels: Structure, Regulation, and Function,&#x201d; Pharmacological Reviews 62, no. 3 (2010): 405&#x2013;496.</Citation></Reference><Reference><Citation>K. A. Szychowski, A. Wnuk, J. Rzemieniec, M. Kajta, T. Leszczy&#x144;ska, and A. K. W&#xf3;jtowicz, &#x201c;Triclosan&#x2010;Evoked Neurotoxicity Involves NMDAR Subunits With the Specific Role of GluN2A in Caspase&#x2010;3&#x2010;Dependent Apoptosis,&#x201d; Molecular Neurobiology 56, no. 1 (2019): 1&#x2013;12.</Citation></Reference><Reference><Citation>J. R. Lim, H. J. Lee, Y. H. Jung, et&#xa0;al., &#x201c;Ethanol&#x2010;Activated CaMKII Signaling Induces Neuronal Apoptosis Through Drp1&#x2010;Mediated Excessive Mitochondrial Fission and JNK1&#x2010;Dependent NLRP3 Inflammasome Activation,&#x201d; Cell Communication and Signaling: CCS 18, no. 1 (2020): 123.</Citation></Reference><Reference><Citation>T. W. Lai, W. C. Shyu, and Y. T. Wang, &#x201c;Stroke Intervention Pathways: NMDA Receptors and Beyond,&#x201d; Trends in Molecular Medicine 17, no. 5 (2011): 266&#x2013;275.</Citation></Reference><Reference><Citation>A. Camacho and L. Massieu, &#x201c;Role of Glutamate Transporters in the Clearance and Release of Glutamate During Ischemia and Its Relation to Neuronal Death,&#x201d; Archives of Medical Research 37, no. 1 (2006): 11&#x2013;18.</Citation></Reference><Reference><Citation>R. R&#xf6;nicke, M. Mikhaylova, S. R&#xf6;nicke, et&#xa0;al., &#x201c;Early Neuronal Dysfunction by Amyloid &#x3b2; Oligomers Depends on Activation of NR2B&#x2010;Containing NMDA Receptors,&#x201d; Neurobiology of Aging 32, no. 12 (2011): 2219&#x2013;2228.</Citation></Reference><Reference><Citation>L. M. Ittner, Y. D. Ke, F. Delerue, et&#xa0;al., &#x201c;Dendritic Function of Tau Mediates Amyloid&#x2010;Beta Toxicity in Alzheimer's Disease Mouse Models,&#x201d; Cell 142, no. 3 (2010): 387&#x2013;397.</Citation></Reference><Reference><Citation>F. Gardoni, C. Sgobio, V. Pendolino, P. Calabresi, M. Di Luca, and B. Picconi, &#x201c;Targeting NR2A&#x2010;Containing NMDA Receptors Reduces L&#x2010;DOPA&#x2010;Induced Dyskinesias,&#x201d; Neurobiology of Aging 33, no. 9 (2012): 2138&#x2013;2144.</Citation></Reference><Reference><Citation>P. Ju and D. Cui, &#x201c;The Involvement of N&#x2010;Methyl&#x2010;D&#x2010;Aspartate Receptor (NMDAR) Subunit NR1 in the Pathophysiology of Schizophrenia,&#x201d; Acta Biochimica et Biophysica Sinica 48, no. 3 (2016): 209&#x2013;219.</Citation></Reference><Reference><Citation>M. A. Sadeghi, S. Hemmati, S. Mohammadi, et&#xa0;al., &#x201c;Chronically Altered NMDAR Signaling in Epilepsy Mediates Comorbid Depression,&#x201d; Acta Neuropathologica Communications 9, no. 1 (2021): 53.</Citation></Reference><Reference><Citation>C. Fan, Y. Gao, G. Liang, et&#xa0;al., &#x201c;Transcriptomics of Gabra4 Knockout Mice Reveals Common NMDAR Pathways Underlying Autism, Memory, and Epilepsy,&#x201d; Molecular Autism 11, no. 1 (2020): 13.</Citation></Reference><Reference><Citation>Q. W. Wang, S. Y. Lu, Y. N. Liu, et&#xa0;al., &#x201c;Synaptotagmin&#x2010;7 Deficiency Induces Mania&#x2010;Like Behavioral Abnormalities Through Attenuating GluN2B Activity,&#x201d; Proceedings of the National Academy of Sciences of the United States of America 117, no. 49 (2020): 31438&#x2013;31447.</Citation></Reference><Reference><Citation>H. Wolosker and D. T. Balu, &#x201c;D&#x2010;Serine as the Gatekeeper of NMDA Receptor Activity: Implications for the Pharmacologic Management of Anxiety Disorders,&#x201d; Translational Psychiatry 10, no. 1 (2020): 184.</Citation></Reference><Reference><Citation>M. Bozic and J. M. Valdivielso, &#x201c;The Potential of Targeting NMDA Receptors Outside the CNS,&#x201d; Expert Opinion on Therapeutic Targets 19, no. 3 (2015): 399&#x2013;413.</Citation></Reference><Reference><Citation>Z. Y. Liu, S. Hu, Q. W. Zhong, C. N. Tian, H. M. Ma, and J. J. Yu, &#x201c;N&#x2010;Methyl&#x2010;D&#x2010;Aspartate Receptor&#x2010;Driven Calcium Influx Potentiates the Adverse Effects of Myocardial Ischemia&#x2010;Reperfusion Injury Ex&#xa0;Vivo,&#x201d; Journal of Cardiovascular Pharmacology 70, no. 5 (2017): 329&#x2013;338.</Citation></Reference><Reference><Citation>S. J. Dumas, G. Bru&#x2010;Mercier, A. Courboulin, et&#xa0;al., &#x201c;NMDA&#x2010;Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension,&#x201d; Circulation 137, no. 22 (2018): 2371&#x2013;2389.</Citation></Reference><Reference><Citation>S. Abbaszadeh, A. Javidmehr, B. Askari, P. M. L. Janssen, and H. Soraya, &#x201c;Memantine, an NMDA Receptor Antagonist, Attenuates Cardiac Remodeling, Lipid Peroxidation and Neutrophil Recruitment in Heart Failure: A Cardioprotective Agent?,&#x201d; Biomedicine &amp; Pharmacotherapy 108 (2018): 1237&#x2013;1243.</Citation></Reference><Reference><Citation>S. Shi, T. Liu, D. Wang, et&#xa0;al., &#x201c;Activation of N&#x2010;Methyl&#x2010;d&#x2010;Aspartate Receptors Reduces Heart Rate Variability and Facilitates Atrial Fibrillation in Rats,&#x201d; Europace 19, no. 7 (2017): 1237&#x2013;1243.</Citation></Reference><Reference><Citation>S. Shi, T. Liu, Y. Li, et&#xa0;al., &#x201c;Chronic N&#x2010;Methyl&#x2010;D&#x2010;Aspartate Receptor Activation Induces Cardiac Electrical Remodeling and Increases Susceptibility to Ventricular Arrhythmias,&#x201d; Pacing and Clinical Electrophysiology 37, no. 10 (2014): 1367&#x2013;1377.</Citation></Reference><Reference><Citation>N. Govoruskina, V. Jakovljevic, V. Zivkovic, et&#xa0;al., &#x201c;The Role of Cardiac N&#x2010;Methyl&#x2010;D&#x2010;Aspartate Receptors in Heart Conditioning&#x2010;Effects on Heart Function and Oxidative Stress,&#x201d; Biomolecules 10, no. 7 (2020): 1065.</Citation></Reference><Reference><Citation>J. L&#xfc;, X. Gao, J. Gu, et&#xa0;al., &#x201c;Nerve Sprouting Contributes to Increased Severity of Ventricular Tachyarrhythmias by Upregulating iGluRs in Rats With Healed Myocardial Necrotic Injury,&#x201d; Journal of Molecular Neuroscience 48, no. 2 (2012): 448&#x2013;455.</Citation></Reference><Reference><Citation>X. Sun, J. Zhong, D. Wang, et&#xa0;al., &#x201c;Increasing Glutamate Promotes Ischemia&#x2010;Reperfusion&#x2010;Induced Ventricular Arrhythmias in Rats In&#xa0;Vivo,&#x201d; Pharmacology 93, no. 1&#x2013;2 (2014): 4&#x2013;9.</Citation></Reference><Reference><Citation>ENCODE Project Consortium, &#x201c;An Integrated Encyclopedia of DNA Elements in the Human Genome,&#x201d; Nature 489, no. 7414 (2012): 57&#x2013;74.</Citation></Reference><Reference><Citation>M. van den Boogaard, L. Y. Wong, F. Tessadori, et&#xa0;al., &#x201c;Genetic Variation in T&#x2010;Box Binding Element Functionally Affects SCN5A/SCN10A Enhancer,&#x201d; Journal of Clinical Investigation 122, no. 7 (2012): 2519&#x2013;2530.</Citation></Reference><Reference><Citation>T. Y. de Soysa, S. S. Ranade, S. Okawa, et&#xa0;al., &#x201c;Single&#x2010;Cell Analysis of Cardiogenesis Reveals Basis for Organ&#x2010;Level Developmental Defects,&#x201d; Nature 572, no. 7767 (2019): 120&#x2013;124.</Citation></Reference><Reference><Citation>M. L. Speir, A. Bhaduri, N. S. Markov, et&#xa0;al., &#x201c;UCSC Cell Browser: Visualize Your Single&#x2010;Cell Data,&#x201d; Bioinformatics 37, no. 23 (2021): 4578&#x2013;4580.</Citation></Reference><Reference><Citation>C. G. Parsons, A. St&#xf6;ffler, and W. Danysz, &#x201c;Memantine: A NMDA Receptor Antagonist That Improves Memory by Restoration of Homeostasis in the Glutamatergic System&#x2014;Too Little Activation Is Bad, Too Much Is Even Worse,&#x201d; Neuropharmacology 53, no. 6 (2007): 699&#x2013;723.</Citation></Reference><Reference><Citation>M. M. Fan and L. A. Raymond, &#x201c;N&#x2010;Methyl&#x2010;D&#x2010;Aspartate (NMDA) Receptor Function and Excitotoxicity in Huntington's Disease,&#x201d; Progress in Neurobiology 81, no. 5&#x2013;6 (2007): 272&#x2013;293.</Citation></Reference><Reference><Citation>X. X. Xu and J. H. Luo, &#x201c;Mutations of N&#x2010;Methyl&#x2010;D&#x2010;Aspartate Receptor Subunits in Epilepsy,&#x201d; Neuroscience Bulletin 34, no. 3 (2018): 549&#x2013;565.</Citation></Reference><Reference><Citation>H. Xu, M. Bae, L. B. Tovar&#x2010;Y&#x2010;Romo, et&#xa0;al., &#x201c;The Human Immunodeficiency Virus Coat Protein gp120 Promotes Forward Trafficking and Surface Clustering of NMDA Receptors in Membrane Microdomains,&#x201d; Journal of Neuroscience 31, no. 47 (2011): 17074&#x2013;17090.</Citation></Reference><Reference><Citation>S. Nattel, A. Maguy, S. Le Bouter, et&#xa0;al., &#x201c;Arrhythmogenic Ion&#x2010;Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation,&#x201d; Physiological Reviews 87, no. 2 (2007): 425&#x2013;456.</Citation></Reference><Reference><Citation>X. Zhai, X. Qiao, L. Zhang, et&#xa0;al., &#x201c;I(K1) Channel Agonist Zacopride Suppresses Ventricular Arrhythmias in Conscious Rats With Healing Myocardial Infarction,&#x201d; Life Sciences 239 (2019): 117075.</Citation></Reference><Reference><Citation>Y. Liu, J. Li, N. Xu, et&#xa0;al., &#x201c;Transcription Factor Meis1 Act as a New Regulator of Ischemic Arrhythmias in Mice,&#x201d; Journal of Advanced Research 39 (2022): 275&#x2013;289.</Citation></Reference><Reference><Citation>A. M. Abdelrady, S. A. Zaitone, N. E. Farag, M. S. Fawzy, and Y. M. Moustafa, &#x201c;Cardiotoxic Effect of Levofloxacin and Ciprofloxacin in Rats With/Without Acute Myocardial Infarction: Impact on Cardiac Rhythm and Cardiac Expression of Kv4.3, Kv1.2 and Nav1.5 Channels,&#x201d; Biomedicine &amp; Pharmacotherapy 92 (2017): 196&#x2013;206.</Citation></Reference><Reference><Citation>S. Wagner, L. S. Maier, and D. M. Bers, &#x201c;Role of Sodium and Calcium Dysregulation in Tachyarrhythmias in Sudden Cardiac Death,&#x201d; Circulation Research 116, no. 12 (2015): 1956&#x2013;1970.</Citation></Reference><Reference><Citation>X. Dong, Y. Liu, H. Niu, et&#xa0;al., &#x201c;Electrophysiological Characterization of a Small Molecule Activator on Human Ether&#x2010;a&#x2010;Go&#x2010;Go&#x2010;Related Gene (hERG) Potassium Channel,&#x201d; Journal of Pharmacological Sciences 140, no. 3 (2019): 284&#x2013;290.</Citation></Reference><Reference><Citation>Y. Gui, D. Li, J. Chen, et&#xa0;al., &#x201c;Soluble Epoxide Hydrolase Inhibitors, t&#x2010;AUCB, Downregulated miR&#x2010;133 in a Mouse Model of Myocardial Infarction,&#x201d; Lipids in Health and Disease 17, no. 1 (2018): 129.</Citation></Reference><Reference><Citation>M. Tymianski, M. P. Charlton, P. L. Carlen, and C. H. Tator, &#x201c;Source Specificity of Early Calcium Neurotoxicity in Cultured Embryonic Spinal Neurons,&#x201d; Journal of Neuroscience 13, no. 5 (1993): 2085&#x2013;2104.</Citation></Reference><Reference><Citation>E. Carafoli, L. Santella, D. Branca, and M. Brini, &#x201c;Generation, Control, and Processing of Cellular Calcium Signals,&#x201d; Critical Reviews in Biochemistry and Molecular Biology 36, no. 2 (2001): 107&#x2013;260.</Citation></Reference><Reference><Citation>M. P. Blaustein and W. J. Lederer, &#x201c;Sodium/Calcium Exchange: Its Physiological Implications,&#x201d; Physiological Reviews 79, no. 3 (1999): 763&#x2013;854.</Citation></Reference><Reference><Citation>L. Kiedrowski, G. Brooker, E. Costa, and J. T. Wroblewski, &#x201c;Glutamate Impairs Neuronal Calcium Extrusion While Reducing Sodium Gradient,&#x201d; Neuron 12, no. 2 (1994): 295&#x2013;300.</Citation></Reference><Reference><Citation>L. Kiedrowski, &#x201c;N&#x2010;Methyl&#x2010;D&#x2010;Aspartate Excitotoxicity: Relationships Among Plasma Membrane Potential, Na(+)/ca(2+) Exchange, Mitochondrial Ca(2+) Overload, and Cytoplasmic Concentrations of Ca(2+), H(+), and K(+),&#x201d; Molecular Pharmacology 56, no. 3 (1999): 619&#x2013;632.</Citation></Reference><Reference><Citation>L. A. Naiche, Z. Harrelson, R. G. Kelly, and V. E. Papaioannou, &#x201c;T&#x2010;Box Genes in Vertebrate Development,&#x201d; Annual Review of Genetics 39 (2005): 219&#x2013;239.</Citation></Reference><Reference><Citation>H. Zhao, F. Wang, W. Zhang, et&#xa0;al., &#x201c;Overexpression of TBX3 in Human Induced Pluripotent Stem Cells (hiPSCs) Increases Their Differentiation Into Cardiac Pacemaker&#x2010;Like Cells,&#x201d; Biomedicine &amp; Pharmacotherapy 130 (2020): 110612.</Citation></Reference><Reference><Citation>T. Hunter and M. Karin, &#x201c;The Regulation of Transcription by Phosphorylation,&#x201d; Cell 70, no. 3 (1992): 375&#x2013;387.</Citation></Reference><Reference><Citation>J. Peres, S. Mowla, and S. Prince, &#x201c;The T&#x2010;Box Transcription Factor, TBX3, Is a Key Substrate of AKT3 in Melanomagenesis,&#x201d; Oncotarget 6, no. 3 (2015): 1821&#x2013;1833.</Citation></Reference><Reference><Citation>R. Omar, A. Cooper, H. M. Maranyane, et&#xa0;al., &#x201c;COL1A2 Is a TBX3 Target That Mediates Its Impact on Fibrosarcoma and Chondrosarcoma Cell Migration,&#x201d; Cancer Letters 459 (2019): 227&#x2013;239.</Citation></Reference><Reference><Citation>H. J. Chen, M. Rojas&#x2010;Soto, A. Oguni, and M. B. Kennedy, &#x201c;A Synaptic Ras&#x2010;GTPase Activating Protein (p135 SynGAP) Inhibited by CaM Kinase II,&#x201d; Neuron 20, no. 5 (1998): 895&#x2013;904.</Citation></Reference><Reference><Citation>A. Yoshii and M. Constantine&#x2010;Paton, &#x201c;BDNF Induces Transport of PSD&#x2010;95 to Dendrites Through PI3K&#x2010;AKT Signaling After NMDA Receptor Activation,&#x201d; Nature Neuroscience 10, no. 6 (2007): 702&#x2013;711.</Citation></Reference><Reference><Citation>M. K. Brittain, T. Brustovetsky, P. L. Sheets, et&#xa0;al., &#x201c;Delayed Calcium Dysregulation in Neurons Requires Both the NMDA Receptor and the Reverse Na+/Ca2+ Exchanger,&#x201d; Neurobiology of Disease 46, no. 1 (2012): 109&#x2013;117.</Citation></Reference><Reference><Citation>M. J. Curtis, J. C. Hancox, A. Farkas, et&#xa0;al., &#x201c;The Lambeth Conventions (II): Guidelines for the Study of Animal and Human Ventricular and Supraventricular Arrhythmias,&#x201d; Pharmacology &amp; Therapeutics 139, no. 2 (2013): 213&#x2013;248.</Citation></Reference><Reference><Citation>Z. Sun, J. Han, W. Zhao, et&#xa0;al., &#x201c;TRPV1 Activation Exacerbates Hypoxia/Reoxygenation&#x2010;Induced Apoptosis in H9C2 Cells via Calcium Overload and Mitochondrial Dysfunction,&#x201d; International Journal of Molecular Sciences 15, no. 10 (2014): 18362&#x2013;18380.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40842968</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2090-6404</ISSN><JournalIssue CitedMedium="Print"><Volume>2025</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Case reports in cardiology</Title><ISOAbbreviation>Case Rep Cardiol</ISOAbbreviation></Journal><ArticleTitle>Pneumococcal Pyopericardium With Xiphoid Osteomyelitis in HIV/AIDS: A Rare but Potentially Fatal Complication.</ArticleTitle><Pagination><StartPage>5008190</StartPage><MedlinePgn>5008190</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5008190</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/cric/5008190</ELocationID><Abstract><AbstractText><b>Background:</b> Purulent pericarditis is a rare, life-threatening condition that has become exceedingly uncommon due to widespread use of antibiotics. However, immunocompromised patients remain susceptible to such opportunistic infections. It is typically caused by direct extension or hematogenous spread from a secondary bacterial source. <b>Case Description:</b> We report a 55-year-old man with HIV cardiomyopathy who was transferred from an outside facility for chest pain and dyspnea, with an electrocardiogram suggestive of an ST-segment elevation myocardial infarction, prompting emergent cardiac catheterization, which revealed normal coronary arteries. A bedside echocardiogram revealed a large pericardial effusion with tamponade physiology, leading to pericardiocentesis. The pericardial fluid analysis revealed a high white blood cell count and a significantly elevated lactate dehydrogenase level, and cultures were positive for <i>Streptococcus pneumoniae</i>. Despite receiving antibiotics, the effusion reaccumulated, necessitating a subxiphoid pericardial wash and drainage. The xiphoid biopsy was consistent with acute osteomyelitis. The patient was discharged with long-term antibiotics and scheduled outpatient follow-ups. <b>Conclusion:</b> This case illustrates an unusual presentation of HIV-AIDS, highlighting advancements in managing pneumococcal pyopericardium with tamponade and the ongoing risk of opportunistic infections despite antiretroviral treatment. Though rare, pyopericardium can be fatal; so prompt diagnosis and multidisciplinary management are essential to improve outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Nihar Jena et al. Case Reports in Cardiology published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jena</LastName><ForeName>Nihar</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7702-9034</Identifier><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeed</LastName><ForeName>Izza</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Mackenzie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tocquica</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7753-5570</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Trinity Health Oakland/Wayne State University, Pontiac, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avula</LastName><ForeName>Sreekant</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3909-2531</Identifier><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayyed</LastName><ForeName>Ramiz</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastidas</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Studeny</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Interventional Cardiology, Marshall University, Huntington, West Virginia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Case Rep Cardiol</MedlineTA><NlmUniqueID>101576452</NlmUniqueID><ISSNLinking>2090-6404</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">Streptococcus pneumoniae</Keyword><Keyword MajorTopicYN="N">pericardial tamponade</Keyword><Keyword MajorTopicYN="N">pyopericardium</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40842968</ArticleId><ArticleId IdType="pmc">PMC12367396</ArticleId><ArticleId IdType="doi">10.1155/cric/5008190</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maisch B., Seferovi&#x107; P. M., Risti&#x107; A. D., et al. Guidelines on the Diagnosis and Management of Pericardial Diseases Executive Summary: The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. European Heart Journal . 2004;25(7):587&#x2013;610. doi: 10.1016/j.ehj.2004.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ehj.2004.02.002</ArticleId><ArticleId IdType="pubmed">15120056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagrist&#xe0;-Sauleda J., Barrab&#xe9;s J. A., Permanyer-Miralda G., Soler-Soler J. Purulent Pericarditis: Review of a 20-Year Experience in a General Hospital. Journal of the American College of Cardiology . 1993;22(6):1661&#x2013;1665. doi: 10.1016/0735-1097(93)90592-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(93)90592-O</ArticleId><ArticleId IdType="pubmed">8227835</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandell L. A., Wunderink R. G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases . 2007;44(Supplement_2):S27&#x2013;S72. doi: 10.1086/511159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/511159</ArticleId><ArticleId IdType="pmc">PMC7107997</ArticleId><ArticleId IdType="pubmed">17278083</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffernan R. T., Barrett N. L., Gallagher K. M., et al. Declining Incidence of Invasive Streptococcus pneumoniae Infections Among Persons With AIDS in an Era of Highly Active Antiretroviral Therapy, 1995&#x2013;2000. Journal of Infectious Diseases . 2005;191(12):2038&#x2013;2045. doi: 10.1086/430356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/430356</ArticleId><ArticleId IdType="pubmed">15897989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind A., Reinsch N., Neuhaus K., et al. Pericardial Effusion of HIV-Infected Patients - Results of a Prospective Multicenter Cohort Study in the Era of Antiretroviral Therapy. European Journal of Medical Research . 2011;16(11):480&#x2013;483. doi: 10.1186/2047-783X-16-11-480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-783X-16-11-480</ArticleId><ArticleId IdType="pmc">PMC3351804</ArticleId><ArticleId IdType="pubmed">22027640</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaduri-McIntosh S., Prasad M., Moltedo J., V&#xe1;zquez M. Purulent Pericarditis Caused by Group A Streptococcus. Texas Heart Institute Journal . 2006;33(4):519&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764956</ArticleId><ArticleId IdType="pubmed">17215986</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith Z. A., Wimbush S. Pneumococcal Pyopericardium Masquerading as Acute Coronary Syndrome. Journal of the Intensive Care Society . 2012;13(1):43&#x2013;46. doi: 10.1177/175114371201300112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/175114371201300112</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir S., Fauci A. S. B-Cell Exhaustion in HIV infection. Current Opinion in HIV and AIDS . 2014;9(5):472&#x2013;477. doi: 10.1097/COH.0000000000000092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COH.0000000000000092</ArticleId><ArticleId IdType="pubmed">25023621</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullers J. A. Insights Into the Interaction Between Influenza Virus and Pneumococcus. Clinical Microbiology Reviews . 2006;19(3):571&#x2013;582. doi: 10.1128/CMR.00058-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00058-05</ArticleId><ArticleId IdType="pmc">PMC1539103</ArticleId><ArticleId IdType="pubmed">16847087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cracknell B. R. S., Ail D. The Unmasking of a Pyopericardium. BMJ Case Reports . 2015;2015 doi: 10.1136/bcr-2014-207441.bcr2014207441</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2014-207441</ArticleId><ArticleId IdType="pmc">PMC4368986</ArticleId><ArticleId IdType="pubmed">25737219</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40843152</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-5204</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Resuscitation plus</Title><ISOAbbreviation>Resusc Plus</ISOAbbreviation></Journal><ArticleTitle>Out of hospital cardiac arrest in STEMI patients: A six-year review of an Irish tertiary referral centre.</ArticleTitle><Pagination><StartPage>101052</StartPage><MedlinePgn>101052</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101052</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.resplu.2025.101052</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="UNASSIGNED">Out of hospital cardiac arrest (OHCA) can complicate ST segment elevation myocardial infarction (STEMI), with a tenfold increase in mortality compared to those presenting without cardiac arrest. This study aimed to characterise STEMI patients presenting with OHCA to a single centre and to investigate the factors affecting their outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A retrospective analysis was performed on all patients on the National Out of Hospital Cardiac Arrest Register that presented over a six-year period with OHCA. The hospital's electronic health record was used to collect data on baseline characteristics, STEMI diagnosis, treatment and outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were 478 OHCA presentations; 75 (16&#xa0;%) were diagnosed with STEMI. Mortality rates were significantly lower amongst the STEMI patients (23&#xa0;% vs 87&#xa0;%). There was no significant difference in the characteristics of STEMI patients transferred directly to the coronary catheterisation lab (CCL) and initially treated in ED. Over 90&#xa0;% of STEMI patients were successfully treated with PCI. Mortality was higher in STEMI patients that were initially transferred to ED, with this factor identified as an independent predictor of mortality. However, transfer to CCL after two hours was not associated with increased mortality, when compared to those transferred within an hour of hospital arrival.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Mortality rates amongst studied STEMI patients presenting with OHCA were high. Although transfer to ED was associated with increased mortality, this finding may be explained by confounding factors, including more profound haemodynamic instability precluding STEMI diagnosis, and/or requiring transfer to ED for stabilisation.</AbstractText><CopyrightInformation>&#xa9; 2025 Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Offiah</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cork University Hospital, Wilton, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahly</LastName><ForeName>Darren</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University College Cork, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelfah</LastName><ForeName>Adel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cork University Hospital, Wilton, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Martin O</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Out of Hospital Cardiac Arrest Registry, National Ambulance Service, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masterson</LastName><ForeName>Siobhan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Ambulance Service, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kearney</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cork University Hospital, Wilton, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deasy</LastName><ForeName>Conor</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Emergency Department, Cork University Hospital, Wilton, Cork, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Resusc Plus</MedlineTA><NlmUniqueID>101774410</NlmUniqueID><ISSNLinking>2666-5204</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Critical care management</Keyword><Keyword MajorTopicYN="N">Out of hospital cardiac arrest</Keyword><Keyword MajorTopicYN="N">Primary percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">ST segment elevation myocardial infarction</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: &#x201c;Siobhan Masterson is an Editorial Board Member for this journal and was not involved in the editorial review or the decision to publish this article. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.&#x201d;.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40843152</ArticleId><ArticleId IdType="pmc">PMC12365332</ArticleId><ArticleId IdType="doi">10.1016/j.resplu.2025.101052</ArticleId><ArticleId IdType="pii">S2666-5204(25)00189-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tranberg T., Lippert F.K., Christensen E.F., et al. Distance to invasive heart centre, performance of acute coronary angiography, and angioplasty and associated outcome in out-of-hospital cardiac arrest: a nationwide study. Eur Heart J. 2017;38(21):1645&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451896</ArticleId><ArticleId IdType="pubmed">28369362</ArticleId></ArticleIdList></Reference><Reference><Citation>Daya M.R., Schmicker R.H., Zive D.M., et al. Out-of-hospital cardiac arrest survival improving over time: results from the Resuscitation Outcomes Consortium (ROC) Resuscitation. 2015;91:108&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433591</ArticleId><ArticleId IdType="pubmed">25676321</ArticleId></ArticleIdList></Reference><Reference><Citation>Irish National Out-of-Hospital Cardiac Arrest Register Steering Group. Out-of-hospital cardiac arrest register annual report 2021. 2022.</Citation></Reference><Reference><Citation>Geri G., Passouant O., Dumas F., et al. Etiological diagnoses of out-of-hospital cardiac arrest survivors admitted to the intensive care unit: insights from a French registry. Resuscitation. 2017;117:66&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602955</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam N., Bataille S., Marijon E., et al. Incidence, mortality, and outcome-predictors of sudden cardiac arrest complicating myocardial infarction prior to hospital admission. Circ Cardiovasc Interv. 2019;12(1)</Citation><ArticleIdList><ArticleId IdType="pubmed">30608874</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudas K., Lappas G., Stewart S., Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006) Circulation. 2011;123(1):46&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21173352</ArticleId></ArticleIdList></Reference><Reference><Citation>Bro-Jeppesen J., Kjaergaard J., Wanscher M., et al. Emergency coronary angiography in comatose cardiac arrest patients: do real-life experiences support the guidelines? Eur Heart J. 2012;1(4):291&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760568</ArticleId><ArticleId IdType="pubmed">24062920</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumas F., Cariou A., Manzo-Silberman S., et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv. 2010;3(3):200&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">20484098</ArticleId></ArticleIdList></Reference><Reference><Citation>Myat A., Song K.-J., Rea T. Out-of-hospital cardiac arrest: current concepts. Lancet. 2018;391(10124):970&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">29536861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yannopoulos D., Bartos J.A., Raveendran G., et al. Coronary artery disease in patients with out-of-hospital refractory ventricular fibrillation cardiac arrest. J Am Coll Cardiol. 2017;70(9):1109&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">28838358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeyons F., Jesel L., Morel O., et al. Out-of-hospital cardiac arrest survivors sent for emergency angiography: a clinical score for predicting acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2017;6(2):103&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">28304194</ArticleId></ArticleIdList></Reference><Reference><Citation>Desch S., Freund A., Akin I., et al. Angiography after out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med. 2021;385(27):2544&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pubmed">34459570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemkes J.S., Janssens G.N., Hoeven N.W.V.D., et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380(15):1397&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yannopoulos D., Bartos J.A., Aufderheide T.P., et al. The evolving role of the cardiac catheterization laboratory in the management of patients with out-of-hospital cardiac arrest: a scientific statement from the American Heart Association. Circulation. 2019;139(12):e530&#x2013;e552.</Citation><ArticleIdList><ArticleId IdType="pubmed">30760026</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller J.E., Engstr&#xf8;m T., Jensen L.O., et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390(15):1382&#x2013;1393.</Citation><ArticleIdList><ArticleId IdType="pubmed">38587239</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Akin I., et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med. 2023;389(14):1286&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">37634145</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Neumann F.-J., et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunau B., Kime N., Leroux B., et al. Association of intra-arrest transport vs continued on-scene resuscitation with survival to hospital discharge among patients with out-of-hospital cardiac arrest. JAMA. 2020;324(11):1058&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492914</ArticleId><ArticleId IdType="pubmed">32930759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40838876</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1758-5341</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>The Gerontologist</Title><ISOAbbreviation>Gerontologist</ISOAbbreviation></Journal><ArticleTitle>A dynamic microsimulation of health outcomes in Mexico's aging population].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">gnaf177</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/geront/gnaf177</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Mexico faces health policy challenges because of rising prevalence of health conditions, a rapidly aging population, and disparities in health care access. Nationally-representative longitudinal surveys released in recent years allow for projections of health care needs that can support policymakers to mitigate these challenges. This study validates the Mexico Future Older Adult Model (MFOAM), a dynamic microsimulation model for Mexico's aging population. Using 2012-2018 data from individuals aged 51+ in the Mexican Health and Aging Study (MHAS), the simulation builds on the Future Elderly Model from the United States.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">The model predicts lifetime health outcomes and risk factors, functional limitations, and mortality. Internal validation compares simulation outcomes to survey data at the individual and cohort level. External validation compares outcomes with 2012-2021 data from the National Health and Nutrition Survey (ENSANUT).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Internal and external validation showed robust performance. Population projections indicated almost a doubling of the 51+ population in Mexico between 2018 and 2051, with increasing prevalence of hypertension (52.3% to 66.1%), diabetes (24.6% to 31.9%), respiratory disease (10.2% to 15.1%), myocardial infarction (5.5% to 9.7%), stroke (4.3% to 8.0%), cancer (3.6% to 7.0%), and functional limitations (6.6% to 10.2%), reflecting national health trends.</AbstractText><AbstractText Label="DISCUSSION AND IMPLICATIONS" NlmCategory="CONCLUSIONS">The MFOAM projects population outcomes through 2051, or specific age cohorts until all members reach the end of their lives. Harmonized variables from the Gateway to Global Aging allow for cross-country comparisons and expansion with other health and economic variables. These forecasts help support policy planning and health care strategies in Mexico.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the Gerontological Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heun-Johnson</LastName><ForeName>Hanke</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4101-2492</Identifier><AffiliationInfo><Affiliation>Leonard D. Schaeffer Center for Health Policy &amp; Economics, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sol Price School of Public Policy, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gracner</LastName><ForeName>Tadeja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Economic and Social Research, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tysinger</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Leonard D. Schaeffer Center for Health Policy &amp; Economics, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sol Price School of Public Policy, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gerontologist</MedlineTA><NlmUniqueID>0375327</NlmUniqueID><ISSNLinking>0016-9013</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease projections</Keyword><Keyword MajorTopicYN="N">cardiometabolic conditions</Keyword><Keyword MajorTopicYN="N">functional limitations</Keyword><Keyword MajorTopicYN="N">health policy</Keyword><Keyword MajorTopicYN="N">population health</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>10</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40838876</ArticleId><ArticleId IdType="doi">10.1093/geront/gnaf177</ArticleId><ArticleId IdType="pii">8239232</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40838793</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-2412</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>European heart journal. Cardiovascular Imaging</Title><ISOAbbreviation>Eur Heart J Cardiovasc Imaging</ISOAbbreviation></Journal><ArticleTitle>Cardiac Ultrasound in Cardiovascular Emergency and Critical Care. A Clinical Consensus Statement of the European Association of Cardiovascular Imaging (EACVI), the Acute CardioVascular Care Association (ACVC) of the ESC, and the European Association of Cardiothoracic Anaesthesia and Intensive Care (EACTAIC).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jeaf246</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjci/jeaf246</ELocationID><Abstract><AbstractText>Cardiac ultrasound (CUS) has emerged as an indispensable bedside diagnostic and monitoring tool in cardiovascular emergencies and critical care, enabling rapid, noninvasive assessment of cardiac structure and function. This multidisciplinary consensus statement, jointly developed by the EACVI, ACVC, and EACTAIC, provides comprehensive, practical guidance on the use of CUS in acute care settings. The document outlines a pathophysiological framework for applying CUS across a wide spectrum of clinical scenarios, including cardiogenic shock, acute myocardial infarction, mechanical complications, acute heart failure, severe valvular disease, pericardial tamponade, pulmonary embolism, and cardiac arrest. It describes key ultrasound modalities, measurement techniques, and diagnostic considerations essential for accurate interpretation and decision-making. Emphasis is placed on integrating CUS with multimodal imaging and organ-specific ultrasound to improve diagnostic accuracy and risk stratification. The consensus further defines recommended training pathways, competence levels, and governance standards to ensure high-quality practice and mitigate medicolegal risks. Looking ahead, the document highlights future perspectives, including the transformative potential of artificial intelligence, big data, and connected technologies to enhance CUS capabilities. By standardising approaches and promoting interdisciplinary collaboration, this statement aims to optimise patient outcomes and advance the role of cardiac ultrasound as a cornerstone of emergency and critical cardiovascular care.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soliman Aboumarie</LastName><ForeName>Hatem</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3254-6820</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Anaesthesia and Critical Care, Harefield Hospital, Royal Brompton and Harefield Hospitals, Hill End Road, UB96JH, Uxbridge, UK. School of Cardiovascular, Metabolic Medicine and Sciences, King's College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavazzi</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia. Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS Viale Camillo Golgi, 19 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Via</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesia and Intensive Care, Istituto Cardiocentro Ticino, Ente Ospedaliero Cantonale, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarracino</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Critical Care Medicine, Azienda Ospedaliero Universitaria Pisana. Via Paradisa, 2 &#xb7; 050 992111, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stankovic</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Clinical Hospital Center Zemun, Department of Cardiology, Faculty of Medicine, University of Belgrade. Vukova 9, 11080 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagendorff</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Leipzig, 04103 Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargani</LastName><ForeName>Luna</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0716-453X</Identifier><AffiliationInfo><Affiliation>Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, via Paradisa 2 5614, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardim</LastName><ForeName>Nuno</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Servi&#xe7;o de Cardiologia Hospital CUF Descobertas, Lisboa. Faculdade de Ci&#xea;ncias M&#xe9;dicas da Universidade Nova de Lisboa, Nova Medical School, Lisboa, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flachskampf</LastName><ForeName>Frank A</ForeName><Initials>FA</Initials><Identifier Source="ORCID">0000-0002-7401-278X</Identifier><AffiliationInfo><Affiliation>Dept.Medical Sciences, Uppsala University, and Clinical Physiology and Cardiology, Uppsala University Hospital, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bax</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7368-0500</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Leiden University Medical Center. The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Chirojit</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Heart Center, University of Leipzig, Department of Anesthesia and Intensive Medicine, Struempellstrasse 39, 04289 Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meineri</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouchez</LastName><ForeName>Stefaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Ghent University Hospital, De Pintelaan, 185, 9000 Ghent, Belgium. Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bence</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiothoracic Anaesthesiology, University Hospitals of Leicester Glenfield Hospital, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skinner</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Nottingham University Hospitals, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosyns</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Cardiology &amp; Intensive Care, Royal Brompton &amp; Harefield Hospitals, National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neskovic</LastName><ForeName>Aleksandar N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Clinical Hospital Center Zemun, Department of Cardiology, Faculty of Medicine, University of Belgrade. Vukova 9, 11080 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Cardiovasc Imaging</MedlineTA><NlmUniqueID>101573788</NlmUniqueID><ISSNLinking>2047-2404</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">cardiac ultrasound</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">echocardiography</Keyword><Keyword MajorTopicYN="N">emergency medicine</Keyword><Keyword MajorTopicYN="N">haemodynamics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40838793</ArticleId><ArticleId IdType="doi">10.1093/ehjci/jeaf246</ArticleId><ArticleId IdType="pii">8239188</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40838370</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-5598</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of hypertension</Title><ISOAbbreviation>J Hypertens</ISOAbbreviation></Journal><ArticleTitle>Long-term safety and efficacy of renal sympathetic denervation in comparison to a population-based cohort: a propensity-matching approach.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/HJH.0000000000004117</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the long-term changes in risk of cardiovascular outcomes and blood pressure (BP) in hypertensive patients treated with renal sympathetic denervation (RDN) as compared to hypertensive controls from a population-based cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective cohort study included patients with office systolic blood pressure (SBP) at least 140&#x200a;mmHg and/or diastolic BP at least 90&#x200a;mmHg. Patients treated with RDN were matched to hypertensive controls from the population-based Rotterdam Study using one-to-many variable-ratio propensity score matching. The primary safety outcome was a composite endpoint of myocardial infarction, coronary revascularization, stroke, renal failure and mortality. The primary efficacy outcome was the 5-year change in office SBP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 53 RDN patients were matched to 238 population-based controls. Median age [25th-75th percentile] was 60.5 [56.5-68.4] years (46% female). Baseline BP &#xb1;SD was 166.1/95.5&#x200a;&#xb1;&#x200a;20.6/10.9&#x200a;mmHg. Patients were prescribed 2.8 [1.5-4.5] defined daily dosages of antihypertensive drugs. The incidence of the primary safety outcome was similar among the RDN group and the control group at 5&#x200a;years [13 vs. 18%; hazard ratio 0.93; 95% confidence interval (CI) 0.36-2.38; P&#x200a;=&#x200a;0.87]. The 5-year change in SBP was -12.0 [-18.0, -6.0] mmHg in the RDN group (P&#x200a;&lt;&#x200a;0.001) and -14.9 [-22.5 to -7.3] mmHg in the control group (P&#x200a;&lt;&#x200a;0.001), with no significant between-group difference [2.9 (-6.6 to 12.4) mmHg; P&#x200a;=&#x200a;0.55].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with uncontrolled hypertension undergoing RDN did not have a significantly lower risk for future adverse cardiovascular events as compared to hypertensive controls from a population-based study. No difference in office BP was observed at 5&#x200a;years. While real-world observational data could provide valuable insights, randomized trials are needed to confirm the role of RDN in improving long-term outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeijen</LastName><ForeName>Victor J M</ForeName><Initials>VJM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thorax Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilly</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thorax Center.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saville</LastName><ForeName>Kari A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thorax Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stricker</LastName><ForeName>Bruno H C</ForeName><Initials>BHC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kardys</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thorax Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Kamran</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Epidemiology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavousi</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daemen</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thorax Center.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Hypertens</MedlineTA><NlmUniqueID>8306882</NlmUniqueID><ISSNLinking>0263-6352</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BP</Keyword><Keyword MajorTopicYN="N">CI</Keyword><Keyword MajorTopicYN="N">DBP</Keyword><Keyword MajorTopicYN="N">DDD</Keyword><Keyword MajorTopicYN="N">Estimated glomerular filtration rate</Keyword><Keyword MajorTopicYN="N">RDN</Keyword><Keyword MajorTopicYN="N">SBP</Keyword><Keyword MajorTopicYN="N">SD</Keyword><Keyword MajorTopicYN="N">blood pressure</Keyword><Keyword MajorTopicYN="N">cohort studies</Keyword><Keyword MajorTopicYN="N">confidence interval</Keyword><Keyword MajorTopicYN="N">defined daily dosage</Keyword><Keyword MajorTopicYN="N">diastolic blood pressure</Keyword><Keyword MajorTopicYN="N">eGFR</Keyword><Keyword MajorTopicYN="N">glomerular filtration rate</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">kidney</Keyword><Keyword MajorTopicYN="N">renal sympathetic denervation</Keyword><Keyword MajorTopicYN="N">standard deviation</Keyword><Keyword MajorTopicYN="N">sympathectomy</Keyword><Keyword MajorTopicYN="N">systolic blood pressure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40838370</ArticleId><ArticleId IdType="doi">10.1097/HJH.0000000000004117</ArticleId><ArticleId IdType="pii">00004872-990000000-00733</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med 2019; 381:243&#x2013;251.</Citation></Reference><Reference><Citation>Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014; 383:1899&#x2013;1911.</Citation></Reference><Reference><Citation>Blood Pressure Lowering Treatment Trialists Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397:1625&#x2013;1636.</Citation></Reference><Reference><Citation>Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387:957&#x2013;967.</Citation></Reference><Reference><Citation>Zeijen VJM, Lafeber M, Versmissen J, Kroon AA, Boersma E, Daemen J. Adequacy of blood pressure control in high-risk hypertensive patients: the DEGREE study. Int J Cardiol 2022; 352:137&#x2013;143.</Citation></Reference><Reference><Citation>NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398:957&#x2013;980.</Citation></Reference><Reference><Citation>Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391:2335&#x2013;2345.</Citation></Reference><Reference><Citation>Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021; 397:2476&#x2013;2486.</Citation></Reference><Reference><Citation>Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II Randomized Clinical Trial. JAMA 2023; 329:651&#x2013;661.</Citation></Reference><Reference><Citation>Kandzari DE. Investigation of catheter-based renal denervation in patients with uncontrolled hypertension in the presence of antihypertensive medications - SPYRAL HTN-ON MED. American Heart Association's (AHA) Scientific Sessions 2022; Chicago, USA.2022.</Citation></Reference><Reference><Citation>Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020; 395:1444&#x2013;1451.</Citation></Reference><Reference><Citation>Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, et al. Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive medications: primary results from the TARGET BP I Randomized Clinical Trial. Circulation 2024; 149:1875&#x2013;1884.</Citation></Reference><Reference><Citation>Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022; 399:1401&#x2013;1410.</Citation></Reference><Reference><Citation>Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 2022; 400:1405&#x2013;1416.</Citation></Reference><Reference><Citation>Mahfoud F, Bohm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019; 40:3474&#x2013;3482.</Citation></Reference><Reference><Citation>Zeijen VJM, Feyz L, Nannan Panday R, Veen K, Versmissen J, Kardys I, et al. Long-term follow-up of patients undergoing renal sympathetic denervation. Clin Res Cardiol 2022; 111:1256&#x2013;1268.</Citation></Reference><Reference><Citation>Al Ghorani H, Kulenthiran S, Recktenwald MJM, Lauder L, Kunz M, Gotzinger F, et al. 10-year outcomes of catheter-based renal denervation in patients with resistant hypertension. J Am Coll Cardiol 2023; 81:517&#x2013;519.</Citation></Reference><Reference><Citation>Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG, et al. Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension 2023; 80:811&#x2013;819.</Citation></Reference><Reference><Citation>Zeijen VJM, Volz S, Zeller T, Mahfoud F, Kunz M, Kuck KH, et al. Long-term safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 8-year results from the ACHIEVE study. Clin Res Cardiol 2024; [Online ahead of print].</Citation></Reference><Reference><Citation>van der Burgh AC, Rizopoulos D, Ikram MA, Hoorn EJ, Chaker L. Determinants of the evolution of kidney function with age. Kidney Int Rep 2021; 6:3054&#x2013;3063.</Citation></Reference><Reference><Citation>Ikram MA, Kieboom BCT, Brouwer WP, Brusselle G, Chaker L, Ghanbari M, et al. The Rotterdam Study. Design update and major findings between 2020 and 2024. Eur J Epidemiol 2024; 39:183&#x2013;206.</Citation></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46:399&#x2013;424.</Citation></Reference><Reference><Citation>Snowden JM, Rose S, Mortimer KM. Implementation of G-computation on a simulated data set: demonstration of a causal inference technique. Am J Epidemiol 2011; 173:731&#x2013;738.</Citation></Reference><Reference><Citation>R Core Team. R version 4.3.0 &#x2019;Already Tomorrow&#x2019;. 2023, April 21.</Citation></Reference><Reference><Citation>Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet 2023; 401:2041&#x2013;2050.</Citation></Reference><Reference><Citation>Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013; 61:457&#x2013;464.</Citation></Reference><Reference><Citation>Pearson JD, Morrell CH, Brant LJ, Landis PK, Fleg JL. Age-associated changes in blood pressure in a longitudinal study of healthy men and women. J Gerontol A Biol Sci Med Sci 1997; 52:M177&#x2013;M183.</Citation></Reference><Reference><Citation>Kotchen JM, McKean HE, Kotchen TA. Blood pressure trends with aging. Hypertension 1982; 4 (5 Pt 2):III128&#x2013;III134.</Citation></Reference><Reference><Citation>Pocock SJ, Bakris G, Bhatt DL, Brar S, Fahy M, Gersh BJ. Regression to the mean in SYMPLICITY HTN-3: implications for design and reporting of future trials. J Am Coll Cardiol 2016; 68:2016&#x2013;2025.</Citation></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019; 394:1816&#x2013;1826.</Citation></Reference><Reference><Citation>Bourque G, Ilin JV, Ruzicka M, Hundemer GL, Shorr R, Hiremath S. Nonadherence is common in patients with apparent resistant hypertension: a systematic review and meta-analysis. Am J Hypertens 2023; 36:394&#x2013;403.</Citation></Reference><Reference><Citation>Peeters LEJ, Kappers MHW, Hesselink DA, van der Net JB, Hartong SCC, van de Laar R, et al. Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial. J Hypertens 2024; 42:169&#x2013;178.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837067</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Ophthalmology science</Title><ISOAbbreviation>Ophthalmol Sci</ISOAbbreviation></Journal><ArticleTitle>Risk of Systemic Health Events and Mortality After Vitrectomy for Diabetic Retinopathy in Patients with Type 2 Diabetes.</ArticleTitle><Pagination><StartPage>100880</StartPage><MedlinePgn>100880</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100880</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xops.2025.100880</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To quantify the risk of mortality, myocardial infarction (MI), stroke, and amputation in patients with type 2 diabetes mellitus (T2DM) who underwent pars plana vitrectomy (PPV) for diabetic retinopathy (DR) compared with those not requiring PPV.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">A retrospective cohort study utilizing the TriNetX US Collaborative Network.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="UNASSIGNED">The study included 9081 patients with T2DM who underwent PPV for DR, 363 116 patients with T2DM with DR but no PPV, 92 645 patients with T2DM without DR, and 3 264 709 healthy individuals, all aged &#x2265;18 years.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We identified cohorts using specific International Classification of Diseases, 10th Revision and Current Procedural Technology codes. We used propensity score matching to adjust for covariates including age, gender, race, ethnicity, systemic pathology, and ocular conditions unrelated to diabetes.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="UNASSIGNED">The primary outcome measures were the hazard ratios (HRs) for mortality, MI, stroke, and amputation at 1, 3, and 5 years after PPV compared with the control groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Patients with T2DM undergoing PPV for DR had higher risk of systemic events and mortality. Compared with patients with DR not requiring PPV, the PPV cohort had a higher risk at 1 year for stroke (HR: 1.51; 95% confidence interval [CI]: 1.03, 2.21) and amputation (HR: 1.85; 95% CI: 1.08, 3.16). At 3 years, the risks for MI (HR: 1.44; 95% CI: 1.17, 1.78), stroke (HR: 1.61; 95% CI: 1.25, 2.07), and amputation (HR: 2.17; 95% CI: 1.54, 3.05) were significantly elevated. At 5 years, the risks for mortality (HR: 1.28; 95% CI: 1.13, 1.43), MI (HR: 1.50; 95% CI: 1.26, 1.78), stroke (HR: 1.54; 95% CI: 1.25, 1.91), and amputation (HR: 2.10; 95% CI: 1.58, 2.81) were all significantly higher. When compared with diabetic patients without DR or healthy patients, the PPV cohort faced higher risk of each health outcome analyzed at intervals of 1, 3, and 5 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We found a significant association between patients with T2DM with DR requiring PPV and an increased risk of mortality, MI, stroke, and amputation compared with non-PPV patients with DR, diabetics without DR, and healthy individuals. These findings underscore the need for monitoring and management of systemic health in diabetic patients undergoing PPV for advanced DR.</AbstractText><AbstractText Label="FINANCIAL DISCLOSURES" NlmCategory="UNASSIGNED">The author(s) have no proprietary or commercial interest in any materials discussed in this article.</AbstractText><CopyrightInformation>&#xa9; 2025 by the American Academy of Ophthalmology&#xe9;.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jester</LastName><ForeName>Dane A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Muhammad Z</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Zain S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimaghaei</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muayad</LastName><ForeName>Jawad</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Texas A&amp;M University, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loya</LastName><ForeName>Asad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cullen Eye Institute, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shakarchi</LastName><ForeName>Ahmed F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallam</LastName><ForeName>Ahmed B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ophthalmol Sci</MedlineTA><NlmUniqueID>9918230896206676</NlmUniqueID><ISSNLinking>2666-9145</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Diabetic retinopathy</Keyword><Keyword MajorTopicYN="N">Pars plana vitrectomy</Keyword><Keyword MajorTopicYN="N">Retrospective cohort study</Keyword><Keyword MajorTopicYN="N">TriNetX research network</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837067</ArticleId><ArticleId IdType="pmc">PMC12363565</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2025.100880</ArticleId><ArticleId IdType="pii">S2666-9145(25)00178-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor R. Understanding the cause of type 2 diabetes. Lancet Diabetes Endocrinol. 2024;12:664&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">39038473</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung T.H., Patel B., Wilmot E.G., Amoaku W.M. Diabetic retinopathy for the non-ophthalmologist. Clin Med. 2022;22:112&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8966825</ArticleId><ArticleId IdType="pubmed">35304370</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo Z.L., Tham Y.C., Yu M., et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic Review and meta-analysis. Ophthalmology. 2021;128:1580&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pubmed">33940045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan M.Z., Rather P.A., Samarah S.M., et al. Current and novel therapeutic approaches for treatment of diabetic macular edema. Cells. 2022;11:1950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221813</ArticleId><ArticleId IdType="pubmed">35741079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusuhara S., Fukushima Y., Ogura S., et al. Pathophysiology of diabetic retinopathy: the old and the new. Diabetes Metab J. 2018;42:364&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202564</ArticleId><ArticleId IdType="pubmed">30362302</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrao S., Nobili A., Natoli G., et al. Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. Acta Diabetol. 2021;58:1225&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316168</ArticleId><ArticleId IdType="pubmed">33890176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamtani M., Kulkarni H., Bihari S., et al. Degree of hyperglycemia independently associates with hospital mortality and length of stay in critically ill, nondiabetic patients: results from the ANZICS CORE binational registry. J Crit Care. 2020;55:149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">31731174</ArticleId></ArticleIdList></Reference><Reference><Citation>The Emerging Risk Factors Collaboration Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215&#x2013;2222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904878</ArticleId><ArticleId IdType="pubmed">20609967</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdu F.A., Galip J., Qi P., et al. Association of stress hyperglycemia ratio and poor long-term prognosis in patients with myocardial infarction with non-obstructive coronary arteries. Cardiovasc Diabetol. 2023;22:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9843969</ArticleId><ArticleId IdType="pubmed">36647062</ArticleId></ArticleIdList></Reference><Reference><Citation>Maida C.D., Daidone M., Pacinella G., et al. Diabetes and ischemic stroke: an old and new relationship an overview of the close interaction between these diseases. Int J Mol Sci. 2022;23:2397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877605</ArticleId><ArticleId IdType="pubmed">35216512</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatnawi N.J., Al-Zoubi N.A., Hawamdeh H.M., et al. Predictors of major lower limb amputation in type 2 diabetic patients referred for hospital care with diabetic foot syndrome. Diabetes Metab Syndr Obes Targets Ther. 2018;11:313&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6018853</ArticleId><ArticleId IdType="pubmed">29950877</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler A.I., Stevens R.J., Neil A., et al. Ukpds 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002;25:894&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">11978687</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R., Klein B.E.K., Moss S.E., Cruickhanks K.J. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol Chic Ill 1960. 1999;117:1487&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">10565517</ArticleId></ArticleIdList></Reference><Reference><Citation>Juutilainen A., Lehto S., R&#xf6;nnemaa T., et al. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care. 2007;30:292&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">17259497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer C.K., Rodrigues T.C., Canani L.H., et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care. 2011;34:1238&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114518</ArticleId><ArticleId IdType="pubmed">21525504</ArticleId></ArticleIdList></Reference><Reference><Citation>Miettinen H., Haffner S.M., Lehto S., et al. Retinopathy predicts coronary heart disease events in NIDDM patients. Diabetes Care. 1996;19:1445&#x2013;1448.</Citation><ArticleIdList><ArticleId IdType="pubmed">8941482</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hecke M.V., Dekker J.M., Stehouwer C.D.A., et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence. Diabetes Care. 2005;28:1383&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920056</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X.H., Sun B., Zhong S., et al. Diabetic retinopathy predicts cardiovascular mortality in diabetes: a meta-analysis. BMC Cardiovasc Disord. 2020;20:478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643303</ArticleId><ArticleId IdType="pubmed">33148188</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Ikram M.K., Cotch M.F., et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease. JAMA Ophthalmol. 2017;135:586&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5593137</ArticleId><ArticleId IdType="pubmed">28472362</ArticleId></ArticleIdList></Reference><Reference><Citation>Modjtahedi B.S., Wu J., Luong T.Q., et al. Severity of diabetic retinopathy and the risk of future cerebrovascular disease, cardiovascular disease, and all-cause mortality. Ophthalmology. 2021;128:1169&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">33359888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu K., Jiang M., Zhou Q., et al. Association of diabetic retinopathy with stroke: a systematic Review and meta-analysis. Front Neurol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007918</ArticleId><ArticleId IdType="pubmed">33796063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalani M., Shinde P. Diabetic retinopathy may covariate with stroke in diabetes mellitus. Cureus. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491626</ArticleId><ArticleId IdType="pubmed">36158371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Cao D., Zhuang X., et al. Diabetic retinopathy may Be a predictor of stroke in patients with diabetes mellitus. J Endocr Soc. 2022;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250809</ArticleId><ArticleId IdType="pubmed">35795810</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss S.E., Klein R., Klein B.E. The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1999;22:951&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">10372248</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin L., Zhang D., Ren Q., et al. Prevalence and risk factors of diabetic retinopathy in diabetic patients: a community based cross-sectional study. Medicine (Baltimore) 2020;99</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478682</ArticleId><ArticleId IdType="pubmed">32118727</ArticleId></ArticleIdList></Reference><Reference><Citation>Borderie G., Foussard N., Larroumet A., et al. Diabetic retinopathy relates to the incidence of foot ulcers and amputations in type 2 diabetes. Diabetes Metab Res Rev. 2023;39</Citation><ArticleIdList><ArticleId IdType="pubmed">36575816</ArticleId></ArticleIdList></Reference><Reference><Citation>Blankenship G.W. Stability of pars plana vitrectomy results for diabetic retinopathy complications: a comparison of five-year and six-month postvitrectomy findings. Arch Ophthalmol. 1981;99:1009&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">7236097</ArticleId></ArticleIdList></Reference><Reference><Citation>Summanen P., Karhunen U., Laatikainen L. Characteristics and survival of diabetic patients undergoing vitreous surgery. Acta Ophthalmol (Copenh) 1987;65:197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">3604610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gollamudi S.R., Smiddy W.E., Schachat A.P., et al. Long-term survival rate after vitreous surgery for complications of diabetic retinopathy. Ophthalmology. 1991;98:18&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">2023726</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchio E., Inamura M., Ohno S., et al. Survival rate after vitreous surgery in patients with diabetic retinopathy. Ophthalmologica. 1993;206:83&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8272329</ArticleId></ArticleIdList></Reference><Reference><Citation>Helbig H., Kellner U., Bornfeld N., Foerster M.H. Life expectancy of diabetic patients undergoing vitreous surgery. Br J Ophthalmol. 1996;80:640&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC505560</ArticleId><ArticleId IdType="pubmed">8795378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lux A., Ostri C., Dyrberg E., et al. Survival rates after diabetic vitrectomy compared with standard diabetes and general populations. Acta Ophthalmol (Copenh) 2012;90:e650&#x2013;e652.</Citation><ArticleIdList><ArticleId IdType="pubmed">22471404</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee P.J., Moya R., Bunce C., et al. Long-term survival rates of patients undergoing vitrectomy for proliferative diabetic retinopathy. Ophthalmic Epidemiol. 2016;23:94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26954846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.Z., Lee K.L., Guest S.J., Worsley D. Long-term survival following diabetic vitrectomy. N Z Med J Online. 2017;130:69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">28207726</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E., Estevez J., Kaidonis G., et al. Long-term survival rates of patients undergoing vitrectomy for diabetic retinopathy in an Australian population: a population-based audit. Clin Exp Ophthalmol. 2019;47:598&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663192</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai W.H., Bai Y.C., Wei J.C.C., et al. Association of primary open-angle glaucoma with diabetic retinopathy among patients with type 1 and type 2 diabetes: a large global database study. Ophthalmology. 2024;131:827&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">38215989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan M.Z., Uwaydat S.H. Reply. Ophthalmology. 2024;131:e43&#x2013;e44.</Citation><ArticleIdList><ArticleId IdType="pubmed">39066766</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawshani A., Rawshani A., Franz&#xe9;n S., et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pubmed">28402770</ArticleId></ArticleIdList></Reference><Reference><Citation>Jelinek H.F., Osman W.M., Khandoker A.H., et al. Clinical profiles, comorbidities and complications of type 2 diabetes mellitus in patients from United Arab Emirates. BMJ Open Diabetes Res Care. 2017;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574445</ArticleId><ArticleId IdType="pubmed">28878941</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglay K., Hannachi H., Joseph Howie P., et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1243&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pubmed">26986190</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40837196</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">0972-978X</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><PubDate><Year>2025</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of orthopaedics</Title><ISOAbbreviation>J Orthop</ISOAbbreviation></Journal><ArticleTitle>Postoperative complications, length of stay, and discharge disposition following single-level anterior lumbar interbody fusion in elderly and octogenarian patients.</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>316</EndPage><MedlinePgn>311-316</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jor.2025.08.002</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Anterior lumbar interbody fusion (ALIF) has become a widely accepted treatment for degenerative lumbar spine pathologies, with increasing prevalence due to its effectiveness in restoring lumbar lordosis and improving spinal balance. This study aims to evaluate postoperative complications, length of stay (LOS), and discharge disposition following ALIF across different age groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 92,800 weighted cases of patients aged 50 and older underwent single-level ALIF in the National Inpatient Sample (NIS) from 2016 to 2020. Patients were stratified into age cohorts (50-64, 65-79, 80+). Exclusions were made for non-elective cases and missing data on key variables. Primary outcomes included postoperative complications (anemia, DVT, myocardial infarction, stroke, acute kidney injury, sepsis, anesthesia-related complications), LOS, and discharge disposition. Statistical comparisons between age groups were conducted using chi-square tests with a Bonferroni correction. Significance was set at <i>P</i>&#xa0;&lt;&#xa0;0.005.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The study identified significant variations in outcomes across age groups. The mean age differed significantly (<i>P</i>&#xa0;&lt;&#xa0;0.001). Older patients had higher rates of comorbidities and complications, with acute post-hemorrhagic anemia being most prevalent in the 65-79 group (16.78&#xa0;%) and sepsis more common in the 80+ group (0.90&#xa0;%). The LOS increased with age (<i>P</i>&#xa0;&lt;&#xa0;0.001), and total admission charges were highest in the 65-79 age group (<i>P</i>&#xa0;=&#xa0;0.004). Routine discharge rates decreased significantly with age, while non-routine discharges increased (<i>P</i>&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Age significantly influences postoperative outcomes following ALIF. Patients aged 65 and older are at increased risk for various complications, longer hospital stays, and non-routine discharges. These findings highlight the need for tailored perioperative care and robust discharge planning to improve outcomes for elderly patients undergoing ALIF. As with all retrospective database studies, this analysis is limited by potential coding inaccuracies and the absence of granular clinical details within the NIS.</AbstractText><CopyrightInformation>&#xa9; 2025 Professor P K Surendran Memorial Education Foundation. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mastrokostas</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Maimonides Medical Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastrokostas</LastName><ForeName>Leonidas E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Maimonides Medical Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavi</LastName><ForeName>Aaron B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razi</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Maimonides Medical Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Donald and Barbara Zucker School of Medicine, Hempstead, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houten</LastName><ForeName>John K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Mount Sinai School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleh</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Maimonides Medical Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bou Monsef</LastName><ForeName>Jad</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Maimonides Medical Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razi</LastName><ForeName>Afshin E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Maimonides Medical Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Mitchell K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Maimonides Medical Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Orthop</MedlineTA><NlmUniqueID>101233220</NlmUniqueID><ISSNLinking>0972-978X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age</Keyword><Keyword MajorTopicYN="N">Anterior lumbar interbody fusion</Keyword><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Discharge disposition</Keyword><Keyword MajorTopicYN="N">Length of stay</Keyword><Keyword MajorTopicYN="N">National inpatient sample</Keyword></KeywordList><CoiStatement>Mitchell K. Ng has the following disclosures: Johnson &amp; Johnson Ethicon Inc. (paid consultant), CurvaFix Inc. (paid consultant), Pacira BioSciences Inc. (paid consultant), Sage Products Inc. (paid consultant), Alafair Biosciences Inc. (paid consultant), Next Science LLC (paid consultant), Bonutti Technologies Inc. (paid consultant), Hippocrates Opportunities Fund LLC (paid consultant), and Ferghana Partners Inc. (paid consultant). All other authors have no other relevant financial disclosures. The author(s) declare that there is no conflict of interest related to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40837196</ArticleId><ArticleId IdType="pmc">PMC12362134</ArticleId><ArticleId IdType="doi">10.1016/j.jor.2025.08.002</ArticleId><ArticleId IdType="pii">S0972-978X(25)00304-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Varshneya K., Medress Z.A., Jensen M., et al. Trends in anterior lumbar interbody fusion in the United States: a MarketScan study from 2007 to 2014. Clin Spine Surg. 2020;33(5):E226&#x2013;E230. doi: 10.1097/BSD.0000000000000904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BSD.0000000000000904</ArticleId><ArticleId IdType="pubmed">31609798</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobbs R.J., Loganathan A., Yeung V., Rao P.J. Indications for anterior lumbar interbody fusion. Orthop Surg. 2013;5(3):153&#x2013;163. doi: 10.1111/OS.12048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/OS.12048</ArticleId><ArticleId IdType="pmc">PMC6583544</ArticleId><ArticleId IdType="pubmed">24002831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobbs R.J., Phan K., Malham G., Seex K., Rao P.J. Lumbar interbody fusion: techniques, indications and comparison of interbody fusion options including PLIF, TLIF, MI-TLIF, OLIF/ATP, LLIF and ALIF. J Spine Surg. 2015;1(1) doi: 10.3978/J.ISSN.2414-469X.2015.10.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.3978/J.ISSN.2414-469X.2015.10.05</ArticleId><ArticleId IdType="pmc">PMC5039869</ArticleId><ArticleId IdType="pubmed">27683674</ArticleId></ArticleIdList></Reference><Reference><Citation>Udby P.M., Bech-Azeddine R. Clinical outcome of stand-alone ALIF compared to posterior instrumentation for degenerative disc disease: a pilot study and a literature review. Clin Neurol Neurosurg. 2015;133:64&#x2013;69. doi: 10.1016/J.CLINEURO.2015.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CLINEURO.2015.03.008</ArticleId><ArticleId IdType="pubmed">25855474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobbs R.J., Phan K., Daly D., Rao P.J., Lennox A. Approach-related complications of anterior lumbar interbody fusion: results of a combined spine and vascular surgical team. Glob Spine J. 2016;6(2):147. doi: 10.1055/S-0035-1557141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/S-0035-1557141</ArticleId><ArticleId IdType="pmc">PMC4771511</ArticleId><ArticleId IdType="pubmed">26933616</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Imagama S., Ando K., et al. Complications associated with spine surgery in patients aged 80 years or older: Japan association of spine surgeons with ambition (JASA) multicenter study. Glob Spine J. 2017;7(7):636. doi: 10.1177/2192568217716144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2192568217716144</ArticleId><ArticleId IdType="pmc">PMC5624380</ArticleId><ArticleId IdType="pubmed">28989842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar C.D., Dietz N., Sharma M., et al. Spine surgery in the octogenarian population: a comparison of demographics, surgical approach, and healthcare utilization with the PearlDiver database. Cureus. 2021;13(4) doi: 10.7759/CUREUS.14561.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/CUREUS.14561</ArticleId><ArticleId IdType="pmc">PMC8133513</ArticleId><ArticleId IdType="pubmed">34026377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielinska N., Podg&#xf3;rski M., Ha&#x142;adaj R., Polguj M. Olewnik &#x141;. Risk factors of intervertebral disc pathology&#x2014;A point of view formerly and today&#x2014;A review. J Clin Med. 2021;10(3):409. doi: 10.3390/JCM10030409. 2021, Vol 10, Page 409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/JCM10030409</ArticleId><ArticleId IdType="pmc">PMC7865549</ArticleId><ArticleId IdType="pubmed">33494410</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Guo C., Meng F., Zhu Z., Xia W., Liu H. Perioperative risk factors related to complications of lumbar spine fusion surgery in elderly patients. BMC Muscoskelet Disord. 2023;24(1) doi: 10.1186/S12891-023-06689-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12891-023-06689-Z</ArticleId><ArticleId IdType="pmc">PMC10347777</ArticleId><ArticleId IdType="pubmed">37452304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C.C., Royse K.E., Prentice H.A., Harris J.E., Guppy K.H. Are octogenarians at higher risk of complications after elective lumbar spinal fusion surgery? Analysis of a cohort of 7880 patients from the Kaiser Permanente Spine registry. Spine. 2022;47(24):1719&#x2013;1727. doi: 10.1097/BRS.0000000000004451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0000000000004451</ArticleId><ArticleId IdType="pubmed">35943246</ArticleId></ArticleIdList></Reference><Reference><Citation>Elixhauser comorbidity software refined for ICD-10-CM. https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp</Citation></Reference><Reference><Citation>Jesse C.M., Mayer L., H&#xe4;ni L., et al. Anterior lumbar interbody fusion in elderly patients: peri- and postoperative complications and clinical outcome. J Neurol Surg Cent Eur Neurosurg. 2023;84(6):548&#x2013;557. doi: 10.1055/S-0042-1757164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/S-0042-1757164</ArticleId><ArticleId IdType="pubmed">37192649</ArticleId></ArticleIdList></Reference><Reference><Citation>Allain J., Delecrin J., Beaurain J., Poignard A., Vila T., Flouzat-Lachaniette C.H. Stand-alone ALIF with integrated intracorporeal anchoring plates in the treatment of degenerative lumbar disc disease: a prospective study on 65 cases. Eur Spine J. 2014;23(10):2136&#x2013;2143. doi: 10.1007/S00586-014-3364-1/FIGURES/7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00586-014-3364-1/FIGURES/7</ArticleId><ArticleId IdType="pubmed">24952630</ArticleId></ArticleIdList></Reference><Reference><Citation>Toma A.A., Hallager D.W., Bech R.D., Carreon L.Y., Andersen M., Udby P.M. Stand-alone ALIF versus TLIF in patients with low back pain &#x2013; a propensity-matched cohort study with two-year follow-up. Brain Spine. 2023;3 doi: 10.1016/J.BAS.2023.102713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BAS.2023.102713</ArticleId><ArticleId IdType="pmc">PMC10668097</ArticleId><ArticleId IdType="pubmed">38021018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamalapathy P.N., Vatani J., Raso J., Hassanzadeh H., Li X. How old is too old?: matched analysis of geriatric patients undergoing anterior lumbar interbody fusion. Clin Neurol Neurosurg. 2022;212 doi: 10.1016/J.CLINEURO.2021.107090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CLINEURO.2021.107090</ArticleId><ArticleId IdType="pubmed">34922291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.W., Oh B.H., Min K.S., Lee M.S., Lee J.B. Complications following spinal surgery in patients aged 85 years and older. Nerve. 2023;9(2):132&#x2013;137. doi: 10.21129/NERVE.2023.00472.</Citation><ArticleIdList><ArticleId IdType="doi">10.21129/NERVE.2023.00472</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacas S., Cole D.J., Cannesson M. Cognitive decline associated with anesthesia and surgery in older patients. JAMA. 2021;326(9):863&#x2013;864. doi: 10.1001/JAMA.2021.4773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2021.4773</ArticleId><ArticleId IdType="pmc">PMC8807795</ArticleId><ArticleId IdType="pubmed">34338712</ArticleId></ArticleIdList></Reference><Reference><Citation>McGirt M.J., Parker S.L., Hilibrand A., et al. Lumbar surgery in the elderly provides significant health benefit in the US health care system: patient-reported outcomes in 4370 patients from the N2QOD registry. Neurosurgery. 2015;77(Suppl 4):S125&#x2013;S135. doi: 10.1227/NEU.0000000000000952. (4)</Citation><ArticleIdList><ArticleId IdType="doi">10.1227/NEU.0000000000000952</ArticleId><ArticleId IdType="pubmed">26378350</ArticleId></ArticleIdList></Reference><Reference><Citation>Adogwa O., Elsamadicy A.A., Vuong V.D., et al. Geriatric comanagement reduces perioperative complications and shortens duration of hospital stay after lumbar spine surgery: a prospective single-institution experience: presented at the 2017 AANS/CNS joint section on disorders of the spine and peripheral nerves. J Neurosurg Spine. 2017;27(6):670&#x2013;675. doi: 10.3171/2017.5.SPINE17199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2017.5.SPINE17199</ArticleId><ArticleId IdType="pubmed">28960161</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrokni A., Tin A.L., Sarraf S., et al. Association of geriatric comanagement and 90-Day postoperative mortality among patients aged 75 years and older with cancer. JAMA Netw Open. 2020;3(8) doi: 10.1001/JAMANETWORKOPEN.2020.9265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANETWORKOPEN.2020.9265</ArticleId><ArticleId IdType="pmc">PMC7439108</ArticleId><ArticleId IdType="pubmed">32822490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mummaneni P.V., Bydon M., Knightly J.J., et al. Identifying patients at risk for nonroutine discharge after surgery for cervical myelopathy: an analysis from the quality outcomes database. J Neurosurg Spine. 2021;35(1):25&#x2013;33. doi: 10.3171/2020.11.SPINE201442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2020.11.SPINE201442</ArticleId><ArticleId IdType="pubmed">33962388</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagman C., Ugiliweneza B., Boakye M., Drazin D. Spine surgery outcomes in elderly patients versus general adult patients in the United States: a MarketScan analysis. World Neurosurg. 2017;103:780&#x2013;788. doi: 10.1016/J.WNEU.2017.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.WNEU.2017.04.001</ArticleId><ArticleId IdType="pubmed">28408265</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh H.J., Lim Z.Y., Yap P., Tang T. Factors associated with prolonged length of stay in older patients. Singap Med J. 2017;58(3):134. doi: 10.11622/SMEDJ.2016158.</Citation><ArticleIdList><ArticleId IdType="doi">10.11622/SMEDJ.2016158</ArticleId><ArticleId IdType="pmc">PMC5360868</ArticleId><ArticleId IdType="pubmed">27609507</ArticleId></ArticleIdList></Reference><Reference><Citation>Abt N.B., McCutcheon B.A., Kerezoudis P., et al. Discharge to a rehabilitation facility is associated with decreased 30-day readmission in elective spinal surgery. J Clin Neurosci. 2017;36:37&#x2013;42. doi: 10.1016/J.JOCN.2016.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JOCN.2016.10.029</ArticleId><ArticleId IdType="pubmed">27810418</ArticleId></ArticleIdList></Reference><Reference><Citation>Strosberg D.S., Housley B.C., Vazquez D., Rushing A., Steinberg S., Jones C. Discharge destination and readmission rates in older trauma patients. J Surg Res. 2017;207:27&#x2013;32. doi: 10.1016/J.JSS.2016.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JSS.2016.07.015</ArticleId><ArticleId IdType="pubmed">27979485</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabacak M., Jagtiani P., Schupper A.J., Carr M.T., Steinberger J., Margetis K. Machine learning for individualized risk estimation in anterior lumbar interbody fusion. Neurosurg Pract. 2024;5(3) doi: 10.1227/neuprac.0000000000000099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1227/neuprac.0000000000000099</ArticleId><ArticleId IdType="pmc">PMC11783634</ArticleId><ArticleId IdType="pubmed">39959899</ArticleId></ArticleIdList></Reference><Reference><Citation>Asserson D.B., Alaouieh D.A., Roy J.M., Schmidt M.H., Bowers C.A. Frailty predicts non-home discharge in anterior lumbar interbody fusion patients. J Neurosurg Sci. 2025;69(3):284&#x2013;289. doi: 10.23736/S0390-5616.24.06179-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0390-5616.24.06179-4</ArticleId><ArticleId IdType="pubmed">38451062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>